
<html lang="en"     class="pb-page"  data-request-id="ac79aa50-88f7-42bb-8318-29c0b21a27fe"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;wgroup:string:ACHS website Group;website:website:acspubs;issue:issue:10.1021/jmcmar.2010.53.issue-15;pageGroup:string:Publication Pages;subPage:string:Full Text;article:article:10.1021/jm901808w"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="dc.Title" content="A Type-II Kinase Inhibitor Capable of Inhibiting the T315I “Gatekeeper” Mutant of Bcr-Abl" /></meta><meta name="dc.Creator" content="Hwan Geun  Choi" /></meta><meta name="dc.Creator" content="Pingda  Ren" /></meta><meta name="dc.Creator" content="Francisco  Adrian" /></meta><meta name="dc.Creator" content="Fangxian  Sun" /></meta><meta name="dc.Creator" content="Hyun Soo  Lee" /></meta><meta name="dc.Creator" content="Xia  Wang" /></meta><meta name="dc.Creator" content="Qiang  Ding" /></meta><meta name="dc.Creator" content="Guobao  Zhang" /></meta><meta name="dc.Creator" content="Yongping  Xie" /></meta><meta name="dc.Creator" content="Jianming  Zhang" /></meta><meta name="dc.Creator" content="Yi  Liu" /></meta><meta name="dc.Creator" content="Tove  Tuntland" /></meta><meta name="dc.Creator" content="Markus  Warmuth" /></meta><meta name="dc.Creator" content="Paul W.  Manley" /></meta><meta name="dc.Creator" content="Jürgen  Mestan" /></meta><meta name="dc.Creator" content="Nathanael S.  Gray" /></meta><meta name="dc.Creator" content="Taebo  Sim" /></meta><meta name="dc.Description" content="The second generation of Bcr-Abl inhibitors nilotinib, dasatinib, and bosutinib developed to override imatinib resistance are not active against the T315I “gatekeeper” mutation. Here we describe a ..." /></meta><meta name="Description" content="The second generation of Bcr-Abl inhibitors nilotinib, dasatinib, and bosutinib developed to override imatinib resistance are not active against the T315I “gatekeeper” mutation. Here we describe a ..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="July 6, 2010" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/jm901808w" /></meta><meta name="dc.Language" content="EN" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="© 2010 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Fjm901808w" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Fjm901808w" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Fjm901808w" /></link>
        
    
    

<title>A Type-II Kinase Inhibitor Capable of Inhibiting the T315I “Gatekeeper” Mutant of Bcr-Abl | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/jm901808w" /></meta><meta property="og:title" content="A Type-II Kinase Inhibitor Capable of Inhibiting the T315I “Gatekeeper” Mutant of Bcr-Abl" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-15/jm901808w/production/images/large/jm-2009-01808w_0004.jpeg" /></meta><meta property="og:description" content="The second generation of Bcr-Abl inhibitors nilotinib, dasatinib, and bosutinib developed to override imatinib resistance are not active against the T315I “gatekeeper” mutation. Here we describe a type-II T315I inhibitor 2 (GNF-7), based upon a 3,4-dihydropyrimido[4,5-d]pyrimidin-2(1H)-one scaffold which is capable of potently inhibiting wild-type and T315I Bcr-Abl as well as other clinically relevant Bcr-Abl mutants such as G250E, Q252H, Y253H, E255K, E255V, F317L, and M351T in biochemical and cellular assays. In addition, compound 2 displayed significant in vivo efficacy against T315I-Bcr-Abl without appreciable toxicity in a bioluminescent xenograft mouse model using a transformed T315I-Bcr-Abl-Ba/F3 cell line that has a stable luciferase expression. Compound 2 is among the first type-II inhibitors capable of inhibiting T315I to be described and will serve as a valuable lead to design the third generation Bcr-Abl kinase inhibitors." /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta><meta name="twitter:description" content="The second generation of Bcr-Abl inhibitors nilotinib, dasatinib, and bosutinib developed to override imatinib resistance are not active against the T315I “gatekeeper” mutation. Here we describe a type-II T315I inhibitor 2 (GNF-7), based upon a 3,4-dihydropyrimido[4,5-d]pyrimidin-2(1H)-one scaffold which is capable of potently inhibiting wild-type and T315I Bcr-Abl as well as other clinically relevant Bcr-Abl mutants such as G250E, Q252H, Y253H, E255K, E255V, F317L, and M351T in biochemical and cellular assays. In addition, compound 2 displayed significant in vivo efficacy against T315I-Bcr-Abl without appreciable toxicity in a bioluminescent xenograft mouse model using a transformed T315I-Bcr-Abl-Ba/F3 cell line that has a stable luciferase expression. Compound 2 is among the first type-II inhibitors capable of inhibiting T315I to be described and will serve as a valuable lead to design the third generation Bcr-Abl kinase inhibitors." /></meta><meta name="twitter:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-15/jm901808w/production/images/large/jm-2009-01808w_0004.jpeg" /></meta><meta name="twitter:title" content="A Type-II Kinase Inhibitor Capable of Inhibiting the T315I “Gatekeeper” Mutant of Bcr-Abl" /></meta>
        
            <meta property="og:type" content="Article" /></meta>
        

        
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/jm901808w"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/ke1q~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-6ee29527b3d8ff00a106.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/jm901808w">
            
        





































    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-12/achre4.2021.54.issue-12/20210615/achre4.2021.54.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-6/amrcda.2021.2.issue-6/20210625/amrcda.2021.2.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-6/aabmcb.2021.4.issue-6/20210621/aabmcb.2021.4.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-6/aaembp.2021.3.issue-6/20210622/aaembp.2021.3.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-6/aaemcq.2021.4.issue-6/20210628/aaemcq.2021.4.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-25/aamick.2021.13.issue-25/20210630/aamick.2021.13.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-6/aanmf6.2021.4.issue-6/20210625/aanmf6.2021.4.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-6/aapmcd.2021.3.issue-6/20210611/aapmcd.2021.3.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-6/abseba.2021.7.issue-6/20210614/abseba.2021.7.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-12/accacs.2021.11.issue-12/20210618/accacs.2021.11.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-6/acscii.2021.7.issue-6/20210623/acscii.2021.7.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-6/acbcct.2021.16.issue-6/20210618/acbcct.2021.16.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-3/achsc5.2021.28.issue-3/20210524/achsc5.2021.28.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-12/acncdm.2021.12.issue-12/20210616/acncdm.2021.12.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-6/aesccq.2021.5.issue-6/20210617/aesccq.2021.5.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-6/aelccp.2021.6.issue-6/20210611/aelccp.2021.6.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-6/aeecco.2021.1.issue-6/20210611/aeecco.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-6/aewcaa.2021.1.issue-6/20210611/aewcaa.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-5/afsthl.2021.1.issue-5/20210618/afsthl.2021.1.issue-5.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-6/aidcbc.2021.7.issue-6/20210611/aidcbc.2021.7.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-6/amlccd.2021.10.issue-6/20210615/amlccd.2021.10.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-6/amlcef.2021.3.issue-6/20210607/amlcef.2021.3.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-6/amclct.2021.12.issue-6/20210610/amclct.2021.12.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-6/ancac3.2021.15.issue-6/20210622/ancac3.2021.15.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-25/acsodf.2021.6.issue-25/20210629/acsodf.2021.6.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-6/apchd5.2021.8.issue-6/20210616/apchd5.2021.8.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-6/ascefj.2021.6.issue-6/20210625/ascefj.2021.6.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-25/ascecg.2021.9.issue-25/20210628/ascecg.2021.9.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-6/asbcd6.2021.10.issue-6/20210618/asbcd6.2021.10.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-25/ancham.2021.93.issue-25/20210629/ancham.2021.93.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-25/bichaw.2021.60.issue-25/20210629/bichaw.2021.60.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-6/bcches.2021.32.issue-6/20210616/bcches.2021.32.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-6/bomaf6.2021.22.issue-6/20210614/bomaf6.2021.22.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-24/cgeabj.2021.99.issue-24/20210628-01/cgeabj.2021.99.issue-24.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-6/crtoec.2021.34.issue-6/20210621/crtoec.2021.34.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-12/chreay.2021.121.issue-12/20210623/chreay.2021.121.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-12/cmatex.2021.33.issue-12/20210622/cmatex.2021.33.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-6/cgdefu.2021.21.issue-6/20210602/cgdefu.2021.21.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-12/enfuem.2021.35.issue-12/20210617/enfuem.2021.35.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-12/esthag.2021.55.issue-12/20210615/esthag.2021.55.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-6/estlcu.2021.8.issue-6/20210608/estlcu.2021.8.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-25/iecred.2021.60.issue-25/20210630/iecred.2021.60.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-12/inocaj.2021.60.issue-12/20210621/inocaj.2021.60.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-6/jaaucr.2021.1.issue-6/20210628/jaaucr.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-25/jafcau.2021.69.issue-25/20210630/jafcau.2021.69.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-6/jceaax.2021.66.issue-6/20210610/jceaax.2021.66.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-6/jceda8.2021.98.issue-6/20210608/jceda8.2021.98.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-6/jcisd8.2021.61.issue-6/20210628/jcisd8.2021.61.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-6/jctcce.2021.17.issue-6/20210608/jctcce.2021.17.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/jmcmar.2021.64.issue-12/20210624/jmcmar.2021.64.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-6/jnprdf.2021.84.issue-6/20210625/jnprdf.2021.84.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-12/joceah.2021.86.issue-12/20210618/joceah.2021.86.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-24/jpcafh.2021.125.issue-24/20210624/jpcafh.2021.125.issue-24.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-24/jpcbfk.2021.125.issue-24/20210624/jpcbfk.2021.125.issue-24.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-24/jpccck.2021.125.issue-24/20210624/jpccck.2021.125.issue-24.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-24/jpclcd.2021.12.issue-24/20210624/jpclcd.2021.12.issue-24.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-6/jprobs.2021.20.issue-6/20210604/jprobs.2021.20.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-25/jacsat.2021.143.issue-25/20210630/jacsat.2021.143.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-6/jamsef.2021.32.issue-6/20210602/jamsef.2021.32.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-25/langd5.2021.37.issue-25/20210629/langd5.2021.37.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-12/mamobx.2021.54.issue-12/20210622/mamobx.2021.54.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-6/mpohbp.2021.18.issue-6/20210607/mpohbp.2021.18.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-12/nalefd.2021.21.issue-12/20210623/nalefd.2021.21.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-12/orlef7.2021.23.issue-12/20210618/orlef7.2021.23.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-6/oprdfk.2021.25.issue-6/20210618/oprdfk.2021.25.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-12/orgnd7.2021.40.issue-12/20210628/orgnd7.2021.40.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Fjm901808w&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Fjm901808w&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/jm901808w&amp;href=/doi/10.1021/jm901808w" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2010</span><span class="cit-fg-volume">, 53</span><span class="cit-fg-issue">, 15</span><span class="cit-fg-pageRange">, 5439-5448</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/53/15" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/jm100076w" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/jm1000584" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">A Type-II Kinase Inhibitor Capable of Inhibiting the T315I “Gatekeeper” Mutant of Bcr-Abl</span></h1><ul class="loa non-jats-loa"><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Hwan+Geun++Choi">Hwan Geun Choi</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>∥</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Pingda++Ren">Pingda Ren</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Francisco++Adrian">Francisco Adrian</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Fangxian++Sun">Fangxian Sun</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Hyun+Soo++Lee">Hyun Soo Lee</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Xia++Wang">Xia Wang</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Qiang++Ding">Qiang Ding</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Guobao++Zhang">Guobao Zhang</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Yongping++Xie">Yongping Xie</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Jianming++Zhang">Jianming Zhang</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Yi++Liu">Yi Liu</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Tove++Tuntland">Tove Tuntland</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Markus++Warmuth">Markus Warmuth</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Paul+W.++Manley">Paul W. Manley</a></span><span class="author-xref-symbol author-aff-symbol"><sup>§</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=J%C3%BCrgen++Mestan">Jürgen Mestan</a></span><span class="author-xref-symbol author-aff-symbol"><sup>§</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Nathanael+S.++Gray">Nathanael S. Gray</a></span><span class="author-xref-symbol "><sup>*</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Taebo++Sim">Taebo Sim</a></span><span class="author-xref-symbol "><sup>*</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>∥</sup></span></span></li><span class="comma-separator"></span></ul><div class="affiliations"><div class="view-affs"><span class="title">View Author Information</span><i class="caret-icon icon-angle-down"></i></div><div class="all-aff-infos hlFld-Affiliation"><div class="aff-info" id="aff1"><span class="aff-symbol">†</span> <span class="aff-text">Dana Farber Cancer Institute, Harvard Medical School, Department of Cancer Biology and Department of Biological Chemistry and Molecular Pharmacology, 250 Longwood Avenue, Seeley G. Mudd Building 628A, Boston, Massachusetts 02115</span></div><div class="aff-info" id="aff2"><span class="aff-symbol">‡</span> <span class="aff-text">Genomics Institute of the Novartis Research Foundation, Department of Chemistry, 10675 John Jay Hopkins Drive, San Diego, California 92121</span></div><div class="aff-info" id="aff3"><span class="aff-symbol">§</span> <span class="aff-text">Novartis Institutes for Biomedical Research, CH-4056 Basel, Switzerland</span></div><div class="aff-info" id="aff4"><span class="aff-symbol">∥</span> <span class="aff-text">Life Sciences Research Division, Korea Institute of Science and Technology, 39-1 Hawolgok-dong, Seongbuk-gu, Seoul 136-791, Korea</span></div><div class="corresp-info"><strong>*</strong>To whom correspondence should be addressed. For T.S.: phone, 82-2-958-6437; fax, 82-2-958-5189; E-mail, <a href="/cdn-cgi/l/email-protection#a4d0c6d7cdc9e4cfcdd7d08ad6c18acfd6"><span class="__cf_email__" data-cfemail="6b1f091802062b0002181f45190e450019">[email protected]</span></a>. For N.S.G.: phone, 1-617-582-8590; fax, 1-617-582-8615; E-mail, <a href="/cdn-cgi/l/email-protection#f69897829e979897939aa99184978fb69290959fd89e978480978492d8939283"><span class="__cf_email__" data-cfemail="9af4fbeef2fbf4fbfff6c5fde8fbe3dafefcf9f3b4f2fbe8ecfbe8feb4fffeef">[email protected]</span></a></div></div></div><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Fjm901808w&amp;href=/doi/10.1021%2Fjm901808w" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2010</span></span><span class="cit-volume">, 53</span><span class="cit-issue">, 15</span><span class="cit-pageRange">, 5439–5448</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">July 6, 2010</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>8 December 2009</li><li><span class="item_label"><b>Published</b> online</span>6 July 2010</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 12 August 2010</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/jm901808w" title="DOI URL">https://doi.org/10.1021/jm901808w</a></div><div class="article_header-article-copyright"><strong>Copyright © 2010 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D5439%26pageCount%3D10%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DHwan%2BGeun%2BChoi%252C%2BPingda%2BRen%252C%2BFrancisco%2BAdrian%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D53%26issueNum%3D15%26contentID%3Djm901808w%26title%3DA%2BType-II%2BKinase%2BInhibitor%2BCapable%2Bof%2BInhibiting%2Bthe%2BT315I%2B%25E2%2580%259CGatekeeper%25E2%2580%259D%2BMutant%2Bof%2BBcr-Abl%26numPages%3D10%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D5448%26publicationDate%3DAugust%2B2010">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/jm901808w"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">4542</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">42</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/jm901808w" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;A Type-II Kinase Inhibitor Capable of Inhibiting the T315I “Gatekeeper” Mutant of Bcr-Abl&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Hwan&quot;,&quot;last_name&quot;:&quot;Geun Choi&quot;},{&quot;first_name&quot;:&quot;Pingda&quot;,&quot;last_name&quot;:&quot;Ren&quot;},{&quot;first_name&quot;:&quot;Francisco&quot;,&quot;last_name&quot;:&quot;Adrian&quot;},{&quot;first_name&quot;:&quot;Fangxian&quot;,&quot;last_name&quot;:&quot;Sun&quot;},{&quot;first_name&quot;:&quot;Hyun&quot;,&quot;last_name&quot;:&quot;Soo Lee&quot;},{&quot;first_name&quot;:&quot;Xia&quot;,&quot;last_name&quot;:&quot;Wang&quot;},{&quot;first_name&quot;:&quot;Qiang&quot;,&quot;last_name&quot;:&quot;Ding&quot;},{&quot;first_name&quot;:&quot;Guobao&quot;,&quot;last_name&quot;:&quot;Zhang&quot;},{&quot;first_name&quot;:&quot;Yongping&quot;,&quot;last_name&quot;:&quot;Xie&quot;},{&quot;first_name&quot;:&quot;Jianming&quot;,&quot;last_name&quot;:&quot;Zhang&quot;},{&quot;first_name&quot;:&quot;Yi&quot;,&quot;last_name&quot;:&quot;Liu&quot;},{&quot;first_name&quot;:&quot;Tove&quot;,&quot;last_name&quot;:&quot;Tuntland&quot;},{&quot;first_name&quot;:&quot;Markus&quot;,&quot;last_name&quot;:&quot;Warmuth&quot;},{&quot;first_name&quot;:&quot;Paul&quot;,&quot;last_name&quot;:&quot;W. Manley&quot;},{&quot;first_name&quot;:&quot;Jürgen&quot;,&quot;last_name&quot;:&quot;Mestan&quot;},{&quot;first_name&quot;:&quot;Nathanael&quot;,&quot;last_name&quot;:&quot;S. Gray&quot;},{&quot;first_name&quot;:&quot;Taebo&quot;,&quot;last_name&quot;:&quot;Sim&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2010&quot;,&quot;month&quot;:&quot;07&quot;,&quot;day&quot;:&quot;06&quot;,&quot;issue&quot;:&quot;15&quot;,&quot;volume&quot;:&quot;53&quot;,&quot;pages&quot;:&quot;5439-5448&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/jm901808w&quot;},&quot;abstract&quot;:&quot;The second generation of Bcr-Abl inhibitors nilotinib, dasatinib, and bosutinib developed to override imatinib resistance are not active against the T315I “gatekeeper” mutation. Here we describe a type-II T315I inhibitor 2 (GNF-7), based upon a 3,4-dihydropyrimido[4,5-d]pyrimidin-2(1H)-one scaffold which is capable of potently inhibiting wild-type and T315I Bcr-Abl as well as other clinically relevant Bcr-Abl mutants such as G250E, Q252H, Y253H, E255K, E255V, F317L, and M351T in biochemical and cellular assays. In addition, compound 2 displayed significant in vivo efficacy against T315I-Bcr-Abl without appreciable toxicity in a bioluminescent xenograft mouse model using a transformed T315I-Bcr-Abl-Ba/F3 cell line that has a stable luciferase expression. Compound 2 is among the first type-II inhibitors capable of inhibiting T315I to be described and will serve as a valuable lead to design the third generation Bcr-Abl kinase inhibitors.&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Fjm901808w&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=jm901808w" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Fjm901808w&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=jm901808w" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Fjm901808w&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=jm901808w" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Fjm901808w&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=jm901808w&amp;href=/doi/10.1021/jm901808w" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/jm901808w" /></input><a href="/doi/pdf/10.1021/jm901808w" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (3 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/jm901808w&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Fjm901808w%26sid%3Dliteratum%253Aachs%26pmid%3D20604564%26genre%3Darticle%26aulast%3DChoi%26date%3D2010%26atitle%3DA%2BType-II%2BKinase%2BInhibitor%2BCapable%2Bof%2BInhibiting%2Bthe%2BT315I%2B%25E2%2580%259CGatekeeper%25E2%2580%259D%2BMutant%2Bof%2BBcr-Abl%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D53%26issue%3D15%26spage%3D5439%26epage%3D5448%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=292464" title="Rodent models">Rodent models</a>,</li><li><a href="/action/doSearch?ConceptID=292528" title="Inhibitors">Inhibitors</a>,</li><li><a href="/action/doSearch?ConceptID=291793" title="Inhibition">Inhibition</a>,</li><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a>,</li><li><a href="/action/doSearch?ConceptID=292186" title="Receptors">Receptors</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/53/15" title="Go to Volume 53, Issue 15"><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-15/jmcmar.2010.53.issue-15/production/jmcmar.2010.53.issue-15.largecover.jpg" alt="Go to Volume 53, Issue 15"/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="f_tgr1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-15/jm901808w/production/images/medium/jm-2009-01808w_0004.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-15/jm901808w/production/images/large/jm-2009-01808w_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm901808w&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">The second generation of Bcr-Abl inhibitors nilotinib, dasatinib, and bosutinib developed to override imatinib resistance are not active against the T315I “gatekeeper” mutation. Here we describe a type-II T315I inhibitor <b>2</b> (<b>GNF</b>-<b>7</b>), based upon a 3,4-dihydropyrimido[4,5-<i>d</i>]pyrimidin-2(1<i>H</i>)-one scaffold which is capable of potently inhibiting wild-type and T315I Bcr-Abl as well as other clinically relevant Bcr-Abl mutants such as G250E, Q252H, Y253H, E255K, E255V, F317L, and M351T in biochemical and cellular assays. In addition, compound <b>2</b> displayed significant in vivo efficacy against T315I-Bcr-Abl without appreciable toxicity in a bioluminescent xenograft mouse model using a transformed T315I-Bcr-Abl-Ba/F3 cell line that has a stable luciferase expression. Compound <b>2</b> is among the first type-II inhibitors capable of inhibiting T315I to be described and will serve as a valuable lead to design the third generation Bcr-Abl kinase inhibitors.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i1">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_74152" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_74152" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The successful development of the Bcr-Abl<a class="ref internalNav" href="#fn1" aria-label="a">a</a><div class="NLM_fn" id="fn1">a<p class="last">Abbreviations: Axl, Axl receptor tyrosine kinase; ATP, adenosine triphosphate; AUC, area under the concentration time curve; Bcr-Abl, breakpoint cluster region abelson tyrosine kinase; BMX, BMX nonreceptor tyrosine kinase; CaMKIV, calcium/calmodulin-dependent protein kinase type IV; CDK, cyclin-dependent kinases; CHK2, checkpoint homologue 2; CK2, casein kinase II; C-Kit, receptor tyrosine kinase for the cytokine stem cell factor; CLs, clearance; Clast, last measured concentration; <i>C</i><sub>max</sub>, maximum concentration observed; <i>m-</i>CPBA, <i>meta</i>-chloroperoxybenzoic acid; C-Raf, V-raf-1 murine leukemia viral oncogene homologue 1; Csk, C-terminal Src kinase; DCM, dichloromethane; DDR, discoidin domain receptor tyrosine kinase; DFG, aspartic acid phenylalanine glycine; DIEA, <i>N</i>,<i>N</i>-diisopropylethylamine; DMF, <i>N</i>,<i>N</i>-dimethylformamide; DMSO, dimethyl sulfoxide; EGFR, epidermal growth factor receptor; <i>F</i>, bioavailability; Fes, feline sarcoma oncogene; FGFR1, fibroblast growth factor receptor 1; FGFR3, fibroblast growth factor receptor 3; FLT3, FMS-like tyrosine kinase 3; FLT3-ITD, FLT3 internal tandem duplication; FT-NMR, Fourier transform nuclear magnetic resonance; GSK3β, glycogen synthase kinase 3β; HATU, 2-(1<i>H</i>-7-azabenzotriazol-1-yl)-1,1,3,3-tetramethyl uronium hexafluorophosphate; IC<sub>50</sub>, half-maximal inhibitory concentration; IKKα, IκB (inhibitor of κ B) kinase α; IKKβ, IκB kinase β; IR, insulin receptor; Jak1,Janus kinase 1; JNK, c-Jun N-terminal kinase; LCK, lymphocyte-specific protein tyrosine kinase; Lyn, v-yes-1 Yamaguchi sarcoma viral related oncogene homologue; MAPK1, mitogen-activated protein kinase 1; MAPKAP-K2, MAP kinase-activated protein kinase 2; MEK1, MAP kinase kinase 1; MKK4, MAP kinase kinase 4; MKK6, MAP kinase kinase 6; NPM-ALK, nucleophosmin-anaplastic lymphoma kinase; p70S6K, p70 S6 kinase; P-loop, phosphate-binding loop; PAK2, p21 activated kinase 2; Pd/C, palladium on carbon or palladium on charcoal; PDGFR, platelet derived growth factor receptor; PDK1, phosphoinositide-dependent kinase-1; PEG, polyethylene glycol; PK, pharmacokinetics; PKBα, AKT family protein kinase; PKCα, protein kinase C α; PKD2, protein kinase D2; PO, peroral (orally); PP1, 4-amino-5-(4-methylphenyl)-7-(<i>t</i>-butyl)pyrazolo[3,4-<i>d</i>]pyrimidine; QD, quaque die/once a day; <i>R</i><sub>f</sub>, retention factor; ROCK-II, Rho-associated coiled-coil containing protein kinase 2; Rsk1, p90 ribosomal S6 kinase 1; SAPK2, stress activated protein kinase 2; SAPK3, stress activated protein kinase 3; SGK, serum/glucocorticoid regulated kinase; SCID, severe combined immunodeficiency; Src, transforming sarcoma inducing gene of Rous sarcoma virus; Syk, spleen tyrosine kinase; <i>T</i>/<i>C</i>, treated versus control (untreated); <i>T</i><sub>1/2</sub>, elimination half-life; TFA, trifluoroacetic acid; THF, tetrahydrofuran; <i>T</i><sub>last</sub>, time of last measured; <i>T</i><sub>max</sub>, time to maximum concentration; TPR-Met, translocated promoter region mesenchymal-epithelial transition factor; TrkC, neurotrophic tyrosine kinase receptor type 3; TrkB, neurotrophic tyrosine kinase receptor type 2; VEGFR2, vascular endothelial growth factor receptor 2; Vss, volume in steady state; UV, ultraviolet; ZAP-70, ζ-chain-associated protein kinase 70.</p></div> inhibitor imatinib for the treatment of chronic myelogenous leukemia (CML) has provided the paradigm for the development of a host of other small molecule inhibitors targeting kinases whose activity becomes deregulated in cancer. One major problem facing the development of selective protein kinase inhibitors is the emergence of drug resistance caused by mutations in the kinase domain. Extensive in vitro and clinical work has elucidated a large number of mutations that confer resistance to imatinib either by directly influencing the drug binding site or by disfavoring the conformational rearrangements required for imatinib to bind. Several second generation Bcr-Abl inhibitors have been developed including nilotinib (AMN107),<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> bosutinib (SKI-606),<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a> and dasatinib (BMS-354825)<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a> that are capable of inhibiting most of the known Bcr-Abl mutants with the exception of the so-called “gatekeeper” mutation T315I.<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a></div><div class="NLM_p last">Several small molecules capable of inhibiting the T315I mutant in biochemical and cellular assays have been reported. (<i>E</i>)-<i>N</i>-Benzyl-2-cyano-3-(3,4-dihydroxyphenyl)acrylamide (AG-490),<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a> an inhibitor of Jak2 which is a kinase implicated in signal transduction downstream of Bcr-Abl, was shown to induce apoptosis in Ba/F3-Bcr-Abl-T315I cell line.<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a> 2-Cyclopentyl-<i>N</i>-(4-(dipropylphosphoryl)phenyl)-9-ethyl-9<i>H</i>-purin-6-amine (AP23846),<a onclick="showRef(event, 'ref7 ref8'); return false;" href="javascript:void(0);" class="ref ref7 ref8">(7, 8)</a> originally developed as a Src kinase inhibitor, inhibits T315I Bcr-Abl dependent cellular proliferation (IC<sub>50</sub> of 297 nM) but also inhibits parental Ba/F3 cell lines, suggesting it possesses additional intracellular targets. <i>N</i>-(4-(4-(5-Methyl-1<i>H</i>-pyrazol-3-ylamino)-6-(4-methylpiperazin-1-yl)pyrimidin-2-ylthio)phenyl)cyclopropanecarboxamide (VX-680, MK-0457),<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a> originally developed as an aurora kinase inhibitor, exhibits potent enzymatic inhibition of T315I-Abl (IC<sub>50</sub> of 30 nM) but only modestly inhibited cellular autophosphorylation (IC<sub>50</sub> of ca. 5 μM) of Ba/F3 transformed with T315I Bcr-Abl.<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> Another Aurora kinase inhibitor, danusertib (PHA-739358),<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> currently being investigated in a phase II clinical trial for patients with relapsed chronic myelogeneous leukemia, exhibited potent inhibition of T315I-Abl enzyme (IC<sub>50</sub> of 5 nM). Crystallographic analysis of danusertib in complex with T315I-Abl reveals<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a> that the isoleucine side chain of T315I mutant does not cause a steric clash with danusertib in contrast to imatinib. (<i>E</i>)-4-(2-(2-(6-(4-(2-Hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazol-5-yl)vinyl)phenol (TG101113),<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> a thiazole-based inhibitor, also exhibited good potency (IC<sub>50</sub> of 66 nM) against T315I mutant enzyme. Another reported class of Bcr-Abl inhibitor is exemplified by (<i>R</i>,<i>E</i>)-2-(5-methoxy-2-((2,4,6-trimethoxystyrylsulfonyl)methyl)phenylamino)propanoic acid (ON012380),<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a> which is claimed to be a non-ATP-competitive Bcr-Abl inhibitor, potently inhibits imatinib-resistant Bcr-Abl mutants such as T315I in cellular and biochemical assays, with IC<sub>50</sub> values below 10 nM. This compound appears to target substrate binding site of Abl kinase domain, but numerous other cellular kinases are inhibited by this compound. It should be noted that most T315I inhibitors disclosed to date are categorized as type-I kinase inhibitors which bind exclusively to the ATP binding site of kinase. Recently, a few compounds from the type-II class that recognize the “DFG-out” conformation have been reported to inhibit T315I. These include (<i>E</i>)-3-(2-(6-(cyclopropylamino)-9<i>H</i>-purin-9-yl)vinyl)-4-methyl-<i>N</i>-(3-(4-methyl-1<i>H</i>-imidazol-1-yl)-5-(trifluoromethyl)phenyl)benzamide (AP24163)<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a> and DSA series compounds.<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> This 9-(arenethenyl)purine analogue exhibited modest potency (IC<sub>50</sub> of 400 nM) against T315I in biochemical and cellular assays and <i>N</i>-(3-(3-(4-(4-methoxyphenylamino)-1,3,5-triazin-2-yl)pyridin-2-ylamino)-4-methylphenyl)-4-((4-methylpiperazin-1-yl)methyl)benzamide (DSA8) showed great potency (IC<sub>50</sub> of 33 nM) on T315I enzyme along with moderate antiproliferative activity (IC<sub>50</sub> of 500 nM) evaluated using T315I Bcr-Abl transformed Ba/F3 cells. A cocrystal structure with wild-type and gatekeeper mutant of Src with a PP1-based type-II inhibitor revealed how the inhibitor could leave ample space for an enlarged gatekeeper residue.<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> Most recently, it has been disclosed that 3-(imidazo[1,2-<i>b</i>]pyridazin-3-ylethynyl)-4-methyl-<i>N</i>-(4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)benzamide (AP24534), an imidazo[1,2-<i>b</i>]pyridazine-based multitargeted kinase inhibitor, possesses potent inhibitory activity against T315I in cellular and in vivo models.<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a></div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_84710" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_84710" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Here we describe a type-II T315I inhibitor (Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a>), based upon a 3,4-dihydropyrimido[4,5-<i>d</i>]pyrimidin-2(1<i>H</i>)-one scaffold which occupies the ATP binding cleft as well as an immediately adjacent hydrophobic pocket of Abl kinase domain. A representative member of this class, <b>1</b> (<b>GNF</b>-<b>6</b>)<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a> was crystallized with Abl and shown to bind in the type-II conformation. The pyrimidopyrimidinone inhibitor described here, <b>2</b>, is capable of inhibiting wild-type and T315I Bcr-Abl activity in biochemical and cellular assays and also inhibits other clinically relevant Bcr-Abl mutants such as G250E, Q252H, Y253H, E255K, E255 V, F317L, and M351T. We also demonstrate that <b>2</b> is capable of inhibiting T315I-Bcr-Abl dependent tumor growth in a murine model of CML.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a></div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-15/jm901808w/production/images/medium/jm-2009-01808w_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-15/jm901808w/production/images/large/jm-2009-01808w_0005.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. 3,4-Dihydropyrimido[4,5-<i>d</i>]pyrimidin-2(1<i>H</i>)-one scaffold for type-II T315I inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-15/jm901808w/production/images/large/jm-2009-01808w_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm901808w&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div id="sec2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i3" class="anchor-spacer"></div><h3 class="article-section__title" id="_i3"> Chemistry</h3><div class="NLM_p">The synthesis of compounds <b>1</b>−<b>4</b> commenced from commercially available ethyl 4-chloro-2-(methylthio)pyrimidine-5-carboxylate. Scheme <a class="ref internalNav" href="#sch1" aria-label="1">1</a> shows an efficient synthetic route for making <b>1</b>−<b>3</b>, all of which bear 3-(trifluoromethyl)benzamide moeity in the “tail region”. The quantitative displacement of chloride group on compound <b>5</b> with methylamine proceeded readily at low reaction temperatures. The reduction of ester compound <b>6</b> with LiAlH<sub>4</sub> followed by oxidation using MnO<sub>2</sub> afforded the corresponding aldehyde compound <b>8</b> in high yields. One-pot reductive amination reaction using Na(CN)BH<sub>3</sub> proceeded smoothly to provide diamine derivative <b>10</b>, which was subsequently subjected to cyclic urea formation with triphosgene to give compound <b>11</b>. An elevated reaction temperature was required to complete this cyclic urea formation. Exposure of the sulfide group of compound <b>11</b> to <i>m-</i>CPBA resulted in the corresponding sulfone compound <b>12</b>, which could be transformed into the desired amine compounds. Ammonia and aniline were readily reacted with this sulfone compound <b>12</b> under simple thermal amination conditions to furnish <b>1</b> and <b>3</b>, respectively, in good (>70%) yields. The synthesis of <b>2</b> required the presence of trifluoroacetic acid and elevated reaction temperature to catalyze the coupling of 6-methylpyridin-3-amine and sulfone compound <b>12</b>.</div><figure id="sch1" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-15/jm901808w/production/images/medium/jm-2009-01808w_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-15/jm901808w/production/images/large/jm-2009-01808w_0006.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 1. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-15/jm901808w/production/images/large/jm-2009-01808w_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm901808w&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) methylamine, THF, 0 °C; (b) LiAlH<sub>4</sub>, THF, 0 °C; (c) MnO<sub>2</sub>, DCM; (d) Na(CN)BH<sub>3</sub>, AcOH, MeOH; (e) triphosgene, DIEA, THF, 0 °C; (f) <i>m</i>-CPBA, DCM, 0 °C; (g) NH<sub>3</sub> in 2-propanol or aniline, 1,4-dioxane, 120 °C.</p></p></figure><div class="NLM_p">Compound <b>4</b> contains 4-methylimidazole group on the 3-(trifluoromethyl)benzamide “tail” in common with nilotinib. Scheme <a class="ref internalNav" href="#sch2" aria-label="2">2</a> describes an effective synthetic route which allows facile modification of 3-(trifluoromethyl)benzamide “tail” as is exemplified by the synthesis of <b>4</b>. Amide coupling reaction of aniline derivative <b>16</b> and carboxylic acid derivative <b>17</b> derived from 3-fluoro-5-(trifluoromethyl)benzonitrile was effected using HATU and DIEA in 89% yield.</div><figure id="sch2" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-15/jm901808w/production/images/medium/jm-2009-01808w_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-15/jm901808w/production/images/large/jm-2009-01808w_0007.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 2. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-15/jm901808w/production/images/large/jm-2009-01808w_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm901808w&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) Na(CN)BH<sub>3</sub>, AcOH, MeOH; (b) triphosgene, DIEA, THF; (c) Pd/C, H<sub>2</sub>, MeOH; (d) HATU, DIEA, DMF; (e) <i>m</i>-CPBA, DCM, 0 °C; (f) methylamine in THF, 1,4-dioxane, 120 °C.</p></p></figure></div><div id="sec2_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i4" class="anchor-spacer"></div><h3 class="article-section__title" id="_i4"> Design Rationale for a Type-II T315I Bcr-Abl Inhibitor</h3><div class="NLM_p">An examination of the cocrystal structures of imatinib,<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> nilotinib,<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> and dasatinib<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> with Abl demonstrate that all three inhibitors form a critical hydrogen bond with the side-chain hydroxyl group of T315I and would also require a significant rearrangement of their binding conformation to accommodate a larger residue at the gatekeeper position. Mutation of this gatekeeper position appears to be a general theme for resistance to kinase inhibitors.<a onclick="showRef(event, 'ref22 ref23 ref24 ref25'); return false;" href="javascript:void(0);" class="ref ref22 ref23 ref24 ref25">(22-25)</a> Pyridopyrimidinones such as <b>20</b> (PD173955, 6-(2,6-dichlorophenyl)-8-methyl-2-[(3-methylsulfanylphenyl)amino]pyrido[6,5-<i>d</i>]pyrimidin-7-one) were originally developed as inhibitors of Src kinase<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a> and receptor tyrosine kinase inhibitors such a EGFR, FGFR, PDGFR, and c-Kit<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a> and were only later demonstrated to possess potent cellular and enzymatic activity on wild-type and mutant forms of Bcr-Abl.<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a> Co-crystal structures of <b>20</b> with Abl (PDB: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1m52">1m52</a>) demonstrate that this compound binds to the ATP-binding site with the kinase otherwise assuming a conformation normally utilized to bind ATP (type-I binding).<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> Interestingly, <b>20</b> exhibits approximately 30-fold more potent cellular activity against Bcr-Abl relative to imatinib, presumably as a consequence of possessing a much higher affinity to the ATP-binding pocket.<a onclick="showRef(event, 'cit28b'); return false;" href="javascript:void(0);" class="ref cit28b">(28b)</a> In contrast, imatinib only exhibits cellular activity against Bcr-Abl and some receptor kinases, such as KIT, PDGFR, and DDR1/2, but is known not to inhibit the cellular activity of any Src-family kinases. The crystal structure of imatinib bound to the kinase domain of c-Abl<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> demonstrated that the compound binds to a conformation of the kinase where the activation loop is in a so-called “in-active” conformation (type-II binding). This binding conformation allows the piperazine-benzamide “tail” moiety of imatinib to access an additional hydrophobic pocket directly adjacent to the ATP binding site. By superimposing the bound conformation of <b>20</b> and nilotinib as depicted in Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a>, it is clear that additional functionality can be appended to the dichlorophenyl ring of <b>20</b> to access this adjacent hydrophobic pocket to create a new “hybrid” structure.<a onclick="showRef(event, 'ref19 ref29'); return false;" href="javascript:void(0);" class="ref ref19 ref29">(19, 29)</a> We hypothesized that the resulting hybrid compound might be able to inhibit the T315I mutation due to enhanced affinity both to the hinge-binding region and to the hydrophobic back-pocket in addition to not forming a hydrogen bond to the gatekeeper position.</div><figure id="fig2" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-15/jm901808w/production/images/medium/jm-2009-01808w_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-15/jm901808w/production/images/large/jm-2009-01808w_0008.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Superimposed structure of <b>20</b> (green sticks) bound to Abl (pink ribbon PDB: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1m52">1m52</a>) and nilotinib (yellow sticks) bound to Abl (PDB: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3cs9">3cs9</a>). Hydrogen bonds are indicated by red hatched lines to key amino acids (blue sticks).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-15/jm901808w/production/images/large/jm-2009-01808w_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm901808w&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i5" class="anchor-spacer"></div><h3 class="article-section__title" id="_i5"> In Vitro Potency</h3><div class="NLM_p">To assess the cellular activity of the compounds, we tested them against wild-type and mutant Bcr-Abl transformed Ba/F3 cells. Wild-type Ba/F3 cells require the presence of interlukin-3 (IL-3) for growth and survival, but Ba/F3 cells transformed by oncogenic kinase such as Bcr-Abl becomes capable of growing in the absence of IL-3, which provides a robust and commonly used assay for selective kinase inhibition.<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a> The first hybrid compound we made, compound <b>1</b>, exhibited an IC<sub>50</sub> of less than 5 nM on wild-type Bcr-Abl and an IC<sub>50</sub> of 303 nM on T315I while exhibiting nonspecific inhibition of untransformed Ba/F3 cells with an IC<sub>50</sub> of 1.7 μM (Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a>). Compound <b>1</b> also effectively inhibited cellular kinase autophosphorylation of T315I-Bcr-Abl-Ba/F3 with an IC<sub>50</sub> of 243 nM, further demonstrating that the antiproliferative activity against this mutant correlates with direct inhibition of the T315I-Abl enzyme. A cocrystal structure<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a> of <b>1</b> with Abl revealed that the compound bound to a conformation that was virtually indistinguishable from that used by imatinib, which clearly validates the design strategy.<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a> We next evaluated how altering the structure in the hinge binding region and hydrophobic back pocket might change the potency of cellular inhibition. We replaced the amino-pyrimidine hinge binding motif of <b>1</b> with the phenylaminopyrimidine motif, which is known to form a stronger interaction with the kinase hinge residues as shown for <b>2</b> and <b>3</b>. These modifications improved absolute cellular potency against T315I as well as increase the ratio for selectivity relative to untransformed Ba/F3 cells. In addition, these modifications resulted in improved inhibitory potency on T315I enzyme as well as against T315I cellular autophosphorylation. We next incorporated a 3-methylimidazole by analogy to nilotinib, and the resulting compound <b>4</b> also demonstrated excellent activity against wild-type and mutant Bcr-Abl (Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a>). In particular, this methylimidazole of <b>4</b> significantly contributes to excellent potency (IC<sub>50</sub> of <5 nM) of <b>4</b> against T315I enzyme.</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. In Vitro Potency Profiling for 3,4-Dihydropyrimido[4,5-<i>d</i>]pyrimidin-2(1<i>H</i>)-one on Bcr-Abl</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" colspan="4" align="center">compd code</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"><b>1</b></th><th class="colsep0 rowsep0" align="center"><b>2</b></th><th class="colsep0 rowsep0" align="center"><b>3</b></th><th class="colsep0 rowsep0" align="center"><b>4</b></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" colspan="5" align="center">Antiproliferative Activity on Native or Bcr-Abl Transformed Ba/F3 Cells (IC<sub>50</sub>, nM)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">native Ba/F3</td><td class="colsep0 rowsep0" align="left">1799</td><td class="colsep0 rowsep0" align="left">1370</td><td class="colsep0 rowsep0" align="left">2690</td><td class="colsep0 rowsep0" align="left">1785</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">wtBcr-Abl</td><td class="colsep0 rowsep0" align="left"><5</td><td class="colsep0 rowsep0" align="left"><5</td><td class="colsep0 rowsep0" align="left"><5</td><td class="colsep0 rowsep0" align="left"><5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">G250E</td><td class="colsep0 rowsep0" align="left">294</td><td class="colsep0 rowsep0" align="left"><5</td><td class="colsep0 rowsep0" align="left">12</td><td class="colsep0 rowsep0" align="left"><5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Q252H</td><td class="colsep0 rowsep0" align="left"><5</td><td class="colsep0 rowsep0" align="left"><5</td><td class="colsep0 rowsep0" align="left">19</td><td class="colsep0 rowsep0" align="left">16</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Y253H</td><td class="colsep0 rowsep0" align="left"><5</td><td class="colsep0 rowsep0" align="left"><5</td><td class="colsep0 rowsep0" align="left"><5</td><td class="colsep0 rowsep0" align="left">15</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">E255K</td><td class="colsep0 rowsep0" align="left"><5</td><td class="colsep0 rowsep0" align="left"><5</td><td class="colsep0 rowsep0" align="left">22</td><td class="colsep0 rowsep0" align="left">13</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">E255 V</td><td class="colsep0 rowsep0" align="left"><5</td><td class="colsep0 rowsep0" align="left"><5</td><td class="colsep0 rowsep0" align="left">27</td><td class="colsep0 rowsep0" align="left">30</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>T315I</b></td><td class="colsep0 rowsep0" align="left"><b>303 (243</b><a class="ref internalNav" href="#t1fn1" aria-label="a">a</a><b>)</b></td><td class="colsep0 rowsep0" align="left"><b>11</b></td><td class="colsep0 rowsep0" align="left"><b>21</b></td><td class="colsep0 rowsep0" align="left"><b>43</b></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">F317L</td><td class="colsep0 rowsep0" align="left"><5</td><td class="colsep0 rowsep0" align="left"><5</td><td class="colsep0 rowsep0" align="left">6</td><td class="colsep0 rowsep0" align="left"><5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">M351T</td><td class="colsep0 rowsep0" align="left"><5</td><td class="colsep0 rowsep0" align="left"><5</td><td class="colsep0 rowsep0" align="left"><5</td><td class="colsep0 rowsep0" align="left"><5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" colspan="5" align="center">Enzymatic Activity (IC<sub>50</sub>, nM)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">c-Abl</td><td class="colsep0 rowsep0" align="left"><5</td><td class="colsep0 rowsep0" align="left">133</td><td class="colsep0 rowsep0" align="left">135</td><td class="colsep0 rowsep0" align="left"><5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">G250E</td><td class="colsep0 rowsep0" align="left">ND</td><td class="colsep0 rowsep0" align="left">136</td><td class="colsep0 rowsep0" align="left">206</td><td class="colsep0 rowsep0" align="left">720</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">E255 V</td><td class="colsep0 rowsep0" align="left"><5</td><td class="colsep0 rowsep0" align="left">122</td><td class="colsep0 rowsep0" align="left"><5</td><td class="colsep0 rowsep0" align="left"><5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>T315I</b></td><td class="colsep0 rowsep0" align="left"><b>1567</b></td><td class="colsep0 rowsep0" align="left"><b>61</b></td><td class="colsep0 rowsep0" align="left"><b>130</b></td><td class="colsep0 rowsep0" align="left"><b><5</b></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">M351T</td><td class="colsep0 rowsep0" align="left"><5</td><td class="colsep0 rowsep0" align="left"><5</td><td class="colsep0 rowsep0" align="left"><5</td><td class="colsep0 rowsep0" align="left">ND</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup>a</sup><p class="last">Inhibitory potency (IC<sub>50</sub>, nM) against cellular kinase autophosphorylation (Elisa), ND means not determined.</p></div></div></div><div class="NLM_p">Compound <b>2</b> displayed excellent growth inhibitory activity against human colon cancer cells (Colo205 and SW620), while a noncancer cell line, HEK293T, was not particularly sensitive to inhibition by <b>2</b> as described in Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a>. As discussed below, the large number of kinases inhibited by <b>2</b> would suggest that additional profiling of this inhibitor against a larger panel of human cancer cell lines<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a> would potentially reveal additional utility for this inhibitor.</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. The Growth Inhibitory Potency (IC<sub>50</sub>, μM) of <b>2</b></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">cell line</th><th class="colsep0 rowsep0" align="center" char=".">IC<sub>50</sub>, μM</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">TPR-Met-Ba/F3</td><td class="colsep0 rowsep0" align="char" char=".">3.401</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">NPM-ALK-Ba/F3</td><td class="colsep0 rowsep0" align="char" char=".">1.466</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">JAK1-Ba/F3</td><td class="colsep0 rowsep0" align="char" char=".">0.044</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">JAK2-Ba/F3</td><td class="colsep0 rowsep0" align="char" char=".">0.127</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">JAK2-V617F−Ba/F3</td><td class="colsep0 rowsep0" align="char" char=".">0.050</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">JAK3-Ba/F3</td><td class="colsep0 rowsep0" align="char" char=".">2.018</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">FGFR3-Ba/F3</td><td class="colsep0 rowsep0" align="char" char=".">0.009</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Flt3-Ba/F3</td><td class="colsep0 rowsep0" align="char" char=".">0.359</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Flt3-ITD-Ba/F3</td><td class="colsep0 rowsep0" align="char" char=".">0.012</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">PDGFR-Ba/F3</td><td class="colsep0 rowsep0" align="char" char=".">0.011</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">TrkC-Ba/F3</td><td class="colsep0 rowsep0" align="char" char=".">0.008</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Colo205</td><td class="colsep0 rowsep0" align="char" char=".">0.005</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">SW620</td><td class="colsep0 rowsep0" align="char" char=".">0.001</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">U87</td><td class="colsep0 rowsep0" align="char" char=".">5.956</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">HEK293T</td><td class="colsep0 rowsep0" align="char" char=".">>10</td></tr></tbody></table></div></div></div><div id="sec2_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i8" class="anchor-spacer"></div><h3 class="article-section__title" id="_i8"> Kinase Selectivity of <b>2</b></h3><div class="NLM_p">We next investigated the kinase selectivity of <b>2</b> against a panel of 41 recombinant kinase enzymes and on a panel of Ba/F3 cell lines transformed with a diverse set of tyrosine kinases as summarized in Tables <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a> and <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a>. This analysis revealed that <b>2</b> is capable of potently inhibiting a large number of tyrosine and serine/threonine kinases. Despite its broad kinase selectivity profile, compound <b>2</b> exhibits some selectivity (4−100-fold) for T315I Bcr-Abl (IC<sub>50</sub> of 11 nM) relative to kinases such as TPR-Met, NPM-ALK, JAK-3, Flt-3. Although the cocrystal structure of <b>1</b> with Abl demonstrates binding to the inactive conformation (type-II), it is possible that an alternative binding conformation is exploited when binding to a subset of the potently inhibited kinases. Further work will be required to investigate to what extent broad inhibition of mutant alleles of Bcr-Abl can be achieved while still maintaining significant selectivity relative to other kinases. Considering that the gatekeeper residue is a crucial kinase selectivity determinant,<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> this will likely present a significant challenge. For example, a recently disclosed type-II inhibitor, imidazo[1,2-<i>b</i>]pyridazine derivative<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a> currently undergoing phase I clinical trials, exhibits high potency against T315I as well as several kinases such as c-Src, Lyn, c-Kit, VEGFR2, FGFR1, and PDGFR.</div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. Kinase Selectivity Profile of <b>2</b>: Enzymatic Activity (% Inhibition) of <b>2</b> at 10 μM</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="char" char="." /></col><col align="left" /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">kinase</th><th class="colsep0 rowsep0" align="center" char=".">% inhibition at 10 μM</th><th class="colsep0 rowsep0" align="center">kinase</th><th class="colsep0 rowsep0" align="center" char=".">% inhibition at 10 μM</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Aurora-A(h)</td><td class="colsep0 rowsep0" align="char" char=".">31</td><td class="colsep0 rowsep0" align="left">MAPKAP-K2(h)</td><td class="colsep0 rowsep0" align="char" char=".">0</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Axl(h)</td><td class="colsep0 rowsep0" align="char" char=".">69</td><td class="colsep0 rowsep0" align="left">MEK1(h)</td><td class="colsep0 rowsep0" align="char" char=".">58</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Bmx(h)</td><td class="colsep0 rowsep0" align="char" char=".">98</td><td class="colsep0 rowsep0" align="left">MKK4(m)</td><td class="colsep0 rowsep0" align="char" char=".">98</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">c-RAF(h)</td><td class="colsep0 rowsep0" align="char" char=".">100</td><td class="colsep0 rowsep0" align="left">MKK6(h)</td><td class="colsep0 rowsep0" align="char" char=".">100</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CaMKIV(h)</td><td class="colsep0 rowsep0" align="char" char=".">0</td><td class="colsep0 rowsep0" align="left">p70S6K(h)</td><td class="colsep0 rowsep0" align="char" char=".">92</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CDK1/cyclinB(h)</td><td class="colsep0 rowsep0" align="char" char=".">3</td><td class="colsep0 rowsep0" align="left">PAK2(h)</td><td class="colsep0 rowsep0" align="char" char=".">45</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CHK2(h)</td><td class="colsep0 rowsep0" align="char" char=".">12</td><td class="colsep0 rowsep0" align="left">PDGFRα(h)</td><td class="colsep0 rowsep0" align="char" char=".">62</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CK2(h)</td><td class="colsep0 rowsep0" align="char" char=".">6</td><td class="colsep0 rowsep0" align="left">PDK1(h)</td><td class="colsep0 rowsep0" align="char" char=".">0</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CSK(h)</td><td class="colsep0 rowsep0" align="char" char=".">100</td><td class="colsep0 rowsep0" align="left">PKBα(h)</td><td class="colsep0 rowsep0" align="char" char=".">7</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Fes(h)</td><td class="colsep0 rowsep0" align="char" char=".">98</td><td class="colsep0 rowsep0" align="left">PKCα(h)-His</td><td class="colsep0 rowsep0" align="char" char=".">51</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">FGFR3(h)</td><td class="colsep0 rowsep0" align="char" char=".">100</td><td class="colsep0 rowsep0" align="left">PKCθ(h)</td><td class="colsep0 rowsep0" align="char" char=".">22</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Flt3(h)</td><td class="colsep0 rowsep0" align="char" char=".">69</td><td class="colsep0 rowsep0" align="left">PKD2(h)</td><td class="colsep0 rowsep0" align="char" char=".">77</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">GSK3ss(h)</td><td class="colsep0 rowsep0" align="char" char=".">59</td><td class="colsep0 rowsep0" align="left">ROCK-II(h)</td><td class="colsep0 rowsep0" align="char" char=".">2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">IKKα(h)</td><td class="colsep0 rowsep0" align="char" char=".">69</td><td class="colsep0 rowsep0" align="left">Rsk1(h)</td><td class="colsep0 rowsep0" align="char" char=".">95</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">IKKss(h)</td><td class="colsep0 rowsep0" align="char" char=".">49</td><td class="colsep0 rowsep0" align="left">SAPK2a(h)</td><td class="colsep0 rowsep0" align="char" char=".">95</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">IR(h)</td><td class="colsep0 rowsep0" align="char" char=".">89</td><td class="colsep0 rowsep0" align="left">SAPK2b(h)</td><td class="colsep0 rowsep0" align="char" char=".">98</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">JNK1α1(h)</td><td class="colsep0 rowsep0" align="char" char=".">97</td><td class="colsep0 rowsep0" align="left">SAPK3(h)</td><td class="colsep0 rowsep0" align="char" char=".">35</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">JNK2α2(h)</td><td class="colsep0 rowsep0" align="char" char=".">99</td><td class="colsep0 rowsep0" align="left">SGK(h)</td><td class="colsep0 rowsep0" align="char" char=".">0</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Lck(h)</td><td class="colsep0 rowsep0" align="char" char=".">99</td><td class="colsep0 rowsep0" align="left">Syk(h)</td><td class="colsep0 rowsep0" align="char" char=".">98</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">MAPK1(h)</td><td class="colsep0 rowsep0" align="char" char=".">68</td><td class="colsep0 rowsep0" align="left">TrkB(h)</td><td class="colsep0 rowsep0" align="char" char=".">100</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="left">ZAP-70(h)</td><td class="colsep0 rowsep0" align="char" char=".">6</td></tr></tbody></table></div></div></div><div id="sec2_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i10" class="anchor-spacer"></div><h3 class="article-section__title" id="_i10"> In Vivo Efficacy and Toxicity of <b>2</b></h3><div class="NLM_p">To investigate whether <b>2</b> could inhibit wild-type and T315I Bcr-Abl at well tolerated doses in vivo, we investigated the tumor efficacy using a luciferase xenograft model. One shortcoming of the original <b>20</b> compound was a poor pharmacokinetic profile in mice. Compound <b>2</b> exhibited excellent pharmacokinetic parameters in mice as depicted in Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a>, with good systemic exposure (AUC = 875.71 h·nM, <i>C</i><sub>max</sub> = 3.6 μM) along with reasonable half-life (<i>t</i><sub>1/2</sub> = 3.2 h) and favorable oral bioavailability (<i>F</i> = 36%) being observed following oral administration of a single dose of 20 mg/kg. Compound <b>2</b> displayed significant in vivo efficacy against T315I-Bcr-Abl in the bioluminescent xenograft mouse model using a transformed T315I-Bcr-Abl-Ba/F3 cell line that has stable luciferase expression. As illustrated in the Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a>, light emission from mice that were administered an oral dose of 10 or 20 mg/kg of <b>2</b> once per day was significantly (<i>T</i>/<i>C</i> 38% and 23%, respectively) reduced compared with that from untreated control mice, indicating that <b>2</b> effectively inhibits tumor growth of T315I-Bcr-Abl-Ba/F3 cells in mice at low doses (10 mg/kg). However, appreciable (>10%) body weight loss was observed in mice treated with doses of <b>2</b> of 20 mg/kg and above which is a common symptom of in vivo toxicity. However, the 10 mg/kg dosing group exhibited only a very small weight change as plotted in the Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a>. The significant body weight loss in the 20 mg/kg group forced the dosing to be discontinued at day 6. An acceptable therapeutic index of <b>2</b> would be anticipated at around 10 mg/kg dose, as remarkable efficacy was observed with little body weight at this dose.</div><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. Pharmacokinetic Properties of <b>2</b> on Balb/C Mouse</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">formulation</th><th class="colsep0 rowsep0" align="center">PEG300 (100%), solution</th><th class="colsep0 rowsep0" align="center">PEG300/water 1:1, solution</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">dosing</td><td class="colsep0 rowsep0" align="left">5 mpk, intravenous</td><td class="colsep0 rowsep0" align="left">20 mpk, peroral</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CLs (mL/min/kg)</td><td class="colsep0 rowsep0" align="left">8.6</td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Vss (L/kg)</td><td class="colsep0 rowsep0" align="left">1.12</td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">AUC (h·nM)</td><td class="colsep0 rowsep0" align="left">18527</td><td class="colsep0 rowsep0" align="left">875.71</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>C</i><sub>max</sub> (nM)</td><td class="colsep0 rowsep0" align="left">11707</td><td class="colsep0 rowsep0" align="left">3616</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>T</i><sub>max</sub> (h)</td><td class="colsep0 rowsep0" align="left">0.03</td><td class="colsep0 rowsep0" align="left">3</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>C</i><sub>last</sub> (nM)</td><td class="colsep0 rowsep0" align="left">10</td><td class="colsep0 rowsep0" align="left">15</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>T</i><sub>last</sub> (h)</td><td class="colsep0 rowsep0" align="left">24</td><td class="colsep0 rowsep0" align="left">24</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>T</i><sub>/2</sub> (h)</td><td class="colsep0 rowsep0" align="left">3.8</td><td class="colsep0 rowsep0" align="left">3.2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>F</i> (%)</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">36</td></tr></tbody></table></div></div><figure id="fig3" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-15/jm901808w/production/images/medium/jm-2009-01808w_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-15/jm901808w/production/images/large/jm-2009-01808w_0001.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Bioluminescent in vivo efficacy study (oral administration, once-daily dosing) for <b>2</b> using Ba/F3-T315I-Bcr-Abl cell line that has stable luciferase expression. Mice were imaged at day 5 and 7 after <b>2</b> treatment.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-15/jm901808w/production/images/large/jm-2009-01808w_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm901808w&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="fig4" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-15/jm901808w/production/images/medium/jm-2009-01808w_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-15/jm901808w/production/images/large/jm-2009-01808w_0003.jpeg" id="_i12" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Mice body weight change during bioluminescent in vivo efficacy study (oral administration, once-daily dosing) for <b>2</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-15/jm901808w/production/images/large/jm-2009-01808w_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm901808w&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i13">Conclusion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_58264" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_58264" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">Our results demonstrate that it is possible to design a type-II inhibitor that can circumvent the T315I Bcr-Abl “gatekeeper” mutation by bridging the ATP and adjacent hydrophobic binding site using a linker segment that can accommodate a larger gatekeeper residue. The ability of the compounds to tolerate diverse gatekeeper amino acids results in compounds with broad kinase selectivity profiles. This study also demonstrates that type-II inhibitors as a class are not necessarily more selective than type-I inhibitors. Compound <b>2</b> is likely to serve as a valuable starting point for developing type-II inhibitors for a variety of kinases of therapeutic interest.</div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i14">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_85007" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_85007" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Detailed experimental procedures for Bcr-Abl kinase assay, Ba/F3 cell proliferation assay, and phosphotyrosine analysis such as autophosphorylation estimation are described in our previous publications.<a onclick="showRef(event, 'ref19 ref33'); return false;" href="javascript:void(0);" class="ref ref19 ref33">(19, 33)</a></div><div id="sec4_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i15" class="anchor-spacer"></div><h3 class="article-section__title" id="_i15">1 In Vivo Efficacy Evaluation Using T315I-Bcr-Abl-Ba/F3 Orthotopic Xenograft Model</h3><div class="NLM_p last">SCID beige female mice, 6−8 weeks old (<i>n</i> = 5 for each <b>2</b> treated or vehicle control group), were injected via tail vein with 1 × 10<sup>6</sup> Ba/F3 cells coexpressing Bcr-abl/T315I mutant and luciferase. Three days postinjection, mice were orally dosed once daily with 10 or 20 mg/kg <b>2</b> for seven days. At day 5 and 7, bioluminescence was quantified using a Xenogen IVIS living imaging system (Caliper LifeSciences, Hopkinton, MA).</div></div><div id="sec4_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i16" class="anchor-spacer"></div><h3 class="article-section__title" id="_i16">2 Experimental Section of PK Study</h3><div class="NLM_p last">Male Balb/c mice, 5−6 weeks old (20−25 g), were obtained from Jackson Laboratory (Bar Harbor, ME). Compound <b>2</b> was dissolved in a 100% PEG300 solution formulation (2.5 mg/mL) and dosed at 5 mg/kg intravenously via the lateral vein (<i>n</i> = 3). The oral dose was prepared in a 1:1 formulation of PEG300 and distilled water and administered at 20 mg/kg via oral gavage (<i>n</i> = 3). Five blood samples (50 μL) were serially drawn via retro orbital sinus within 24 h after dosing. Plasma concentrations of <b>2</b> were quantified utilizing a liquid chromatography/mass spectrometry (LC/MS/MS) assay. Pharmacokinetic parameters were calculated by noncompartmental regression analysis using Winnonlin 4.0 software (Pharsight, Mountain View, CA).</div></div><div id="sec4_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i17" class="anchor-spacer"></div><h3 class="article-section__title" id="_i17">3 Chemistry</h3><div class="NLM_p">Reactions were monitored by thin layer chromatography (TLC) with 0.25 mm E. Merck precoated silica gel plates (60 F254). Visualization was accomplished with either UV light, or by immersion in solutions of ninhydrin, <i>p</i>-anisaldehyde, or phosphomolybdic acid (PMA) followed by heating on a hot plate for about 10 s. Purification of reaction products was carried out by flash chromatography using Kieselgel 60 Art 9385 (230−400 mesh). The purity of all compounds was over 95% and was analyzed with Waters LCMS system (Waters 2998 photodiode array detector, Waters 3100 mass detector, Waters SFO system fluidics organizer, Waters 2545 binary gradient module, Waters Reagent Manager, Waters 2767 sample manager) using SunFireTM C18 column (4.6 mm × 50 mm, 5 μm particle size): solvent gradient = 60% (or 95%) A at 0 min, 1% A at 5 min; solvent A = 0.035% TFA in Water; solvent B = 0.035% TFA in MeOH; flow rate: 3.0 (or 2.5) mL/min. <sup>1</sup>H NMR and <sup>13</sup>C NMR spectra were obtained using a Bruker 400 MHz FT-NMR (400 MHz for <sup>1</sup>H, and 100 MHz for <sup>13</sup>C), or a Varian Inova-600 (600 MHz for <sup>1</sup>H) spectrometer. Chemical shifts are reported relative to chloroform (δ = 7.26) for <sup>1</sup>H NMR and chloroform (δ = 77.2) for <sup>13</sup>C NMR or dimethyl sulfoxide (δ = 2.50) for <sup>1</sup>H NMR and dimethyl sulfoxide (δ = 39.5) for <sup>13</sup>C NMR. Data are reported as (br = broad, s = singlet, d = doublet, t = triplet, q = quartet, m = multiplet). High resolution mass spectra were recorded on a 4.7 T IonSpec ESI-FTMS or a Micromass LCT ESI-TOF mass spectrometer.</div><div id="sec4_3_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i18" class="anchor-spacer"></div><h4 class="article-section__title" id="_i18"> Ethyl 4-(Methylamino)-2-(methylthio)pyrimidine-5-carboxylate (<b>6</b>)</h4><div class="NLM_p last">To a solution of compound <b>5</b> (1.0 g, 4.3 mmol) in THF (14.3 mL) was added 2.0 M methylamine solution in THF (5.37 mL, 10.7 mmol) at 0 °C, and the reaction mixture was stirred at room temperature for 1 h. The reaction mixture was partitioned between ethyl acetate (50 mL) and saturated NaHCO<sub>3</sub> (30 mL). The organic layer was washed with brine, dried over MgSO<sub>4</sub>, filtered through a pad of celite, and concentrated under reduced pressure. The resulting white solid title compound (950 mg, 97% yield) was used for the next step without further purification. <i>R</i><sub>f</sub> = 0.47 (1/4 ethyl acetate/hexane). <sup>1</sup>H NMR 600 MHz (CDCl<sub>3</sub>) δ 8.60 (s, 1H), 8.16 (bs, 1H), 4.32 (q, <i>J</i> = 7.2 Hz, <i>J</i> = 13.8 Hz, 2H), 3.07 (d, <i>J</i> = 5.4 Hz, 3H), 2.54 (s, 3H), 1.36 (t, <i>J</i> = 7.2 Hz, 3H). <sup>1</sup>H NMR 400 MHz (DMSO-<i>d</i><sub>6</sub>) δ 8.49 (s, 1H), 8.23 (bs, 1H), 4.26 (q, <i>J</i> = 7.1 Hz, <i>J</i> = 14.1 Hz, 2H), 2.96 (d, <i>J</i> = 4.8 Hz, 3H), 2.48 (s, 3H), 1.28 (t, <i>J</i> = 7.1 Hz, 3H). <sup>13</sup>C NMR 100 MHz (DMSO-<i>d</i><sub>6</sub>) δ 175.49, 166.22, 160.14, 158.13, 101.26. 61.01, 27.80, 14.53, 14.04. HRMS (ESI) <i>m</i>/<i>z</i> [M + Na]<sup>+</sup> calcd 250.0626, found 250.0628.</div></div><div id="sec4_3_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i19" class="anchor-spacer"></div><h4 class="article-section__title" id="_i19"> (4-(Methylamino)-2-(methylthio)pyrimidin-5-yl)methanol (<b>7</b>)</h4><div class="NLM_p last">To a solution of compound <b>6</b> (300 mg, 1.32 mmol) in THF (6.6 mL) was added 2.0 M lithium aluminum hydride solution in THF (0.79 mL, 1.58 mmol) at 0 °C. The reaction mixture was stirred at room temperature for 2 h and treated with saturated NH<sub>4</sub>Cl solution (2 mL). After stirred at room temperature for 30 min, the reaction mixture was filtered through a pad of celite. The filtrate was partitioned between ethyl acetate (30 mL) and water (20 mL). The organic layer was washed with brine, dried over MgSO<sub>4</sub>, filtered through a pad of celite, and concentrated under reduced pressure. The resulting white solid (210 mg, 86% yield) was used for the next step without further purification. <i>R</i><sub>f</sub> = 0.37 (100% ethyl acetate). <sup>1</sup>H NMR 600 MHz (CDCl<sub>3</sub>) δ 7.61 (s, 1H), 5.90 (bs, 1H), 4.76 (s, 2H), 3.03 (d, <i>J</i> = 5.4 Hz, 3H), 2.51 (s, 3H). <sup>1</sup>H NMR 400 MHz (DMSO-<i>d</i><sub>6</sub>) δ 7.80 (s, 1H), 6.81 (bs, 1H), 5.05, (t, <i>J</i> = 5.4 Hz, 1H), 4.28 (d, <i>J</i> = 5.2 Hz, 2H), 2.84 (d, <i>J</i> = 4.6 Hz, 3H), 2.41 (s, 3H). <sup>13</sup>C NMR 100 MHz (DMSO-<i>d</i><sub>6</sub>) δ 169.17, 160.45, 152.04, 113.90, 57.99, 27.71, 13.79. HRMS (ESI) <i>m</i>/<i>z</i> [M + Na]<sup>+</sup> calcd 208.0521, found 208.0520.</div></div><div id="sec4_3_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i20" class="anchor-spacer"></div><h4 class="article-section__title" id="_i20"> 4-(Methylamino)-2-(methylthio)pyrimidine-5-carbaldehyde (<b>8</b>)</h4><div class="NLM_p last">To a solution of compound <b>7</b> (210 mg, 1.14 mmol) in dichloromethane (3.8 mL) was added activated manganese(IV) oxide (980 mg, 11.4 mmol) at room temperature and stirred for overnight. The reaction mixture was filtered through a pad of celite and concentrated under reduced pressure. The resulting crude product was purified by flash silica gel chromatography with ethyl acetate/hexane (1/9 to 1/4) to give (190 mg, 89% yield) of the title product as a white solid. <i>R</i><sub>f</sub> = 0.29 (1/4 ethyl acetate/hexane). <sup>1</sup>H NMR 600 MHz (CDCl<sub>3</sub>) δ 9.67 (s, 1H), 8.52 (bs, 1H), 8.27 (s, 1H), 3.10 (d, <i>J</i> = 5.4 Hz, 3H), 2.54 (s, 3H). <sup>1</sup>H NMR 400 MHz (DMSO-<i>d</i><sub>6</sub>) δ 9.75 (s, 1H), 8.62 (bs, 1H), 8.49 (s, 1H), 2.98 (d, <i>J</i> = 4.8 Hz, 3H), 2.49 (s, 3H). <sup>13</sup>C NMR 100 MHz (DMSO-<i>d</i><sub>6</sub>) δ 192.11, 176.34, 163.80, 158.87, 109.95, 27.57, 14.12. LCMS <i>m</i>/<i>z</i> 184.2 [M + H]<sup>+</sup>.</div></div><div id="sec4_3_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i21" class="anchor-spacer"></div><h4 class="article-section__title" id="_i21"> <i>N</i>-(3-Amino-4-methylphenyl)-3-(trifluoromethyl)benzamide (<b>9</b>)</h4><div class="NLM_p">To a solution of 4-methyl-3-nitrobenzenamine (2.0 g, 13.15 mmol) in dried THF (65 mL) were added DIEA (3.26 mL, 19.73 mmol) and 3-(trifluoromethyl)benzoyl chloride (3.0 g, 14.46 mmol) at 0 °C. The reaction mixture stirred for 3 h at room temperature. The reaction mixture was partitioned between ethyl acetate (100 mL) and saturated NaHCO<sub>3</sub> (50 mL). The organic layer was washed with brine, dried over MgSO<sub>4</sub>, filtered through a pad of celite, and concentrated under reduced pressure. The resulting white solid, <i>N</i>-(4-methyl-3-nitrophenyl)-3-(trifluoromethyl)benzamide (3.9 g, 91% yield) was used for the next step without further purification. <i>R</i><sub>f</sub> = 0.41 (1/4 ethyl acetate/hexane). <sup>1</sup>H NMR 400 MHz (DMSO-<i>d</i><sub>6</sub>) δ 10.75 (s, 1H), 8.51 (d, <i>J</i> = 1.6, 1H), 8.30 (s, 1H), 8.27 (d, <i>J</i> = 7.8 Hz, 1H), 8.00 (m, 2H), 7.80 (t, <i>J</i> = 7.7 Hz, 1H), 7.48 (d, <i>J</i> = 8.4 Hz, 1H), 2.48 (s, 3H). <sup>13</sup>C NMR 100 MHz (DMSO-<i>d</i><sub>6</sub>) δ 164.72, 148.90, 138.22, 135.56, 133.52, 132.37, 130.27, 129.86, 129.54, 128.95, 128.49, 125.39, 124.72, 116.14, 19.75. HRMS (ESI) <i>m</i>/<i>z</i> [M + Na]<sup>+</sup> calcd 347.0619, found 347.0621.</div><div class="NLM_p last">To a solution of <i>N</i>-(4-methyl-3-nitrophenyl)-3-(trifluoromethyl)benzamide (3.0 g, 9.2 mmol) in methanol (40 mL) was added 10% Pd/C (300 mg). After two vacuum/H<sub>2</sub> cycles to replace air inside the reaction flask with hydrogen, the reaction mixture was stirred at room temperature under a hydrogen balloon for 4 h. The reaction mixture was filtered through a pad of celite and concentrated under reduced pressure. The title compound (2.4 g, 88% yield) was used for the next step without further purification. <i>R</i><sub>f</sub> = 0.14 (1/4 ethyl acetate/hexane). <sup>1</sup>H NMR 400 MHz (DMSO-<i>d</i><sub>6</sub>) δ 10.17 (s, 1H), 8.27 (s, 1H), 8.25 (d, J = 7.9 Hz, 1H), 7.91 (d, <i>J</i> = 7.8 Hz, 1H), 7.75 (t, <i>J</i> = 7.7 Hz, 1H), 7.15 (s, 1H), 6.87 (m, 2H), 4.89 (s, 2H), 2.04 (s, 3H). <sup>13</sup>C NMR 100 MHz (DMSO-<i>d</i><sub>6</sub>) δ 164.02, 147.05, 137.70, 136.62, 132.18, 130.20, 130.00, 129.75, 129.43, 128.22, 124.62, 117.67, 109.39, 106.99, 17.45. HRMS (ESI) <i>m</i>/<i>z</i> [M + H]<sup>+</sup> calcd 317.0878, found 317.0879.</div></div><div id="sec4_3_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i22" class="anchor-spacer"></div><h4 class="article-section__title" id="_i22"> <i>N</i>-(4-Methyl-3-((4-(methylamino)-2-(methylthio)pyrimidin-5-yl)methylamino)phenyl)-3-(trifluoromethyl)benzamide (<b>10</b>)</h4><div class="NLM_p last">To a solution of compound <b>8</b> (190 mg, 1.03 mmol) in methanol (5.2 mL) were added acetic acid (0.12 mL, 2.06 mmol), compound <b>9</b> (304 mg, 1.03 mmol), and Na(CN)BH<sub>3</sub> (323 mg, 5.15 mmol) at room temperature and stirred for overnight. The reaction mixture was partitioned between ethyl acetate (30 mL) and saturated NaHCO<sub>3</sub> (20 mL), and then the water layer was extracted with ethyl acetate (10 mL × 3). The combined organic layer was washed with brine, dried over MgSO<sub>4</sub>, filtered through a pad of celite, and concentrated under reduced pressure. The resulting crude product was purified by silica gel chromatography with ethyl acetate/hexane (1/4 to 2/3) to give (334 mg, 63% yield) of the title product as a white solid. <i>R</i><sub>f</sub> = 0.21 (2/3 ethyl acetate/hexane). <sup>1</sup>H NMR 400 MHz (CDCl<sub>3</sub>) δ 8.55 (s, 1H), 8.11 (s, 1H), 8.04 (d, J = 7.8 Hz, 1H), 7.76 (s, 1H), 7.74 (d, <i>J</i> = 7.8 Hz, 1H), 7.54 (t, <i>J</i> = 7.8 Hz, 1H), 7.23 (s, 1H), 7.02 (d, <i>J</i> = 8.0 Hz, 1H), 6.97 (dd, <i>J</i> = 1.7 Hz, <i>J</i> = 7.9 Hz, 1H), 5.86 (m, 1H), 3.98 (s, 2H), 3.41 (bs, 1H), 3.01 (d, <i>J</i> = 4.85 Hz, 3H), 2.51 (s, 3H), 2.07 (s, 3H). <sup>13</sup>C NMR 100 MHz (CDCl<sub>3</sub>) δ 171.17, 164.59, 161.14, 153.43, 145.99, 137.03, 135.79, 131.22, 130.89, 130.45, 129.25, 128.18, 124.14, 120.09, 110.69, 109.33, 103.89, 43.57, 27.60, 17.11, 14.02. HRMS (ESI) <i>m</i>/<i>z</i> [M + Na]<sup>+</sup> calcd 484.1395, found 484.1398.</div></div><div id="sec4_3_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i23" class="anchor-spacer"></div><h4 class="article-section__title" id="_i23"> <i>N</i>-(4-Methyl-3-(1-methyl-7-(methylthio)-2-oxo-1,2-dihydropyrimido[4,5-<i>d</i>]pyrimidin-3(4<i>H</i>)-yl)phenyl)-3-(trifluoromethyl)benzamide (<b>11</b>)</h4><div class="NLM_p last">To a solution of compound <b>10</b> (334 mg, 0.73 mmol) in 1,4-dioxane (3.65 mL) were added DIEA (0.36 mL, 2.19 mmol) and triphosgene (70 mg, 0.24 mmol) at 0 °C and stirred at room temperature for 1 h. The precipitate was filtered off and the filtrate was stirred at 110 °C for 3 h. The reaction mixture was cooled to room temperature and was partitioned between ethyl acetate (20 mL) and saturated NaHCO<sub>3</sub> (20 mL) solution. The organic layer was washed with brine, dried over MgSO<sub>4</sub>, filtered through a pad of celite, and concentrated under reduced pressure. The resulting crude product was purified by silica gel chromatography with ethyl acetate/hexane (1/4 to 2/3) to give (230 mg, 65% yield) of the title product as a white solid. <i>R</i><sub>f</sub> = 0.25 (2/3 ethyl acetate/hexane). <sup>1</sup>H NMR 600 MHz (CDCl<sub>3</sub>) δ 8.98 (s, 1H), 8.13 (s, 1H), 8.08 (d, <i>J</i> = 7.8 Hz, 1H), 8.03 (s, 1H), 7.73 (m, 2H), 7.56 (t, <i>J</i> = 7.8 Hz, 1H), 7.29 (d, <i>J</i> = 8.4 Hz, 1H), 7.03 (d, <i>J</i> = 8.4 Hz, 1H), 4.68 (d, <i>J</i> = 14.4 Hz, 1H), 4.42 (d, <i>J</i> = 14.4 Hz, 1H), 3.51 (s, 3H), 2.59 (s, 3H), 1.72 (s, 3H). <sup>1</sup>H NMR 400 MHz (DMSO-<i>d</i><sub>6</sub>) δ 10.52 (s, 1H), 8.41 (s, 1H), 8.24 (m, 2H), 7.97 (d, J = 7.6 Hz, 1H), 7.79 (m, 2H), 7.63 (dd, <i>J</i> = 1.9 Hz, <i>J</i> = 8.2 Hz, 1H), 7.31 (d, <i>J</i> = 6.3 Hz, 1H), 4.78 (d, <i>J</i> = 14.6 Hz, 1H), 4.59 (d, <i>J</i> = 14.6 Hz, 1H), 3.38 (s, 3H), 2.49 (s, 3H), 2.07 (s, 3H). <sup>13</sup>C NMR 100 MHz (DMSO-<i>d</i><sub>6</sub>) δ 170.34, 164.33, 156.87, 152.76, 152.23, 141.38, 138.06, 136.06, 132.29, 131.39, 131.25, 130.26, 128.66, 124.61, 120.38, 119.77, 108.31, 46.87, 28.53, 17.23, 14.07. HRMS (ESI) <i>m</i>/<i>z</i> [M + Na]<sup>+</sup> calcd 510.1187, found 510.1186.</div></div><div id="sec4_3_7" class="NLM_sec NLM_sec_level_3"><div id="ac_i24" class="anchor-spacer"></div><h4 class="article-section__title" id="_i24"> <i>N</i>-(4-Methyl-3-(1-methyl-7-(methylsulfonyl)-2-oxo-1,2-dihydropyrimido[4,5-<i>d</i>]pyrimidin-3(4<i>H</i>)-yl)phenyl)-3-(trifluoromethyl)benzamide (<b>12</b>)</h4><div class="NLM_p last">To a solution of compound <b>11</b> (230 mg, 0.47 mmol) in dichloromethane (2 mL) was added <i>m</i>-chloroperbenzoic acid (245 mg, 1.42 mmol) at 0 °C. The reaction mixture was stirred for 30 min at 0 °C and then stirred for additional 3 h at room temperature. The reaction mixture was partitioned between dichloromethane (20 mL) and saturated NaHCO<sub>3</sub> (20 mL). The organic layer was washed with brine and dried over MgSO<sub>4</sub>, filtered through a pad of celite, and concentrated under reduced pressure. The resulting white solid (200 mg, 81% yield) was used for the next step without further purification. <i>R</i><sub>f</sub> = 0.50 (4/1 ethyl acetate/hexane). <sup>1</sup>H NMR 600 MHz (DMSO-<i>d</i><sub>6</sub>) δ 10.52 (s, 1H), 8.57 (s, 1H), 8.28 (s, 1H), 8.24 (d, <i>J</i> = 8.4 Hz, 1H), 7.96 (d, <i>J</i> = 7.8 Hz, 1H), 7.84 (dd, <i>J</i> = 1.8 Hz, <i>J</i> = 9.6 Hz, 1H), 7.78 (t, <i>J</i> = 7.8 Hz, 1H), 7.62 (d, <i>J</i> = 8.4 Hz, 1H), 7.31 (d, <i>J</i> = 8.4 Hz, 1H), 4.93 (d, <i>J</i> = 15.6 Hz, 1H), 4.75 (d, <i>J</i> = 15.6 Hz, 1H), 3.39 (s, 3H), 2.47 (s, 3H), 2.12 (s, 3H). <sup>1</sup>H NMR 400 MHz (CDCl<sub>3</sub>) δ 9.05 (s, 1H), 8.24 (s, 1H), 8.11 (s, 1H), 8.08 (d, <i>J</i> = 7.7 Hz, 1H), 7.72 (m, 2H), 7.56 (t, <i>J</i> = 7.7 Hz, 1H), 7.31 (d, <i>J</i> = 8.2 Hz, 1H), 7.02 (d, <i>J</i> = 8.3 Hz, 1H), 4.81 (d, <i>J</i> = 15.8 Hz, 1H), 4.59 (d, <i>J</i> = 15.8 Hz, 1H), 3.47 (s, 3H), 3.33 (s, 3H), 1.67 (s, 3H). <sup>13</sup>C NMR 100 MHz (CDCl<sub>3</sub>) δ 164.90, 164.19, 158.12, 152.38, 152.31, 139.21, 137.75, 135.27, 131.39, 131.23, 130.78, 130.13, 129.21, 128.24, 127.85, 124.25, 120.88, 119.52, 114.54, 47.07, 39.03, 29.00, 16.31. HRMS (ESI) <i>m</i>/<i>z</i> [M + Na]<sup>+</sup> calcd 542.1086, found 542.1088.</div></div><div id="sec4_3_8" class="NLM_sec NLM_sec_level_3"><div id="ac_i25" class="anchor-spacer"></div><h4 class="article-section__title" id="_i25"> <i>N</i>-(3-(7-Amino-1-methyl-2-oxo-1,2-dihydropyrimido[4,5-<i>d</i>]pyrimidin-3(4<i>H</i>)-yl)-4-methylphenyl)-3-(trifluoromethyl)benzamide (<b>1</b>)</h4><div class="NLM_p last">To a solution of compound <b>12</b> (100 mg, 019 mmol) in 1,4-dioxane (1.0 mL) was added 2.0 M ammonia in 2-propanol (0.97 mL, 1.93 mmol). The reaction mixture was stirred for 24 h at 120 °C in sealed reaction vessel. The reaction mixture was cooled to room temperature and concentrated under reduced pressure. The crude reaction mixture was partitioned between ethyl acetate (10 mL), and the water layer was extracted with ethyl acetate (5 mL × 3). The combined organic layer was washed with brine, dried with MgSO<sub>4</sub>, filtered through a pad of celite, and concentrated under reduced pressure. The resulting crude product was purified by silica gel chromatography with MeOH/CH<sub>2</sub>Cl<sub>2</sub> (1/99 to 5/95) to give (68 mg, 77% yield) of the title product as a white solid. <i>R</i><sub>f</sub> = 0.27 (5/95 MeOH/CH<sub>2</sub>Cl<sub>2</sub>). <sup>1</sup>H NMR 400 MHz (DMSO-<i>d</i><sub>6</sub>) δ 10.52 (s, 1H), 8.29 (s, 1H), 8.26 (d, J = 7.9 Hz, 1H), 7.97 (d, <i>J</i> = 7.9 Hz, 1H), 7.92 (s, 1H), 7.78 (t, <i>J</i> = 7.8 Hz, 1H), 7.74 (d, <i>J</i> = 2.1 Hz, 1H), 7.64 (dd, <i>J</i> = 2.0 Hz, <i>J</i> = 8.3 Hz, 1H), 7.30 (d, <i>J</i> = 8.4 Hz, 1H), 6.57 (s, 2H), 4.60 (d, <i>J</i> = 13.8 Hz, 1H), 4.42 (d, <i>J</i> = 13.8 Hz, 1H), 3.23 (s, 3H), 2.07 (s, 3H). <sup>13</sup>C NMR 100 MHz (DMSO-<i>d</i><sub>6</sub>) δ 164.32, 163.22, 157.51, 153.94, 152.91, 141.80, 138.02, 136.07, 132.30, 131.38, 131.17, 130.25, 128.65, 124.61, 120.16, 119.80, 100.86, 47.08, 28.35, 17.27. HRMS (ESI) <i>m</i>/<i>z</i> [M + Na]<sup>+</sup> calcd 479.1419, found 479.1417.</div></div><div id="sec4_3_9" class="NLM_sec NLM_sec_level_3"><div id="ac_i26" class="anchor-spacer"></div><h4 class="article-section__title" id="_i26"> <i>N</i>-(4-Methyl-3-(1-methyl-7-(6-methylpyridin-3-ylamino)-2-oxo-1,2-dihydropyrimido[4,5-<i>d</i>]pyrimidin-3(4<i>H</i>)-yl)phenyl)-3-(trifluoromethyl)benzamide (<b>2</b>)</h4><div class="NLM_p last">To a solution of compound <b>12</b> (100 mg, 019 mmol) in 1,4-dioxane (1.0 mL) were added 6-methylpyridin-3-amine (104 mg, 0.96 mmol) and trifluoroacetic acid (73 uL, 0.96 mmol). The reaction mixture was stirred for 48 h at 120 °C. The reaction mixture was cooled to room temperature and was concentrated. The crude reaction mixture was partitioned between ethyl acetate (20 mL) and saturated NaHCO<sub>3</sub> (20 mL) solution. The organic layer was washed with brine, dried with MgSO<sub>4</sub>, filtered through a pad of celite, and concentrated under reduced pressure. The resulting crude product was purified by silica gel chromatography with MeOH/CH<sub>2</sub>Cl<sub>2</sub> (1/99 to 5/95) to give (34 mg, 32% yield) of the title product as a white solid. <i>R</i><sub>f</sub> = 0.23 (5/95 MeOH/CH<sub>2</sub>Cl<sub>2</sub>). <sup>1</sup>H NMR 600 MHz (DMSO-<i>d</i><sub>6</sub>) δ 10.50 (s, 1H), 9.61 (s, 1H), 8.77 (d, J = 3.0 Hz, 1H), 8.28 (s, 1H), 8.25 (d, <i>J</i> = 8.4 Hz, 1H), 8.13 (s, 1H), 8.04 (dd, <i>J</i> = 2.4 Hz, <i>J</i> = 8.4 Hz, 1H), 7.95 (d, <i>J</i> = 7.8 Hz, 1H), 7.78 (m, 2H), 7.63 (dd, <i>J</i> = 1.8 Hz, <i>J</i> = 8.4 Hz, 1H), 7.30 (d, <i>J</i> = 8.4 Hz, 1H), 7.16 (d, <i>J</i> = 9.0 Hz, 1H), 4.69 (d, <i>J</i> = 13.8 Hz, 1H), 4.52 (d, <i>J</i> = 13.8 Hz, 1H), 3.32 (s, 3H), 2.40 (s, 3H), 2.12 (s, 3H). <sup>1</sup>H NMR 400 MHz (CDCl<sub>3</sub>) δ 9.19 (s, 1H), 8.74 (d, <i>J</i> = 2.2 Hz, 1H), 8.17 (s, 1H), 8.13 (d, <i>J</i> = 7.7 Hz, 1H), 8.00 (dd, <i>J</i> = 2.3 Hz, <i>J</i> = 8.4 Hz, 1H), 7.94 (s, 1H), 7.74 (d, J = 7.7 Hz, 1H), 7.69 (s, 1H), 7.56 (m, 2H), 7.30 (d, <i>J</i> = 8.2 Hz, 1H), 7.17 (d, <i>J</i> = 8.4 Hz, 1H), 7.00 (d, <i>J</i> = 8.4 Hz, 1H), 4.64 (d, <i>J</i> = 14.1 Hz, 1H), 4.42 (d, <i>J</i> = 14.2 Hz, 1H), 3.51 (s, 3H), 2.54 (s, 3H), 1.62 (s, 3H). <sup>13</sup>C NMR 100 MHz (CDCl<sub>3</sub>) δ 164.23, 159.20, 157.48, 153.49, 152.88, 152.19, 140.43, 139.91, 137.72, 135.61, 133.71, 131.38, 131.02, 130.87, 129.05, 128.06, 127.23, 124.38, 123.05, 120.72, 120.03, 102.73, 47.29, 28.73, 23.61, 16.24. HRMS (ESI) <i>m</i>/<i>z</i> [M + Na]<sup>+</sup> calcd 570.1841, found 542.1839.</div></div><div id="sec4_3_10" class="NLM_sec NLM_sec_level_3"><div id="ac_i27" class="anchor-spacer"></div><h4 class="article-section__title" id="_i27"> <i>N</i>-(4-Methyl-3-(1-methyl-2-oxo-7-(phenylamino)-1,2-dihydropyrimido[4,5-<i>d</i>]pyrimidin-3(4<i>H</i>)-yl)phenyl)-3-(trifluoromethyl)benzamide (<b>3</b>)</h4><div class="NLM_p last">To a solution of compound <b>12</b> (100 mg, 019 mmol) in 1,4-dioxane (0.5 mL) was added aniline (0.17 mL, 1.93 mmol). The reaction mixture was stirred for 24 h at 130 °C. The reaction mixture was cooled to room temperature and concentrated under reduced pressure. The crude reaction mixture was partitioned between ethyl acetate (10 mL), and the water layer was extracted with ethyl acetate (5 mL × 3). The combined organic layer was washed with brine, dried with MgSO<sub>4</sub>, filtered through a pad of celite, and concentrated under reduced pressure. The resulting crude product was purified by silica gel chromatography with MeOH/CH<sub>2</sub>Cl<sub>2</sub> (1/99 to 5/95) to give (72 mg, 70% yield) of the title product as a white solid. <i>R</i><sub>f</sub> = 0.30 (5/95 MeOH/CH<sub>2</sub>Cl<sub>2</sub>). <sup>1</sup>H NMR 400 MHz (DMSO-<i>d</i><sub>6</sub>) δ 10.53 (s, 1H), 9.56 (s, 1H), 8.30 (s, 1H), 8.21 (d, J = 7.9 Hz, 1H), 8.14 (s, 1H), 7.97 (d, <i>J</i> = 7.8 Hz, 1H), 7.78 (m, 4H), 7.65 (dd, <i>J</i> = 2.0 Hz, <i>J</i> = 8.3 Hz, 1H), 7.29 (m, 3H), 6.93 (t, <i>J</i> = 7.4 Hz, 1H), 4.71 (d, <i>J</i> = 14.1 Hz, 1H), 4.53 (d, <i>J</i> = 13.8 Hz, 1H), 3.26 (s, 3H), 2.13 (s, 3H). <sup>13</sup>C NMR 100 MHz (DMSO-<i>d</i><sub>6</sub>) δ 164.33, 159.46, 157.39, 153.65, 152.65, 141.67, 141.02, 138.06, 136.08, 132.30, 131.42, 131.22, 130.25, 128.95, 128.64, 124.62, 121.75, 120.26, 119.82, 119.25, 103.12, 47.12, 28.70, 17.27. HRMS (ESI) <i>m</i>/<i>z</i> [M + Na]<sup>+</sup> calcd 555.1732, found 555.1730.</div></div><div id="sec4_3_11" class="NLM_sec NLM_sec_level_3"><div id="ac_i28" class="anchor-spacer"></div><h4 class="article-section__title" id="_i28"> <i>N</i>-Methyl-5-((2-methyl-5-nitrophenylamino)methyl)-2-(methylthio)pyrimidin-4-amine (<b>14</b>)</h4><div class="NLM_p last">To a solution of compound <b>8</b> (500 mg, 2.73 mmol) in methanol (10 mL) were added acetic acid (0.31 mL, 2.06 mmol), 2-methyl-5-nitrobenzenamine (415 mg, 2.73 mmol), and Na(CN)BH<sub>3</sub> (858 mg, 13.66 mmol) at room temperature and stirred for overnight. The reaction mixture was partitioned between ethyl acetate (50 mL) and saturated NaHCO<sub>3</sub> (30 mL), and then the water layer was extracted with ethyl acetate (30 mL × 3). The combined organic layer was washed with brine, dried over MgSO<sub>4</sub>, filtered through a pad of celite, and concentrated under reduced pressure. The resulting crude product was purified by silica gel chromatography with ethyl acetate/hexane (1/4 to 2/3) to give (310 mg, 36% yield) of the title product as a yellow solid. <i>R</i><sub>f</sub> = 0.30 (2/3 ethyl acetate/hexane). <sup>1</sup>H NMR 400 MHz (DMSO-<i>d</i><sub>6</sub>) δ 7.86 (s, 1H), 7.38 (dd, <i>J</i> = 2.1 Hz, <i>J</i> = 8.6 Hz, 1H), 7.22 (d, <i>J</i> = 8.2 Hz, 1H), 7.18 (d, <i>J</i> = 2.0 Hz, 1H), 7.14 (m, 1H), 5.98 (m, 1H), 4.18 (d, <i>J</i> = 5.5 Hz, 2H), 2.88 (d, <i>J</i> = 4.5 Hz, 3H), 2.36 (s, 3H), 2.20 (s, 3H). <sup>13</sup>C NMR 100 MHz (DMSO-<i>d</i><sub>6</sub>) δ 169.21, 160.48, 152.97, 147.41, 147.12, 131.10, 130.72, 111.25, 109.93, 103.22, 27.81, 18.41, 13.78. HRMS (ESI) <i>m</i>/<i>z</i> [M + Na]<sup>+</sup> calcd 342.1001, found 342.1003.</div></div><div id="sec4_3_12" class="NLM_sec NLM_sec_level_3"><div id="ac_i29" class="anchor-spacer"></div><h4 class="article-section__title" id="_i29"> 1-Methyl-3-(2-methyl-5-nitrophenyl)-7-(methylthio)-3,4-dihydropyrimido[4,5-<i>d</i>]pyrimidin-2(1<i>H</i>)-one (<b>15</b>)</h4><div class="NLM_p last">To a solution of compound <b>14</b> (200 mg, 0.63 mmol) in 1,4-dioxane (3.0 mL) were added DIEA (0.31 mL, 1.88 mmol) and triphosgene (65 mg, 0.22 mmol) at 0 °C and stirred at room temperature for 1 h. The precipitate was filtered off and the filtrate was stirred at 110 °C for 3 h. The reaction mixture was cooled to room temperature and was partitioned between ethyl acetate (20 mL) and saturated NaHCO<sub>3</sub> (20 mL) solution. The organic layer was washed with brine, dried over MgSO<sub>4</sub>, filtered through a pad of celite, and concentrated under reduced pressure. The resulting crude product was purified by silica gel chromatography with ethyl acetate/hexane (1/4 to 2/3) to give (170 mg, 78% yield) of the title product as a yellow solid. <i>R</i><sub>f</sub> = 0.39 (2/3 ethyl acetate/hexane). <sup>1</sup>H NMR 400 MHz (CDCl<sub>3</sub>) δ 8.16 (d, <i>J</i> = 2.2 Hz, 1H), 8.15 (dd, <i>J</i> = 2.3 Hz, <i>J</i> = 8.3 Hz, 1H), 8.10 (s, 1H), 7.49 (d, <i>J</i> = 8.3 Hz, 1H), 4.85 (d, <i>J</i> = 14.1 Hz, 1H), 4.52 (d, <i>J</i> = 14.6 Hz, 1H), 3.47 (s, 3H), 2.59 (s, 3H), 2.33 (s, 3H). <sup>13</sup>C NMR 100 MHz (CDCl<sub>3</sub>) δ 172.29, 156.49, 152.38, 151.97, 147.04, 144.22, 141.34, 132.00, 122.97, 122.35, 106.31, 47.16, 28.59, 18.17, 14.23. HRMS (ESI) <i>m</i>/<i>z</i> [M + Na]<sup>+</sup> calcd 368.0793, found 368.0794.</div></div><div id="sec4_3_13" class="NLM_sec NLM_sec_level_3"><div id="ac_i30" class="anchor-spacer"></div><h4 class="article-section__title" id="_i30"> 3-(5-Amino-2-methylphenyl)-1-methyl-7-(methylthio)-3,4-dihydropyrimido[4,5-<i>d</i>]pyrimidin-2(1<i>H</i>)-one (<b>16</b>)</h4><div class="NLM_p last">To a solution of compound <b>15</b> (150 mg, 0.43 mmol) in methanol (2 mL) was added 10% Pd/C (15 mg). After two vacuum/H<sub>2</sub> cycles to replace air inside the reaction flask with hydrogen balloon, the reaction mixture was stirred at room temperature for 6 h. The reaction mixture was filtered through a pad of Celite and concentrated under reduced pressure. The title product (130 mg, 94% yield) was used for the next step without further purification. <i>R</i><sub>f</sub> = 0.31 (4/1 ethyl acetate/hexane). <sup>1</sup>H NMR 400 MHz (CDCl<sub>3</sub>) δ 8.03 (s, 1H), 7.06 (d, <i>J</i> = 8.1 Hz, 1H), 6.62 (dd, <i>J</i> = 2.4 Hz, <i>J</i> = 8.1 Hz, 1H), 6.56 (d, <i>J</i> = 2.3 Hz, 1H), 4.66 (d, <i>J</i> = 14.6 Hz, 1H), 4.48 (d, <i>J</i> = 14.6 Hz, 1H), 3.44 (s, 3H), 2.57 (s, 3H), 2.09 (s, 3H). <sup>13</sup>C NMR 100 MHz (CDCl<sub>3</sub>) δ 171.71, 156.82, 152.50, 151.67, 145.75, 141.05, 131.97, 124.93, 115.43, 113.56, 160.82, 47.19, 28.44, 16.64, 14.20. HRMS (ESI) <i>m</i>/<i>z</i> [M + Na]<sup>+</sup> calcd 338.1052, found 338.1055.</div></div><div id="sec4_3_14" class="NLM_sec NLM_sec_level_3"><div id="ac_i31" class="anchor-spacer"></div><h4 class="article-section__title" id="_i31"> 3-(4-Methyl-1<i>H</i>-imidazol-1-yl)-5-(trifluoromethyl)benzoic Acid (<b>17</b>)</h4><div class="NLM_p">To a solution of 3-fluoro-5-(trifluoromethyl)benzonitrile (5.0 g, 26.45 mmol) in <i>N</i>,<i>N</i>-dimethylacetamide (25 mL) was added 4-methyl imidazole (6.5 g, 79.36 mmol). The reaction mixture was stirred at 150 °C for 24 h. The reaction mixture was cooled to room temperature. The crude reaction mixture was partitioned between ethyl acetate (100 mL), and the water layer was extracted with ethyl acetate (5 mL × 3). The combined organic layer was washed with brine, dried with MgSO<sub>4</sub>, filtered through a pad of celite, and concentrated under reduced pressure. The resulting crude product was purified by silica gel chromatography with ethyl acetate/hexane (1/3 to 2/1) to give (4.8 g, 73% yield) 3-(4-methyl-1<i>H</i>-imidazol-1-yl)-5-(trifluoromethyl)benzonitrile as a white solid. <i>R</i><sub>f</sub> = 0.21 (3/2 ethyl acetate/hexane). <sup>1</sup>H NMR 400 MHz (DMSO-<i>d</i><sub>6</sub>) δ 8.53 (s, 1H), 8.45 (s, 1H), 8.40 (s, 1H), 8.24 (s, 1H), 7.71 (s, 1H), 2.15 (s, 3H). <sup>13</sup>C NMR 100 MHz (DMSO-<i>d</i><sub>6</sub>) δ 139.60, 138.64, 135.73, 132.38, 132.5, 127.22, 126.89, 121.07, 117.45, 114.55, 114.44, 14.00. HRMS (ESI) <i>m</i>/<i>z</i> [M + Na]<sup>+</sup> calcd 274.0568, found 274.0569.</div><div class="NLM_p last">To a solution of 3-(4-methyl-1<i>H</i>-imidazol-1-yl)-5-(trifluoromethyl)benzonitrile (3 g, 11.95 mmol) in dioxane (30 mL) was added 2 N NaOH solution (30 mL, 59.76 mmol). The reaction mixture was stirred for 24 h under reflux condition. The reaction mixture was cooled to room temperature, and the organic solvent was removed under reduced pressure. To a reaction mixture was added 6N HCl solution until white solid (pH = 4−5) precipitated. The produced white solid was filtered and dried over nitrogen gas flow. The title compound (2.6 g, 80% yield) was used for the next step without further purification. <sup>1</sup>H NMR 400 MHz (DMSO-<i>d</i><sub>6</sub>) δ 8.51 (s, 1H), 8.35 (s, 1H), 8.40 (s, 1H), 8.29 (s, 1H), 8.07 (s, 1H), 7.74 (s, 1H), 2.17 (s, 3H). <sup>13</sup>C NMR 100 MHz (DMSO-<i>d</i><sub>6</sub>) δ 165.81, 138.72, 138.39, 135.70, 134.41, 131.64, 131.31, 124.46, 123.59, 121.14, 115.0, 13.68. HRMS (ESI) <i>m</i>/<i>z</i> [M + H]<sup>+</sup> calcd 271.0689, found 271.0691.</div></div><div id="sec4_3_15" class="NLM_sec NLM_sec_level_3"><div id="ac_i32" class="anchor-spacer"></div><h4 class="article-section__title" id="_i32"> 3-(4-Methyl-1<i>H</i>-imidazol-1-yl)-<i>N</i>-(4-methyl-3-(1-methyl-7-(methylthio)-2-oxo-1,2-dihydropyrimido[4,5-<i>d</i>]pyrimidin-3(4<i>H</i>)-yl)phenyl)-5-(trifluoromethyl)benzamide (<b>18</b>)</h4><div class="NLM_p last">To a solution of compound <b>16</b> (100 mg, 0.32 mmol) in dried DMF (1.5 mL) were added compound <b>17</b> (86 mg, 0.32 mmol), HATU (362 mg, 0.95 mmol), and DIEA (0.26 mL, 1.58 mmol). The reaction mixture was stirred for 24 h at room temperature. The reaction mixture was partitioned between ethyl acetate (5 mL) and water (5 mL), and then the water layer was extracted with ethyl acetate (5 mL × 3). The combined organic layer was washed with brine, dried over MgSO<sub>4</sub>, filtered through a pad of celite, and concentrated under reduced pressure. The resulting crude product was purified by silica gel chromatography with MeOH/CH<sub>2</sub>Cl<sub>2</sub> (1/95 to 5/95) to give (161 mg, 89% yield) of the title product as a white solid. <i>R</i><sub>f</sub> = 0.28 (5/95 MeOH/CH<sub>2</sub>Cl<sub>2</sub>). <sup>1</sup>H NMR 400 MHz (CDCl<sub>3</sub>) δ 9.47 (s, 1H), 8.14 (m, 2H), 8.04 (s, 1H), 7.88 (s, 1H), 7.71 (s, 1H), 7.60 (s, 1H), 7.39 (d, <i>J</i> = 7.5 Hz, 1H), 7.10 (s, 1H), 7.02 (d, <i>J</i> = 8.4 Hz, 1H), 4.68 (d, <i>J</i> = 14.7 Hz, 1H), 4.46 (d, <i>J</i> = 14.7 Hz, 1H), 3.47 (s, 3H), 2.59 (s, 3H), 2.28 (s, 3H), 1.68 (s, 3H). <sup>13</sup>C NMR 100 MHz (CDCl<sub>3</sub>) δ 172.11, 163.03, 156.32, 153.62, 152.04, 140.61, 139.78, 138.00, 137.64, 134.47, 132.73, 132.40, 131.16, 130.89, 124.49, 123.32, 122.64, 120.85, 120.01, 119.80, 114.15, 105.34, 47.21, 28.48, 16.36, 14.22, 13.60. HRMS (ESI) <i>m</i>/<i>z</i> [M + Na]<sup>+</sup> calcd 590.1562, found 590.1563.</div></div><div id="sec4_3_16" class="NLM_sec NLM_sec_level_3"><div id="ac_i33" class="anchor-spacer"></div><h4 class="article-section__title" id="_i33"> 3-(4-Methyl-1<i>H</i>-imidazol-1-yl)-<i>N</i>-(4-methyl-3-(1-methyl-7-(methylsulfonyl)-2-oxo-1,2-dihydropyrimido[4,5-<i>d</i>]pyrimidin-3(4<i>H</i>)-yl)phenyl)-5-(trifluoromethyl)benzamide (<b>19</b>)</h4><div class="NLM_p last">To a solution of compound <b>18</b> (130 mg, 0.23 mmol) in dichloromethane (1 mL) was added <i>m</i>-chloroperbenzoic acid (158 mg, 0.91 mmol) at 0 °C. The reaction mixture was stirred for 30 min at 0 °C and then stirred for 3 h at room temperature. The reaction mixture was partitioned between dichloromethane (10 mL) and saturated NaHCO<sub>3</sub> (10 mL). The organic layer was washed with brine, dried over MgSO<sub>4</sub>, filtered through a pad of celite, and concentrated under reduce pressure. The resulting white solid (122 mg, 88% yield) was used for the next step without further purification. <i>R</i><sub>f</sub> = 0.27 (5/95 MeOH/CH<sub>2</sub>Cl<sub>2</sub>). <sup>1</sup>H NMR 400 MHz (DMSO-<i>d</i><sub>6</sub>) δ 10.66 (s, 1H), 8.58 (s, 1H), 8.47 (s, 1H), 8.39 (s, 1H), 8.23 (s, 1H), 8.16 (s, 1H), 7.85 (m, 1H), 7.69 (s, 1H), 7.67 (dd, <i>J</i> = 1.9 Hz, <i>J</i> = 8.3 Hz, 1H), 7.34 (d, <i>J</i> = 8.4 Hz, 1H), 4.94 (d, <i>J</i> = 15.6 Hz, 1H), 4.77 (d, <i>J</i> = 15.6 Hz, 1H), 3.40 (s, 3H), 3.35 (s, 3H), 2.14 (s, 3H), 2.10 (s, 3H). <sup>13</sup>C NMR 100 MHz (DMSO-<i>d</i><sub>6</sub>) δ 164.63, 163.56, 158.19, 153.02, 151.55, 141.01, 139.42, 138.21, 137.96, 137.84, 135.72, 131.63, 131.48, 131.38, 123.06, 122.33, 120.64, 119.83, 119.63, 115.94, 114.72, 47.14, 28.95, 17.20, 14.00.HRMS (ESI) <i>m</i>/<i>z</i> [M + Na]<sup>+</sup> calcd 622.1460, found 622.1463.</div></div><div id="sec4_3_17" class="NLM_sec NLM_sec_level_3"><div id="ac_i34" class="anchor-spacer"></div><h4 class="article-section__title" id="_i34"> 3-(4-Methyl-1<i>H</i>-imidazol-1-yl)-<i>N</i>-(4-methyl-3-(1-methyl-7-(methylamino)-2-oxo-1,2-dihydropyrimido[4,5-<i>d</i>]pyrimidin-3(4<i>H</i>)-yl)phenyl)-5-(trifluoromethyl)benzamide (<b>4</b>)</h4><div class="NLM_p last">To a solution of compound <b>19</b> (100 mg, 0.16 mmol) in 1,4-dioxane (2.0 mL) was added 2.0 M methylamine in THF (0.83 mL, 1.67 mmol). The reaction mixture was stirred for 24 h at 120 °C in the sealed reaction vessel. The reaction mixture was cooled to room temperature and concentrated under reduced pressure. The crude reaction mixture was partitioned between ethyl acetate (10 mL), and the water layer was extracted with ethyl acetate (5 mL × 3). The combined organic layer was washed with brine, dried over MgSO<sub>4</sub>, filtered through a pad of celite, and concentrated under reduced pressure. The resulting crude product was purified by silica gel chromatography with MeOH/CH<sub>2</sub>Cl<sub>2</sub> (1/99 to 5/95) to give (75 mg, 82% yield) of the title product as a white solid. <i>R</i><sub>f</sub> = 0.23 (5/95 MeOH/CH<sub>2</sub>Cl<sub>2</sub>). <sup>1</sup>H NMR 400 MHz (CDCl<sub>3</sub>) 9.49 (s, 1H), 8.15 (s, 2H), 7.89 (s, 1H), 7.83 (s, 1H), 7.69 (s, 1H), 7.49 (s, 1H), 7.46 (d, <i>J</i> = 7.9 Hz, 1H), 7.10 (s, 1H), 6.98 (d, <i>J</i> = 8.4 Hz, 1H), 5.18 (m, 1H), 4.56 (d, <i>J</i> = 13.8 Hz, 1H), 4.35 (d, <i>J</i> = 13.8 Hz, 1H), 3.36 (s, 3H), 3.03 (d, <i>J</i> = 5.0 Hz, 3H), 2.28 (s, 3H), 1.60 (s, 3H). <sup>13</sup>C NMR 100 MHz (CDCl<sub>3</sub>) δ 163.01, 162.45, 157.13, 154.23, 153.09, 140.58, 140.07, 137.94, 137.83, 137.72, 134.51, 132.64, 132.31, 131.00, 130.73, 124.53, 123.38, 122.84, 120.19, 119.66, 119.10, 114.16, 47.38, 28.44, 28.20, 16.22, 13.64. HRMS (ESI) <i>m</i>/<i>z</i> [M + Na]<sup>+</sup> calcd 573.1950, found 573.1952.</div></div></div></div><div class="NLM_back"><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_03747" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_03747" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Nathanael S. Gray</span> - <span class="hlFld-Affiliation affiliation">Dana Farber Cancer Institute, Harvard Medical School, Department of Cancer Biology and Department of Biological Chemistry and Molecular Pharmacology, 250 Longwood Avenue, Seeley G. Mudd Building 628A, Boston, Massachusetts 02115</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#097d6b7a60644962607a7d277b6c27627b2967687d616867686c65566e7b6870496d6f6a602761687b7f687b6d276c6d7c"><span class="__cf_email__" data-cfemail="770315041e1a371c1e0403590512591c05">[email protected]</span> <span class="__cf_email__" data-cfemail="ea848b9e828b848b8f86b58d988b93aa8e8c8983c4828b989c8b988ec48f8e9f">[email protected]</span></a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Taebo Sim</span> - <span class="hlFld-Affiliation affiliation">Genomics Institute of the Novartis Research Foundation, Department of Chemistry, 10675 John Jay Hopkins Drive, San Diego, California 92121</span>; 
    <span class="hlFld-Affiliation affiliation">Life Sciences Research Division, Korea Institute of Science and Technology, 39-1 Hawolgok-dong, Seongbuk-gu, Seoul 136-791, Korea</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#abdfc9d8c2c6ebc0c2d8df85d9ce85c0d98bc5cadfc3cac5cacec7f4ccd9cad2ebcfcdc8c285c3cad9ddcad9cf85cecfde"><span class="__cf_email__" data-cfemail="a6d2c4d5cfcbe6cdcfd5d288d4c388cdd4">[email protected]</span> <span class="__cf_email__" data-cfemail="3b555a4f535a555a5e57645c495a427b5f5d585215535a494d5a495f155e5f4e">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Hwan Geun Choi</span> - <span class="hlFld-Affiliation affiliation">Dana Farber Cancer Institute, Harvard Medical School, Department of Cancer Biology and Department of Biological Chemistry and Molecular Pharmacology, 250 Longwood Avenue, Seeley G. Mudd Building 628A, Boston, Massachusetts 02115</span>; 
    <span class="hlFld-Affiliation affiliation">Life Sciences Research Division, Korea Institute of Science and Technology, 39-1 Hawolgok-dong, Seongbuk-gu, Seoul 136-791, Korea</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Pingda Ren</span> - <span class="hlFld-Affiliation affiliation">Genomics Institute of the Novartis Research Foundation, Department of Chemistry, 10675 John Jay Hopkins Drive, San Diego, California 92121</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Francisco Adrian</span> - <span class="hlFld-Affiliation affiliation">Genomics Institute of the Novartis Research Foundation, Department of Chemistry, 10675 John Jay Hopkins Drive, San Diego, California 92121</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Fangxian Sun</span> - <span class="hlFld-Affiliation affiliation">Genomics Institute of the Novartis Research Foundation, Department of Chemistry, 10675 John Jay Hopkins Drive, San Diego, California 92121</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Hyun Soo Lee</span> - <span class="hlFld-Affiliation affiliation">Genomics Institute of the Novartis Research Foundation, Department of Chemistry, 10675 John Jay Hopkins Drive, San Diego, California 92121</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Xia Wang</span> - <span class="hlFld-Affiliation affiliation">Genomics Institute of the Novartis Research Foundation, Department of Chemistry, 10675 John Jay Hopkins Drive, San Diego, California 92121</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Qiang Ding</span> - <span class="hlFld-Affiliation affiliation">Genomics Institute of the Novartis Research Foundation, Department of Chemistry, 10675 John Jay Hopkins Drive, San Diego, California 92121</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Guobao Zhang</span> - <span class="hlFld-Affiliation affiliation">Genomics Institute of the Novartis Research Foundation, Department of Chemistry, 10675 John Jay Hopkins Drive, San Diego, California 92121</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Yongping Xie</span> - <span class="hlFld-Affiliation affiliation">Genomics Institute of the Novartis Research Foundation, Department of Chemistry, 10675 John Jay Hopkins Drive, San Diego, California 92121</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jianming Zhang</span> - <span class="hlFld-Affiliation affiliation">Dana Farber Cancer Institute, Harvard Medical School, Department of Cancer Biology and Department of Biological Chemistry and Molecular Pharmacology, 250 Longwood Avenue, Seeley G. Mudd Building 628A, Boston, Massachusetts 02115</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Yi Liu</span> - <span class="hlFld-Affiliation affiliation">Genomics Institute of the Novartis Research Foundation, Department of Chemistry, 10675 John Jay Hopkins Drive, San Diego, California 92121</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Tove Tuntland</span> - <span class="hlFld-Affiliation affiliation">Genomics Institute of the Novartis Research Foundation, Department of Chemistry, 10675 John Jay Hopkins Drive, San Diego, California 92121</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Markus Warmuth</span> - <span class="hlFld-Affiliation affiliation">Genomics Institute of the Novartis Research Foundation, Department of Chemistry, 10675 John Jay Hopkins Drive, San Diego, California 92121</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Paul W. Manley</span> - <span class="hlFld-Affiliation affiliation">Novartis Institutes for Biomedical Research, CH-4056 Basel, Switzerland</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jürgen Mestan</span> - <span class="hlFld-Affiliation affiliation">Novartis Institutes for Biomedical Research, CH-4056 Basel, Switzerland</span></div></li></ul></li><li></li><li></li><li></li></ul></div><div class="testing" data-doi="10.1021/jm901808w" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="ack"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i35">Acknowledgment</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_60280" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_60280" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">We thank Sungjoon Kim, Xiang-ju Gu for Ba/F3 cell proliferation assay, and acknowledge scientific guidance from Peter G. Schultz.</p></div><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i36">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_77811" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_77811" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 33 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group">Weisberg, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Manley, P. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Breitenstein, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bruggen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cowan-Jacob, S. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ray, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huntly, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fabbro, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fendrich, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hall-Meyers, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kung, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mestan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Daley, G. Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Callahan, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Catley, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cavazza, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Azam, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neuberg, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wright, R. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gilliland, D. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Griffin, J. D.</span><span> </span><span class="NLM_article-title">Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl</span> <span class="citation_source-journal">Cancer Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x"> (</span><span class="NLM_issue">2</span><span class="NLM_x">) </span> <span class="NLM_fpage">129</span><span class="NLM_x">–</span> <span class="NLM_lpage">141</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Fjm901808w&amp;key=10.1016%2Fj.ccr.2005.01.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Fjm901808w&amp;key=15710326" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Fjm901808w&amp;key=1%3ACAS%3A528%3ADC%252BD2MXitFygu7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2005&pages=129-141&issue=2&author=E.+Weisbergauthor=P.+W.+Manleyauthor=W.+Breitensteinauthor=J.+Bruggenauthor=S.+W.+Cowan-Jacobauthor=A.+Rayauthor=B.+Huntlyauthor=D.+Fabbroauthor=G.+Fendrichauthor=E.+Hall-Meyersauthor=A.+L.+Kungauthor=J.+Mestanauthor=G.+Q.+Daleyauthor=L.+Callahanauthor=L.+Catleyauthor=C.+Cavazzaauthor=M.+Azamauthor=D.+Neubergauthor=R.+D.+Wrightauthor=D.+G.+Gillilandauthor=J.+D.+Griffin&title=Characterization+of+AMN107%2C+a+selective+inhibitor+of+native+and+mutant+Bcr-Abl"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl</span></div><div class="casAuthors">Weisberg, Ellen; Manley, Paul W.; Breitenstein, Werner; Brueggen, Josef; Cowan-Jacob, Sandra W.; Ray, Arghya; Huntly, Brian; Fabbro, Doriano; Fendrich, Gabriele; Hall-Meyers, Elizabeth; Kung, Andrew L.; Mestan, Juergen; Daley, George Q.; Callahan, Linda; Catley, Laurie; Cavazza, Cara; Mohammed, Azam; Neuberg, Donna; Wright, Renee D.; Gilliland, D. Gary; Griffin, James D.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Cell</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">129-141</span>CODEN:
                <span class="NLM_cas:coden">CCAECI</span>;
        ISSN:<span class="NLM_cas:issn">1535-6108</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">The Bcr-Abl tyrosine kinase oncogene causes chronic myelogenous leukemia (CML) and Philadelphia chromosome-pos. (Ph+) acute lymphoblastic leukemia (ALL).  We describe a novel selective inhibitor of Bcr-Abl, AMN107 (IC50 < 30 nM), which is significantly more potent than imatinib, and active against a no. of imatinib-resistant Bcr-Abl mutants.  Crystallog. anal. of Abl-AMN107 complexes provides a structural explanation for the differential activity of AMN107 and imatinib against imatinib-resistant Bcr-Abl.  Consistent with its in vitro and pharmacokinetic profile, AMN107 prolonged survival of mice injected with Bcr-Abl-transformed hematopoietic cell lines or primary marrow cells, and prolonged survival in imatinib-resistant CML mouse models.  AMN107 is a promising new inhibitor for the therapy of CML and Ph+ ALL.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGow6QF3qX2uO7Vg90H21EOLACvtfcHk0ljpth6_nccmCQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXitFygu7o%253D&md5=d28e1a54b982951f8d3e6ef1d2d3b2eb</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1016%2Fj.ccr.2005.01.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ccr.2005.01.007%26sid%3Dliteratum%253Aachs%26aulast%3DWeisberg%26aufirst%3DE.%26aulast%3DManley%26aufirst%3DP.%2BW.%26aulast%3DBreitenstein%26aufirst%3DW.%26aulast%3DBruggen%26aufirst%3DJ.%26aulast%3DCowan-Jacob%26aufirst%3DS.%2BW.%26aulast%3DRay%26aufirst%3DA.%26aulast%3DHuntly%26aufirst%3DB.%26aulast%3DFabbro%26aufirst%3DD.%26aulast%3DFendrich%26aufirst%3DG.%26aulast%3DHall-Meyers%26aufirst%3DE.%26aulast%3DKung%26aufirst%3DA.%2BL.%26aulast%3DMestan%26aufirst%3DJ.%26aulast%3DDaley%26aufirst%3DG.%2BQ.%26aulast%3DCallahan%26aufirst%3DL.%26aulast%3DCatley%26aufirst%3DL.%26aulast%3DCavazza%26aufirst%3DC.%26aulast%3DAzam%26aufirst%3DM.%26aulast%3DNeuberg%26aufirst%3DD.%26aulast%3DWright%26aufirst%3DR.%2BD.%26aulast%3DGilliland%26aufirst%3DD.%2BG.%26aulast%3DGriffin%26aufirst%3DJ.%2BD.%26atitle%3DCharacterization%2520of%2520AMN107%252C%2520a%2520selective%2520inhibitor%2520of%2520native%2520and%2520mutant%2520Bcr-Abl%26jtitle%3DCancer%2520Cell%26date%3D2005%26volume%3D7%26issue%3D2%26spage%3D129%26epage%3D141" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group">Puttini, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coluccia, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boschelli, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cleris, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marchesi, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Donella-Deana, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ahmed, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Redaelli, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Piazza, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Magistroni, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Andreoni, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scapozza, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Formelli, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gambacorti-Passerini, C.</span><span> </span><span class="NLM_article-title">In vitro and in vivo activity of SKI-606, a novel Src-Abl inhibitor, against imatinib-resistant Bcr-Abl+ neoplastic cells</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">66</span><span class="NLM_x"> (</span><span class="NLM_issue">23</span><span class="NLM_x">) </span> <span class="NLM_fpage">11314</span><span class="NLM_x">–</span> <span class="NLM_lpage">11322</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=2006&pages=11314-11322&issue=23&author=M.+Puttiniauthor=A.+M.+Colucciaauthor=F.+Boschelliauthor=L.+Clerisauthor=E.+Marchesiauthor=A.+Donella-Deanaauthor=S.+Ahmedauthor=S.+Redaelliauthor=R.+Piazzaauthor=V.+Magistroniauthor=F.+Andreoniauthor=L.+Scapozzaauthor=F.+Formelliauthor=C.+Gambacorti-Passerini&title=In+vitro+and+in+vivo+activity+of+SKI-606%2C+a+novel+Src-Abl+inhibitor%2C+against+imatinib-resistant+Bcr-Abl%2B+neoplastic+cells"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPuttini%26aufirst%3DM.%26aulast%3DColuccia%26aufirst%3DA.%2BM.%26aulast%3DBoschelli%26aufirst%3DF.%26aulast%3DCleris%26aufirst%3DL.%26aulast%3DMarchesi%26aufirst%3DE.%26aulast%3DDonella-Deana%26aufirst%3DA.%26aulast%3DAhmed%26aufirst%3DS.%26aulast%3DRedaelli%26aufirst%3DS.%26aulast%3DPiazza%26aufirst%3DR.%26aulast%3DMagistroni%26aufirst%3DV.%26aulast%3DAndreoni%26aufirst%3DF.%26aulast%3DScapozza%26aufirst%3DL.%26aulast%3DFormelli%26aufirst%3DF.%26aulast%3DGambacorti-Passerini%26aufirst%3DC.%26atitle%3DIn%2520vitro%2520and%2520in%2520vivo%2520activity%2520of%2520SKI-606%252C%2520a%2520novel%2520Src-Abl%2520inhibitor%252C%2520against%2520imatinib-resistant%2520Bcr-Abl%252B%2520neoplastic%2520cells%26jtitle%3DCancer%2520Res.%26date%3D2006%26volume%3D66%26issue%3D23%26spage%3D11314%26epage%3D11322" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group">Shah, N. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tran, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, F. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Norris, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sawyers, C. L.</span><span> </span><span class="NLM_article-title">Overriding imatinib resistance with a novel ABL kinase inhibitor</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">305</span><span class="NLM_x"> (</span><span class="NLM_issue">5682</span><span class="NLM_x">) </span> <span class="NLM_fpage">399</span><span class="NLM_x">–</span> <span class="NLM_lpage">401</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Fjm901808w&amp;key=10.1126%2Fscience.1099480" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Fjm901808w&amp;key=15256671" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Fjm901808w&amp;key=1%3ACAS%3A528%3ADC%252BD2cXls1egtrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=305&publication_year=2004&pages=399-401&issue=5682&author=N.+P.+Shahauthor=C.+Tranauthor=F.+Y.+Leeauthor=P.+Chenauthor=D.+Norrisauthor=C.+L.+Sawyers&title=Overriding+imatinib+resistance+with+a+novel+ABL+kinase+inhibitor"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Overriding Imatinib Resistance with a Novel ABL Kinase Inhibitor</span></div><div class="casAuthors">Shah, Neil P.; Tran, Chris; Lee, Francis Y.; Chen, Ping; Norris, Derek; Sawyers, Charles L.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">305</span>
        (<span class="NLM_cas:issue">5682</span>),
    <span class="NLM_cas:pages">399-402</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">Resistance to the ABL kinase inhibitor imatinib (STI571 or Gleevec) in chronic myeloid leukemia (CML) occurs through selection for tumor cells harboring BCR-ABL kinase domain point mutations that interfere with drug binding.  Crystallog. studies predict that most imatinib-resistant mutants should remain sensitive to inhibitors that bind ABL with less stringent conformational requirements.  BMS-354825 is an orally bioavailable ABL kinase inhibitor with two-log increased potency relative to imatinib that retains activity against 14 of 15 imatinib-resistant BCR-ABL mutants.  BMS-354825 prolongs survival of mice with BCR-ABL-driven disease and inhibits proliferation of BCR-ABL-pos. bone marrow progenitor cells from patients with imatinib-sensitive and imatinib-resistant CML.  These data illustrate how mol. insight into kinase inhibitor resistance can guide the design of second-generation targeted therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp0O0Lhe8nKCrVg90H21EOLACvtfcHk0li21xMrk_1VKQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXls1egtrY%253D&md5=b3827c3419b4c6b57893b11fd68f1f96</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1126%2Fscience.1099480&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1099480%26sid%3Dliteratum%253Aachs%26aulast%3DShah%26aufirst%3DN.%2BP.%26aulast%3DTran%26aufirst%3DC.%26aulast%3DLee%26aufirst%3DF.%2BY.%26aulast%3DChen%26aufirst%3DP.%26aulast%3DNorris%26aufirst%3DD.%26aulast%3DSawyers%26aufirst%3DC.%2BL.%26atitle%3DOverriding%2520imatinib%2520resistance%2520with%2520a%2520novel%2520ABL%2520kinase%2520inhibitor%26jtitle%3DScience%26date%3D2004%26volume%3D305%26issue%3D5682%26spage%3D399%26epage%3D401" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group">O’Hare, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walters, D. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deininger, M. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Druker, B. J.</span><span> </span><span class="NLM_article-title">AMN107: tightening the grip of imatinib</span> <span class="citation_source-journal">Cancer Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x"> (</span><span class="NLM_issue">2</span><span class="NLM_x">) </span> <span class="NLM_fpage">117</span><span class="NLM_x">–</span> <span class="NLM_lpage">119</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2005&pages=117-119&issue=2&author=T.+O%E2%80%99Hareauthor=D.+K.+Waltersauthor=M.+W.+Deiningerauthor=B.+J.+Druker&title=AMN107%3A+tightening+the+grip+of+imatinib"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DO%25E2%2580%2599Hare%26aufirst%3DT.%26aulast%3DWalters%26aufirst%3DD.%2BK.%26aulast%3DDeininger%26aufirst%3DM.%2BW.%26aulast%3DDruker%26aufirst%3DB.%2BJ.%26atitle%3DAMN107%253A%2520tightening%2520the%2520grip%2520of%2520imatinib%26jtitle%3DCancer%2520Cell%26date%3D2005%26volume%3D7%26issue%3D2%26spage%3D117%26epage%3D119" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group">Miyamoto, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sugita, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Inukai, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lijima, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tezuka, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kojika, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakamura, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kagami, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakazawa, S.</span><span> </span><span class="NLM_article-title">The JAK2 inhibitor AG490 predominantly abrogates the growth of human B-precursor leukemic cells with 11q23 translocation or Philadelphia chromosome</span> <span class="citation_source-journal">Leukemia</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x"> (</span><span class="NLM_issue">11</span><span class="NLM_x">) </span> <span class="NLM_fpage">1758</span><span class="NLM_x">–</span> <span class="NLM_lpage">1768</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2001&pages=1758-1768&issue=11&author=N.+Miyamotoauthor=K.+Sugitaauthor=K.+Goiauthor=T.+Inukaiauthor=K.+Lijimaauthor=T.+Tezukaauthor=S.+Kojikaauthor=M.+Nakamuraauthor=K.+Kagamiauthor=S.+Nakazawa&title=The+JAK2+inhibitor+AG490+predominantly+abrogates+the+growth+of+human+B-precursor+leukemic+cells+with+11q23+translocation+or+Philadelphia+chromosome"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMiyamoto%26aufirst%3DN.%26aulast%3DSugita%26aufirst%3DK.%26aulast%3DGoi%26aufirst%3DK.%26aulast%3DInukai%26aufirst%3DT.%26aulast%3DLijima%26aufirst%3DK.%26aulast%3DTezuka%26aufirst%3DT.%26aulast%3DKojika%26aufirst%3DS.%26aulast%3DNakamura%26aufirst%3DM.%26aulast%3DKagami%26aufirst%3DK.%26aulast%3DNakazawa%26aufirst%3DS.%26atitle%3DThe%2520JAK2%2520inhibitor%2520AG490%2520predominantly%2520abrogates%2520the%2520growth%2520of%2520human%2520B-precursor%2520leukemic%2520cells%2520with%252011q23%2520translocation%2520or%2520Philadelphia%2520chromosome%26jtitle%3DLeukemia%26date%3D2001%26volume%3D15%26issue%3D11%26spage%3D1758%26epage%3D1768" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group">Samanta, A. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kantarjian, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arlinghaus, R. B.</span><span> </span><span class="NLM_article-title">Janus kinase 2: a critical target in chronic myelogenous leukemia</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">66</span><span class="NLM_x"> (</span><span class="NLM_issue">13</span><span class="NLM_x">) </span> <span class="NLM_fpage">6468</span><span class="NLM_x">–</span> <span class="NLM_lpage">6472</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=2006&pages=6468-6472&issue=13&author=A.+K.+Samantaauthor=H.+Linauthor=T.+Sunauthor=H.+Kantarjianauthor=R.+B.+Arlinghaus&title=Janus+kinase+2%3A+a+critical+target+in+chronic+myelogenous+leukemia"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSamanta%26aufirst%3DA.%2BK.%26aulast%3DLin%26aufirst%3DH.%26aulast%3DSun%26aufirst%3DT.%26aulast%3DKantarjian%26aufirst%3DH.%26aulast%3DArlinghaus%26aufirst%3DR.%2BB.%26atitle%3DJanus%2520kinase%25202%253A%2520a%2520critical%2520target%2520in%2520chronic%2520myelogenous%2520leukemia%26jtitle%3DCancer%2520Res.%26date%3D2006%26volume%3D66%26issue%3D13%26spage%3D6468%26epage%3D6472" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group">Summy, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trevino, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lesslie, D. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baker, C. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shakespeare, W. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sundaramoorthi, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Metcalf, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keats, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sawyer, T. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gallick, G. E.</span><span> </span><span class="NLM_article-title">AP23846, a novel and highly potent Src family kinase inhibitor, reduces vascular endothelial growth factor and interleukin-8 expression in human solid tumor cell lines and abrogates downstream angiogenic processes</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x"> (</span><span class="NLM_issue">12</span><span class="NLM_x">) </span> <span class="NLM_fpage">1900</span><span class="NLM_x">–</span> <span class="NLM_lpage">1911</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Fjm901808w&amp;key=10.1158%2F1535-7163.MCT-05-0171" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Fjm901808w&amp;key=16373705" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Fjm901808w&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtlCnsrvI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2005&pages=1900-1911&issue=12&author=J.+M.+Summyauthor=J.+G.+Trevinoauthor=D.+P.+Lesslieauthor=C.+H.+Bakerauthor=W.+C.+Shakespeareauthor=Y.+Wangauthor=R.+Sundaramoorthiauthor=C.+A.+Metcalfauthor=J.+A.+Keatsauthor=T.+K.+Sawyerauthor=G.+E.+Gallick&title=AP23846%2C+a+novel+and+highly+potent+Src+family+kinase+inhibitor%2C+reduces+vascular+endothelial+growth+factor+and+interleukin-8+expression+in+human+solid+tumor+cell+lines+and+abrogates+downstream+angiogenic+processes"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">AP23846, a novel and highly potent Src family kinase inhibitor, reduces vascular endothelial growth factor and interleukin-8 expression in human solid tumor cell lines and abrogates downstream angiogenic processes</span></div><div class="casAuthors">Summy, Justin M.; Trevino, Jose G.; Lesslie, Donald P.; Baker, Cheryl H.; Shakespeare, William C.; Wang, Yihan; Sundaramoorthi, Raji; Metcalf, Chester A., III; Keats, Jeffrey A.; Sawyer, Tomi K.; Gallick, Gary E.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1900-1911</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">C-Src is frequently activated in human malignancies, including colon, breast, and pancreatic carcinomas.  Several recent studies have shown that activation of Src family kinases leads to tumor progression and metastasis by increasing cellular migration and invasion, promoting cell growth and survival, and deregulating expression of proangiogenic mols.  Therefore, selective inhibitors of Src are being developed for cancer therapy.  In this study, we characterize the biol. effects of the novel ATP-based Src family kinase inhibitor, AP23846, in tumor cells with high Src activity.  As a lead compd., AP23846 is a potent c-Src kinase inhibitor (IC50 ∼0.5 nmol/L in vitro, ∼10-fold more potent than PP2, the most widely used com. available Src family kinase inhibitor).  At concns. of 1 μmol/L, AP23846 led to complete Src inhibition for 48 h in cells.  No cytotoxicity was obsd. under these conditions, although proliferation rates were slower.  Therefore, this was an excellent inhibitor to examine Src-regulated signaling pathways in tumor cells.  AP23846 reduced cellular migration, vascular endothelial growth factor, and interleukin-8 in a dose-dependent fashion in pancreatic adenocarcinoma cells grown in vitro.  Correspondingly, cell culture supernatants from L3.6pl pancreatic adenocarcinoma cells pretreated with AP23846 failed to promote migration of hepatic endothelial cells in vitro and failed to support angiogenesis into gel foams implanted s.c. in mice in vivo.  These results suggest that Src inhibitors affect biol. properties of tumor progression and may be useful as cancer therapeutic agents in more advanced disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqD5msxlHP037Vg90H21EOLACvtfcHk0ljWG-h_bycrZA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtlCnsrvI&md5=4eedd79332fe6eb3cf23407e55286739</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-05-0171&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-05-0171%26sid%3Dliteratum%253Aachs%26aulast%3DSummy%26aufirst%3DJ.%2BM.%26aulast%3DTrevino%26aufirst%3DJ.%2BG.%26aulast%3DLesslie%26aufirst%3DD.%2BP.%26aulast%3DBaker%26aufirst%3DC.%2BH.%26aulast%3DShakespeare%26aufirst%3DW.%2BC.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DSundaramoorthi%26aufirst%3DR.%26aulast%3DMetcalf%26aufirst%3DC.%2BA.%26aulast%3DKeats%26aufirst%3DJ.%2BA.%26aulast%3DSawyer%26aufirst%3DT.%2BK.%26aulast%3DGallick%26aufirst%3DG.%2BE.%26atitle%3DAP23846%252C%2520a%2520novel%2520and%2520highly%2520potent%2520Src%2520family%2520kinase%2520inhibitor%252C%2520reduces%2520vascular%2520endothelial%2520growth%2520factor%2520and%2520interleukin-8%2520expression%2520in%2520human%2520solid%2520tumor%2520cell%2520lines%2520and%2520abrogates%2520downstream%2520angiogenic%2520processes%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2005%26volume%3D4%26issue%3D12%26spage%3D1900%26epage%3D1911" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group">Azam, M</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nardi, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shakespeare, W. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Metcalf, C. A.,  III</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bohacek, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sundaramoorthi, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sliz, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Veach, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bornmann, W. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clarkson, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dalgarno, D. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sawyer, T. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Daley, G. Q.</span><span> </span><span class="NLM_article-title">Activity of dual SRC-ABL inhibitors highlights the role of BCR/ABL kinase dynamics in drug resistance</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U.S.A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">103</span><span class="NLM_x"> (</span><span class="NLM_issue">24</span><span class="NLM_x">) </span> <span class="NLM_fpage">9244</span><span class="NLM_x">–</span> <span class="NLM_lpage">9249</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=103&publication_year=2006&pages=9244-9249&issue=24&author=M+Azamauthor=V.+Nardiauthor=W.+C.+Shakespeareauthor=C.+A.+Metcalfauthor=R.+S.+Bohacekauthor=Y.+Wangauthor=R.+Sundaramoorthiauthor=P.+Slizauthor=D.+R.+Veachauthor=W.+G.+Bornmannauthor=B.+Clarksonauthor=D.+C.+Dalgarnoauthor=T.+K.+Sawyerauthor=G.+Q.+Daley&title=Activity+of+dual+SRC-ABL+inhibitors+highlights+the+role+of+BCR%2FABL+kinase+dynamics+in+drug+resistance"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DAzam%26aufirst%3DM%26aulast%3DNardi%26aufirst%3DV.%26aulast%3DShakespeare%26aufirst%3DW.%2BC.%26aulast%3DMetcalf%26aufirst%3DC.%2BA.%26aulast%3DBohacek%26aufirst%3DR.%2BS.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DSundaramoorthi%26aufirst%3DR.%26aulast%3DSliz%26aufirst%3DP.%26aulast%3DVeach%26aufirst%3DD.%2BR.%26aulast%3DBornmann%26aufirst%3DW.%2BG.%26aulast%3DClarkson%26aufirst%3DB.%26aulast%3DDalgarno%26aufirst%3DD.%2BC.%26aulast%3DSawyer%26aufirst%3DT.%2BK.%26aulast%3DDaley%26aufirst%3DG.%2BQ.%26atitle%3DActivity%2520of%2520dual%2520SRC-ABL%2520inhibitors%2520highlights%2520the%2520role%2520of%2520BCR%252FABL%2520kinase%2520dynamics%2520in%2520drug%2520resistance%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2006%26volume%3D103%26issue%3D24%26spage%3D9244%26epage%3D9249" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group">Harrington, E. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bebbington, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moore, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rasmussen, R. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ajose-Adeogun, A. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakayama, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Graham, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Demur, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hercend, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Diu-Hercend, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Su, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Golec, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, K. M.</span><span> </span><span class="NLM_article-title">VX-680, a potent and selective small-molecule inhibitor of the Aurora kinases, suppresses tumor growth in vivo</span> <span class="citation_source-journal">Nature Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x"> (</span><span class="NLM_issue">3</span><span class="NLM_x">) </span> <span class="NLM_fpage">262</span><span class="NLM_x">–</span> <span class="NLM_lpage">267</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2004&pages=262-267&issue=3&author=E.+A.+Harringtonauthor=D.+Bebbingtonauthor=J.+Mooreauthor=R.+K.+Rasmussenauthor=A.+O.+Ajose-Adeogunauthor=T.+Nakayamaauthor=J.+A.+Grahamauthor=C.+Demurauthor=T.+Hercendauthor=A.+Diu-Hercendauthor=M.+Suauthor=J.+M.+Golecauthor=K.+M.+Miller&title=VX-680%2C+a+potent+and+selective+small-molecule+inhibitor+of+the+Aurora+kinases%2C+suppresses+tumor+growth+in+vivo"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHarrington%26aufirst%3DE.%2BA.%26aulast%3DBebbington%26aufirst%3DD.%26aulast%3DMoore%26aufirst%3DJ.%26aulast%3DRasmussen%26aufirst%3DR.%2BK.%26aulast%3DAjose-Adeogun%26aufirst%3DA.%2BO.%26aulast%3DNakayama%26aufirst%3DT.%26aulast%3DGraham%26aufirst%3DJ.%2BA.%26aulast%3DDemur%26aufirst%3DC.%26aulast%3DHercend%26aufirst%3DT.%26aulast%3DDiu-Hercend%26aufirst%3DA.%26aulast%3DSu%26aufirst%3DM.%26aulast%3DGolec%26aufirst%3DJ.%2BM.%26aulast%3DMiller%26aufirst%3DK.%2BM.%26atitle%3DVX-680%252C%2520a%2520potent%2520and%2520selective%2520small-molecule%2520inhibitor%2520of%2520the%2520Aurora%2520kinases%252C%2520suppresses%2520tumor%2520growth%2520in%2520vivo%26jtitle%3DNature%2520Med.%26date%3D2004%26volume%3D10%26issue%3D3%26spage%3D262%26epage%3D267" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group">Carter, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wodicka, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shah, N. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Velasco, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fabian, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Treiber, D. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Milanov, Z. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Atteridge, C. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Biggs, W. H.,  3rd</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Edeen, P. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Floyd, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ford, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grotzfeld, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Herrgard, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Insko, D. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mehta, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, H. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pao, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sawyers, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Varmus, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zarrinkar, P. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lockhart, D. J.</span><span> </span><span class="NLM_article-title">Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci U.S.A</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">102</span><span class="NLM_x"> (</span><span class="NLM_issue">31</span><span class="NLM_x">) </span> <span class="NLM_fpage">11011</span><span class="NLM_x">–</span> <span class="NLM_lpage">11016</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=102&publication_year=2005&pages=11011-11016&issue=31&author=T.+A.+Carterauthor=L.+M.+Wodickaauthor=N.+P.+Shahauthor=A.+M.+Velascoauthor=M.+A.+Fabianauthor=D.+K.+Treiberauthor=Z.+V.+Milanovauthor=C.+E.+Atteridgeauthor=W.+H.+Biggsauthor=P.+T.+Edeenauthor=M.+Floydauthor=J.+M.+Fordauthor=R.+M.+Grotzfeldauthor=S.+Herrgardauthor=D.+E.+Inskoauthor=S.+A.+Mehtaauthor=H.+K.+Patelauthor=W.+Paoauthor=C.+L.+Sawyersauthor=H.+Varmusauthor=P.+P.+Zarrinkarauthor=D.+J.+Lockhart&title=Inhibition+of+drug-resistant+mutants+of+ABL%2C+KIT%2C+and+EGF+receptor+kinases"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCarter%26aufirst%3DT.%2BA.%26aulast%3DWodicka%26aufirst%3DL.%2BM.%26aulast%3DShah%26aufirst%3DN.%2BP.%26aulast%3DVelasco%26aufirst%3DA.%2BM.%26aulast%3DFabian%26aufirst%3DM.%2BA.%26aulast%3DTreiber%26aufirst%3DD.%2BK.%26aulast%3DMilanov%26aufirst%3DZ.%2BV.%26aulast%3DAtteridge%26aufirst%3DC.%2BE.%26aulast%3DBiggs%26aufirst%3DW.%2BH.%26aulast%3DEdeen%26aufirst%3DP.%2BT.%26aulast%3DFloyd%26aufirst%3DM.%26aulast%3DFord%26aufirst%3DJ.%2BM.%26aulast%3DGrotzfeld%26aufirst%3DR.%2BM.%26aulast%3DHerrgard%26aufirst%3DS.%26aulast%3DInsko%26aufirst%3DD.%2BE.%26aulast%3DMehta%26aufirst%3DS.%2BA.%26aulast%3DPatel%26aufirst%3DH.%2BK.%26aulast%3DPao%26aufirst%3DW.%26aulast%3DSawyers%26aufirst%3DC.%2BL.%26aulast%3DVarmus%26aufirst%3DH.%26aulast%3DZarrinkar%26aufirst%3DP.%2BP.%26aulast%3DLockhart%26aufirst%3DD.%2BJ.%26atitle%3DInhibition%2520of%2520drug-resistant%2520mutants%2520of%2520ABL%252C%2520KIT%252C%2520and%2520EGF%2520receptor%2520kinases%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci%2520U.S.A%26date%3D2005%26volume%3D102%26issue%3D31%26spage%3D11011%26epage%3D11016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group">Carpinelli, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ceruti, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giorgini, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cappella, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gianellini, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Croci, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Degrassi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Texido, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rocchetti, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vianello, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rusconi, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Storici, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zugnoni, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arrigoni, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Soncini, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alli, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patton, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marsiglio, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ballinari, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pesenti, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fancelli, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moll, J.</span><span> </span><span class="NLM_article-title">PHA-739358, a potent inhibitor of Aurora kinases with a selective target inhibition profile relevant to cancer</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x"> (</span><span class="NLM_issue">12</span><span class="NLM_x">) </span> <span class="NLM_fpage">3158</span><span class="NLM_x">–</span> <span class="NLM_lpage">3168</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Fjm901808w&amp;key=10.1158%2F1535-7163.MCT-07-0444" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Fjm901808w&amp;key=18089710" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Fjm901808w&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhsVCjsr3M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2007&pages=3158-3168&issue=12&author=P.+Carpinelliauthor=R.+Cerutiauthor=M.+L.+Giorginiauthor=P.+Cappellaauthor=L.+Gianelliniauthor=V.+Crociauthor=A.+Degrassiauthor=G.+Texidoauthor=M.+Rocchettiauthor=P.+Vianelloauthor=L.+Rusconiauthor=P.+Storiciauthor=P.+Zugnoniauthor=C.+Arrigoniauthor=C.+Sonciniauthor=C.+Alliauthor=V.+Pattonauthor=A.+Marsiglioauthor=D.+Ballinariauthor=E.+Pesentiauthor=D.+Fancelliauthor=J.+Moll&title=PHA-739358%2C+a+potent+inhibitor+of+Aurora+kinases+with+a+selective+target+inhibition+profile+relevant+to+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">PHA-739358, a potent inhibitor of Aurora kinases with a selective target inhibition profile relevant to cancer</span></div><div class="casAuthors">Carpinelli, Patrizia; Ceruti, Roberta; Giorgini, Maria Laura; Cappella, Paolo; Gianellini, Laura; Croci, Valter; Degrassi, Anna; Texido, Gemma; Rocchetti, Maurizio; Vianello, Paola; Rusconi, Luisa; Storici, Paola; Zugnoni, Paola; Arrigoni, Claudio; Soncini, Chiara; Alli, Cristina; Patton, Veronica; Marsiglio, Aurelio; Ballinari, Dario; Pesenti, Enrico; Fancelli, Daniele; Moll, Juergen</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">12, Pt. 1</span>),
    <span class="NLM_cas:pages">3158-3168</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">PHA-739358 is a small-mol. 3-aminopyrazole deriv. with strong activity against Aurora kinases and cross-reactivities with some receptor tyrosine kinases relevant for cancer.  PHA-739358 inhibits all Aurora kinase family members and shows a dominant Aurora B kinase inhibition-related cellular phenotype and mechanism of action in cells in vitro and in vivo. p53 status-dependent endoreduplication is obsd. upon treatment of cells with PHA-739358, and phosphorylation of histone H3 in Ser10 is inhibited.  The compd. has significant antitumor activity in different xenografts and spontaneous and transgenic animal tumor models and shows a favorable pharmacokinetic and safety profile.  In vivo target modulation is obsd. as assessed by the inhibition of the phosphorylation of histone H3, which has been validated preclinically as a candidate biomarker for the clin. phase.  Pharmacokinetics/pharmacodynamics modeling was used to define drug potency and to support the prediction of active clin. doses and schedules.  We conclude that PHA-739358, which is currently tested in clin. trials, has great therapeutic potential in anticancer therapy in a wide range of cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqfveLDPYzNGLVg90H21EOLACvtfcHk0ljhdeFaAwmmIg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhsVCjsr3M&md5=695fc55d72717a86f96818ca23fc71b8</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-07-0444&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-07-0444%26sid%3Dliteratum%253Aachs%26aulast%3DCarpinelli%26aufirst%3DP.%26aulast%3DCeruti%26aufirst%3DR.%26aulast%3DGiorgini%26aufirst%3DM.%2BL.%26aulast%3DCappella%26aufirst%3DP.%26aulast%3DGianellini%26aufirst%3DL.%26aulast%3DCroci%26aufirst%3DV.%26aulast%3DDegrassi%26aufirst%3DA.%26aulast%3DTexido%26aufirst%3DG.%26aulast%3DRocchetti%26aufirst%3DM.%26aulast%3DVianello%26aufirst%3DP.%26aulast%3DRusconi%26aufirst%3DL.%26aulast%3DStorici%26aufirst%3DP.%26aulast%3DZugnoni%26aufirst%3DP.%26aulast%3DArrigoni%26aufirst%3DC.%26aulast%3DSoncini%26aufirst%3DC.%26aulast%3DAlli%26aufirst%3DC.%26aulast%3DPatton%26aufirst%3DV.%26aulast%3DMarsiglio%26aufirst%3DA.%26aulast%3DBallinari%26aufirst%3DD.%26aulast%3DPesenti%26aufirst%3DE.%26aulast%3DFancelli%26aufirst%3DD.%26aulast%3DMoll%26aufirst%3DJ.%26atitle%3DPHA-739358%252C%2520a%2520potent%2520inhibitor%2520of%2520Aurora%2520kinases%2520with%2520a%2520selective%2520target%2520inhibition%2520profile%2520relevant%2520to%2520cancer%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2007%26volume%3D6%26issue%3D12%26spage%3D3158%26epage%3D3168" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group">Modugno, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Casale, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Soncini, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosettani, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Colombo, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lupi, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rusconi, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fancelli, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carpinelli, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cameron, A. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Isacchi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moll, J.</span><span> </span><span class="NLM_article-title">Crystal structure of the T315I Abl mutant in complex with the aurora kinases inhibitor PHA-739358</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">67</span><span class="NLM_x"> (</span><span class="NLM_issue">17</span><span class="NLM_x">) </span> <span class="NLM_fpage">7987</span><span class="NLM_x">–</span> <span class="NLM_lpage">7990</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=2007&pages=7987-7990&issue=17&author=M.+Modugnoauthor=E.+Casaleauthor=C.+Sonciniauthor=P.+Rosettaniauthor=R.+Colomboauthor=R.+Lupiauthor=L.+Rusconiauthor=D.+Fancelliauthor=P.+Carpinelliauthor=A.+D.+Cameronauthor=A.+Isacchiauthor=J.+Moll&title=Crystal+structure+of+the+T315I+Abl+mutant+in+complex+with+the+aurora+kinases+inhibitor+PHA-739358"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DModugno%26aufirst%3DM.%26aulast%3DCasale%26aufirst%3DE.%26aulast%3DSoncini%26aufirst%3DC.%26aulast%3DRosettani%26aufirst%3DP.%26aulast%3DColombo%26aufirst%3DR.%26aulast%3DLupi%26aufirst%3DR.%26aulast%3DRusconi%26aufirst%3DL.%26aulast%3DFancelli%26aufirst%3DD.%26aulast%3DCarpinelli%26aufirst%3DP.%26aulast%3DCameron%26aufirst%3DA.%2BD.%26aulast%3DIsacchi%26aufirst%3DA.%26aulast%3DMoll%26aufirst%3DJ.%26atitle%3DCrystal%2520structure%2520of%2520the%2520T315I%2520Abl%2520mutant%2520in%2520complex%2520with%2520the%2520aurora%2520kinases%2520inhibitor%2520PHA-739358%26jtitle%3DCancer%2520Res.%26date%3D2007%26volume%3D67%26issue%3D17%26spage%3D7987%26epage%3D7990" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group">Noronha, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cao, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chow, C. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dneprovskaia, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fine, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hood, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klebansky, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lohse, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mak, C. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McPherson, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Palanki, M. S. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pathak, V. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Renick, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Soll, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zeng, B.</span><span> </span><span class="NLM_article-title">Inhibitors of ABL and the ABL-T315I mutation</span> <span class="citation_source-journal">Curr. Top. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x"> (</span><span class="NLM_issue">10</span><span class="NLM_x">) </span> <span class="NLM_fpage">905</span><span class="NLM_x">–</span> <span class="NLM_lpage">921</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Fjm901808w&amp;key=10.2174%2F156802608784911635" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Fjm901808w&amp;key=18673174" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Fjm901808w&amp;key=1%3ACAS%3A528%3ADC%252BD1cXnsVantL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2008&pages=905-921&issue=10&author=G.+Noronhaauthor=J.+Caoauthor=C.+P.+Chowauthor=E.+Dneprovskaiaauthor=R.+M.+Fineauthor=J.+Hoodauthor=X.+Kangauthor=B.+Klebanskyauthor=D.+Lohseauthor=C.+C.+Makauthor=A.+McPhersonauthor=M.+S.+S.+Palankiauthor=V.+P.+Pathakauthor=J.+Renickauthor=R.+Sollauthor=B.+Zeng&title=Inhibitors+of+ABL+and+the+ABL-T315I+mutation"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibitors of ABL and the ABL-T315I mutation</span></div><div class="casAuthors">Noronha, Glenn; Cao, Jianguo; Chow, Chun P.; Dneprovskaia, Elena; Fine, Richard M.; Hood, John; Kang, Xinshan; Klebansky, Boris; Lohse, Dan; Mak, Chi Ching; McPherson, Andrew; Palanki, Moorthy S. S.; Pathak, Ved P.; Renick, Joel; Soll, Richard; Zeng, Binqi</div><div class="citationInfo"><span class="NLM_cas:title">Current Topics in Medicinal Chemistry (Sharjah, United Arab Emirates)</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">905-921</span>CODEN:
                <span class="NLM_cas:coden">CTMCCL</span>;
        ISSN:<span class="NLM_cas:issn">1568-0266</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Chronic myelogenous leukemia (CML) is a hematol. stem cell disorder caused by increased and unregulated growth of myeloid cells in the bone marrow, and the accumulation of excessive white blood cells.  Abelson tyrosine kinase (ABL) is a non-receptor tyrosine kinase involved in cell growth and proliferation and is usually under tight control.  However, 95% of CML patients have the ABL gene from chromosome 9 fused with the breakpoint cluster (BCR) gene from chromosome 22, resulting in a short chromosome known as the Philadelphia chromosome.  This Philadelphia chromosome is responsible for the prodn. of BCR-ABL, a constitutively active tyrosine kinase that causes uncontrolled cellular proliferation.  An ABL inhibitor, imatinib, was approved by the FDA for the treatment of CML, and is currently used as first line therapy.  However, a high percentage of clin. relapse has been obsd. due to long term treatment with imatinib.  A majority of these relapsed patients have several point mutations at and around the ATP binding pocket of the ABL kinase domain in BCR-ABL.  To address the resistance of mutated BCR-ABL to imatinib, 2nd generation inhibitors such as dasatinib, and nilotinib were developed.  These compds. were approved for the treatment of CML patients who are resistant to imatinib.  All of the BCR-ABL mutants are inhibited by the 2nd generation inhibitors with the exception of the T3151 mutant.  Several 3rd generation inhibitors such as AP24534, VX-680 (MK-0457), PHA-739358, PPY-A, XL-228, SGX-70393, FTY720 and TG101113 are being developed to target the T3151 mutation.  The early results from these compds. are encouraging and it is anticipated that physicians will have addnl. drugs at their disposal for the treatment of patients with the mutated BCR-ABL-T315I.  The success of these inhibitors has greater implication not only in CML, but also in other diseases driven by kinases where the mutated gatekeeper residue plays a major role.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpCjbrW8rt8HbVg90H21EOLACvtfcHk0ljhdeFaAwmmIg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXnsVantL8%253D&md5=c61dc3941c9fd71ddd4ed02732e80998</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.2174%2F156802608784911635&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F156802608784911635%26sid%3Dliteratum%253Aachs%26aulast%3DNoronha%26aufirst%3DG.%26aulast%3DCao%26aufirst%3DJ.%26aulast%3DChow%26aufirst%3DC.%2BP.%26aulast%3DDneprovskaia%26aufirst%3DE.%26aulast%3DFine%26aufirst%3DR.%2BM.%26aulast%3DHood%26aufirst%3DJ.%26aulast%3DKang%26aufirst%3DX.%26aulast%3DKlebansky%26aufirst%3DB.%26aulast%3DLohse%26aufirst%3DD.%26aulast%3DMak%26aufirst%3DC.%2BC.%26aulast%3DMcPherson%26aufirst%3DA.%26aulast%3DPalanki%26aufirst%3DM.%2BS.%2BS.%26aulast%3DPathak%26aufirst%3DV.%2BP.%26aulast%3DRenick%26aufirst%3DJ.%26aulast%3DSoll%26aufirst%3DR.%26aulast%3DZeng%26aufirst%3DB.%26atitle%3DInhibitors%2520of%2520ABL%2520and%2520the%2520ABL-T315I%2520mutation%26jtitle%3DCurr.%2520Top.%2520Med.%2520Chem.%26date%3D2008%26volume%3D8%26issue%3D10%26spage%3D905%26epage%3D921" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group">Gumireddy, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baker, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cosenza, S. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">John, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kang, A. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robell, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reddy, M. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reddy, E. P.</span><span> </span><span class="NLM_article-title">A non-ATP-competitive inhibitor of BCR-ABL overrides imatinib resistance</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U.S.A</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">102</span><span class="NLM_x"> (</span><span class="NLM_issue">6</span><span class="NLM_x">) </span> <span class="NLM_fpage">1992</span><span class="NLM_x">–</span> <span class="NLM_lpage">1997</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=102&publication_year=2005&pages=1992-1997&issue=6&author=K.+Gumireddyauthor=S.+J.+Bakerauthor=S.+C.+Cosenzaauthor=P.+Johnauthor=A.+D.+Kangauthor=K.+A.+Robellauthor=M.+V.+Reddyauthor=E.+P.+Reddy&title=A+non-ATP-competitive+inhibitor+of+BCR-ABL+overrides+imatinib+resistance"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGumireddy%26aufirst%3DK.%26aulast%3DBaker%26aufirst%3DS.%2BJ.%26aulast%3DCosenza%26aufirst%3DS.%2BC.%26aulast%3DJohn%26aufirst%3DP.%26aulast%3DKang%26aufirst%3DA.%2BD.%26aulast%3DRobell%26aufirst%3DK.%2BA.%26aulast%3DReddy%26aufirst%3DM.%2BV.%26aulast%3DReddy%26aufirst%3DE.%2BP.%26atitle%3DA%2520non-ATP-competitive%2520inhibitor%2520of%2520BCR-ABL%2520overrides%2520imatinib%2520resistance%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A%26date%3D2005%26volume%3D102%26issue%3D6%26spage%3D1992%26epage%3D1997" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group">Huang, W. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Azam, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wen, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sundaramoorthi, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomas, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Banda, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lentini, S. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Das, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keats, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wardwell, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ning, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Snodgrass, J. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Broudy, M. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Russian, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Daley, G. Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iuliucci, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dalgarno, D. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clackson, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sawyer, T. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shakespeare, W. C.</span><span> </span><span class="NLM_article-title">9-(Arenethenyl)purines as Dual Src/Abl Kinase Inhibitors Targeting the Inactive Conformation: Design, Synthesis, and Biological Evaluation</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">52</span><span class="NLM_x"> (</span><span class="NLM_issue">15</span><span class="NLM_x">) </span> <span class="NLM_fpage">4743</span><span class="NLM_x">–</span> <span class="NLM_lpage">47565</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm900166t" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=4743-47565&issue=15&author=W.+S.+Huangauthor=X.+Zhuauthor=Y.+Wangauthor=M.+Azamauthor=D.+Wenauthor=R.+Sundaramoorthiauthor=R.+M.+Thomasauthor=S.+Liuauthor=G.+Bandaauthor=S.+P.+Lentiniauthor=S.+Dasauthor=Q.+Xuauthor=J.+Keatsauthor=F.+Wangauthor=S.+Wardwellauthor=Y.+Ningauthor=J.+T.+Snodgrassauthor=M.+I.+Broudyauthor=K.+Russianauthor=G.+Q.+Daleyauthor=J.+Iuliucciauthor=D.+C.+Dalgarnoauthor=T.+Clacksonauthor=T.+K.+Sawyerauthor=W.+C.+Shakespeare&title=9-%28Arenethenyl%29purines+as+Dual+Src%2FAbl+Kinase+Inhibitors+Targeting+the+Inactive+Conformation%3A+Design%2C+Synthesis%2C+and+Biological+Evaluation"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1021%2Fjm900166t&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm900166t%26sid%3Dliteratum%253Aachs%26aulast%3DHuang%26aufirst%3DW.%2BS.%26aulast%3DZhu%26aufirst%3DX.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DAzam%26aufirst%3DM.%26aulast%3DWen%26aufirst%3DD.%26aulast%3DSundaramoorthi%26aufirst%3DR.%26aulast%3DThomas%26aufirst%3DR.%2BM.%26aulast%3DLiu%26aufirst%3DS.%26aulast%3DBanda%26aufirst%3DG.%26aulast%3DLentini%26aufirst%3DS.%2BP.%26aulast%3DDas%26aufirst%3DS.%26aulast%3DXu%26aufirst%3DQ.%26aulast%3DKeats%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DF.%26aulast%3DWardwell%26aufirst%3DS.%26aulast%3DNing%26aufirst%3DY.%26aulast%3DSnodgrass%26aufirst%3DJ.%2BT.%26aulast%3DBroudy%26aufirst%3DM.%2BI.%26aulast%3DRussian%26aufirst%3DK.%26aulast%3DDaley%26aufirst%3DG.%2BQ.%26aulast%3DIuliucci%26aufirst%3DJ.%26aulast%3DDalgarno%26aufirst%3DD.%2BC.%26aulast%3DClackson%26aufirst%3DT.%26aulast%3DSawyer%26aufirst%3DT.%2BK.%26aulast%3DShakespeare%26aufirst%3DW.%2BC.%26atitle%3D9-%2528Arenethenyl%2529purines%2520as%2520Dual%2520Src%252FAbl%2520Kinase%2520Inhibitors%2520Targeting%2520the%2520Inactive%2520Conformation%253A%2520Design%252C%2520Synthesis%252C%2520and%2520Biological%2520Evaluation%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26issue%3D15%26spage%3D4743%26epage%3D47565" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group">Seeliger, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ranjitkar, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kasap, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shan, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shaw, D. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shah, N. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuriyan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maly, D. J.</span><span> </span><span class="NLM_article-title">Equally potent inhibition of c-Src and Abl by compounds that recognize inactive kinase conformations</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">69</span><span class="NLM_x"> (</span><span class="NLM_issue">6</span><span class="NLM_x">) </span> <span class="NLM_fpage">2384</span><span class="NLM_x">–</span> <span class="NLM_lpage">2392</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=69&publication_year=2009&pages=2384-2392&issue=6&author=M.+A.+Seeligerauthor=P.+Ranjitkarauthor=C.+Kasapauthor=Y.+Shanauthor=D.+E.+Shawauthor=N.+P.+Shahauthor=J.+Kuriyanauthor=D.+J.+Maly&title=Equally+potent+inhibition+of+c-Src+and+Abl+by+compounds+that+recognize+inactive+kinase+conformations"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSeeliger%26aufirst%3DM.%2BA.%26aulast%3DRanjitkar%26aufirst%3DP.%26aulast%3DKasap%26aufirst%3DC.%26aulast%3DShan%26aufirst%3DY.%26aulast%3DShaw%26aufirst%3DD.%2BE.%26aulast%3DShah%26aufirst%3DN.%2BP.%26aulast%3DKuriyan%26aufirst%3DJ.%26aulast%3DMaly%26aufirst%3DD.%2BJ.%26atitle%3DEqually%2520potent%2520inhibition%2520of%2520c-Src%2520and%2520Abl%2520by%2520compounds%2520that%2520recognize%2520inactive%2520kinase%2520conformations%26jtitle%3DCancer%2520Res.%26date%3D2009%26volume%3D69%26issue%3D6%26spage%3D2384%26epage%3D2392" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group">Dar, A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lopez, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shokat, K. M.</span><span> </span><span class="NLM_article-title">Small molecule recognition of c-Src via the Imatinib-binding conformation</span> <span class="citation_source-journal">Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x"> (</span><span class="NLM_issue">10</span><span class="NLM_x">) </span> <span class="NLM_fpage">1015</span><span class="NLM_x">–</span> <span class="NLM_lpage">1022</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Fjm901808w&amp;key=10.1016%2Fj.chembiol.2008.09.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Fjm901808w&amp;key=18940662" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Fjm901808w&amp;key=1%3ACAS%3A528%3ADC%252BD1cXht1KmsrfP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2008&pages=1015-1022&issue=10&author=A.+C.+Darauthor=M.+S.+Lopezauthor=K.+M.+Shokat&title=Small+molecule+recognition+of+c-Src+via+the+Imatinib-binding+conformation"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Small Molecule Recognition of c-Src via the Imatinib-Binding Conformation</span></div><div class="casAuthors">Dar, Arvin C.; Lopez, Michael S.; Shokat, Kevan M.</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry & Biology (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1015-1022</span>CODEN:
                <span class="NLM_cas:coden">CBOLE2</span>;
        ISSN:<span class="NLM_cas:issn">1074-5521</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Summary: The cancer drug, Imatinib, is a selective Abl kinase inhibitor that does not inhibit the closely related kinase c-Src.  This one drug and its ability to selectively inhibit Abl over c-Src has been a guiding principle in virtually all kinase drug discovery efforts in the last 15 years.  A prominent hypothesis explaining the selectivity of Imatinib is that Abl has an intrinsic ability to adopt an inactive conformation (termed DFG-out), whereas c-Src appears to pay a high intrinsic energetic penalty for adopting this conformation, effectively excluding Imatinib from its ATP pocket.  This explanation of the difference in binding affinity of Imatinib for Abl vs. c-Src makes the striking prediction that it would not be possible to design an inhibitor that binds to the DFG-out conformation of c-Src with high affinity.  The authors report the discovery of a series of such inhibitors.  The authors use structure-activity relationships and x-ray crystallog. to confirm the authors' findings.  These studies suggest that small mols. are capable of inducing the generally unfavorable DFG-out conformation in c-Src.  Structural comparison between c-Src in complex with these inhibitors allows the authors to speculate on the differential selectivity of Imatinib for c-Src and Abl.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpgbxnfmxtR-LVg90H21EOLACvtfcHk0li9Oy_TRW8zxA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXht1KmsrfP&md5=f1047f4a56359511939164a3c2604cb6</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1016%2Fj.chembiol.2008.09.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chembiol.2008.09.007%26sid%3Dliteratum%253Aachs%26aulast%3DDar%26aufirst%3DA.%2BC.%26aulast%3DLopez%26aufirst%3DM.%2BS.%26aulast%3DShokat%26aufirst%3DK.%2BM.%26atitle%3DSmall%2520molecule%2520recognition%2520of%2520c-Src%2520via%2520the%2520Imatinib-binding%2520conformation%26jtitle%3DChem.%2520Biol.%26date%3D2008%26volume%3D15%26issue%3D10%26spage%3D1015%26epage%3D1022" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group">O’Hare, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shakespeare, W. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eide, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rivera, V. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adrian, L. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, W.-S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Metcalf Iii, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tyner, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Loriaux, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Corbin, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wardwell, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ning, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keats, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sundaramoorthi, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomas, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Snodgrass, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Commodore, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sawyer, T. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dalgarno, D. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deininger, M. W. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Druker, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clackson, T.</span><span> </span><span class="NLM_article-title">AP24534, a Pan-BCR-ABL Inhibitor for Chronic Myeloid Leukemia, Potently Inhibits the T315I Mutant and Overcomes Mutation-Based Resistance</span> <span class="citation_source-journal">Cancer Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x"> (</span><span class="NLM_issue">5</span><span class="NLM_x">) </span> <span class="NLM_fpage">401</span><span class="NLM_x">–</span> <span class="NLM_lpage">412</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2009&pages=401-412&issue=5&author=T.+O%E2%80%99Hareauthor=W.+C.+Shakespeareauthor=X.+Zhuauthor=C.+A.+Eideauthor=V.+M.+Riveraauthor=F.+Wangauthor=L.+T.+Adrianauthor=T.+Zhouauthor=W.-S.+Huangauthor=Q.+Xuauthor=C.+A.+Metcalf+Iiiauthor=J.+W.+Tynerauthor=M.+M.+Loriauxauthor=A.+S.+Corbinauthor=S.+Wardwellauthor=Y.+Ningauthor=J.+A.+Keatsauthor=Y.+Wangauthor=R.+Sundaramoorthiauthor=M.+Thomasauthor=D.+Zhouauthor=J.+Snodgrassauthor=L.+Commodoreauthor=T.+K.+Sawyerauthor=D.+C.+Dalgarnoauthor=M.+W.+N.+Deiningerauthor=B.+J.+Drukerauthor=T.+Clackson&title=AP24534%2C+a+Pan-BCR-ABL+Inhibitor+for+Chronic+Myeloid+Leukemia%2C+Potently+Inhibits+the+T315I+Mutant+and+Overcomes+Mutation-Based+Resistance"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DO%25E2%2580%2599Hare%26aufirst%3DT.%26aulast%3DShakespeare%26aufirst%3DW.%2BC.%26aulast%3DZhu%26aufirst%3DX.%26aulast%3DEide%26aufirst%3DC.%2BA.%26aulast%3DRivera%26aufirst%3DV.%2BM.%26aulast%3DWang%26aufirst%3DF.%26aulast%3DAdrian%26aufirst%3DL.%2BT.%26aulast%3DZhou%26aufirst%3DT.%26aulast%3DHuang%26aufirst%3DW.-S.%26aulast%3DXu%26aufirst%3DQ.%26aulast%3DMetcalf%2BIii%26aufirst%3DC.%2BA.%26aulast%3DTyner%26aufirst%3DJ.%2BW.%26aulast%3DLoriaux%26aufirst%3DM.%2BM.%26aulast%3DCorbin%26aufirst%3DA.%2BS.%26aulast%3DWardwell%26aufirst%3DS.%26aulast%3DNing%26aufirst%3DY.%26aulast%3DKeats%26aufirst%3DJ.%2BA.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DSundaramoorthi%26aufirst%3DR.%26aulast%3DThomas%26aufirst%3DM.%26aulast%3DZhou%26aufirst%3DD.%26aulast%3DSnodgrass%26aufirst%3DJ.%26aulast%3DCommodore%26aufirst%3DL.%26aulast%3DSawyer%26aufirst%3DT.%2BK.%26aulast%3DDalgarno%26aufirst%3DD.%2BC.%26aulast%3DDeininger%26aufirst%3DM.%2BW.%2BN.%26aulast%3DDruker%26aufirst%3DB.%2BJ.%26aulast%3DClackson%26aufirst%3DT.%26atitle%3DAP24534%252C%2520a%2520Pan-BCR-ABL%2520Inhibitor%2520for%2520Chronic%2520Myeloid%2520Leukemia%252C%2520Potently%2520Inhibits%2520the%2520T315I%2520Mutant%2520and%2520Overcomes%2520Mutation-Based%2520Resistance%26jtitle%3DCancer%2520Cell%26date%3D2009%26volume%3D16%26issue%3D5%26spage%3D401%26epage%3D412" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group">Okram, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nagle, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adrian, F. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ren, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sim, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xie, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xia, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spraggon, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Warmuth, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gray, N. S.</span><span> </span><span class="NLM_article-title">A general strategy for creating “inactive-conformation” abl inhibitors</span> <span class="citation_source-journal">Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x"> (</span><span class="NLM_issue">7</span><span class="NLM_x">) </span> <span class="NLM_fpage">779</span><span class="NLM_x">–</span> <span class="NLM_lpage">786</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Fjm901808w&amp;key=10.1016%2Fj.chembiol.2006.05.015" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Fjm901808w&amp;key=16873026" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Fjm901808w&amp;key=1%3ACAS%3A528%3ADC%252BD28XntlGisL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2006&pages=779-786&issue=7&author=B.+Okramauthor=A.+Nagleauthor=F.+J.+Adrianauthor=C.+Leeauthor=P.+Renauthor=X.+Wangauthor=T.+Simauthor=Y.+Xieauthor=G.+Xiaauthor=G.+Spraggonauthor=M.+Warmuthauthor=Y.+Liuauthor=N.+S.+Gray&title=A+general+strategy+for+creating+%E2%80%9Cinactive-conformation%E2%80%9D+abl+inhibitors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">A General Strategy for Creating "Inactive-Conformation" Abl Inhibitors</span></div><div class="casAuthors">Okram, Barun; Nagle, Advait; Adrian, Francisco J.; Lee, Christian; Ren, Pingda; Wang, Xia; Sim, Taebo; Xie, Yongping; Wang, Xing; Xia, Gang; Spraggon, Glen; Warmuth, Markus; Liu, Yi; Gray, Nathanael S.</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry & Biology (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">779-786</span>CODEN:
                <span class="NLM_cas:coden">CBOLE2</span>;
        ISSN:<span class="NLM_cas:issn">1074-5521</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Summary: Kinase inhibitors that bind to the ATP cleft can be broadly classified into two groups: Those that bind exclusively to the ATP site with the kinase assuming a conformation otherwise conducive to phosphotransfer (type I), and those that exploit a hydrophobic site immediately adjacent to the ATP pocket made accessible by a conformational rearrangement of the activation loop (type II).  To date, all type II inhibitors were discovered by using structure-activity-guided optimization strategies.  Here, we describe a general pharmacophore model of type II inhibition that enables a rational "hybrid-design" approach whereby a 3-trifluoromethylbenzamide functionality is appended to four distinct type I scaffolds in order to convert them into their corresponding type II counterparts.  We demonstrate that the designed compds. function as type II inhibitors by using biochem. and cellular kinase assays and by cocrystallog. with Abl.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqEmN-Rh-LxOLVg90H21EOLACvtfcHk0lj_6L7uHP36lQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XntlGisL0%253D&md5=84514353c00e20f85225f62d00dc2529</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1016%2Fj.chembiol.2006.05.015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chembiol.2006.05.015%26sid%3Dliteratum%253Aachs%26aulast%3DOkram%26aufirst%3DB.%26aulast%3DNagle%26aufirst%3DA.%26aulast%3DAdrian%26aufirst%3DF.%2BJ.%26aulast%3DLee%26aufirst%3DC.%26aulast%3DRen%26aufirst%3DP.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DSim%26aufirst%3DT.%26aulast%3DXie%26aufirst%3DY.%26aulast%3DXia%26aufirst%3DG.%26aulast%3DSpraggon%26aufirst%3DG.%26aulast%3DWarmuth%26aufirst%3DM.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DGray%26aufirst%3DN.%2BS.%26atitle%3DA%2520general%2520strategy%2520for%2520creating%2520%25E2%2580%259Cinactive-conformation%25E2%2580%259D%2520abl%2520inhibitors%26jtitle%3DChem.%2520Biol.%26date%3D2006%26volume%3D13%26issue%3D7%26spage%3D779%26epage%3D786" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group">Nagar, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bornmann, W. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pellicena, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schindler, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Veach, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, W. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clarkson, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuriyan, J.</span><span> </span><span class="NLM_article-title">Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571)</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">62</span><span class="NLM_x"> (</span><span class="NLM_issue">15</span><span class="NLM_x">) </span> <span class="NLM_fpage">4236</span><span class="NLM_x">–</span> <span class="NLM_lpage">4243</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Fjm901808w&amp;key=12154025" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Fjm901808w&amp;key=1%3ACAS%3A528%3ADC%252BD38XlvFeltLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2002&pages=4236-4243&issue=15&author=B.+Nagarauthor=W.+G.+Bornmannauthor=P.+Pellicenaauthor=T.+Schindlerauthor=D.+R.+Veachauthor=W.+T.+Millerauthor=B.+Clarksonauthor=J.+Kuriyan&title=Crystal+structures+of+the+kinase+domain+of+c-Abl+in+complex+with+the+small+molecule+inhibitors+PD173955+and+imatinib+%28STI-571%29"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571)</span></div><div class="casAuthors">Nagar, Bhushan; Bornmann, William G.; Pellicena, Patricia; Schindler, Thomas; Veach, Darren R.; Miller, W. Todd; Clarkson, Bayard; Kuriyan, John</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">4236-4243</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The inadvertent fusion of the bcr gene with the abl gene results in a constitutively active tyrosine kinase (Bcr-Abl) that transforms cells and causes chronic myelogenous leukemia.  Small mol. inhibitors of Bcr-Abl that bind to the kinase domain can be used to treat chronic myelogenous leukemia.  We report crystal structures of the kinase domain of Abl in complex with two such inhibitors, imatinib (also known as STI-571 and Gleevec) and PD173955 (Parke-Davis).  Both compds. bind to the canonical ATP-binding site of the kinase domain, but they do so in different ways.  As shown previously in a crystal structure of Abl bound to a smaller variant of STI-571, STI-571 captures a specific inactive conformation of the activation loop of Abl in which the loop mimics bound peptide substrate.  In contrast, PD173955 binds to a conformation of Abl in which the activation loop resembles that of an active kinase.  The structure suggests that PD173955 would be insensitive to whether the conformation of the activation loop corresponds to active kinases or to that seen in the STI-571 complex.  In vitro kinase assays confirm that this is the case and indicate that PD173955 is at least 10-fold more inhibitory than STI-571.  The structures suggest that PD173955 achieves its greater potency over STI-571 by being able to target multiple forms of Abl (active or inactive), whereas STI-571 requires a specific inactive conformation of Abl.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp-5qYZHMOZCrVg90H21EOLACvtfcHk0lj_6L7uHP36lQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XlvFeltLY%253D&md5=843213cd6038ed82a0e43dce56e81a91</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DNagar%26aufirst%3DB.%26aulast%3DBornmann%26aufirst%3DW.%2BG.%26aulast%3DPellicena%26aufirst%3DP.%26aulast%3DSchindler%26aufirst%3DT.%26aulast%3DVeach%26aufirst%3DD.%2BR.%26aulast%3DMiller%26aufirst%3DW.%2BT.%26aulast%3DClarkson%26aufirst%3DB.%26aulast%3DKuriyan%26aufirst%3DJ.%26atitle%3DCrystal%2520structures%2520of%2520the%2520kinase%2520domain%2520of%2520c-Abl%2520in%2520complex%2520with%2520the%2520small%2520molecule%2520inhibitors%2520PD173955%2520and%2520imatinib%2520%2528STI-571%2529%26jtitle%3DCancer%2520Res.%26date%3D2002%26volume%3D62%26issue%3D15%26spage%3D4236%26epage%3D4243" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group">Tokarski, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Newitt, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, C. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheng, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wittekind, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kiefer, S. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kish, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, F. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Borzillerri, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lombardo, L. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xie, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klei, H. E.</span><span> </span><span class="NLM_article-title">The structure of Dasatinib (BMS-354825) bound to activated ABL kinase domain elucidates its inhibitory activity against imatinib-resistant ABL mutants</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">66</span><span class="NLM_x"> (</span><span class="NLM_issue">11</span><span class="NLM_x">) </span> <span class="NLM_fpage">5790</span><span class="NLM_x">–</span> <span class="NLM_lpage">5797</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Fjm901808w&amp;key=10.1158%2F0008-5472.CAN-05-4187" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Fjm901808w&amp;key=16740718" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Fjm901808w&amp;key=1%3ACAS%3A528%3ADC%252BD28XltFyjtbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=2006&pages=5790-5797&issue=11&author=J.+S.+Tokarskiauthor=J.+A.+Newittauthor=C.+Y.+Changauthor=J.+D.+Chengauthor=M.+Wittekindauthor=S.+E.+Kieferauthor=K.+Kishauthor=F.+Y.+Leeauthor=R.+Borzillerriauthor=L.+J.+Lombardoauthor=D.+Xieauthor=Y.+Zhangauthor=H.+E.+Klei&title=The+structure+of+Dasatinib+%28BMS-354825%29+bound+to+activated+ABL+kinase+domain+elucidates+its+inhibitory+activity+against+imatinib-resistant+ABL+mutants"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">The Structure of Dasatinib (BMS-354825) Bound to Activated ABL Kinase Domain Elucidates Its Inhibitory Activity against Imatinib-Resistant ABL Mutants</span></div><div class="casAuthors">Tokarski, John S.; Newitt, John A.; Chang, Chieh Ying J.; Cheng, Janet D.; Wittekind, Michael; Kiefer, Susan E.; Kish, Kevin; Lee, Francis Y. F.; Borzillerri, Robert; Lombardo, Louis J.; Xie, Dianlin; Zhang, Yaqun; Klei, Herbert E.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">66</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">5790-5797</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Chronic myeloid leukemia (CML) is caused by the constitutively activated tyrosine kinase breakpoint cluster (BCR)-ABL.  Current frontline therapy for CML is imatinib, an inhibitor of BCR-ABL.  Although imatinib has a high rate of clin. success in early phase CML, treatment resistance is problematic, particularly in later stages of the disease, and is frequently mediated by mutations in BCR-ABL.  Dasatinib (BMS-354825) is a multitargeted tyrosine kinase inhibitor that targets oncogenic pathways and is a more potent inhibitor than imatinib against wild-type BCR-ABL.  It has also shown preclin. activity against all but one of the imatinib-resistant BCR-ABL mutants tested to date.  Anal. of the crystal structure of dasatinib-bound ABL kinase suggests that the increased binding affinity of dasatinib over imatinib is at least partially due to its ability to recognize multiple states of BCR-ABL.  The structure also provides an explanation for the activity of dasatinib against imatinib-resistant BCR-ABL mutants.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqLZE4le_VTErVg90H21EOLACvtfcHk0liAwdWdbP36PA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XltFyjtbw%253D&md5=f48b46b8c7c38a9888a6de41f84c94fa</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-05-4187&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-05-4187%26sid%3Dliteratum%253Aachs%26aulast%3DTokarski%26aufirst%3DJ.%2BS.%26aulast%3DNewitt%26aufirst%3DJ.%2BA.%26aulast%3DChang%26aufirst%3DC.%2BY.%26aulast%3DCheng%26aufirst%3DJ.%2BD.%26aulast%3DWittekind%26aufirst%3DM.%26aulast%3DKiefer%26aufirst%3DS.%2BE.%26aulast%3DKish%26aufirst%3DK.%26aulast%3DLee%26aufirst%3DF.%2BY.%26aulast%3DBorzillerri%26aufirst%3DR.%26aulast%3DLombardo%26aufirst%3DL.%2BJ.%26aulast%3DXie%26aufirst%3DD.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DKlei%26aufirst%3DH.%2BE.%26atitle%3DThe%2520structure%2520of%2520Dasatinib%2520%2528BMS-354825%2529%2520bound%2520to%2520activated%2520ABL%2520kinase%2520domain%2520elucidates%2520its%2520inhibitory%2520activity%2520against%2520imatinib-resistant%2520ABL%2520mutants%26jtitle%3DCancer%2520Res.%26date%3D2006%26volume%3D66%26issue%3D11%26spage%3D5790%26epage%3D5797" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group">Pao, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, V. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Politi, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Riely, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Somwar, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zakowski, M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kris, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Varmus, H.</span><span> </span><span class="NLM_article-title">Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain</span> <span class="citation_source-journal">PLoS Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x"> (</span><span class="NLM_issue">3</span><span class="NLM_x">) </span> <span class="NLM_fpage">e73</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2005&pages=e73&issue=3&author=W.+Paoauthor=V.+A.+Millerauthor=K.+A.+Politiauthor=G.+J.+Rielyauthor=R.+Somwarauthor=M.+F.+Zakowskiauthor=M.+G.+Krisauthor=H.+Varmus&title=Acquired+resistance+of+lung+adenocarcinomas+to+gefitinib+or+erlotinib+is+associated+with+a+second+mutation+in+the+EGFR+kinase+domain"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPao%26aufirst%3DW.%26aulast%3DMiller%26aufirst%3DV.%2BA.%26aulast%3DPoliti%26aufirst%3DK.%2BA.%26aulast%3DRiely%26aufirst%3DG.%2BJ.%26aulast%3DSomwar%26aufirst%3DR.%26aulast%3DZakowski%26aufirst%3DM.%2BF.%26aulast%3DKris%26aufirst%3DM.%2BG.%26aulast%3DVarmus%26aufirst%3DH.%26atitle%3DAcquired%2520resistance%2520of%2520lung%2520adenocarcinomas%2520to%2520gefitinib%2520or%2520erlotinib%2520is%2520associated%2520with%2520a%2520second%2520mutation%2520in%2520the%2520EGFR%2520kinase%2520domain%26jtitle%3DPLoS%2520Med.%26date%3D2005%26volume%3D2%26issue%3D3%26spage%3De73" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group">Fabbro, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ruetz, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bodis, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pruschy, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Csermak, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Man, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Campochiaro, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wood, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Reilly, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyer, T.</span><span> </span><span class="NLM_article-title">PKC412-a protein kinase inhibitor with a broad therapeutic potential</span> <span class="citation_source-journal">Anti-Cancer Drug Des.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x"> (</span><span class="NLM_issue">1</span><span class="NLM_x">) </span> <span class="NLM_fpage">17</span><span class="NLM_x">–</span> <span class="NLM_lpage">28</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2000&pages=17-28&issue=1&author=D.+Fabbroauthor=S.+Ruetzauthor=S.+Bodisauthor=M.+Pruschyauthor=K.+Csermakauthor=A.+Manauthor=P.+Campochiaroauthor=J.+Woodauthor=T.+O%E2%80%99Reillyauthor=T.+Meyer&title=PKC412-a+protein+kinase+inhibitor+with+a+broad+therapeutic+potential"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DFabbro%26aufirst%3DD.%26aulast%3DRuetz%26aufirst%3DS.%26aulast%3DBodis%26aufirst%3DS.%26aulast%3DPruschy%26aufirst%3DM.%26aulast%3DCsermak%26aufirst%3DK.%26aulast%3DMan%26aufirst%3DA.%26aulast%3DCampochiaro%26aufirst%3DP.%26aulast%3DWood%26aufirst%3DJ.%26aulast%3DO%25E2%2580%2599Reilly%26aufirst%3DT.%26aulast%3DMeyer%26aufirst%3DT.%26atitle%3DPKC412-a%2520protein%2520kinase%2520inhibitor%2520with%2520a%2520broad%2520therapeutic%2520potential%26jtitle%3DAnti-Cancer%2520Drug%2520Des.%26date%3D2000%26volume%3D15%26issue%3D1%26spage%3D17%26epage%3D28" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group">Cools, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mentens, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Furet, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fabbro, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clark, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Griffin, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marynen, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gilliland, D. G.</span><span> </span><span class="NLM_article-title">Prediction of resistance to small molecule FLT3 inhibitors: implications for molecularly targeted therapy of acute leukemia</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">64</span><span class="NLM_x"> (</span><span class="NLM_issue">18</span><span class="NLM_x">) </span> <span class="NLM_fpage">6385</span><span class="NLM_x">–</span> <span class="NLM_lpage">6389</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=2004&pages=6385-6389&issue=18&author=J.+Coolsauthor=N.+Mentensauthor=P.+Furetauthor=D.+Fabbroauthor=J.+J.+Clarkauthor=J.+D.+Griffinauthor=P.+Marynenauthor=D.+G.+Gilliland&title=Prediction+of+resistance+to+small+molecule+FLT3+inhibitors%3A+implications+for+molecularly+targeted+therapy+of+acute+leukemia"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCools%26aufirst%3DJ.%26aulast%3DMentens%26aufirst%3DN.%26aulast%3DFuret%26aufirst%3DP.%26aulast%3DFabbro%26aufirst%3DD.%26aulast%3DClark%26aufirst%3DJ.%2BJ.%26aulast%3DGriffin%26aufirst%3DJ.%2BD.%26aulast%3DMarynen%26aufirst%3DP.%26aulast%3DGilliland%26aufirst%3DD.%2BG.%26atitle%3DPrediction%2520of%2520resistance%2520to%2520small%2520molecule%2520FLT3%2520inhibitors%253A%2520implications%2520for%2520molecularly%2520targeted%2520therapy%2520of%2520acute%2520leukemia%26jtitle%3DCancer%2520Res.%26date%3D2004%26volume%3D64%26issue%3D18%26spage%3D6385%26epage%3D6389" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Cools, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DeAngelo, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gotlib, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stover, E. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Legare, R. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cortes, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kutok, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clark, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Galinsky, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Griffin, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cross, N. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tefferi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Malone, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alam, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schrier, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schmid, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rose, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vandenberghe, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Verhoef, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boogaerts, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wlodarska, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kantarjian, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marynen, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coutre, S. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stone, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gilliland, D. G.</span><span> </span><span class="NLM_article-title">A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">348</span><span class="NLM_x"> (</span><span class="NLM_issue">13</span><span class="NLM_x">) </span> <span class="NLM_fpage">1201</span><span class="NLM_x">–</span> <span class="NLM_lpage">1214</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25a&amp;dbid=16&amp;doi=10.1021%2Fjm901808w&amp;key=10.1056%2FNEJMoa025217" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25a&amp;dbid=8&amp;doi=10.1021%2Fjm901808w&amp;key=12660384" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25a&amp;dbid=32&amp;doi=10.1021%2Fjm901808w&amp;key=1%3ACAS%3A528%3ADC%252BD3sXisVCqtrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=348&publication_year=2003&pages=1201-1214&issue=13&author=J.+Coolsauthor=D.+J.+DeAngeloauthor=J.+Gotlibauthor=E.+H.+Stoverauthor=R.+D.+Legareauthor=J.+Cortesauthor=J.+Kutokauthor=J.+Clarkauthor=I.+Galinskyauthor=J.+D.+Griffinauthor=N.+C.+Crossauthor=A.+Tefferiauthor=J.+Maloneauthor=R.+Alamauthor=S.+L.+Schrierauthor=J.+Schmidauthor=M.+Roseauthor=P.+Vandenbergheauthor=G.+Verhoefauthor=M.+Boogaertsauthor=I.+Wlodarskaauthor=H.+Kantarjianauthor=P.+Marynenauthor=S.+E.+Coutreauthor=R.+Stoneauthor=D.+G.+Gilliland&title=A+tyrosine+kinase+created+by+fusion+of+the+PDGFRA+and+FIP1L1+genes+as+a+therapeutic+target+of+imatinib+in+idiopathic+hypereosinophilic+syndrome"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25aR"><div class="casContent"><span class="casTitleNuber">25a</span><div class="casTitle"><span class="NLM_cas:atitle">A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome</span></div><div class="casAuthors">Cools, Jan; Daniel, Ph. D.; DeAngelo, J.; Gotlib, Jason; Stover, Elizabeth H.; Phil, M.; Legare, Robert D.; Cortes, Jorges; Lutok, Jeffrey; Clark, Jennifer; Galinsky, Ilene; Griffin, James D.; Cross, Nicholas, C. P.; Tefferi, Ayalew; Malone, James; Alam, Fafeul; Schrier, Stanley L.; Schmid, Janet; Rose, Michal; Vandenberghe, Peter; Verhoef, Gregor; Boogaerts, Marc; Wlodarska, Iwona; Kantarjian, Hagop; Marynen, Peter; Coutre, Steven E.; Stone, Richard; Gilliland, D. Gary</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">348</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">1201-1214</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Idiopathic hypereosinophilic syndrome involves a prolonged state of eosinophilia assocd. with organ dysfunction.  It is of unknown cause.  Recent reports of responses to imatinib in patients with the syndrome suggested that an activated kinase such as ABL, platelet-derived growth factor receptor (PDGFR), or KIT, all of which are inhibited by imatinib, might be the cause.  We treated 11 patients with the hypereosinophilic syndrome with imatinib and identified the mol. basis for the response.  Nine of the 11 patients treated with imatinib had responses lasting more than three months in which the eosinophil count returned to normal.  One such patient had a complex chromosomal abnormality, leading to the identification of a fusion of the Fip1H-like 1 (FIP1L1) gene to the PDGFRα (PDGFRA) gene generated by an interstitial deletion on chromosome 4q12.  FIP1L1-PDGFRα is a constitutively activated tyrosine kinase that transforms hematopoietic cells and is inhibited by imatinib (50% inhibitory concn., 3.2 nM).  The FIP1L1-PDGFRA fusion gene was subsequently detected in 9 of 16 patients with the syndrome and in 5 of the 9 patients with responses to imatinib that lasted more than three months.  Relapse in one patient correlated with the appearance of a T674I mutation in PDGFRA that confers resistance to imatinib.  The hypereosinophilic syndrome may result from a novel fusion tyrosine kinase-FIP1L1-PDGFRα-that is a consequence of an interstitial chromosomal deletion.  The acquisition of a T674I resistance mutation at the time of relapse demonstrates that FIP1L1-PDGFRα is the target of imatinib.  Our data indicate that the deletion of genetic material may result in gain-of-function fusion proteins.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo_ae4JFIom8LVg90H21EOLACvtfcHk0ljmbIbWhUqv8w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXisVCqtrY%253D&md5=1f0cc5760c701bf0ae35bcb7c0727d65</span></div><a href="/servlet/linkout?suffix=cit25a&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa025217&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa025217%26sid%3Dliteratum%253Aachs%26aulast%3DCools%26aufirst%3DJ.%26aulast%3DDeAngelo%26aufirst%3DD.%2BJ.%26aulast%3DGotlib%26aufirst%3DJ.%26aulast%3DStover%26aufirst%3DE.%2BH.%26aulast%3DLegare%26aufirst%3DR.%2BD.%26aulast%3DCortes%26aufirst%3DJ.%26aulast%3DKutok%26aufirst%3DJ.%26aulast%3DClark%26aufirst%3DJ.%26aulast%3DGalinsky%26aufirst%3DI.%26aulast%3DGriffin%26aufirst%3DJ.%2BD.%26aulast%3DCross%26aufirst%3DN.%2BC.%26aulast%3DTefferi%26aufirst%3DA.%26aulast%3DMalone%26aufirst%3DJ.%26aulast%3DAlam%26aufirst%3DR.%26aulast%3DSchrier%26aufirst%3DS.%2BL.%26aulast%3DSchmid%26aufirst%3DJ.%26aulast%3DRose%26aufirst%3DM.%26aulast%3DVandenberghe%26aufirst%3DP.%26aulast%3DVerhoef%26aufirst%3DG.%26aulast%3DBoogaerts%26aufirst%3DM.%26aulast%3DWlodarska%26aufirst%3DI.%26aulast%3DKantarjian%26aufirst%3DH.%26aulast%3DMarynen%26aufirst%3DP.%26aulast%3DCoutre%26aufirst%3DS.%2BE.%26aulast%3DStone%26aufirst%3DR.%26aulast%3DGilliland%26aufirst%3DD.%2BG.%26atitle%3DA%2520tyrosine%2520kinase%2520created%2520by%2520fusion%2520of%2520the%2520PDGFRA%2520and%2520FIP1L1%2520genes%2520as%2520a%2520therapeutic%2520target%2520of%2520imatinib%2520in%2520idiopathic%2520hypereosinophilic%2520syndrome%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2003%26volume%3D348%26issue%3D13%26spage%3D1201%26epage%3D1214" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit25b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Blencke, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zech, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Engkvist, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greff, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Orfi, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Horvath, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keri, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ullrich, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Daub, H.</span><span> </span><span class="NLM_article-title">Characterization of a conserved structural determinant controlling protein kinase sensitivity to selective inhibitors</span> <span class="citation_source-journal">Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x"> (</span><span class="NLM_issue">5</span><span class="NLM_x">) </span> <span class="NLM_fpage">691</span><span class="NLM_x">–</span> <span class="NLM_lpage">701</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25b&amp;dbid=16&amp;doi=10.1021%2Fjm901808w&amp;key=10.1016%2Fj.chembiol.2004.02.029" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25b&amp;dbid=8&amp;doi=10.1021%2Fjm901808w&amp;key=15157880" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25b&amp;dbid=32&amp;doi=10.1021%2Fjm901808w&amp;key=1%3ACAS%3A528%3ADC%252BD2cXktF2qsro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2004&pages=691-701&issue=5&author=S.+Blenckeauthor=B.+Zechauthor=O.+Engkvistauthor=Z.+Greffauthor=L.+Orfiauthor=Z.+Horvathauthor=G.+Keriauthor=A.+Ullrichauthor=H.+Daub&title=Characterization+of+a+conserved+structural+determinant+controlling+protein+kinase+sensitivity+to+selective+inhibitors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25bR"><div class="casContent"><span class="casTitleNuber">25b</span><div class="casTitle"><span class="NLM_cas:atitle">Characterization of a Conserved Structural Determinant Controlling Protein Kinase Sensitivity to Selective Inhibitors</span></div><div class="casAuthors">Blencke, Stephanie; Zech, Birgit; Engkvist, Ola; Greff, Zoltan; Orfi, Laszlo; Horvath, Zoltan; Keri, Gyoergy; Ullrich, Axel; Daub, Henrik</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry & Biology</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">691-701</span>CODEN:
                <span class="NLM_cas:coden">CBOLE2</span>;
        ISSN:<span class="NLM_cas:issn">1074-5521</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Some protein kinases are known to acquire resistance to selective small mol. inhibitors upon mutation of a conserved threonine at the ATP binding site to a larger residue.  Here, we performed a comprehensive mutational anal. of this structural element and detd. the cellular sensitivities of several disease-relevant tyrosine kinases against various inhibitors.  Mutant kinases possessing a larger side chain at the crit. site showed resistance to most compds. tested, such as ZD1839, PP1, AG1296, STI571, and a pyrido[2,3-d]pyrimidine inhibitor.  In contrast, indolinones affected both wild-type and mutant kinases with similar potencies.  Resistant mutants were established for pharmacol. anal. of βPDGF receptor-mediated signaling and allowed the generation of a drug-inducible system of cellular Src kinase activity.  Our data establish a conserved structural determinant of protein kinase sensitivity relevant for both signal transduction research and drug development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqWLToAufPZDbVg90H21EOLACvtfcHk0ljmbIbWhUqv8w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXktF2qsro%253D&md5=3224f7453efd9b60f5102e300d195aa0</span></div><a href="/servlet/linkout?suffix=cit25b&amp;dbid=16384&amp;doi=10.1016%2Fj.chembiol.2004.02.029&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chembiol.2004.02.029%26sid%3Dliteratum%253Aachs%26aulast%3DBlencke%26aufirst%3DS.%26aulast%3DZech%26aufirst%3DB.%26aulast%3DEngkvist%26aufirst%3DO.%26aulast%3DGreff%26aufirst%3DZ.%26aulast%3DOrfi%26aufirst%3DL.%26aulast%3DHorvath%26aufirst%3DZ.%26aulast%3DKeri%26aufirst%3DG.%26aulast%3DUllrich%26aufirst%3DA.%26aulast%3DDaub%26aufirst%3DH.%26atitle%3DCharacterization%2520of%2520a%2520conserved%2520structural%2520determinant%2520controlling%2520protein%2520kinase%2520sensitivity%2520to%2520selective%2520inhibitors%26jtitle%3DChem.%2520Biol.%26date%3D2004%26volume%3D11%26issue%3D5%26spage%3D691%26epage%3D701" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group">Kraker, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hartl, B. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Amar, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barvian, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Showalter, H. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moore, C. W.</span><span> </span><span class="NLM_article-title">Biochemical and cellular effects of c-Src kinase-selective pyrido[2,3-<i>d</i>]pyrimidine tyrosine kinase inhibitors</span> <span class="citation_source-journal">Biochem. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">60</span><span class="NLM_x"> (</span><span class="NLM_issue">7</span><span class="NLM_x">) </span> <span class="NLM_fpage">885</span><span class="NLM_x">–</span> <span class="NLM_lpage">898</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2000&pages=885-898&issue=7&author=A.+J.+Krakerauthor=B.+G.+Hartlauthor=A.+M.+Amarauthor=M.+R.+Barvianauthor=H.+D.+Showalterauthor=C.+W.+Moore&title=Biochemical+and+cellular+effects+of+c-Src+kinase-selective+pyrido%5B2%2C3-d%5Dpyrimidine+tyrosine+kinase+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKraker%26aufirst%3DA.%2BJ.%26aulast%3DHartl%26aufirst%3DB.%2BG.%26aulast%3DAmar%26aufirst%3DA.%2BM.%26aulast%3DBarvian%26aufirst%3DM.%2BR.%26aulast%3DShowalter%26aufirst%3DH.%2BD.%26aulast%3DMoore%26aufirst%3DC.%2BW.%26atitle%3DBiochemical%2520and%2520cellular%2520effects%2520of%2520c-Src%2520kinase-selective%2520pyrido%255B2%252C3-d%255Dpyrimidine%2520tyrosine%2520kinase%2520inhibitors%26jtitle%3DBiochem.%2520Pharmacol.%26date%3D2000%26volume%3D60%26issue%3D7%26spage%3D885%26epage%3D898" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Panek, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, G. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klutchko, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Batley, B. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dahring, T. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hamby, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hallak, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Doherty, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keiser, J. A.</span><span> </span><span class="NLM_article-title">In vitro pharmacological characterization of PD 166285, a new nanomolar potent and broadly active protein tyrosine kinase inhibitor</span> <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">283</span><span class="NLM_x"> (</span><span class="NLM_issue">3</span><span class="NLM_x">) </span> <span class="NLM_fpage">1433</span><span class="NLM_x">–</span> <span class="NLM_lpage">1444</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27a&amp;dbid=8&amp;doi=10.1021%2Fjm901808w&amp;key=9400019" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27a&amp;dbid=32&amp;doi=10.1021%2Fjm901808w&amp;key=1%3ACAS%3A528%3ADyaK1cXis1Kgtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=283&publication_year=1997&pages=1433-1444&issue=3&author=R.+L.+Panekauthor=G.+H.+Luauthor=S.+R.+Klutchkoauthor=B.+L.+Batleyauthor=T.+K.+Dahringauthor=J.+M.+Hambyauthor=H.+Hallakauthor=A.+M.+Dohertyauthor=J.+A.+Keiser&title=In+vitro+pharmacological+characterization+of+PD+166285%2C+a+new+nanomolar+potent+and+broadly+active+protein+tyrosine+kinase+inhibitor"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27aR"><div class="casContent"><span class="casTitleNuber">27a</span><div class="casTitle"><span class="NLM_cas:atitle">In vitro pharmacological characterization of PD 166285, a new nanomolar potent and broadly active protein tyrosine kinase inhibitor</span></div><div class="casAuthors">Panek, Robert L.; Lu, Gina H.; Klutchko, Sylvester R.; Batley, Brian L.; Dahring, Tawny K.; Hamby, James M.; Hallak, Hussein; Doherty, Annette M.; Keiser, Joan A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">283</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1433-1444</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">Williams & Wilkins</span>)
        </div><div class="casAbstract">PD 166285, a novel protein tyrosine kinase inhibitor of a new structural class, the 6-aryl-pyrido[2,3-d]pyrimidines, was synthesized as the most potent and sol. analog of a series of small mols. originally identified by screening a compd. library with assays that measured protein tyrosine kinase activity.  PD 166285 was found to inhibit Src nonreceptor tyrosine kinase, fibroblast growth factor receptor-1, epidermal growth factor receptor and platelet-derived growth factor receptor beta subunit (PDGFR-β), tyrosine kinases with half-maximal inhibitory potencies (IC50 values) of 8.4 ± 2.3 nM (n = 6), 39.3 ± 2.8 nM (n = 16), 87.5 ± 13.7 nM (n = 6) and 98.3 ± 7.9 nM (n = 16), resp.  PD 166285 also demonstrated inhibitory activity against mitogen-activated protein kinase (IC50 = 5 μM) and protein kinase C (IC50 = 22.7 μM).  PD 166285 was further characterized as an ATP competitive inhibitor of Src nonreceptor tyrosine kinase, PDGFR-β, fibroblast growth factor receptor-1 and epidermal growth factor receptor tyrosine kinases.  In addn., PD 166285 inhibited PDGF- and EGF-stimulated receptor autophosphorylation in vascular smooth muscle cells (VSMCs) and A431 cells, resp., and basic fibroblast growth factor-mediated tyrosine phosphorylation in Sf9 cells, with IC50 values of 6.5 nM, 1.6 μM and 97.3 nM, resp., further establishing a tyrosine kinase mechanism of inhibition.  The inhibition of PDGF receptor autophosphorylation in VSMCs by PD 166285 was long lasting and persisted for 4 days after a single 1-h exposure followed by extensive washing.  The PDGF-induced tyrosine phosphorylation of the 44- and 42-kDa mitogen-activated protein kinase isoforms was also blocked as a result of the inhibition of PDGF-stimulated receptor autophosphorylation by PD 166285 in VSMCs.  The effects of PD 166285 were also demonstrated in functional assays of cell attachment, migration and proliferation, in which vascular cell adhesion to vitronectin, PDGF-directed chemotaxis and serum-stimulated cell growth were all potently inhibited with IC50 values of 80 yo 120 nM.  Finally, PD 166285 uniquely demonstrated potent inhibition of phorbol ester-induced prodn. of 92-kDa gelatinase A (MMP-9) in VSMC without affecting 72-kDa gelatinase B (MMP-2) as measured by gelatin zymog.  These results highlight the biol. characteristics of PD 166285 as a broadly active protein tyrosine kinase capable of potently inhibiting a no. of kinase mediated cellular functions, including cell attachment, movement and replication.  The potential therapeutic utility of this broadly acting inhibitor as an antiproliferative and antimigratory agent could extend to such diseases as cancer, atherosclerosis and restenosis, in which redundancies in protein kinase signaling pathways are known to exist.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrHoOZBC_QVz7Vg90H21EOLACvtfcHk0ljTK61b1MUPfw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXis1Kgtw%253D%253D&md5=3e7482966affffd55ac16f0f9b8d600e</span></div><a href="/servlet/linkout?suffix=cit27a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPanek%26aufirst%3DR.%2BL.%26aulast%3DLu%26aufirst%3DG.%2BH.%26aulast%3DKlutchko%26aufirst%3DS.%2BR.%26aulast%3DBatley%26aufirst%3DB.%2BL.%26aulast%3DDahring%26aufirst%3DT.%2BK.%26aulast%3DHamby%26aufirst%3DJ.%2BM.%26aulast%3DHallak%26aufirst%3DH.%26aulast%3DDoherty%26aufirst%3DA.%2BM.%26aulast%3DKeiser%26aufirst%3DJ.%2BA.%26atitle%3DIn%2520vitro%2520pharmacological%2520characterization%2520of%2520PD%2520166285%252C%2520a%2520new%2520nanomolar%2520potent%2520and%2520broadly%2520active%2520protein%2520tyrosine%2520kinase%2520inhibitor%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D1997%26volume%3D283%26issue%3D3%26spage%3D1433%26epage%3D1444" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit27b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Klutchko, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hamby, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boschelli, D. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kraker, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Amar, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hartl, B. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shen, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klohs, W. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steinkampf, R. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Driscoll, D. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nelson, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Elliott, W. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roberts, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stoner, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vincent, P. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dykes, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Panek, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, G. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Major, T. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dahring, T. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hallak, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bradford, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Showalter, H. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Doherty, A. M.</span><span> </span><span class="NLM_article-title">2-Substituted aminopyrido[2,3-<i>d</i>]pyrimidin-7(8<i>H</i>)-ones. Structure−activity relationships against selected tyrosine kinases and in vitro and in vivo anticancer activity</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">41</span><span class="NLM_x"> (</span><span class="NLM_issue">17</span><span class="NLM_x">) </span> <span class="NLM_fpage">3276</span><span class="NLM_x">–</span> <span class="NLM_lpage">3292</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm9802259" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=1998&pages=3276-3292&issue=17&author=S.+R.+Klutchkoauthor=J.+M.+Hambyauthor=D.+H.+Boschelliauthor=Z.+Wuauthor=A.+J.+Krakerauthor=A.+M.+Amarauthor=B.+G.+Hartlauthor=C.+Shenauthor=W.+D.+Klohsauthor=R.+W.+Steinkampfauthor=D.+L.+Driscollauthor=J.+M.+Nelsonauthor=W.+L.+Elliottauthor=B.+J.+Robertsauthor=C.+L.+Stonerauthor=P.+W.+Vincentauthor=D.+J.+Dykesauthor=R.+L.+Panekauthor=G.+H.+Luauthor=T.+C.+Majorauthor=T.+K.+Dahringauthor=H.+Hallakauthor=L.+A.+Bradfordauthor=H.+D.+Showalterauthor=A.+M.+Doherty&title=2-Substituted+aminopyrido%5B2%2C3-d%5Dpyrimidin-7%288H%29-ones.+Structure%E2%88%92activity+relationships+against+selected+tyrosine+kinases+and+in+vitro+and+in+vivo+anticancer+activity"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit27b&amp;dbid=16384&amp;doi=10.1021%2Fjm9802259&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm9802259%26sid%3Dliteratum%253Aachs%26aulast%3DKlutchko%26aufirst%3DS.%2BR.%26aulast%3DHamby%26aufirst%3DJ.%2BM.%26aulast%3DBoschelli%26aufirst%3DD.%2BH.%26aulast%3DWu%26aufirst%3DZ.%26aulast%3DKraker%26aufirst%3DA.%2BJ.%26aulast%3DAmar%26aufirst%3DA.%2BM.%26aulast%3DHartl%26aufirst%3DB.%2BG.%26aulast%3DShen%26aufirst%3DC.%26aulast%3DKlohs%26aufirst%3DW.%2BD.%26aulast%3DSteinkampf%26aufirst%3DR.%2BW.%26aulast%3DDriscoll%26aufirst%3DD.%2BL.%26aulast%3DNelson%26aufirst%3DJ.%2BM.%26aulast%3DElliott%26aufirst%3DW.%2BL.%26aulast%3DRoberts%26aufirst%3DB.%2BJ.%26aulast%3DStoner%26aufirst%3DC.%2BL.%26aulast%3DVincent%26aufirst%3DP.%2BW.%26aulast%3DDykes%26aufirst%3DD.%2BJ.%26aulast%3DPanek%26aufirst%3DR.%2BL.%26aulast%3DLu%26aufirst%3DG.%2BH.%26aulast%3DMajor%26aufirst%3DT.%2BC.%26aulast%3DDahring%26aufirst%3DT.%2BK.%26aulast%3DHallak%26aufirst%3DH.%26aulast%3DBradford%26aufirst%3DL.%2BA.%26aulast%3DShowalter%26aufirst%3DH.%2BD.%26aulast%3DDoherty%26aufirst%3DA.%2BM.%26atitle%3D2-Substituted%2520aminopyrido%255B2%252C3-d%255Dpyrimidin-7%25288H%2529-ones.%2520Structure%25E2%2588%2592activity%2520relationships%2520against%2520selected%2520tyrosine%2520kinases%2520and%2520in%2520vitro%2520and%2520in%2520vivo%2520anticancer%2520activity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1998%26volume%3D41%26issue%3D17%26spage%3D3276%26epage%3D3292" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Dorsey, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jove, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kraker, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, J.</span><span> </span><span class="NLM_article-title">The pyrido[2,3-<i>d</i>]pyrimidine derivative PD180970 inhibits p210Bcr-Abl tyrosine kinase and induces apoptosis of K562 leukemic cells</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">60</span><span class="NLM_x"> (</span><span class="NLM_issue">12</span><span class="NLM_x">) </span> <span class="NLM_fpage">3127</span><span class="NLM_x">–</span> <span class="NLM_lpage">3131</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2000&pages=3127-3131&issue=12&author=J.+F.+Dorseyauthor=R.+Joveauthor=A.+J.+Krakerauthor=J.+Wu&title=The+pyrido%5B2%2C3-d%5Dpyrimidine+derivative+PD180970+inhibits+p210Bcr-Abl+tyrosine+kinase+and+induces+apoptosis+of+K562+leukemic+cells"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DDorsey%26aufirst%3DJ.%2BF.%26aulast%3DJove%26aufirst%3DR.%26aulast%3DKraker%26aufirst%3DA.%2BJ.%26aulast%3DWu%26aufirst%3DJ.%26atitle%3DThe%2520pyrido%255B2%252C3-d%255Dpyrimidine%2520derivative%2520PD180970%2520inhibits%2520p210Bcr-Abl%2520tyrosine%2520kinase%2520and%2520induces%2520apoptosis%2520of%2520K562%2520leukemic%2520cells%26jtitle%3DCancer%2520Res.%26date%3D2000%26volume%3D60%26issue%3D12%26spage%3D3127%26epage%3D3131" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit28b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Wisniewski, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lambek, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Strife, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Veach, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nagar, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Young, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schindler, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bornmann, W. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bertino, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuriyan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clarkson, B.</span><span> </span><span class="NLM_article-title">Characterization of potent inhibitors of the Bcr-Abl and the c-kit receptor tyrosine kinases</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">62</span><span class="NLM_x"> (</span><span class="NLM_issue">15</span><span class="NLM_x">) </span> <span class="NLM_fpage">4244</span><span class="NLM_x">–</span> <span class="NLM_lpage">4255</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28b&amp;dbid=8&amp;doi=10.1021%2Fjm901808w&amp;key=12154026" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28b&amp;dbid=32&amp;doi=10.1021%2Fjm901808w&amp;key=1%3ACAS%3A528%3ADC%252BD38XlvFeltLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2002&pages=4244-4255&issue=15&author=D.+Wisniewskiauthor=C.+L.+Lambekauthor=C.+Liuauthor=A.+Strifeauthor=D.+R.+Veachauthor=B.+Nagarauthor=M.+A.+Youngauthor=T.+Schindlerauthor=W.+G.+Bornmannauthor=J.+R.+Bertinoauthor=J.+Kuriyanauthor=B.+Clarkson&title=Characterization+of+potent+inhibitors+of+the+Bcr-Abl+and+the+c-kit+receptor+tyrosine+kinases"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28bR"><div class="casContent"><span class="casTitleNuber">28b</span><div class="casTitle"><span class="NLM_cas:atitle">Characterization of potent inhibitors of the Bcr-Abl and the c-kit receptor tyrosine kinases</span></div><div class="casAuthors">Wisniewski, David; Lambek, Caryl L.; Liu, Chongyuan; Strife, Annabel; Veach, Darren R.; Nagar, Bhushan; Young, Matthew A.; Schindler, Thomas; Bornmann, William G.; Bertino, Joseph R.; Kuriyan, John; Clarkson, Bayard</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">4244-4255</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The early stage of chronic myelogenous leukemia (CML) is caused by the tyrosine kinase Bcr-Abl.  Imatinib mesylate (also known as STI-571 and Gleevec), a tyrosine kinase inhibitor, has shown encouraging results in CML clin. trials and has become a paradigm for targeted cancer therapeutics.  Recent reports of resistance to imatinib argue for further development of therapies for CML.  During studies of signal transduction, we obsd. that the pyrido[2,3-d]pyrimidine src tyrosine kinase inhibitor PD173955 inhibited Bcr-Abl-dependent cell growth.  Subsequently, a related compd., PD180970, was reported as a potent inhibitor of Bcr-Abl.  We have compared the potency of these two compds. and four other analogs with imatinib on Bcr-Abl-dependent cell growth, cytokine-dependent cell growth, and tyrosine kinase inhibition.  PD173955 inhibited Bcr-Abl-dependent cell growth with an IC50 of 2-35 nM in different cell lines.  Fluorescence-activated cell-sorting analyses of cells treated with PD173955 showed cell cycle arrest in G1.  PD173955 has an IC50 of 1-2 nM in kinase inhibition assays of Bcr-Abl, and in cellular growth assays it inhibits Bcr-Abl-dependent substrate tyrosine phosphorylation.  Of the six pyrido[2,3-d]pyrimidine analogs studied, PD166326 was the most potent inhibitor of Bcr-Abl-dependent cell growth.  PD173955 inhibited kit ligand-dependent c-kit autophosphorylation (IC50 = ∼25 nM) and kit ligand-dependent proliferation of M07e cells (IC50 = 40 nM) but had a lesser effect on interleukin 3-dependent (IC50 = 250 nM) or granulocyte macrophage colony-stimulating factor (IC50 = 1 μM)-dependent cell growth.  These compds. are potent inhibitors of both the Bcr-Abl and c-kit receptor tyrosine kinases and deserve further study as potential treatments for both CML and for diseases in which c-kit has a role.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq6S_NVW4-7b7Vg90H21EOLACvtfcHk0ljTK61b1MUPfw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XlvFeltLc%253D&md5=4c570635dc54053856a8fb14e10aefa6</span></div><a href="/servlet/linkout?suffix=cit28b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWisniewski%26aufirst%3DD.%26aulast%3DLambek%26aufirst%3DC.%2BL.%26aulast%3DLiu%26aufirst%3DC.%26aulast%3DStrife%26aufirst%3DA.%26aulast%3DVeach%26aufirst%3DD.%2BR.%26aulast%3DNagar%26aufirst%3DB.%26aulast%3DYoung%26aufirst%3DM.%2BA.%26aulast%3DSchindler%26aufirst%3DT.%26aulast%3DBornmann%26aufirst%3DW.%2BG.%26aulast%3DBertino%26aufirst%3DJ.%2BR.%26aulast%3DKuriyan%26aufirst%3DJ.%26aulast%3DClarkson%26aufirst%3DB.%26atitle%3DCharacterization%2520of%2520potent%2520inhibitors%2520of%2520the%2520Bcr-Abl%2520and%2520the%2520c-kit%2520receptor%2520tyrosine%2520kinases%26jtitle%3DCancer%2520Res.%26date%3D2002%26volume%3D62%26issue%3D15%26spage%3D4244%26epage%3D4255" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group">Cowan-Jacob, S. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guez, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fendrich, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Griffin, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fabbro, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Furet, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liebetanz, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mestan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Manley, P. W.</span><span> </span><span class="NLM_article-title">Imatinib (STI571) resistance in chronic myelogenous leukemia: molecular basis of the underlying mechanisms and potential strategies for treatment</span> <span class="citation_source-journal">Mini-Rev. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x"> (</span><span class="NLM_issue">3</span><span class="NLM_x">) </span> <span class="NLM_fpage">285</span><span class="NLM_x">–</span> <span class="NLM_lpage">299</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2004&pages=285-299&issue=3&author=S.+W.+Cowan-Jacobauthor=V.+Guezauthor=G.+Fendrichauthor=J.+D.+Griffinauthor=D.+Fabbroauthor=P.+Furetauthor=J.+Liebetanzauthor=J.+Mestanauthor=P.+W.+Manley&title=Imatinib+%28STI571%29+resistance+in+chronic+myelogenous+leukemia%3A+molecular+basis+of+the+underlying+mechanisms+and+potential+strategies+for+treatment"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCowan-Jacob%26aufirst%3DS.%2BW.%26aulast%3DGuez%26aufirst%3DV.%26aulast%3DFendrich%26aufirst%3DG.%26aulast%3DGriffin%26aufirst%3DJ.%2BD.%26aulast%3DFabbro%26aufirst%3DD.%26aulast%3DFuret%26aufirst%3DP.%26aulast%3DLiebetanz%26aufirst%3DJ.%26aulast%3DMestan%26aufirst%3DJ.%26aulast%3DManley%26aufirst%3DP.%2BW.%26atitle%3DImatinib%2520%2528STI571%2529%2520resistance%2520in%2520chronic%2520myelogenous%2520leukemia%253A%2520molecular%2520basis%2520of%2520the%2520underlying%2520mechanisms%2520and%2520potential%2520strategies%2520for%2520treatment%26jtitle%3DMini-Rev.%2520Med.%2520Chem.%26date%3D2004%26volume%3D4%26issue%3D3%26spage%3D285%26epage%3D299" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Melnick, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Janes, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, J. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sipes, D. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gunderson, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jarnes, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matzen, J. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garcia, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hood, T. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beigi, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xia, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harig, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Asatryan, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yan, S. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gu, X. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saadat, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">King, F. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shaw, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Su, A. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Downs, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gray, N. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schultz, P. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Warmuth, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Caldwell, J. S.</span><span> </span><span class="NLM_article-title">An efficient rapid system for profiling the cellular activities of molecular libraries</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U.S.A</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">103</span><span class="NLM_x"> (</span><span class="NLM_issue">9</span><span class="NLM_x">) </span> <span class="NLM_fpage">3153</span><span class="NLM_x">–</span> <span class="NLM_lpage">3158</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=103&publication_year=2006&pages=3153-3158&issue=9&author=J.+S.+Melnickauthor=J.+Janesauthor=S.+Kimauthor=J.+Y.+Changauthor=D.+G.+Sipesauthor=D.+Gundersonauthor=L.+Jarnesauthor=J.+T.+Matzenauthor=M.+E.+Garciaauthor=T.+L.+Hoodauthor=R.+Beigiauthor=G.+Xiaauthor=R.+A.+Harigauthor=H.+Asatryanauthor=S.+F.+Yanauthor=Y.+Zhouauthor=X.+J.+Guauthor=A.+Saadatauthor=V.+Zhouauthor=F.+J.+Kingauthor=C.+M.+Shawauthor=A.+I.+Suauthor=R.+Downsauthor=N.+S.+Grayauthor=P.+G.+Schultzauthor=M.+Warmuthauthor=J.+S.+Caldwell&title=An+efficient+rapid+system+for+profiling+the+cellular+activities+of+molecular+libraries"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit30a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMelnick%26aufirst%3DJ.%2BS.%26aulast%3DJanes%26aufirst%3DJ.%26aulast%3DKim%26aufirst%3DS.%26aulast%3DChang%26aufirst%3DJ.%2BY.%26aulast%3DSipes%26aufirst%3DD.%2BG.%26aulast%3DGunderson%26aufirst%3DD.%26aulast%3DJarnes%26aufirst%3DL.%26aulast%3DMatzen%26aufirst%3DJ.%2BT.%26aulast%3DGarcia%26aufirst%3DM.%2BE.%26aulast%3DHood%26aufirst%3DT.%2BL.%26aulast%3DBeigi%26aufirst%3DR.%26aulast%3DXia%26aufirst%3DG.%26aulast%3DHarig%26aufirst%3DR.%2BA.%26aulast%3DAsatryan%26aufirst%3DH.%26aulast%3DYan%26aufirst%3DS.%2BF.%26aulast%3DZhou%26aufirst%3DY.%26aulast%3DGu%26aufirst%3DX.%2BJ.%26aulast%3DSaadat%26aufirst%3DA.%26aulast%3DZhou%26aufirst%3DV.%26aulast%3DKing%26aufirst%3DF.%2BJ.%26aulast%3DShaw%26aufirst%3DC.%2BM.%26aulast%3DSu%26aufirst%3DA.%2BI.%26aulast%3DDowns%26aufirst%3DR.%26aulast%3DGray%26aufirst%3DN.%2BS.%26aulast%3DSchultz%26aufirst%3DP.%2BG.%26aulast%3DWarmuth%26aufirst%3DM.%26aulast%3DCaldwell%26aufirst%3DJ.%2BS.%26atitle%3DAn%2520efficient%2520rapid%2520system%2520for%2520profiling%2520the%2520cellular%2520activities%2520of%2520molecular%2520libraries%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A%26date%3D2006%26volume%3D103%26issue%3D9%26spage%3D3153%26epage%3D3158" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit30b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Warmuth, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gu, X. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xia, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adrian, F.</span><span> </span><span class="NLM_article-title">Ba/F3 cells and their use in kinase drug discovery</span> <span class="citation_source-journal">Curr. Opin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x"> (</span><span class="NLM_issue">1</span><span class="NLM_x">) </span> <span class="NLM_fpage">55</span><span class="NLM_x">–</span> <span class="NLM_lpage">60</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30b&amp;dbid=16&amp;doi=10.1021%2Fjm901808w&amp;key=10.1097%2FCCO.0b013e328011a25f" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30b&amp;dbid=8&amp;doi=10.1021%2Fjm901808w&amp;key=17133113" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30b&amp;dbid=32&amp;doi=10.1021%2Fjm901808w&amp;key=1%3ACAS%3A528%3ADC%252BD28Xht1Cnt7%252FL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2007&pages=55-60&issue=1&author=M.+Warmuthauthor=S.+Kimauthor=X.+J.+Guauthor=G.+Xiaauthor=F.+Adrian&title=Ba%2FF3+cells+and+their+use+in+kinase+drug+discovery"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30bR"><div class="casContent"><span class="casTitleNuber">30b</span><div class="casTitle"><span class="NLM_cas:atitle">Ba/F3 cells and their use in kinase drug discovery</span></div><div class="casAuthors">Warmuth, Markus; Kim, Sungjoon; Gu, Xiang-ju; Xia, Gang; Adrian, Francisco</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Oncology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">55-60</span>CODEN:
                <span class="NLM_cas:coden">CUOOE8</span>;
        ISSN:<span class="NLM_cas:issn">1040-8746</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">A review.  Purpose of review: Due to their ability to function as dominant oncogenes, protein kinases have become favored targets in the quest for 'molecularly-targeted' cancer chemotherapeutics.  The discovery of a large no. of cancer-assocd. mutations in the kinome, and the progress in developing specific small-mol. kinase inhibitors has increased the need for accurate, reproducible, and efficient kinase activity-dependent cellular assay systems.  Recent findings: Ba/F3, a murine interleukin-3 dependent pro-B cell line is increasingly popular as a model system for assessing both the potency and downstream signaling of kinase oncogenes, and the ability of small-mol. kinase inhibitors to block kinase activity.  Facilitated by their growth properties, Ba/F3 cells have recently been adapted to high-throughput assay formats for compd. profiling.  Further, several published approaches show promise in predicting resistance to small-mol. kinase inhibitors elicited by point mutations interfering with inhibitor binding.  Summary: Ba/F3 cells are an increasingly popular tool in kinase drug discovery.  The ability to test the transforming capacity of newly identified kinase mutations, and to profile drug candidates and compd. libraries in high-throughput fashion, combined with the use of Ba/F3 cells to predict clin. resistance will greatly facilitate developments in this field.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqXQmhiRwGlDLVg90H21EOLACvtfcHk0lhO5NgmW6ODZA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xht1Cnt7%252FL&md5=a7f8d84dfedea69d408edb571e2eead9</span></div><a href="/servlet/linkout?suffix=cit30b&amp;dbid=16384&amp;doi=10.1097%2FCCO.0b013e328011a25f&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FCCO.0b013e328011a25f%26sid%3Dliteratum%253Aachs%26aulast%3DWarmuth%26aufirst%3DM.%26aulast%3DKim%26aufirst%3DS.%26aulast%3DGu%26aufirst%3DX.%2BJ.%26aulast%3DXia%26aufirst%3DG.%26aulast%3DAdrian%26aufirst%3DF.%26atitle%3DBa%252FF3%2520cells%2520and%2520their%2520use%2520in%2520kinase%2520drug%2520discovery%26jtitle%3DCurr.%2520Opin.%2520Oncol.%26date%3D2007%26volume%3D19%26issue%3D1%26spage%3D55%26epage%3D60" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group">Liu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gray, N. S.</span><span> </span><span class="NLM_article-title">Rational design of inhibitors that bind to inactive kinase conformations</span> <span class="citation_source-journal">Nature Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x"> (</span><span class="NLM_issue">7</span><span class="NLM_x">) </span> <span class="NLM_fpage">358</span><span class="NLM_x">–</span> <span class="NLM_lpage">364</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Fjm901808w&amp;key=10.1038%2Fnchembio799" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Fjm901808w&amp;key=16783341" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Fjm901808w&amp;key=1%3ACAS%3A528%3ADC%252BD28XlvFGjs7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2006&pages=358-364&issue=7&author=Y.+Liuauthor=N.+S.+Gray&title=Rational+design+of+inhibitors+that+bind+to+inactive+kinase+conformations"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Rational design of inhibitors that bind to inactive kinase conformations</span></div><div class="casAuthors">Liu, Yi; Gray, Nathanael S.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">358-364</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The majority of kinase inhibitors, known as type I inhibitors that have been developed so far target the ATP binding site of the kinase in its active conformation, in which the activation loop is phosphorylated.  Recently, crystal structures of inhibitors such as imatinib, BIRB796, and sorafenib (BAY43-9006), known as type II inhibitors, have revealed a new binding mode that exploits an addnl. binding site immediately adjacent to the region occupied by ATP.  This pocket is made accessible by an activation-loop rearrangement that is characteristic of kinases in an inactive conformation.  The examn. of binding features of known type II inhibitors is discussed and a pharmacophore model currently used in the design of a new generation of structurally diverse type II inhibitors is presented.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrxahsMPlhgDbVg90H21EOLACvtfcHk0lhO5NgmW6ODZA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XlvFGjs7g%253D&md5=4a9347a44a2cf4a412c9741fdcc5696b</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1038%2Fnchembio799&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio799%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DGray%26aufirst%3DN.%2BS.%26atitle%3DRational%2520design%2520of%2520inhibitors%2520that%2520bind%2520to%2520inactive%2520kinase%2520conformations%26jtitle%3DNature%2520Chem.%2520Biol.%26date%3D2006%26volume%3D2%26issue%3D7%26spage%3D358%26epage%3D364" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group">McDermott, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sharma, S. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dowell, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greninger, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Montagut, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lamb, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Archibald, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raudales, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tam, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rothenberg, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Supko, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sordella, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ulkus, L. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iafrate, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maheswaran, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Njauw, C. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsao, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Drew, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hanke, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ma, X.-J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Erlander, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gray, N. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haber, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Settleman, J.</span><span> </span><span class="NLM_article-title">Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U.S.A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">104</span><span class="NLM_x"> (</span><span class="NLM_issue">50</span><span class="NLM_x">) </span> <span class="NLM_fpage">19936</span><span class="NLM_x">–</span> <span class="NLM_lpage">19941</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=104&publication_year=2007&pages=19936-19941&issue=50&author=U.+McDermottauthor=S.+V.+Sharmaauthor=L.+Dowellauthor=P.+Greningerauthor=C.+Montagutauthor=J.+Lambauthor=H.+Archibaldauthor=R.+Raudalesauthor=A.+Tamauthor=D.+Leeauthor=S.+M.+Rothenbergauthor=J.+G.+Supkoauthor=R.+Sordellaauthor=L.+E.+Ulkusauthor=A.+J.+Iafrateauthor=S.+Maheswaranauthor=C.+N.+Njauwauthor=H.+Tsaoauthor=L.+Drewauthor=J.+H.+Hankeauthor=X.-J.+Maauthor=M.+G.+Erlanderauthor=N.+S.+Grayauthor=D.+A.+Haberauthor=J.+Settleman&title=Identification+of+genotype-correlated+sensitivity+to+selective+kinase+inhibitors+by+using+high-throughput+tumor+cell+line+profiling"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMcDermott%26aufirst%3DU.%26aulast%3DSharma%26aufirst%3DS.%2BV.%26aulast%3DDowell%26aufirst%3DL.%26aulast%3DGreninger%26aufirst%3DP.%26aulast%3DMontagut%26aufirst%3DC.%26aulast%3DLamb%26aufirst%3DJ.%26aulast%3DArchibald%26aufirst%3DH.%26aulast%3DRaudales%26aufirst%3DR.%26aulast%3DTam%26aufirst%3DA.%26aulast%3DLee%26aufirst%3DD.%26aulast%3DRothenberg%26aufirst%3DS.%2BM.%26aulast%3DSupko%26aufirst%3DJ.%2BG.%26aulast%3DSordella%26aufirst%3DR.%26aulast%3DUlkus%26aufirst%3DL.%2BE.%26aulast%3DIafrate%26aufirst%3DA.%2BJ.%26aulast%3DMaheswaran%26aufirst%3DS.%26aulast%3DNjauw%26aufirst%3DC.%2BN.%26aulast%3DTsao%26aufirst%3DH.%26aulast%3DDrew%26aufirst%3DL.%26aulast%3DHanke%26aufirst%3DJ.%2BH.%26aulast%3DMa%26aufirst%3DX.-J.%26aulast%3DErlander%26aufirst%3DM.%2BG.%26aulast%3DGray%26aufirst%3DN.%2BS.%26aulast%3DHaber%26aufirst%3DD.%2BA.%26aulast%3DSettleman%26aufirst%3DJ.%26atitle%3DIdentification%2520of%2520genotype-correlated%2520sensitivity%2520to%2520selective%2520kinase%2520inhibitors%2520by%2520using%2520high-throughput%2520tumor%2520cell%2520line%2520profiling%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2007%26volume%3D104%26issue%3D50%26spage%3D19936%26epage%3D19941" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group">Adrian, F. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ding, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sim, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Velentza, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sloan, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hur, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ding, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Manley, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mestan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fabbro, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gray, N. S.</span><span> </span><span class="NLM_article-title">Allosteric inhibitors of Bcr-abl-dependent cell proliferation</span> <span class="citation_source-journal">Nature Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x"> (</span><span class="NLM_issue">2</span><span class="NLM_x">) </span> <span class="NLM_fpage">95</span><span class="NLM_x">–</span> <span class="NLM_lpage">102</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Fjm901808w&amp;key=10.1038%2Fnchembio760" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Fjm901808w&amp;key=16415863" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Fjm901808w&amp;key=1%3ACAS%3A528%3ADC%252BD28XkvF2rsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2006&pages=95-102&issue=2&author=F.+J.+Adrianauthor=Q.+Dingauthor=T.+Simauthor=A.+Velentzaauthor=C.+Sloanauthor=Y.+Liuauthor=G.+Zhangauthor=W.+Hurauthor=S.+Dingauthor=P.+Manleyauthor=J.+Mestanauthor=D.+Fabbroauthor=N.+S.+Gray&title=Allosteric+inhibitors+of+Bcr-abl-dependent+cell+proliferation"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Allosteric inhibitors of Bcr-abl-dependent cell proliferation</span></div><div class="casAuthors">Adrian, Francisco J.; Ding, Qiang; Sim, Taebo; Velentza, Anastasia; Sloan, Christine; Liu, Yi; Zhang, Guobao; Hur, Wooyoung; Ding, Sheng; Manley, Paul; Mestan, Juergen; Fabbro, Doriano; Gray, Nathanael S.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">95-102</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Chronic myelogenous leukemia (CML) is a myeloproliferative disorder characterized at the mol. level by the expression of Bcr-abl, a 210-kDa fusion protein with deregulated tyrosine kinase activity.  Encouraged by the clin. validation of Bcr-abl as the target for the treatment of CML by imatinib, we sought to identify pharmacol. agents that could target this kinase by a distinct mechanism.  We report the discovery of a new class of Bcr-abl inhibitors using an unbiased differential cytotoxicity screen of a combinatorial kinase-directed heterocycle library.  Compds. in this class (exemplified by GNF-2) show exclusive antiproliferative activity toward Bcr-abl-transformed cells, with potencies similar to imatinib, while showing no inhibition of the kinase activity of full-length or catalytic domain of c-abl.  We propose that this new class of compds. inhibits Bcr-abl kinase activity through an allosteric non-ATP competitive mechanism.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqqjXG0lHqHurVg90H21EOLACvtfcHk0lhO5NgmW6ODZA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XkvF2rsA%253D%253D&md5=c8617fecb6092d71ae163e7cda1e8f94</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1038%2Fnchembio760&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio760%26sid%3Dliteratum%253Aachs%26aulast%3DAdrian%26aufirst%3DF.%2BJ.%26aulast%3DDing%26aufirst%3DQ.%26aulast%3DSim%26aufirst%3DT.%26aulast%3DVelentza%26aufirst%3DA.%26aulast%3DSloan%26aufirst%3DC.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DG.%26aulast%3DHur%26aufirst%3DW.%26aulast%3DDing%26aufirst%3DS.%26aulast%3DManley%26aufirst%3DP.%26aulast%3DMestan%26aufirst%3DJ.%26aulast%3DFabbro%26aufirst%3DD.%26aulast%3DGray%26aufirst%3DN.%2BS.%26atitle%3DAllosteric%2520inhibitors%2520of%2520Bcr-abl-dependent%2520cell%2520proliferation%26jtitle%3DNature%2520Chem.%2520Biol.%26date%3D2006%26volume%3D2%26issue%3D2%26spage%3D95%26epage%3D102" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25a','cit25b'],'ref26':['cit26'],'ref27':['cit27a','cit27b'],'ref28':['cit28a','cit28b'],'ref29':['cit29'],'ref30':['cit30a','cit30b'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 42 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Hanna Cho, Injae Shin, Eunhye Ju, Seunghye Choi, Wooyoung Hur, Haelee Kim, Eunmi Hong, Nam Doo Kim, Hwan Geun Choi, Nathanael S. Gray, <span class="NLM_string-name hlFld-ContribAuthor">Taebo Sim</span>. </span><span class="cited-content_cbyCitation_article-title">First SAR Study for Overriding NRAS Mutant Driven Acute Myeloid Leukemia. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2018,</strong> <em>61 </em>
                                    (18)
                                     , 8353-8373. <a href="https://doi.org/10.1021/acs.jmedchem.8b00882" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.8b00882</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.8b00882&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.8b00882%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DFirst%252BSAR%252BStudy%252Bfor%252BOverriding%252BNRAS%252BMutant%252BDriven%252BAcute%252BMyeloid%252BLeukemia%26aulast%3DCho%26aufirst%3DHanna%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D04062018%26date%3D11092018%26date%3D28082018%26volume%3D61%26issue%3D18%26spage%3D8353%26epage%3D8373" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xiaofei  Liang</span>, <span class="hlFld-ContribAuthor ">Fengchao  Lv</span>, <span class="hlFld-ContribAuthor ">Beilei  Wang</span>, <span class="hlFld-ContribAuthor ">Kailin  Yu</span>, <span class="hlFld-ContribAuthor ">Hong  Wu</span>, <span class="hlFld-ContribAuthor ">Ziping  Qi</span>, <span class="hlFld-ContribAuthor ">Zongru  Jiang</span>, <span class="hlFld-ContribAuthor ">Cheng  Chen</span>, <span class="hlFld-ContribAuthor ">Aoli  Wang</span>, <span class="hlFld-ContribAuthor ">Weili  Miao</span>, <span class="hlFld-ContribAuthor ">Wenchao  Wang</span>, <span class="hlFld-ContribAuthor ">Zhenquan  Hu</span>, <span class="hlFld-ContribAuthor ">Juan  Liu</span>, <span class="hlFld-ContribAuthor ">Xiaochuan  Liu</span>, <span class="hlFld-ContribAuthor ">Zheng  Zhao</span>, <span class="hlFld-ContribAuthor ">Li  Wang</span>, <span class="hlFld-ContribAuthor ">Shanchuan  Zhang</span>, <span class="hlFld-ContribAuthor ">Zi  Ye</span>, <span class="hlFld-ContribAuthor ">Chu  Wang</span>, <span class="hlFld-ContribAuthor ">Tao  Ren</span>, <span class="hlFld-ContribAuthor ">Yinsheng  Wang</span>, <span class="hlFld-ContribAuthor ">Qingsong  Liu</span>, and <span class="hlFld-ContribAuthor ">Jing  Liu</span>  . </span><span class="cited-content_cbyCitation_article-title">Discovery of 2-((3-Acrylamido-4-methylphenyl)amino)-N-(2-methyl-5-(3,4,5-trimethoxybenzamido)phenyl)-4-(methylamino)pyrimidine-5-carboxamide (CHMFL-BMX-078) as a Highly Potent and Selective Type II Irreversible Bone Marrow Kinase in the X Chromosome (BMX) Kinase Inhibitor. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2017,</strong> <em>60 </em>
                                    (5)
                                     , 1793-1816. <a href="https://doi.org/10.1021/acs.jmedchem.6b01413" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.6b01413</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.6b01413&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.6b01413%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252B2-%252528%2525283-Acrylamido-4-methylphenyl%252529amino%252529-N-%2525282-methyl-5-%2525283%25252C4%25252C5-trimethoxybenzamido%252529phenyl%252529-4-%252528methylamino%252529pyrimidine-5-carboxamide%252B%252528CHMFL-BMX-078%252529%252Bas%252Ba%252BHighly%252BPotent%252Band%252BSelective%252BType%252BII%252BIrreversible%252BBone%252BMarrow%252BKinase%252Bin%252Bthe%252BX%252BChromosome%252B%252528BMX%252529%252BKinase%252BInhibitor%26aulast%3DLiang%26aufirst%3DXiaofei%26date%3D2017%26date%3D2017%26date%3D2016%26date%3D22092016%26date%3D14022017%26date%3D09032017%26date%3D31012017%26volume%3D60%26issue%3D5%26spage%3D1793%26epage%3D1816" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Bénédicte  Daydé-Cazals</span>, <span class="hlFld-ContribAuthor ">Bénédicte  Fauvel</span>, <span class="hlFld-ContribAuthor ">Mathilde  Singer</span>, <span class="hlFld-ContribAuthor ">Clémence  Feneyrolles</span>, <span class="hlFld-ContribAuthor ">Benoit  Bestgen</span>, <span class="hlFld-ContribAuthor ">Fanny  Gassiot</span>, <span class="hlFld-ContribAuthor ">Aurélia  Spenlinhauer</span>, <span class="hlFld-ContribAuthor ">Pierre  Warnault</span>, <span class="hlFld-ContribAuthor ">Nathalie  Van Hijfte</span>, <span class="hlFld-ContribAuthor ">Nozha  Borjini</span>, <span class="hlFld-ContribAuthor ">Gwénaël  Chevé</span>, and <span class="hlFld-ContribAuthor ">Abdelaziz  Yasri</span>  . </span><span class="cited-content_cbyCitation_article-title">Rational Design, Synthesis, and Biological Evaluation of 7-Azaindole Derivatives as Potent Focused Multi-Targeted Kinase Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2016,</strong> <em>59 </em>
                                    (8)
                                     , 3886-3905. <a href="https://doi.org/10.1021/acs.jmedchem.6b00087" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.6b00087</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.6b00087&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.6b00087%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DRational%252BDesign%25252C%252BSynthesis%25252C%252Band%252BBiological%252BEvaluation%252Bof%252B7-Azaindole%252BDerivatives%252Bas%252BPotent%252BFocused%252BMulti-Targeted%252BKinase%252BInhibitors%26aulast%3DDayd%25C3%25A9-Cazals%26aufirst%3DB%25C3%25A9n%25C3%25A9dicte%26date%3D2016%26date%3D2016%26date%3D2016%26date%3D19012016%26date%3D15042016%26date%3D28042016%26date%3D24032016%26volume%3D59%26issue%3D8%26spage%3D3886%26epage%3D3905" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xiaofei  Liang</span>, <span class="hlFld-ContribAuthor ">Xiaochuan  Liu</span>, <span class="hlFld-ContribAuthor ">Beilei  Wang</span>, <span class="hlFld-ContribAuthor ">Fengming  Zou</span>, <span class="hlFld-ContribAuthor ">Aoli  Wang</span>, <span class="hlFld-ContribAuthor ">Shuang  Qi</span>, <span class="hlFld-ContribAuthor ">Cheng  Chen</span>, <span class="hlFld-ContribAuthor ">Zheng  Zhao</span>, <span class="hlFld-ContribAuthor ">Wenchao  Wang</span>, <span class="hlFld-ContribAuthor ">Ziping  Qi</span>, <span class="hlFld-ContribAuthor ">Fengchao  Lv</span>, <span class="hlFld-ContribAuthor ">Zhenquan  Hu</span>, <span class="hlFld-ContribAuthor ">Li  Wang</span>, <span class="hlFld-ContribAuthor ">Shanchun  Zhang</span>, <span class="hlFld-ContribAuthor ">Qingsong  Liu</span>, and <span class="hlFld-ContribAuthor ">Jing  Liu</span>  . </span><span class="cited-content_cbyCitation_article-title">Discovery of 2-((3-Amino-4-methylphenyl)amino)-N-(2-methyl-5-(3-(trifluoromethyl)benzamido)phenyl)-4-(methylamino)pyrimidine-5-carboxamide (CHMFL-ABL-053) as a Potent, Selective, and Orally Available BCR-ABL/SRC/p38 Kinase Inhibitor for Chronic Myeloid Leukemia. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2016,</strong> <em>59 </em>
                                    (5)
                                     , 1984-2004. <a href="https://doi.org/10.1021/acs.jmedchem.5b01618" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.5b01618</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.5b01618&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.5b01618%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252B2-%252528%2525283-Amino-4-methylphenyl%252529amino%252529-N-%2525282-methyl-5-%2525283-%252528trifluoromethyl%252529benzamido%252529phenyl%252529-4-%252528methylamino%252529pyrimidine-5-carboxamide%252B%252528CHMFL-ABL-053%252529%252Bas%252Ba%252BPotent%25252C%252BSelective%25252C%252Band%252BOrally%252BAvailable%252BBCR-ABL%25252FSRC%25252Fp38%252BKinase%252BInhibitor%252Bfor%252BChronic%252BMyeloid%252BLeukemia%26aulast%3DLiang%26aufirst%3DXiaofei%26date%3D2016%26date%3D2016%26date%3D2015%26date%3D15102015%26date%3D05022016%26date%3D10032016%26date%3D20012016%26volume%3D59%26issue%3D5%26spage%3D1984%26epage%3D2004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Andrea  Unzue</span>, <span class="hlFld-ContribAuthor ">Jing  Dong</span>, <span class="hlFld-ContribAuthor ">Karine  Lafleur</span>, <span class="hlFld-ContribAuthor ">Hongtao  Zhao</span>, <span class="hlFld-ContribAuthor ">Emilie  Frugier</span>, <span class="hlFld-ContribAuthor ">Amedeo  Caflisch</span>, and <span class="hlFld-ContribAuthor ">Cristina  Nevado</span>  . </span><span class="cited-content_cbyCitation_article-title">Pyrrolo[3,2-b]quinoxaline Derivatives as Types I1/2 and II Eph Tyrosine Kinase Inhibitors: Structure-Based Design, Synthesis, and in Vivo Validation. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2014,</strong> <em>57 </em>
                                    (15)
                                     , 6834-6844. <a href="https://doi.org/10.1021/jm5009242" title="DOI URL">https://doi.org/10.1021/jm5009242</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/jm5009242&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fjm5009242%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DPyrrolo%25255B3%25252C2-b%25255Dquinoxaline%252BDerivatives%252Bas%252BTypes%252BI1%25252F2%252Band%252BII%252BEph%252BTyrosine%252BKinase%252BInhibitors%25253A%252BStructure-Based%252BDesign%25252C%252BSynthesis%25252C%252Band%252Bin%252BVivo%252BValidation%26aulast%3DUnzue%26aufirst%3DAndrea%26date%3D2014%26date%3D2014%26date%3D2014%26date%3D18062014%26date%3D30072014%26date%3D14082014%26volume%3D57%26issue%3D15%26spage%3D6834%26epage%3D6844" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Hwangseo  Park</span>, <span class="hlFld-ContribAuthor ">Seunghee  Hong</span>, <span class="hlFld-ContribAuthor ">Jinhee  Kim</span>, and <span class="hlFld-ContribAuthor ">Sungwoo  Hong</span>  . </span><span class="cited-content_cbyCitation_article-title">Discovery of Picomolar ABL Kinase Inhibitors Equipotent for Wild Type and T315I Mutant via Structure-Based de Novo Design. </span><span class="cited-content_cbyCitation_journal-name">Journal of the American Chemical Society</span><span> <strong>2013,</strong> <em>135 </em>
                                    (22)
                                     , 8227-8237. <a href="https://doi.org/10.1021/ja311756u" title="DOI URL">https://doi.org/10.1021/ja311756u</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/ja311756u&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fja311756u%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520the%2520American%2520Chemical%2520Society%26atitle%3DDiscovery%252Bof%252BPicomolar%252BABL%252BKinase%252BInhibitors%252BEquipotent%252Bfor%252BWild%252BType%252Band%252BT315I%252BMutant%252Bvia%252BStructure-Based%252Bde%252BNovo%252BDesign%26aulast%3DPark%26aufirst%3DHwangseo%26date%3D2013%26date%3D2013%26date%3D2012%26date%3D03122012%26date%3D24052013%26date%3D05062013%26date%3D16052013%26volume%3D135%26issue%3D22%26spage%3D8227%26epage%3D8237" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Seunghee  Hong</span>, <span class="hlFld-ContribAuthor ">Jinhee  Kim</span>, <span class="hlFld-ContribAuthor ">Sun-Mi  Yun</span>, <span class="hlFld-ContribAuthor ">Hyunseung  Lee</span>, <span class="hlFld-ContribAuthor ">Yoonsu  Park</span>, <span class="hlFld-ContribAuthor ">Soon-Sun  Hong</span>, and <span class="hlFld-ContribAuthor ">Sungwoo  Hong</span>  . </span><span class="cited-content_cbyCitation_article-title">Discovery of New Benzothiazole-Based Inhibitors of Breakpoint Cluster Region-Abelson Kinase Including the T315I Mutant. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2013,</strong> <em>56 </em>
                                    (9)
                                     , 3531-3545. <a href="https://doi.org/10.1021/jm301891t" title="DOI URL">https://doi.org/10.1021/jm301891t</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/jm301891t&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fjm301891t%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252BNew%252BBenzothiazole-Based%252BInhibitors%252Bof%252BBreakpoint%252BCluster%252BRegion-Abelson%252BKinase%252BIncluding%252Bthe%252BT315I%252BMutant%26aulast%3DHong%26aufirst%3DSeunghee%26date%3D2013%26date%3D2013%26date%3D2012%26date%3D22122012%26date%3D19042013%26date%3D09052013%26volume%3D56%26issue%3D9%26spage%3D3531%26epage%3D3545" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yupeng  Li</span>, <span class="hlFld-ContribAuthor ">Mengjie  Shen</span>, <span class="hlFld-ContribAuthor ">Zhang  Zhang</span>, <span class="hlFld-ContribAuthor ">Jinfeng  Luo</span>, <span class="hlFld-ContribAuthor ">Xiaofen  Pan</span>, <span class="hlFld-ContribAuthor ">Xiaoyun  Lu</span>, <span class="hlFld-ContribAuthor ">Huoyou  Long</span>, <span class="hlFld-ContribAuthor ">Donghai  Wen</span>, <span class="hlFld-ContribAuthor ">Fengxiang  Zhang</span>, <span class="hlFld-ContribAuthor ">Fang  Leng</span>, <span class="hlFld-ContribAuthor ">Yingjun  Li</span>, <span class="hlFld-ContribAuthor ">Zhengchao  Tu</span>, <span class="hlFld-ContribAuthor ">Xiaomei  Ren</span>, and <span class="hlFld-ContribAuthor ">Ke  Ding</span>  . </span><span class="cited-content_cbyCitation_article-title">Design, Synthesis, and Biological Evaluation of 3-(1H-1,2,3-Triazol-1-yl)benzamide Derivatives as Potent Pan Bcr-Abl Inhibitors Including the Threonine315→Isoleucine315 Mutant. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2012,</strong> <em>55 </em>
                                    (22)
                                     , 10033-10046. <a href="https://doi.org/10.1021/jm301188x" title="DOI URL">https://doi.org/10.1021/jm301188x</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/jm301188x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fjm301188x%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDesign%25252C%252BSynthesis%25252C%252Band%252BBiological%252BEvaluation%252Bof%252B3-%2525281H-1%25252C2%25252C3-Triazol-1-yl%252529benzamide%252BDerivatives%252Bas%252BPotent%252BPan%252BBcr-Abl%252BInhibitors%252BIncluding%252Bthe%252BThreonine315%2525E2%252586%252592Isoleucine315%252BMutant%26aulast%3DLi%26aufirst%3DYupeng%26date%3D2012%26date%3D2012%26date%3D2012%26date%3D12082012%26date%3D01112012%26date%3D26112012%26date%3D22102012%26volume%3D55%26issue%3D22%26spage%3D10033%26epage%3D10046" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Shaohua  Chang</span>, <span class="hlFld-ContribAuthor ">Lianwen  Zhang</span>, <span class="hlFld-ContribAuthor ">Shilin  Xu</span>, <span class="hlFld-ContribAuthor ">Jinfeng  Luo</span>, <span class="hlFld-ContribAuthor ">Xiaoyun  Lu</span>, <span class="hlFld-ContribAuthor ">Zhang  Zhang</span>, <span class="hlFld-ContribAuthor ">Tianfeng  Xu</span>, <span class="hlFld-ContribAuthor ">Yingxue  Liu</span>, <span class="hlFld-ContribAuthor ">Zhengchao  Tu</span>, <span class="hlFld-ContribAuthor ">Yong  Xu</span>, <span class="hlFld-ContribAuthor ">Xiaomei  Ren</span>, <span class="hlFld-ContribAuthor ">Meiyu  Geng</span>, <span class="hlFld-ContribAuthor ">Jian  Ding</span>, <span class="hlFld-ContribAuthor ">Duanqing  Pei</span>, and <span class="hlFld-ContribAuthor ">Ke  Ding</span>  . </span><span class="cited-content_cbyCitation_article-title">Design, Synthesis, and Biological Evaluation of Novel Conformationally Constrained Inhibitors Targeting Epidermal Growth Factor Receptor Threonine790 → Methionine790 Mutant. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2012,</strong> <em>55 </em>
                                    (6)
                                     , 2711-2723. <a href="https://doi.org/10.1021/jm201591k" title="DOI URL">https://doi.org/10.1021/jm201591k</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/jm201591k&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fjm201591k%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDesign%25252C%252BSynthesis%25252C%252Band%252BBiological%252BEvaluation%252Bof%252BNovel%252BConformationally%252BConstrained%252BInhibitors%252BTargeting%252BEpidermal%252BGrowth%252BFactor%252BReceptor%252BThreonine790%252B%2525E2%252586%252592%252BMethionine790%252BMutant%26aulast%3DChang%26aufirst%3DShaohua%26date%3D2012%26date%3D2012%26date%3D2011%26date%3D25112011%26date%3D01032012%26date%3D22032012%26date%3D16022012%26volume%3D55%26issue%3D6%26spage%3D2711%26epage%3D2723" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Namkyoung  Kim</span>, <span class="hlFld-ContribAuthor ">Injae  Shin</span>, <span class="hlFld-ContribAuthor ">Jiwon  Lee</span>, <span class="hlFld-ContribAuthor ">Eunhye  Jeon</span>, <span class="hlFld-ContribAuthor ">Younghoon  Kim</span>, <span class="hlFld-ContribAuthor ">Seongshick  Ryu</span>, <span class="hlFld-ContribAuthor ">Eunhye  Ju</span>, <span class="hlFld-ContribAuthor ">Wonjeong  Cho</span>, <span class="hlFld-ContribAuthor ">Taebo  Sim</span>. </span><span class="cited-content_cbyCitation_article-title">Novel and Potent Small Molecules against Melanoma Harboring BRAF Class I/II/III Mutants for Overcoming Drug Resistance. </span><span class="cited-content_cbyCitation_journal-name">International Journal of Molecular Sciences</span><span> <strong>2021,</strong> <em>22 </em>
                                    (7)
                                     , 3783. <a href="https://doi.org/10.3390/ijms22073783" title="DOI URL">https://doi.org/10.3390/ijms22073783</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/ijms22073783&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fijms22073783%26sid%3Dliteratum%253Aachs%26jtitle%3DInternational%2520Journal%2520of%2520Molecular%2520Sciences%26atitle%3DNovel%252Band%252BPotent%252BSmall%252BMolecules%252Bagainst%252BMelanoma%252BHarboring%252BBRAF%252BClass%252BI%25252FII%25252FIII%252BMutants%252Bfor%252BOvercoming%252BDrug%252BResistance%26aulast%3DKim%26aufirst%3DNamkyoung%26date%3D2021%26date%3D2021%26volume%3D22%26issue%3D7%26spage%3D3783" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ashraf K.  El-Damasy</span>, <span class="hlFld-ContribAuthor ">Heewon  Jin</span>, <span class="hlFld-ContribAuthor ">Seon Hee  Seo</span>, <span class="hlFld-ContribAuthor ">Eun-Kyoung  Bang</span>, <span class="hlFld-ContribAuthor ">Gyochang  Keum</span>. </span><span class="cited-content_cbyCitation_article-title">Design, synthesis, and biological evaluations of novel 3-amino-4-ethynyl indazole derivatives as Bcr-Abl kinase inhibitors with potent cellular antileukemic activity. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>207 </em>, 112710. <a href="https://doi.org/10.1016/j.ejmech.2020.112710" title="DOI URL">https://doi.org/10.1016/j.ejmech.2020.112710</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2020.112710&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2020.112710%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDesign%25252C%252Bsynthesis%25252C%252Band%252Bbiological%252Bevaluations%252Bof%252Bnovel%252B3-amino-4-ethynyl%252Bindazole%252Bderivatives%252Bas%252BBcr-Abl%252Bkinase%252Binhibitors%252Bwith%252Bpotent%252Bcellular%252Bantileukemic%252Bactivity%26aulast%3DEl-Damasy%26aufirst%3DAshraf%2BK.%26date%3D2020%26volume%3D207%26spage%3D112710" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Seung-Hye  Choi</span>, <span class="hlFld-ContribAuthor ">Injae  Shin</span>, <span class="hlFld-ContribAuthor ">Namdoo  Kim</span>, <span class="hlFld-ContribAuthor ">Yunju  Nam</span>, <span class="hlFld-ContribAuthor ">Taebo  Sim</span>. </span><span class="cited-content_cbyCitation_article-title">The first small molecules capable of strongly suppressing proliferation of cancer cells harboring BRAF class I/II/III mutations. </span><span class="cited-content_cbyCitation_journal-name">Biochemical and Biophysical Research Communications</span><span> <strong>2020,</strong> <em>532 </em>
                                    (2)
                                     , 315-320. <a href="https://doi.org/10.1016/j.bbrc.2020.07.110" title="DOI URL">https://doi.org/10.1016/j.bbrc.2020.07.110</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bbrc.2020.07.110&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bbrc.2020.07.110%26sid%3Dliteratum%253Aachs%26jtitle%3DBiochemical%2520and%2520Biophysical%2520Research%2520Communications%26atitle%3DThe%252Bfirst%252Bsmall%252Bmolecules%252Bcapable%252Bof%252Bstrongly%252Bsuppressing%252Bproliferation%252Bof%252Bcancer%252Bcells%252Bharboring%252BBRAF%252Bclass%252BI%25252FII%25252FIII%252Bmutations%26aulast%3DChoi%26aufirst%3DSeung-Hye%26date%3D2020%26volume%3D532%26issue%3D2%26spage%3D315%26epage%3D320" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xia  Qin</span>, <span class="hlFld-ContribAuthor ">Longmiao  Hu</span>, <span class="hlFld-ContribAuthor ">Shen-nan  Shi</span>, <span class="hlFld-ContribAuthor ">Xiaofei  Chen</span>, <span class="hlFld-ContribAuthor ">Chunlin  Zhuang</span>, <span class="hlFld-ContribAuthor ">Wen  Zhang</span>, <span class="hlFld-ContribAuthor ">Siriporn  Jitkaew</span>, <span class="hlFld-ContribAuthor ">Xiufeng  Pang</span>, <span class="hlFld-ContribAuthor ">Jianqiang  Yu</span>, <span class="hlFld-ContribAuthor ">Ye-xiong  Tan</span>, <span class="hlFld-ContribAuthor ">Hong-yang  Wang</span>, <span class="hlFld-ContribAuthor ">Zhenyu  Cai</span>. </span><span class="cited-content_cbyCitation_article-title">The Bcr-Abl inhibitor GNF-7 inhibits necroptosis and ameliorates acute kidney injury by targeting RIPK1 and RIPK3 kinases. </span><span class="cited-content_cbyCitation_journal-name">Biochemical Pharmacology</span><span> <strong>2020,</strong> <em>177 </em>, 113947. <a href="https://doi.org/10.1016/j.bcp.2020.113947" title="DOI URL">https://doi.org/10.1016/j.bcp.2020.113947</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bcp.2020.113947&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bcp.2020.113947%26sid%3Dliteratum%253Aachs%26jtitle%3DBiochemical%2520Pharmacology%26atitle%3DThe%252BBcr-Abl%252Binhibitor%252BGNF-7%252Binhibits%252Bnecroptosis%252Band%252Bameliorates%252Bacute%252Bkidney%252Binjury%252Bby%252Btargeting%252BRIPK1%252Band%252BRIPK3%252Bkinases%26aulast%3DQin%26aufirst%3DXia%26date%3D2020%26volume%3D177%26spage%3D113947" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Si  Chen</span>, <span class="hlFld-ContribAuthor ">Ge  Liu</span>, <span class="hlFld-ContribAuthor ">Jungang  Chen</span>, <span class="hlFld-ContribAuthor ">Ao  Hu</span>, <span class="hlFld-ContribAuthor ">Li  Zhang</span>, <span class="hlFld-ContribAuthor ">Wenyu  Sun</span>, <span class="hlFld-ContribAuthor ">Wei  Tang</span>, <span class="hlFld-ContribAuthor ">Chunlan  Liu</span>, <span class="hlFld-ContribAuthor ">Haiwei  Zhang</span>, <span class="hlFld-ContribAuthor ">Chang  Ke</span>, <span class="hlFld-ContribAuthor ">Jianguo  Wu</span>, <span class="hlFld-ContribAuthor ">Xulin  Chen</span>. </span><span class="cited-content_cbyCitation_article-title">Ponatinib Protects Mice From Lethal Influenza Infection by Suppressing Cytokine Storm. </span><span class="cited-content_cbyCitation_journal-name">Frontiers in Immunology</span><span> <strong>2019,</strong> <em>10 </em><a href="https://doi.org/10.3389/fimmu.2019.01393" title="DOI URL">https://doi.org/10.3389/fimmu.2019.01393</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3389/fimmu.2019.01393&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3389%2Ffimmu.2019.01393%26sid%3Dliteratum%253Aachs%26jtitle%3DFrontiers%2520in%2520Immunology%26atitle%3DPonatinib%252BProtects%252BMice%252BFrom%252BLethal%252BInfluenza%252BInfection%252Bby%252BSuppressing%252BCytokine%252BStorm%26aulast%3DChen%26aufirst%3DSi%26date%3D2019%26date%3D2019%26volume%3D10" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Tom  Baladi</span>, <span class="hlFld-ContribAuthor ">Jessy  Aziz</span>, <span class="hlFld-ContribAuthor ">Florent  Dufour</span>, <span class="hlFld-ContribAuthor ">Valentina  Abet</span>, <span class="hlFld-ContribAuthor ">Véronique  Stoven</span>, <span class="hlFld-ContribAuthor ">François  Radvanyi</span>, <span class="hlFld-ContribAuthor ">Florent  Poyer</span>, <span class="hlFld-ContribAuthor ">Ting-Di  Wu</span>, <span class="hlFld-ContribAuthor ">Jean-Luc  Guerquin-Kern</span>, <span class="hlFld-ContribAuthor ">Isabelle  Bernard-Pierrot</span>, <span class="hlFld-ContribAuthor ">Sergio Marco  Garrido</span>, <span class="hlFld-ContribAuthor ">Sandrine  Piguel</span>. </span><span class="cited-content_cbyCitation_article-title">Design, synthesis, biological evaluation and cellular imaging of imidazo[4,5-b]pyridine derivatives as potent and selective TAM inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry</span><span> <strong>2018,</strong> <em>26 </em>
                                    (20)
                                     , 5510-5530. <a href="https://doi.org/10.1016/j.bmc.2018.09.031" title="DOI URL">https://doi.org/10.1016/j.bmc.2018.09.031</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmc.2018.09.031&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmc.2018.09.031%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%26atitle%3DDesign%25252C%252Bsynthesis%25252C%252Bbiological%252Bevaluation%252Band%252Bcellular%252Bimaging%252Bof%252Bimidazo%25255B4%25252C5-b%25255Dpyridine%252Bderivatives%252Bas%252Bpotent%252Band%252Bselective%252BTAM%252Binhibitors%26aulast%3DBaladi%26aufirst%3DTom%26date%3D2018%26volume%3D26%26issue%3D20%26spage%3D5510%26epage%3D5530" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Rakshamani  Tripathi</span>, <span class="hlFld-ContribAuthor ">Zulong  Liu</span>, <span class="hlFld-ContribAuthor ">Rina  Plattner</span>. </span><span class="cited-content_cbyCitation_article-title">Enabling Tumor Growth and Progression: Recent Progress in Unraveling the Functions of ABL Kinases in Solid Tumor Cells. </span><span class="cited-content_cbyCitation_journal-name">Current Pharmacology Reports</span><span> <strong>2018,</strong> <em>4 </em>
                                    (5)
                                     , 367-379. <a href="https://doi.org/10.1007/s40495-018-0149-y" title="DOI URL">https://doi.org/10.1007/s40495-018-0149-y</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s40495-018-0149-y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs40495-018-0149-y%26sid%3Dliteratum%253Aachs%26jtitle%3DCurrent%2520Pharmacology%2520Reports%26atitle%3DEnabling%252BTumor%252BGrowth%252Band%252BProgression%25253A%252BRecent%252BProgress%252Bin%252BUnraveling%252Bthe%252BFunctions%252Bof%252BABL%252BKinases%252Bin%252BSolid%252BTumor%252BCells%26aulast%3DTripathi%26aufirst%3DRakshamani%26date%3D2018%26date%3D2018%26volume%3D4%26issue%3D5%26spage%3D367%26epage%3D379" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">James D.  Vasta</span>, <span class="hlFld-ContribAuthor ">Cesear R.  Corona</span>, <span class="hlFld-ContribAuthor ">Jennifer  Wilkinson</span>, <span class="hlFld-ContribAuthor ">Chad A.  Zimprich</span>, <span class="hlFld-ContribAuthor ">James R.  Hartnett</span>, <span class="hlFld-ContribAuthor ">Morgan R.  Ingold</span>, <span class="hlFld-ContribAuthor ">Kristopher  Zimmerman</span>, <span class="hlFld-ContribAuthor ">Thomas  Machleidt</span>, <span class="hlFld-ContribAuthor ">Thomas A.  Kirkland</span>, <span class="hlFld-ContribAuthor ">Kristin G.  Huwiler</span>, <span class="hlFld-ContribAuthor ">Rachel Friedman  Ohana</span>, <span class="hlFld-ContribAuthor ">Michael  Slater</span>, <span class="hlFld-ContribAuthor ">Paul  Otto</span>, <span class="hlFld-ContribAuthor ">Mei  Cong</span>, <span class="hlFld-ContribAuthor ">Carrow I.  Wells</span>, <span class="hlFld-ContribAuthor ">Benedict-Tilman  Berger</span>, <span class="hlFld-ContribAuthor ">Thomas  Hanke</span>, <span class="hlFld-ContribAuthor ">Carina  Glas</span>, <span class="hlFld-ContribAuthor ">Ke  Ding</span>, <span class="hlFld-ContribAuthor ">David H.  Drewry</span>, <span class="hlFld-ContribAuthor ">Kilian V.M.  Huber</span>, <span class="hlFld-ContribAuthor ">Timothy M.  Willson</span>, <span class="hlFld-ContribAuthor ">Stefan  Knapp</span>, <span class="hlFld-ContribAuthor ">Susanne  Müller</span>, <span class="hlFld-ContribAuthor ">Poncho L.  Meisenheimer</span>, <span class="hlFld-ContribAuthor ">Frank  Fan</span>, <span class="hlFld-ContribAuthor ">Keith V.  Wood</span>, <span class="hlFld-ContribAuthor ">Matthew B.  Robers</span>. </span><span class="cited-content_cbyCitation_article-title">Quantitative, Wide-Spectrum Kinase Profiling in Live Cells for Assessing the Effect of Cellular ATP on Target Engagement. </span><span class="cited-content_cbyCitation_journal-name">Cell Chemical Biology</span><span> <strong>2018,</strong> <em>25 </em>
                                    (2)
                                     , 206-214.e11. <a href="https://doi.org/10.1016/j.chembiol.2017.10.010" title="DOI URL">https://doi.org/10.1016/j.chembiol.2017.10.010</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.chembiol.2017.10.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.chembiol.2017.10.010%26sid%3Dliteratum%253Aachs%26jtitle%3DCell%2520Chemical%2520Biology%26atitle%3DQuantitative%25252C%252BWide-Spectrum%252BKinase%252BProfiling%252Bin%252BLive%252BCells%252Bfor%252BAssessing%252Bthe%252BEffect%252Bof%252BCellular%252BATP%252Bon%252BTarget%252BEngagement%26aulast%3DVasta%26aufirst%3DJames%2BD.%26date%3D2018%26volume%3D25%26issue%3D2%26spage%3D206%26epage%3D214.e11" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Paul W.  Manley</span>, <span class="hlFld-ContribAuthor ">Nikolaus J.  Stiefl</span>. </span><span class="cited-content_cbyCitation_article-title">Progress in the Discovery of BCR-ABL Kinase Inhibitors for the Treatment of Leukemia. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2017,</strong>,, 1-37. <a href="https://doi.org/10.1007/7355_2017_5" title="DOI URL">https://doi.org/10.1007/7355_2017_5</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/7355_2017_5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2F7355_2017_5%26sid%3Dliteratum%253Aachs%26atitle%3DProgress%252Bin%252Bthe%252BDiscovery%252Bof%252BBCR-ABL%252BKinase%252BInhibitors%252Bfor%252Bthe%252BTreatment%252Bof%252BLeukemia%26aulast%3DManley%26aufirst%3DPaul%2BW.%26date%3D2017%26spage%3D1%26epage%3D37%26pub%3DSpringer%2520International%2520Publishing%26atitle%3DCancer%252BII%26aulast%3DWaring%26aufirst%3DMichael%2BJ.%26date%3D2018%26volume%3D28" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Giuseppe  Tridente</span>. </span><span class="cited-content_cbyCitation_article-title">Bosutinib. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2017,</strong>,, 415-434. <a href="https://doi.org/10.1016/B978-0-12-809400-6.00019-6" title="DOI URL">https://doi.org/10.1016/B978-0-12-809400-6.00019-6</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/B978-0-12-809400-6.00019-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2FB978-0-12-809400-6.00019-6%26sid%3Dliteratum%253Aachs%26atitle%3DBosutinib%26aulast%3DTridente%26aufirst%3DGiuseppe%26date%3D2017%26spage%3D415%26epage%3D434%26pub%3DElsevier%26atitle%3DAdverse%252BEvents%252Band%252BOncotargeted%252BKinase%252BInhibitors%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xiaoyun  Lu</span>, <span class="hlFld-ContribAuthor ">Zhang  Zhang</span>, <span class="hlFld-ContribAuthor ">Xiaomei  Ren</span>, <span class="hlFld-ContribAuthor ">Deping  Wang</span>, <span class="hlFld-ContribAuthor ">Ke  Ding</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis and identification of GZD856 as an orally bioavailable Bcr-Abl
              T315I
              inhibitor overcoming acquired imatinib resistance. </span><span class="cited-content_cbyCitation_journal-name">Journal of Enzyme Inhibition and Medicinal Chemistry</span><span> <strong>2017,</strong> <em>32 </em>
                                    (1)
                                     , 331-336. <a href="https://doi.org/10.1080/14756366.2016.1250757" title="DOI URL">https://doi.org/10.1080/14756366.2016.1250757</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/14756366.2016.1250757&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F14756366.2016.1250757%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Enzyme%2520Inhibition%2520and%2520Medicinal%2520Chemistry%26atitle%3DSynthesis%252Band%252Bidentification%252Bof%252BGZD856%252Bas%252Ban%252Borally%252Bbioavailable%252BBcr-Abl%252BT315I%252Binhibitor%252Bovercoming%252Bacquired%252Bimatinib%252Bresistance%26aulast%3DLu%26aufirst%3DXiaoyun%26date%3D2017%26date%3D2017%26volume%3D32%26issue%3D1%26spage%3D331%26epage%3D336" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Liming  Hu</span>, <span class="hlFld-ContribAuthor ">Tingting  Cao</span>, <span class="hlFld-ContribAuthor ">Yongjuan  Lv</span>, <span class="hlFld-ContribAuthor ">Yiming  Ding</span>, <span class="hlFld-ContribAuthor ">Leifu  Yang</span>, <span class="hlFld-ContribAuthor ">Qiang  Zhang</span>, <span class="hlFld-ContribAuthor ">Mingzhou  Guo</span>. </span><span class="cited-content_cbyCitation_article-title">Design, synthesis, and biological activity of 4-(imidazo[1,2- b ]pyridazin-3-yl)-1 H -pyrazol-1-yl-phenylbenzamide derivatives as BCR–ABL kinase inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2016,</strong> <em>26 </em>
                                    (23)
                                     , 5830-5835. <a href="https://doi.org/10.1016/j.bmcl.2016.10.007" title="DOI URL">https://doi.org/10.1016/j.bmcl.2016.10.007</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2016.10.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2016.10.007%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DDesign%25252C%252Bsynthesis%25252C%252Band%252Bbiological%252Bactivity%252Bof%252B4-%252528imidazo%25255B1%25252C2-%252Bb%252B%25255Dpyridazin-3-yl%252529-1%252BH%252B-pyrazol-1-yl-phenylbenzamide%252Bderivatives%252Bas%252BBCR%2525E2%252580%252593ABL%252Bkinase%252Binhibitors%26aulast%3DHu%26aufirst%3DLiming%26date%3D2016%26volume%3D26%26issue%3D23%26spage%3D5830%26epage%3D5835" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Pedro Alves  Bezerra Morais</span>, <span class="hlFld-ContribAuthor ">Renata Dalmaschio  Daltoé</span>, <span class="hlFld-ContribAuthor ">Heberth de  Paula</span>. </span><span class="cited-content_cbyCitation_article-title">Opening the door to the development of novel Abl kinase inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Future Medicinal Chemistry</span><span> <strong>2016,</strong> <em>8 </em>
                                    (17)
                                     , 2143-2165. <a href="https://doi.org/10.4155/fmc-2016-0155" title="DOI URL">https://doi.org/10.4155/fmc-2016-0155</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.4155/fmc-2016-0155&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.4155%2Ffmc-2016-0155%26sid%3Dliteratum%253Aachs%26jtitle%3DFuture%2520Medicinal%2520Chemistry%26atitle%3DOpening%252Bthe%252Bdoor%252Bto%252Bthe%252Bdevelopment%252Bof%252Bnovel%252BAbl%252Bkinase%252Binhibitors%26aulast%3DBezerra%2BMorais%26aufirst%3DPedro%2BAlves%26date%3D2016%26volume%3D8%26issue%3D17%26spage%3D2143%26epage%3D2165" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Sahil  Sharma</span>, <span class="hlFld-ContribAuthor ">Jagjeet  Singh</span>, <span class="hlFld-ContribAuthor ">Ritu  Ojha</span>, <span class="hlFld-ContribAuthor ">Harbinder  Singh</span>, <span class="hlFld-ContribAuthor ">Manpreet  Kaur</span>, <span class="hlFld-ContribAuthor ">P.M.S.  Bedi</span>, <span class="hlFld-ContribAuthor ">Kunal  Nepali</span>. </span><span class="cited-content_cbyCitation_article-title">Design strategies, structure activity relationship and mechanistic insights for purines as kinase inhibitors. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2016,</strong> <em>112 </em>, 298-346. <a href="https://doi.org/10.1016/j.ejmech.2016.02.018" title="DOI URL">https://doi.org/10.1016/j.ejmech.2016.02.018</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2016.02.018&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2016.02.018%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDesign%252Bstrategies%25252C%252Bstructure%252Bactivity%252Brelationship%252Band%252Bmechanistic%252Binsights%252Bfor%252Bpurines%252Bas%252Bkinase%252Binhibitors%26aulast%3DSharma%26aufirst%3DSahil%26date%3D2016%26volume%3D112%26spage%3D298%26epage%3D346" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xiaoyun  Lu</span>, <span class="hlFld-ContribAuthor ">Zhang  Zhang</span>, <span class="hlFld-ContribAuthor ">Xiaomei  Ren</span>, <span class="hlFld-ContribAuthor ">Xiaofeng  Pan</span>, <span class="hlFld-ContribAuthor ">Deping  Wang</span>, <span class="hlFld-ContribAuthor ">Xiaoxi  Zhuang</span>, <span class="hlFld-ContribAuthor ">Jingfeng  Luo</span>, <span class="hlFld-ContribAuthor ">Rongmin  Yu</span>, <span class="hlFld-ContribAuthor ">Ke  Ding</span>. </span><span class="cited-content_cbyCitation_article-title">Hybrid pyrimidine alkynyls inhibit the clinically resistance related Bcr-AblT315I mutant. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2015,</strong> <em>25 </em>
                                    (17)
                                     , 3458-3463. <a href="https://doi.org/10.1016/j.bmcl.2015.07.006" title="DOI URL">https://doi.org/10.1016/j.bmcl.2015.07.006</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2015.07.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2015.07.006%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DHybrid%252Bpyrimidine%252Balkynyls%252Binhibit%252Bthe%252Bclinically%252Bresistance%252Brelated%252BBcr-AblT315I%252Bmutant%26aulast%3DLu%26aufirst%3DXiaoyun%26date%3D2015%26volume%3D25%26issue%3D17%26spage%3D3458%26epage%3D3463" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yan  Li</span>, <span class="hlFld-ContribAuthor ">Michel  Delamar</span>, <span class="hlFld-ContribAuthor ">Patricia  Busca</span>, <span class="hlFld-ContribAuthor ">Guillaume  Prestat</span>, <span class="hlFld-ContribAuthor ">Laurent  Le Corre</span>, <span class="hlFld-ContribAuthor ">Laurence  Legeai-Mallet</span>, <span class="hlFld-ContribAuthor ">RongJing  Hu</span>, <span class="hlFld-ContribAuthor ">Ruisheng  Zhang</span>, <span class="hlFld-ContribAuthor ">Florent  Barbault</span>. </span><span class="cited-content_cbyCitation_article-title">Molecular modeling study of the induced-fit effect on kinase inhibition: the case of fibroblast growth factor receptor 3 (FGFR3). </span><span class="cited-content_cbyCitation_journal-name">Journal of Computer-Aided Molecular Design</span><span> <strong>2015,</strong> <em>29 </em>
                                    (7)
                                     , 619-641. <a href="https://doi.org/10.1007/s10822-015-9841-8" title="DOI URL">https://doi.org/10.1007/s10822-015-9841-8</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s10822-015-9841-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs10822-015-9841-8%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Computer-Aided%2520Molecular%2520Design%26atitle%3DMolecular%252Bmodeling%252Bstudy%252Bof%252Bthe%252Binduced-fit%252Beffect%252Bon%252Bkinase%252Binhibition%25253A%252Bthe%252Bcase%252Bof%252Bfibroblast%252Bgrowth%252Bfactor%252Breceptor%252B3%252B%252528FGFR3%252529%26aulast%3DLi%26aufirst%3DYan%26date%3D2015%26date%3D2015%26volume%3D29%26issue%3D7%26spage%3D619%26epage%3D641" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Atsushi  Nonami</span>, <span class="hlFld-ContribAuthor ">Martin  Sattler</span>, <span class="hlFld-ContribAuthor ">Ellen  Weisberg</span>, <span class="hlFld-ContribAuthor ">Qingsong  Liu</span>, <span class="hlFld-ContribAuthor ">Jianming  Zhang</span>, <span class="hlFld-ContribAuthor ">Matthew P.  Patricelli</span>, <span class="hlFld-ContribAuthor ">Amanda L.  Christie</span>, <span class="hlFld-ContribAuthor ">Amy M.  Saur</span>, <span class="hlFld-ContribAuthor ">Nancy E.  Kohl</span>, <span class="hlFld-ContribAuthor ">Andrew L.  Kung</span>, <span class="hlFld-ContribAuthor ">Hojong  Yoon</span>, <span class="hlFld-ContribAuthor ">Taebo  Sim</span>, <span class="hlFld-ContribAuthor ">Nathanael S.  Gray</span>, <span class="hlFld-ContribAuthor ">James D.  Griffin</span>. </span><span class="cited-content_cbyCitation_article-title">Identification of novel therapeutic targets in acute leukemias with NRAS mutations using a pharmacologic approach. </span><span class="cited-content_cbyCitation_journal-name">Blood</span><span> <strong>2015,</strong> <em>125 </em>
                                    (20)
                                     , 3133-3143. <a href="https://doi.org/10.1182/blood-2014-12-615906" title="DOI URL">https://doi.org/10.1182/blood-2014-12-615906</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1182/blood-2014-12-615906&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1182%2Fblood-2014-12-615906%26sid%3Dliteratum%253Aachs%26jtitle%3DBlood%26atitle%3DIdentification%252Bof%252Bnovel%252Btherapeutic%252Btargets%252Bin%252Bacute%252Bleukemias%252Bwith%252BNRAS%252Bmutations%252Busing%252Ba%252Bpharmacologic%252Bapproach%26aulast%3DNonami%26aufirst%3DAtsushi%26date%3D2015%26volume%3D125%26issue%3D20%26spage%3D3133%26epage%3D3143" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Tom D.  Bunney</span>, <span class="hlFld-ContribAuthor ">Shunzhou  Wan</span>, <span class="hlFld-ContribAuthor ">Nethaji  Thiyagarajan</span>, <span class="hlFld-ContribAuthor ">Ludovico  Sutto</span>, <span class="hlFld-ContribAuthor ">Sarah V.  Williams</span>, <span class="hlFld-ContribAuthor ">Paul  Ashford</span>, <span class="hlFld-ContribAuthor ">Hans  Koss</span>, <span class="hlFld-ContribAuthor ">Margaret A.  Knowles</span>, <span class="hlFld-ContribAuthor ">Francesco L.  Gervasio</span>, <span class="hlFld-ContribAuthor ">Peter V.  Coveney</span>, <span class="hlFld-ContribAuthor ">Matilda  Katan</span>. </span><span class="cited-content_cbyCitation_article-title">The Effect of Mutations on Drug Sensitivity and Kinase Activity of Fibroblast Growth Factor Receptors: A Combined Experimental and Theoretical Study. </span><span class="cited-content_cbyCitation_journal-name">EBioMedicine</span><span> <strong>2015,</strong> <em>2 </em>
                                    (3)
                                     , 194-204. <a href="https://doi.org/10.1016/j.ebiom.2015.02.009" title="DOI URL">https://doi.org/10.1016/j.ebiom.2015.02.009</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ebiom.2015.02.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ebiom.2015.02.009%26sid%3Dliteratum%253Aachs%26jtitle%3DEBioMedicine%26atitle%3DThe%252BEffect%252Bof%252BMutations%252Bon%252BDrug%252BSensitivity%252Band%252BKinase%252BActivity%252Bof%252BFibroblast%252BGrowth%252BFactor%252BReceptors%25253A%252BA%252BCombined%252BExperimental%252Band%252BTheoretical%252BStudy%26aulast%3DBunney%26aufirst%3DTom%2BD.%26date%3D2015%26volume%3D2%26issue%3D3%26spage%3D194%26epage%3D204" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ellen  Weisberg</span>, <span class="hlFld-ContribAuthor ">Atsushi  Nonami</span>, <span class="hlFld-ContribAuthor ">James D.  Griffin</span>. </span><span class="cited-content_cbyCitation_article-title">Combination therapy with nilotinib for drug-sensitive and drug-resistant BCR-ABL-positive leukemia and other malignancies. </span><span class="cited-content_cbyCitation_journal-name">Archives of Toxicology</span><span> <strong>2014,</strong> <em>88 </em>
                                    (12)
                                     , 2233-2242. <a href="https://doi.org/10.1007/s00204-014-1385-5" title="DOI URL">https://doi.org/10.1007/s00204-014-1385-5</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s00204-014-1385-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs00204-014-1385-5%26sid%3Dliteratum%253Aachs%26jtitle%3DArchives%2520of%2520Toxicology%26atitle%3DCombination%252Btherapy%252Bwith%252Bnilotinib%252Bfor%252Bdrug-sensitive%252Band%252Bdrug-resistant%252BBCR-ABL-positive%252Bleukemia%252Band%252Bother%252Bmalignancies%26aulast%3DWeisberg%26aufirst%3DEllen%26date%3D2014%26date%3D2014%26volume%3D88%26issue%3D12%26spage%3D2233%26epage%3D2242" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">DingBiao  Zou</span>, <span class="hlFld-ContribAuthor ">YaTao  Qiu</span>, <span class="hlFld-ContribAuthor ">ZhengChao  Tu</span>, <span class="hlFld-ContribAuthor ">ChenZhong  Liao</span>, <span class="hlFld-ContribAuthor ">JinFeng  Luo</span>, <span class="hlFld-ContribAuthor ">QingQing  Meng</span>, <span class="hlFld-ContribAuthor ">RiSheng  Yao</span>, <span class="hlFld-ContribAuthor ">Zheng  Li</span>, <span class="hlFld-ContribAuthor ">Sheng  Jiang</span>. </span><span class="cited-content_cbyCitation_article-title">Biological evaluation of 2-methylpyrimidine derivatives as active pan Bcr-Abl inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Science China Chemistry</span><span> <strong>2014,</strong> <em>57 </em>
                                    (6)
                                     , 823-832. <a href="https://doi.org/10.1007/s11426-013-5011-9" title="DOI URL">https://doi.org/10.1007/s11426-013-5011-9</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s11426-013-5011-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs11426-013-5011-9%26sid%3Dliteratum%253Aachs%26jtitle%3DScience%2520China%2520Chemistry%26atitle%3DBiological%252Bevaluation%252Bof%252B2-methylpyrimidine%252Bderivatives%252Bas%252Bactive%252Bpan%252BBcr-Abl%252Binhibitors%26aulast%3DZou%26aufirst%3DDingBiao%26date%3D2014%26date%3D2013%26volume%3D57%26issue%3D6%26spage%3D823%26epage%3D832" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Mingxing  Liu</span>, <span class="hlFld-ContribAuthor ">Jiarong  Li</span>, <span class="hlFld-ContribAuthor ">Shu  Chen</span>, <span class="hlFld-ContribAuthor ">Danfei  Huang</span>, <span class="hlFld-ContribAuthor ">Hongxin  Chai</span>, <span class="hlFld-ContribAuthor ">Qi  Zhang</span>, <span class="hlFld-ContribAuthor ">Daxin  Shi</span>. </span><span class="cited-content_cbyCitation_article-title">One-pot NHC-assisted access to 2,3-dihydropyrimido[4,5-d]pyrimidin-4(1H)-ones. </span><span class="cited-content_cbyCitation_journal-name">RSC Adv.</span><span> <strong>2014,</strong> <em>4 </em>
                                    (67)
                                     , 35629-35634. <a href="https://doi.org/10.1039/C4RA05346J" title="DOI URL">https://doi.org/10.1039/C4RA05346J</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C4RA05346J&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC4RA05346J%26sid%3Dliteratum%253Aachs%26jtitle%3DRSC%2520Adv.%26atitle%3DOne-pot%252BNHC-assisted%252Baccess%252Bto%252B2%25252C3-dihydropyrimido%25255B4%25252C5-d%25255Dpyrimidin-4%2525281H%252529-ones%26aulast%3DLiu%26aufirst%3DMingxing%26date%3D2014%26date%3D2014%26volume%3D4%26issue%3D67%26spage%3D35629%26epage%3D35634" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Rosa M.  Suárez</span>, <span class="hlFld-ContribAuthor ">Franciane  Chevot</span>, <span class="hlFld-ContribAuthor ">Andrea  Cavagnino</span>, <span class="hlFld-ContribAuthor ">Nicolas  Saettel</span>, <span class="hlFld-ContribAuthor ">François  Radvanyi</span>, <span class="hlFld-ContribAuthor ">Sandrine  Piguel</span>, <span class="hlFld-ContribAuthor ">Isabelle  Bernard-Pierrot</span>, <span class="hlFld-ContribAuthor ">Véronique  Stoven</span>, <span class="hlFld-ContribAuthor ">Michel  Legraverend</span>. </span><span class="cited-content_cbyCitation_article-title">Inhibitors of the TAM subfamily of tyrosine kinases: Synthesis and biological evaluation. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2013,</strong> <em>61 </em>, 2-25. <a href="https://doi.org/10.1016/j.ejmech.2012.06.005" title="DOI URL">https://doi.org/10.1016/j.ejmech.2012.06.005</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2012.06.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2012.06.005%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DInhibitors%252Bof%252Bthe%252BTAM%252Bsubfamily%252Bof%252Btyrosine%252Bkinases%25253A%252BSynthesis%252Band%252Bbiological%252Bevaluation%26aulast%3DSu%25C3%25A1rez%26aufirst%3DRosa%2BM.%26date%3D2013%26volume%3D61%26spage%3D2%26epage%3D25" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Mamduh  Khateb</span>, <span class="hlFld-ContribAuthor ">Nili  Ruimi</span>, <span class="hlFld-ContribAuthor ">Hazem  Khamisie</span>, <span class="hlFld-ContribAuthor ">Yousef  Najajreh</span>, <span class="hlFld-ContribAuthor ">Afsar  Mian</span>, <span class="hlFld-ContribAuthor ">Anna  Metodieva</span>, <span class="hlFld-ContribAuthor ">Martin  Ruthardt</span>, <span class="hlFld-ContribAuthor ">Jamal  Mahajna</span>. </span><span class="cited-content_cbyCitation_article-title">Overcoming Bcr-Abl T315I mutation by combination of GNF-2 and ATP competitors in an Abl-independent mechanism. </span><span class="cited-content_cbyCitation_journal-name">BMC Cancer</span><span> <strong>2012,</strong> <em>12 </em>
                                    (1)
                                     <a href="https://doi.org/10.1186/1471-2407-12-563" title="DOI URL">https://doi.org/10.1186/1471-2407-12-563</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1186/1471-2407-12-563&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1186%2F1471-2407-12-563%26sid%3Dliteratum%253Aachs%26jtitle%3DBMC%2520Cancer%26atitle%3DOvercoming%252BBcr-Abl%252BT315I%252Bmutation%252Bby%252Bcombination%252Bof%252BGNF-2%252Band%252BATP%252Bcompetitors%252Bin%252Ban%252BAbl-independent%252Bmechanism%26aulast%3DKhateb%26aufirst%3DMamduh%26date%3D2012%26date%3D2012%26volume%3D12%26issue%3D1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Lindsay M.  LaFave</span>, <span class="hlFld-ContribAuthor ">Ross L.  Levine</span>. </span><span class="cited-content_cbyCitation_article-title">JAK2 the future: therapeutic strategies for JAK-dependent malignancies. </span><span class="cited-content_cbyCitation_journal-name">Trends in Pharmacological Sciences</span><span> <strong>2012,</strong> <em>33 </em>
                                    (11)
                                     , 574-582. <a href="https://doi.org/10.1016/j.tips.2012.08.005" title="DOI URL">https://doi.org/10.1016/j.tips.2012.08.005</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.tips.2012.08.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.tips.2012.08.005%26sid%3Dliteratum%253Aachs%26jtitle%3DTrends%2520in%2520Pharmacological%2520Sciences%26atitle%3DJAK2%252Bthe%252Bfuture%25253A%252Btherapeutic%252Bstrategies%252Bfor%252BJAK-dependent%252Bmalignancies%26aulast%3DLaFave%26aufirst%3DLindsay%2BM.%26date%3D2012%26volume%3D33%26issue%3D11%26spage%3D574%26epage%3D582" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Hwangseo  Park</span>, <span class="hlFld-ContribAuthor ">Seunghee  Hong</span>, <span class="hlFld-ContribAuthor ">Sungwoo  Hong</span>. </span><span class="cited-content_cbyCitation_article-title">Identification of common inhibitors of wild-type and T315I mutant of BCR-ABL through the parallel structure-based virtual screening. </span><span class="cited-content_cbyCitation_journal-name">Journal of Computer-Aided Molecular Design</span><span> <strong>2012,</strong> <em>26 </em>
                                    (8)
                                     , 983-992. <a href="https://doi.org/10.1007/s10822-012-9593-7" title="DOI URL">https://doi.org/10.1007/s10822-012-9593-7</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s10822-012-9593-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs10822-012-9593-7%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Computer-Aided%2520Molecular%2520Design%26atitle%3DIdentification%252Bof%252Bcommon%252Binhibitors%252Bof%252Bwild-type%252Band%252BT315I%252Bmutant%252Bof%252BBCR-ABL%252Bthrough%252Bthe%252Bparallel%252Bstructure-based%252Bvirtual%252Bscreening%26aulast%3DPark%26aufirst%3DHwangseo%26date%3D2012%26date%3D2012%26volume%3D26%26issue%3D8%26spage%3D983%26epage%3D992" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Hwan Geun  Choi</span>, <span class="hlFld-ContribAuthor ">Jianming  Zhang</span>, <span class="hlFld-ContribAuthor ">Ellen  Weisberg</span>, <span class="hlFld-ContribAuthor ">James D.  Griffin</span>, <span class="hlFld-ContribAuthor ">Taebo  Sim</span>, <span class="hlFld-ContribAuthor ">Nathanael S.  Gray</span>. </span><span class="cited-content_cbyCitation_article-title">Development of ‘DFG-out’ inhibitors of gatekeeper mutant kinases. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2012,</strong> <em>22 </em>
                                    (16)
                                     , 5297-5302. <a href="https://doi.org/10.1016/j.bmcl.2012.06.036" title="DOI URL">https://doi.org/10.1016/j.bmcl.2012.06.036</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2012.06.036&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2012.06.036%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DDevelopment%252Bof%252B%2525E2%252580%252598DFG-out%2525E2%252580%252599%252Binhibitors%252Bof%252Bgatekeeper%252Bmutant%252Bkinases%26aulast%3DChoi%26aufirst%3DHwan%2BGeun%26date%3D2012%26volume%3D22%26issue%3D16%26spage%3D5297%26epage%3D5302" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xianming  Deng</span>, <span class="hlFld-ContribAuthor ">Wenjun  Zhou</span>, <span class="hlFld-ContribAuthor ">Ellen  Weisberg</span>, <span class="hlFld-ContribAuthor ">Jinhua  Wang</span>, <span class="hlFld-ContribAuthor ">Jianming  Zhang</span>, <span class="hlFld-ContribAuthor ">Takaaki  Sasaki</span>, <span class="hlFld-ContribAuthor ">Erik  Nelson</span>, <span class="hlFld-ContribAuthor ">James D.  Griffin</span>, <span class="hlFld-ContribAuthor ">Pasi A.  Jänne</span>, <span class="hlFld-ContribAuthor ">Nathanael S.  Gray</span>. </span><span class="cited-content_cbyCitation_article-title">An amino-indazole scaffold with spectrum selective kinase inhibition of FLT3, PDGFRα and kit. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2012,</strong> <em>22 </em>
                                    (14)
                                     , 4579-4584. <a href="https://doi.org/10.1016/j.bmcl.2012.05.107" title="DOI URL">https://doi.org/10.1016/j.bmcl.2012.05.107</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2012.05.107&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2012.05.107%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DAn%252Bamino-indazole%252Bscaffold%252Bwith%252Bspectrum%252Bselective%252Bkinase%252Binhibition%252Bof%252BFLT3%25252C%252BPDGFR%2525CE%2525B1%252Band%252Bkit%26aulast%3DDeng%26aufirst%3DXianming%26date%3D2012%26volume%3D22%26issue%3D14%26spage%3D4579%26epage%3D4584" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Bissan  Al-Lazikani</span>, <span class="hlFld-ContribAuthor ">Udai  Banerji</span>, <span class="hlFld-ContribAuthor ">Paul  Workman</span>. </span><span class="cited-content_cbyCitation_article-title">Combinatorial drug therapy for cancer in the post-genomic era. </span><span class="cited-content_cbyCitation_journal-name">Nature Biotechnology</span><span> <strong>2012,</strong> <em>30 </em>
                                    (7)
                                     , 679-692. <a href="https://doi.org/10.1038/nbt.2284" title="DOI URL">https://doi.org/10.1038/nbt.2284</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/nbt.2284&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Fnbt.2284%26sid%3Dliteratum%253Aachs%26jtitle%3DNature%2520Biotechnology%26atitle%3DCombinatorial%252Bdrug%252Btherapy%252Bfor%252Bcancer%252Bin%252Bthe%252Bpost-genomic%252Bera%26aulast%3DAl-Lazikani%26aufirst%3DBissan%26date%3D2012%26date%3D2012%26volume%3D30%26issue%3D7%26spage%3D679%26epage%3D692" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jonathan P.  DiNitto</span>, <span class="hlFld-ContribAuthor ">Joe C.  Wu</span>. </span><span class="cited-content_cbyCitation_article-title">Molecular mechanisms of drug resistance in tyrosine kinases cAbl and cKit. </span><span class="cited-content_cbyCitation_journal-name">Critical Reviews in Biochemistry and Molecular Biology</span><span> <strong>2011,</strong> <em>46 </em>
                                    (4)
                                     , 295-309. <a href="https://doi.org/10.3109/10409238.2011.578612" title="DOI URL">https://doi.org/10.3109/10409238.2011.578612</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3109/10409238.2011.578612&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3109%2F10409238.2011.578612%26sid%3Dliteratum%253Aachs%26jtitle%3DCritical%2520Reviews%2520in%2520Biochemistry%2520and%2520Molecular%2520Biology%26atitle%3DMolecular%252Bmechanisms%252Bof%252Bdrug%252Bresistance%252Bin%252Btyrosine%252Bkinases%252BcAbl%252Band%252BcKit%26aulast%3DDiNitto%26aufirst%3DJonathan%2BP.%26date%3D2011%26date%3D2011%26volume%3D46%26issue%3D4%26spage%3D295%26epage%3D309" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ailing  Zhao</span>, <span class="hlFld-ContribAuthor ">Xin  Gao</span>, <span class="hlFld-ContribAuthor ">Yuanxiang  Wang</span>, <span class="hlFld-ContribAuthor ">Jing  Ai</span>, <span class="hlFld-ContribAuthor ">Ying  Wang</span>, <span class="hlFld-ContribAuthor ">Yi  Chen</span>, <span class="hlFld-ContribAuthor ">Meiyu  Geng</span>, <span class="hlFld-ContribAuthor ">Ao  Zhang</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of novel c-Met kinase inhibitors bearing a thieno[2,3-d]pyrimidine or furo[2,3-d]pyrimidine scaffold. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry</span><span> <strong>2011,</strong> <em>19 </em>
                                    (13)
                                     , 3906-3918. <a href="https://doi.org/10.1016/j.bmc.2011.05.038" title="DOI URL">https://doi.org/10.1016/j.bmc.2011.05.038</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmc.2011.05.038&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmc.2011.05.038%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252Bnovel%252Bc-Met%252Bkinase%252Binhibitors%252Bbearing%252Ba%252Bthieno%25255B2%25252C3-d%25255Dpyrimidine%252Bor%252Bfuro%25255B2%25252C3-d%25255Dpyrimidine%252Bscaffold%26aulast%3DZhao%26aufirst%3DAiling%26date%3D2011%26volume%3D19%26issue%3D13%26spage%3D3906%26epage%3D3918" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Deping  Wang</span>, <span class="hlFld-ContribAuthor ">Zhang  Zhang</span>, <span class="hlFld-ContribAuthor ">Xiaoyun  Lu</span>, <span class="hlFld-ContribAuthor ">Yubing  Feng</span>, <span class="hlFld-ContribAuthor ">Kun  Luo</span>, <span class="hlFld-ContribAuthor ">Jirong  Gan</span>, <span class="hlFld-ContribAuthor ">Liu  Yingxue</span>, <span class="hlFld-ContribAuthor ">Junting  Wan</span>, <span class="hlFld-ContribAuthor ">Xiang  Li</span>, <span class="hlFld-ContribAuthor ">Fengxiang  Zhang</span>, <span class="hlFld-ContribAuthor ">Zhengchao  Tu</span>, <span class="hlFld-ContribAuthor ">Qian  Cai</span>, <span class="hlFld-ContribAuthor ">Xiaomei  Ren</span>, <span class="hlFld-ContribAuthor ">Ke  Ding</span>. </span><span class="cited-content_cbyCitation_article-title">Hybrid compounds as new Bcr/Abl inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2011,</strong> <em>21 </em>
                                    (7)
                                     , 1965-1968. <a href="https://doi.org/10.1016/j.bmcl.2011.02.029" title="DOI URL">https://doi.org/10.1016/j.bmcl.2011.02.029</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2011.02.029&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2011.02.029%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DHybrid%252Bcompounds%252Bas%252Bnew%252BBcr%25252FAbl%252Binhibitors%26aulast%3DWang%26aufirst%3DDeping%26date%3D2011%26volume%3D21%26issue%3D7%26spage%3D1965%26epage%3D1968" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Susan  Branford</span>, <span class="hlFld-ContribAuthor ">Timothy P  Hughes</span>. </span><span class="cited-content_cbyCitation_article-title">Mutational analysis in chronic myeloid leukemia: when and what to do?. </span><span class="cited-content_cbyCitation_journal-name">Current Opinion in Hematology</span><span> <strong>2011,</strong> <em>18 </em>
                                    (2)
                                     , 111-116. <a href="https://doi.org/10.1097/MOH.0b013e32834399ef" title="DOI URL">https://doi.org/10.1097/MOH.0b013e32834399ef</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1097/MOH.0b013e32834399ef&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1097%2FMOH.0b013e32834399ef%26sid%3Dliteratum%253Aachs%26jtitle%3DCurrent%2520Opinion%2520in%2520Hematology%26atitle%3DMutational%252Banalysis%252Bin%252Bchronic%252Bmyeloid%252Bleukemia%25253A%252Bwhen%252Band%252Bwhat%252Bto%252Bdo%25253F%26aulast%3DBranford%26aufirst%3DSusan%26date%3D2011%26volume%3D18%26issue%3D2%26spage%3D111%26epage%3D116" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Rina  Barouch-Bentov</span>, <span class="hlFld-ContribAuthor ">Karsten  Sauer</span>. </span><span class="cited-content_cbyCitation_article-title">Mechanisms of drug resistance in kinases. </span><span class="cited-content_cbyCitation_journal-name">Expert Opinion on Investigational Drugs</span><span> <strong>2011,</strong> <em>20 </em>
                                    (2)
                                     , 153-208. <a href="https://doi.org/10.1517/13543784.2011.546344" title="DOI URL">https://doi.org/10.1517/13543784.2011.546344</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1517/13543784.2011.546344&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1517%2F13543784.2011.546344%26sid%3Dliteratum%253Aachs%26jtitle%3DExpert%2520Opinion%2520on%2520Investigational%2520Drugs%26atitle%3DMechanisms%252Bof%252Bdrug%252Bresistance%252Bin%252Bkinases%26aulast%3DBarouch-Bentov%26aufirst%3DRina%26date%3D2011%26date%3D2011%26volume%3D20%26issue%3D2%26spage%3D153%26epage%3D208" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="f_tgr1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-15/jm901808w/production/images/medium/jm-2009-01808w_0004.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-15/jm901808w/production/images/large/jm-2009-01808w_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm901808w&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-15/jm901808w/production/images/medium/jm-2009-01808w_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-15/jm901808w/production/images/large/jm-2009-01808w_0005.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. 3,4-Dihydropyrimido[4,5-<i>d</i>]pyrimidin-2(1<i>H</i>)-one scaffold for type-II T315I inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-15/jm901808w/production/images/large/jm-2009-01808w_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm901808w&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-15/jm901808w/production/images/medium/jm-2009-01808w_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-15/jm901808w/production/images/large/jm-2009-01808w_0006.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 1. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-15/jm901808w/production/images/large/jm-2009-01808w_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm901808w&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) methylamine, THF, 0 °C; (b) LiAlH<sub>4</sub>, THF, 0 °C; (c) MnO<sub>2</sub>, DCM; (d) Na(CN)BH<sub>3</sub>, AcOH, MeOH; (e) triphosgene, DIEA, THF, 0 °C; (f) <i>m</i>-CPBA, DCM, 0 °C; (g) NH<sub>3</sub> in 2-propanol or aniline, 1,4-dioxane, 120 °C.</p></p></figure><figure data-id="sch2" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-15/jm901808w/production/images/medium/jm-2009-01808w_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-15/jm901808w/production/images/large/jm-2009-01808w_0007.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 2. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-15/jm901808w/production/images/large/jm-2009-01808w_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm901808w&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) Na(CN)BH<sub>3</sub>, AcOH, MeOH; (b) triphosgene, DIEA, THF; (c) Pd/C, H<sub>2</sub>, MeOH; (d) HATU, DIEA, DMF; (e) <i>m</i>-CPBA, DCM, 0 °C; (f) methylamine in THF, 1,4-dioxane, 120 °C.</p></p></figure><figure data-id="fig2" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-15/jm901808w/production/images/medium/jm-2009-01808w_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-15/jm901808w/production/images/large/jm-2009-01808w_0008.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Superimposed structure of <b>20</b> (green sticks) bound to Abl (pink ribbon PDB: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1m52">1m52</a>) and nilotinib (yellow sticks) bound to Abl (PDB: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3cs9">3cs9</a>). Hydrogen bonds are indicated by red hatched lines to key amino acids (blue sticks).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-15/jm901808w/production/images/large/jm-2009-01808w_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm901808w&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-15/jm901808w/production/images/medium/jm-2009-01808w_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-15/jm901808w/production/images/large/jm-2009-01808w_0001.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Bioluminescent in vivo efficacy study (oral administration, once-daily dosing) for <b>2</b> using Ba/F3-T315I-Bcr-Abl cell line that has stable luciferase expression. Mice were imaged at day 5 and 7 after <b>2</b> treatment.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-15/jm901808w/production/images/large/jm-2009-01808w_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm901808w&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-15/jm901808w/production/images/medium/jm-2009-01808w_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-15/jm901808w/production/images/large/jm-2009-01808w_0003.jpeg" id="rightTab-_i12" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Mice body weight change during bioluminescent in vivo efficacy study (oral administration, once-daily dosing) for <b>2</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-15/jm901808w/production/images/large/jm-2009-01808w_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm901808w&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i36">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_78473" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_78473" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 33 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group">Weisberg, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Manley, P. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Breitenstein, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bruggen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cowan-Jacob, S. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ray, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huntly, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fabbro, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fendrich, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hall-Meyers, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kung, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mestan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Daley, G. Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Callahan, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Catley, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cavazza, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Azam, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neuberg, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wright, R. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gilliland, D. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Griffin, J. D.</span><span> </span><span class="NLM_article-title">Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl</span> <span class="citation_source-journal">Cancer Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x"> (</span><span class="NLM_issue">2</span><span class="NLM_x">) </span> <span class="NLM_fpage">129</span><span class="NLM_x">–</span> <span class="NLM_lpage">141</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Fjm901808w&amp;key=10.1016%2Fj.ccr.2005.01.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Fjm901808w&amp;key=15710326" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Fjm901808w&amp;key=1%3ACAS%3A528%3ADC%252BD2MXitFygu7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2005&pages=129-141&issue=2&author=E.+Weisbergauthor=P.+W.+Manleyauthor=W.+Breitensteinauthor=J.+Bruggenauthor=S.+W.+Cowan-Jacobauthor=A.+Rayauthor=B.+Huntlyauthor=D.+Fabbroauthor=G.+Fendrichauthor=E.+Hall-Meyersauthor=A.+L.+Kungauthor=J.+Mestanauthor=G.+Q.+Daleyauthor=L.+Callahanauthor=L.+Catleyauthor=C.+Cavazzaauthor=M.+Azamauthor=D.+Neubergauthor=R.+D.+Wrightauthor=D.+G.+Gillilandauthor=J.+D.+Griffin&title=Characterization+of+AMN107%2C+a+selective+inhibitor+of+native+and+mutant+Bcr-Abl"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl</span></div><div class="casAuthors">Weisberg, Ellen; Manley, Paul W.; Breitenstein, Werner; Brueggen, Josef; Cowan-Jacob, Sandra W.; Ray, Arghya; Huntly, Brian; Fabbro, Doriano; Fendrich, Gabriele; Hall-Meyers, Elizabeth; Kung, Andrew L.; Mestan, Juergen; Daley, George Q.; Callahan, Linda; Catley, Laurie; Cavazza, Cara; Mohammed, Azam; Neuberg, Donna; Wright, Renee D.; Gilliland, D. Gary; Griffin, James D.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Cell</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">129-141</span>CODEN:
                <span class="NLM_cas:coden">CCAECI</span>;
        ISSN:<span class="NLM_cas:issn">1535-6108</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">The Bcr-Abl tyrosine kinase oncogene causes chronic myelogenous leukemia (CML) and Philadelphia chromosome-pos. (Ph+) acute lymphoblastic leukemia (ALL).  We describe a novel selective inhibitor of Bcr-Abl, AMN107 (IC50 < 30 nM), which is significantly more potent than imatinib, and active against a no. of imatinib-resistant Bcr-Abl mutants.  Crystallog. anal. of Abl-AMN107 complexes provides a structural explanation for the differential activity of AMN107 and imatinib against imatinib-resistant Bcr-Abl.  Consistent with its in vitro and pharmacokinetic profile, AMN107 prolonged survival of mice injected with Bcr-Abl-transformed hematopoietic cell lines or primary marrow cells, and prolonged survival in imatinib-resistant CML mouse models.  AMN107 is a promising new inhibitor for the therapy of CML and Ph+ ALL.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGow6QF3qX2uO7Vg90H21EOLACvtfcHk0ljZeFnTDmZ4gw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXitFygu7o%253D&md5=d28e1a54b982951f8d3e6ef1d2d3b2eb</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1016%2Fj.ccr.2005.01.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ccr.2005.01.007%26sid%3Dliteratum%253Aachs%26aulast%3DWeisberg%26aufirst%3DE.%26aulast%3DManley%26aufirst%3DP.%2BW.%26aulast%3DBreitenstein%26aufirst%3DW.%26aulast%3DBruggen%26aufirst%3DJ.%26aulast%3DCowan-Jacob%26aufirst%3DS.%2BW.%26aulast%3DRay%26aufirst%3DA.%26aulast%3DHuntly%26aufirst%3DB.%26aulast%3DFabbro%26aufirst%3DD.%26aulast%3DFendrich%26aufirst%3DG.%26aulast%3DHall-Meyers%26aufirst%3DE.%26aulast%3DKung%26aufirst%3DA.%2BL.%26aulast%3DMestan%26aufirst%3DJ.%26aulast%3DDaley%26aufirst%3DG.%2BQ.%26aulast%3DCallahan%26aufirst%3DL.%26aulast%3DCatley%26aufirst%3DL.%26aulast%3DCavazza%26aufirst%3DC.%26aulast%3DAzam%26aufirst%3DM.%26aulast%3DNeuberg%26aufirst%3DD.%26aulast%3DWright%26aufirst%3DR.%2BD.%26aulast%3DGilliland%26aufirst%3DD.%2BG.%26aulast%3DGriffin%26aufirst%3DJ.%2BD.%26atitle%3DCharacterization%2520of%2520AMN107%252C%2520a%2520selective%2520inhibitor%2520of%2520native%2520and%2520mutant%2520Bcr-Abl%26jtitle%3DCancer%2520Cell%26date%3D2005%26volume%3D7%26issue%3D2%26spage%3D129%26epage%3D141" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group">Puttini, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coluccia, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boschelli, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cleris, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marchesi, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Donella-Deana, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ahmed, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Redaelli, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Piazza, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Magistroni, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Andreoni, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scapozza, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Formelli, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gambacorti-Passerini, C.</span><span> </span><span class="NLM_article-title">In vitro and in vivo activity of SKI-606, a novel Src-Abl inhibitor, against imatinib-resistant Bcr-Abl+ neoplastic cells</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">66</span><span class="NLM_x"> (</span><span class="NLM_issue">23</span><span class="NLM_x">) </span> <span class="NLM_fpage">11314</span><span class="NLM_x">–</span> <span class="NLM_lpage">11322</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=2006&pages=11314-11322&issue=23&author=M.+Puttiniauthor=A.+M.+Colucciaauthor=F.+Boschelliauthor=L.+Clerisauthor=E.+Marchesiauthor=A.+Donella-Deanaauthor=S.+Ahmedauthor=S.+Redaelliauthor=R.+Piazzaauthor=V.+Magistroniauthor=F.+Andreoniauthor=L.+Scapozzaauthor=F.+Formelliauthor=C.+Gambacorti-Passerini&title=In+vitro+and+in+vivo+activity+of+SKI-606%2C+a+novel+Src-Abl+inhibitor%2C+against+imatinib-resistant+Bcr-Abl%2B+neoplastic+cells"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPuttini%26aufirst%3DM.%26aulast%3DColuccia%26aufirst%3DA.%2BM.%26aulast%3DBoschelli%26aufirst%3DF.%26aulast%3DCleris%26aufirst%3DL.%26aulast%3DMarchesi%26aufirst%3DE.%26aulast%3DDonella-Deana%26aufirst%3DA.%26aulast%3DAhmed%26aufirst%3DS.%26aulast%3DRedaelli%26aufirst%3DS.%26aulast%3DPiazza%26aufirst%3DR.%26aulast%3DMagistroni%26aufirst%3DV.%26aulast%3DAndreoni%26aufirst%3DF.%26aulast%3DScapozza%26aufirst%3DL.%26aulast%3DFormelli%26aufirst%3DF.%26aulast%3DGambacorti-Passerini%26aufirst%3DC.%26atitle%3DIn%2520vitro%2520and%2520in%2520vivo%2520activity%2520of%2520SKI-606%252C%2520a%2520novel%2520Src-Abl%2520inhibitor%252C%2520against%2520imatinib-resistant%2520Bcr-Abl%252B%2520neoplastic%2520cells%26jtitle%3DCancer%2520Res.%26date%3D2006%26volume%3D66%26issue%3D23%26spage%3D11314%26epage%3D11322" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group">Shah, N. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tran, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, F. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Norris, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sawyers, C. L.</span><span> </span><span class="NLM_article-title">Overriding imatinib resistance with a novel ABL kinase inhibitor</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">305</span><span class="NLM_x"> (</span><span class="NLM_issue">5682</span><span class="NLM_x">) </span> <span class="NLM_fpage">399</span><span class="NLM_x">–</span> <span class="NLM_lpage">401</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Fjm901808w&amp;key=10.1126%2Fscience.1099480" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Fjm901808w&amp;key=15256671" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Fjm901808w&amp;key=1%3ACAS%3A528%3ADC%252BD2cXls1egtrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=305&publication_year=2004&pages=399-401&issue=5682&author=N.+P.+Shahauthor=C.+Tranauthor=F.+Y.+Leeauthor=P.+Chenauthor=D.+Norrisauthor=C.+L.+Sawyers&title=Overriding+imatinib+resistance+with+a+novel+ABL+kinase+inhibitor"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Overriding Imatinib Resistance with a Novel ABL Kinase Inhibitor</span></div><div class="casAuthors">Shah, Neil P.; Tran, Chris; Lee, Francis Y.; Chen, Ping; Norris, Derek; Sawyers, Charles L.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">305</span>
        (<span class="NLM_cas:issue">5682</span>),
    <span class="NLM_cas:pages">399-402</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">Resistance to the ABL kinase inhibitor imatinib (STI571 or Gleevec) in chronic myeloid leukemia (CML) occurs through selection for tumor cells harboring BCR-ABL kinase domain point mutations that interfere with drug binding.  Crystallog. studies predict that most imatinib-resistant mutants should remain sensitive to inhibitors that bind ABL with less stringent conformational requirements.  BMS-354825 is an orally bioavailable ABL kinase inhibitor with two-log increased potency relative to imatinib that retains activity against 14 of 15 imatinib-resistant BCR-ABL mutants.  BMS-354825 prolongs survival of mice with BCR-ABL-driven disease and inhibits proliferation of BCR-ABL-pos. bone marrow progenitor cells from patients with imatinib-sensitive and imatinib-resistant CML.  These data illustrate how mol. insight into kinase inhibitor resistance can guide the design of second-generation targeted therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp0O0Lhe8nKCrVg90H21EOLACvtfcHk0ljrJskV0DyrTQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXls1egtrY%253D&md5=b3827c3419b4c6b57893b11fd68f1f96</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1126%2Fscience.1099480&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1099480%26sid%3Dliteratum%253Aachs%26aulast%3DShah%26aufirst%3DN.%2BP.%26aulast%3DTran%26aufirst%3DC.%26aulast%3DLee%26aufirst%3DF.%2BY.%26aulast%3DChen%26aufirst%3DP.%26aulast%3DNorris%26aufirst%3DD.%26aulast%3DSawyers%26aufirst%3DC.%2BL.%26atitle%3DOverriding%2520imatinib%2520resistance%2520with%2520a%2520novel%2520ABL%2520kinase%2520inhibitor%26jtitle%3DScience%26date%3D2004%26volume%3D305%26issue%3D5682%26spage%3D399%26epage%3D401" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group">O’Hare, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walters, D. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deininger, M. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Druker, B. J.</span><span> </span><span class="NLM_article-title">AMN107: tightening the grip of imatinib</span> <span class="citation_source-journal">Cancer Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x"> (</span><span class="NLM_issue">2</span><span class="NLM_x">) </span> <span class="NLM_fpage">117</span><span class="NLM_x">–</span> <span class="NLM_lpage">119</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2005&pages=117-119&issue=2&author=T.+O%E2%80%99Hareauthor=D.+K.+Waltersauthor=M.+W.+Deiningerauthor=B.+J.+Druker&title=AMN107%3A+tightening+the+grip+of+imatinib"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DO%25E2%2580%2599Hare%26aufirst%3DT.%26aulast%3DWalters%26aufirst%3DD.%2BK.%26aulast%3DDeininger%26aufirst%3DM.%2BW.%26aulast%3DDruker%26aufirst%3DB.%2BJ.%26atitle%3DAMN107%253A%2520tightening%2520the%2520grip%2520of%2520imatinib%26jtitle%3DCancer%2520Cell%26date%3D2005%26volume%3D7%26issue%3D2%26spage%3D117%26epage%3D119" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group">Miyamoto, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sugita, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Inukai, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lijima, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tezuka, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kojika, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakamura, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kagami, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakazawa, S.</span><span> </span><span class="NLM_article-title">The JAK2 inhibitor AG490 predominantly abrogates the growth of human B-precursor leukemic cells with 11q23 translocation or Philadelphia chromosome</span> <span class="citation_source-journal">Leukemia</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x"> (</span><span class="NLM_issue">11</span><span class="NLM_x">) </span> <span class="NLM_fpage">1758</span><span class="NLM_x">–</span> <span class="NLM_lpage">1768</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2001&pages=1758-1768&issue=11&author=N.+Miyamotoauthor=K.+Sugitaauthor=K.+Goiauthor=T.+Inukaiauthor=K.+Lijimaauthor=T.+Tezukaauthor=S.+Kojikaauthor=M.+Nakamuraauthor=K.+Kagamiauthor=S.+Nakazawa&title=The+JAK2+inhibitor+AG490+predominantly+abrogates+the+growth+of+human+B-precursor+leukemic+cells+with+11q23+translocation+or+Philadelphia+chromosome"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMiyamoto%26aufirst%3DN.%26aulast%3DSugita%26aufirst%3DK.%26aulast%3DGoi%26aufirst%3DK.%26aulast%3DInukai%26aufirst%3DT.%26aulast%3DLijima%26aufirst%3DK.%26aulast%3DTezuka%26aufirst%3DT.%26aulast%3DKojika%26aufirst%3DS.%26aulast%3DNakamura%26aufirst%3DM.%26aulast%3DKagami%26aufirst%3DK.%26aulast%3DNakazawa%26aufirst%3DS.%26atitle%3DThe%2520JAK2%2520inhibitor%2520AG490%2520predominantly%2520abrogates%2520the%2520growth%2520of%2520human%2520B-precursor%2520leukemic%2520cells%2520with%252011q23%2520translocation%2520or%2520Philadelphia%2520chromosome%26jtitle%3DLeukemia%26date%3D2001%26volume%3D15%26issue%3D11%26spage%3D1758%26epage%3D1768" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group">Samanta, A. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kantarjian, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arlinghaus, R. B.</span><span> </span><span class="NLM_article-title">Janus kinase 2: a critical target in chronic myelogenous leukemia</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">66</span><span class="NLM_x"> (</span><span class="NLM_issue">13</span><span class="NLM_x">) </span> <span class="NLM_fpage">6468</span><span class="NLM_x">–</span> <span class="NLM_lpage">6472</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=2006&pages=6468-6472&issue=13&author=A.+K.+Samantaauthor=H.+Linauthor=T.+Sunauthor=H.+Kantarjianauthor=R.+B.+Arlinghaus&title=Janus+kinase+2%3A+a+critical+target+in+chronic+myelogenous+leukemia"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSamanta%26aufirst%3DA.%2BK.%26aulast%3DLin%26aufirst%3DH.%26aulast%3DSun%26aufirst%3DT.%26aulast%3DKantarjian%26aufirst%3DH.%26aulast%3DArlinghaus%26aufirst%3DR.%2BB.%26atitle%3DJanus%2520kinase%25202%253A%2520a%2520critical%2520target%2520in%2520chronic%2520myelogenous%2520leukemia%26jtitle%3DCancer%2520Res.%26date%3D2006%26volume%3D66%26issue%3D13%26spage%3D6468%26epage%3D6472" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group">Summy, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trevino, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lesslie, D. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baker, C. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shakespeare, W. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sundaramoorthi, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Metcalf, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keats, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sawyer, T. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gallick, G. E.</span><span> </span><span class="NLM_article-title">AP23846, a novel and highly potent Src family kinase inhibitor, reduces vascular endothelial growth factor and interleukin-8 expression in human solid tumor cell lines and abrogates downstream angiogenic processes</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x"> (</span><span class="NLM_issue">12</span><span class="NLM_x">) </span> <span class="NLM_fpage">1900</span><span class="NLM_x">–</span> <span class="NLM_lpage">1911</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Fjm901808w&amp;key=10.1158%2F1535-7163.MCT-05-0171" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Fjm901808w&amp;key=16373705" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Fjm901808w&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtlCnsrvI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2005&pages=1900-1911&issue=12&author=J.+M.+Summyauthor=J.+G.+Trevinoauthor=D.+P.+Lesslieauthor=C.+H.+Bakerauthor=W.+C.+Shakespeareauthor=Y.+Wangauthor=R.+Sundaramoorthiauthor=C.+A.+Metcalfauthor=J.+A.+Keatsauthor=T.+K.+Sawyerauthor=G.+E.+Gallick&title=AP23846%2C+a+novel+and+highly+potent+Src+family+kinase+inhibitor%2C+reduces+vascular+endothelial+growth+factor+and+interleukin-8+expression+in+human+solid+tumor+cell+lines+and+abrogates+downstream+angiogenic+processes"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">AP23846, a novel and highly potent Src family kinase inhibitor, reduces vascular endothelial growth factor and interleukin-8 expression in human solid tumor cell lines and abrogates downstream angiogenic processes</span></div><div class="casAuthors">Summy, Justin M.; Trevino, Jose G.; Lesslie, Donald P.; Baker, Cheryl H.; Shakespeare, William C.; Wang, Yihan; Sundaramoorthi, Raji; Metcalf, Chester A., III; Keats, Jeffrey A.; Sawyer, Tomi K.; Gallick, Gary E.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1900-1911</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">C-Src is frequently activated in human malignancies, including colon, breast, and pancreatic carcinomas.  Several recent studies have shown that activation of Src family kinases leads to tumor progression and metastasis by increasing cellular migration and invasion, promoting cell growth and survival, and deregulating expression of proangiogenic mols.  Therefore, selective inhibitors of Src are being developed for cancer therapy.  In this study, we characterize the biol. effects of the novel ATP-based Src family kinase inhibitor, AP23846, in tumor cells with high Src activity.  As a lead compd., AP23846 is a potent c-Src kinase inhibitor (IC50 ∼0.5 nmol/L in vitro, ∼10-fold more potent than PP2, the most widely used com. available Src family kinase inhibitor).  At concns. of 1 μmol/L, AP23846 led to complete Src inhibition for 48 h in cells.  No cytotoxicity was obsd. under these conditions, although proliferation rates were slower.  Therefore, this was an excellent inhibitor to examine Src-regulated signaling pathways in tumor cells.  AP23846 reduced cellular migration, vascular endothelial growth factor, and interleukin-8 in a dose-dependent fashion in pancreatic adenocarcinoma cells grown in vitro.  Correspondingly, cell culture supernatants from L3.6pl pancreatic adenocarcinoma cells pretreated with AP23846 failed to promote migration of hepatic endothelial cells in vitro and failed to support angiogenesis into gel foams implanted s.c. in mice in vivo.  These results suggest that Src inhibitors affect biol. properties of tumor progression and may be useful as cancer therapeutic agents in more advanced disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqD5msxlHP037Vg90H21EOLACvtfcHk0liPNY_XhF8FBg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtlCnsrvI&md5=4eedd79332fe6eb3cf23407e55286739</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-05-0171&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-05-0171%26sid%3Dliteratum%253Aachs%26aulast%3DSummy%26aufirst%3DJ.%2BM.%26aulast%3DTrevino%26aufirst%3DJ.%2BG.%26aulast%3DLesslie%26aufirst%3DD.%2BP.%26aulast%3DBaker%26aufirst%3DC.%2BH.%26aulast%3DShakespeare%26aufirst%3DW.%2BC.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DSundaramoorthi%26aufirst%3DR.%26aulast%3DMetcalf%26aufirst%3DC.%2BA.%26aulast%3DKeats%26aufirst%3DJ.%2BA.%26aulast%3DSawyer%26aufirst%3DT.%2BK.%26aulast%3DGallick%26aufirst%3DG.%2BE.%26atitle%3DAP23846%252C%2520a%2520novel%2520and%2520highly%2520potent%2520Src%2520family%2520kinase%2520inhibitor%252C%2520reduces%2520vascular%2520endothelial%2520growth%2520factor%2520and%2520interleukin-8%2520expression%2520in%2520human%2520solid%2520tumor%2520cell%2520lines%2520and%2520abrogates%2520downstream%2520angiogenic%2520processes%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2005%26volume%3D4%26issue%3D12%26spage%3D1900%26epage%3D1911" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group">Azam, M</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nardi, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shakespeare, W. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Metcalf, C. A.,  III</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bohacek, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sundaramoorthi, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sliz, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Veach, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bornmann, W. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clarkson, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dalgarno, D. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sawyer, T. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Daley, G. Q.</span><span> </span><span class="NLM_article-title">Activity of dual SRC-ABL inhibitors highlights the role of BCR/ABL kinase dynamics in drug resistance</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U.S.A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">103</span><span class="NLM_x"> (</span><span class="NLM_issue">24</span><span class="NLM_x">) </span> <span class="NLM_fpage">9244</span><span class="NLM_x">–</span> <span class="NLM_lpage">9249</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=103&publication_year=2006&pages=9244-9249&issue=24&author=M+Azamauthor=V.+Nardiauthor=W.+C.+Shakespeareauthor=C.+A.+Metcalfauthor=R.+S.+Bohacekauthor=Y.+Wangauthor=R.+Sundaramoorthiauthor=P.+Slizauthor=D.+R.+Veachauthor=W.+G.+Bornmannauthor=B.+Clarksonauthor=D.+C.+Dalgarnoauthor=T.+K.+Sawyerauthor=G.+Q.+Daley&title=Activity+of+dual+SRC-ABL+inhibitors+highlights+the+role+of+BCR%2FABL+kinase+dynamics+in+drug+resistance"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DAzam%26aufirst%3DM%26aulast%3DNardi%26aufirst%3DV.%26aulast%3DShakespeare%26aufirst%3DW.%2BC.%26aulast%3DMetcalf%26aufirst%3DC.%2BA.%26aulast%3DBohacek%26aufirst%3DR.%2BS.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DSundaramoorthi%26aufirst%3DR.%26aulast%3DSliz%26aufirst%3DP.%26aulast%3DVeach%26aufirst%3DD.%2BR.%26aulast%3DBornmann%26aufirst%3DW.%2BG.%26aulast%3DClarkson%26aufirst%3DB.%26aulast%3DDalgarno%26aufirst%3DD.%2BC.%26aulast%3DSawyer%26aufirst%3DT.%2BK.%26aulast%3DDaley%26aufirst%3DG.%2BQ.%26atitle%3DActivity%2520of%2520dual%2520SRC-ABL%2520inhibitors%2520highlights%2520the%2520role%2520of%2520BCR%252FABL%2520kinase%2520dynamics%2520in%2520drug%2520resistance%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2006%26volume%3D103%26issue%3D24%26spage%3D9244%26epage%3D9249" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group">Harrington, E. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bebbington, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moore, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rasmussen, R. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ajose-Adeogun, A. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakayama, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Graham, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Demur, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hercend, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Diu-Hercend, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Su, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Golec, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, K. M.</span><span> </span><span class="NLM_article-title">VX-680, a potent and selective small-molecule inhibitor of the Aurora kinases, suppresses tumor growth in vivo</span> <span class="citation_source-journal">Nature Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x"> (</span><span class="NLM_issue">3</span><span class="NLM_x">) </span> <span class="NLM_fpage">262</span><span class="NLM_x">–</span> <span class="NLM_lpage">267</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2004&pages=262-267&issue=3&author=E.+A.+Harringtonauthor=D.+Bebbingtonauthor=J.+Mooreauthor=R.+K.+Rasmussenauthor=A.+O.+Ajose-Adeogunauthor=T.+Nakayamaauthor=J.+A.+Grahamauthor=C.+Demurauthor=T.+Hercendauthor=A.+Diu-Hercendauthor=M.+Suauthor=J.+M.+Golecauthor=K.+M.+Miller&title=VX-680%2C+a+potent+and+selective+small-molecule+inhibitor+of+the+Aurora+kinases%2C+suppresses+tumor+growth+in+vivo"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHarrington%26aufirst%3DE.%2BA.%26aulast%3DBebbington%26aufirst%3DD.%26aulast%3DMoore%26aufirst%3DJ.%26aulast%3DRasmussen%26aufirst%3DR.%2BK.%26aulast%3DAjose-Adeogun%26aufirst%3DA.%2BO.%26aulast%3DNakayama%26aufirst%3DT.%26aulast%3DGraham%26aufirst%3DJ.%2BA.%26aulast%3DDemur%26aufirst%3DC.%26aulast%3DHercend%26aufirst%3DT.%26aulast%3DDiu-Hercend%26aufirst%3DA.%26aulast%3DSu%26aufirst%3DM.%26aulast%3DGolec%26aufirst%3DJ.%2BM.%26aulast%3DMiller%26aufirst%3DK.%2BM.%26atitle%3DVX-680%252C%2520a%2520potent%2520and%2520selective%2520small-molecule%2520inhibitor%2520of%2520the%2520Aurora%2520kinases%252C%2520suppresses%2520tumor%2520growth%2520in%2520vivo%26jtitle%3DNature%2520Med.%26date%3D2004%26volume%3D10%26issue%3D3%26spage%3D262%26epage%3D267" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group">Carter, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wodicka, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shah, N. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Velasco, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fabian, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Treiber, D. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Milanov, Z. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Atteridge, C. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Biggs, W. H.,  3rd</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Edeen, P. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Floyd, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ford, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grotzfeld, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Herrgard, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Insko, D. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mehta, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, H. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pao, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sawyers, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Varmus, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zarrinkar, P. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lockhart, D. J.</span><span> </span><span class="NLM_article-title">Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci U.S.A</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">102</span><span class="NLM_x"> (</span><span class="NLM_issue">31</span><span class="NLM_x">) </span> <span class="NLM_fpage">11011</span><span class="NLM_x">–</span> <span class="NLM_lpage">11016</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=102&publication_year=2005&pages=11011-11016&issue=31&author=T.+A.+Carterauthor=L.+M.+Wodickaauthor=N.+P.+Shahauthor=A.+M.+Velascoauthor=M.+A.+Fabianauthor=D.+K.+Treiberauthor=Z.+V.+Milanovauthor=C.+E.+Atteridgeauthor=W.+H.+Biggsauthor=P.+T.+Edeenauthor=M.+Floydauthor=J.+M.+Fordauthor=R.+M.+Grotzfeldauthor=S.+Herrgardauthor=D.+E.+Inskoauthor=S.+A.+Mehtaauthor=H.+K.+Patelauthor=W.+Paoauthor=C.+L.+Sawyersauthor=H.+Varmusauthor=P.+P.+Zarrinkarauthor=D.+J.+Lockhart&title=Inhibition+of+drug-resistant+mutants+of+ABL%2C+KIT%2C+and+EGF+receptor+kinases"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCarter%26aufirst%3DT.%2BA.%26aulast%3DWodicka%26aufirst%3DL.%2BM.%26aulast%3DShah%26aufirst%3DN.%2BP.%26aulast%3DVelasco%26aufirst%3DA.%2BM.%26aulast%3DFabian%26aufirst%3DM.%2BA.%26aulast%3DTreiber%26aufirst%3DD.%2BK.%26aulast%3DMilanov%26aufirst%3DZ.%2BV.%26aulast%3DAtteridge%26aufirst%3DC.%2BE.%26aulast%3DBiggs%26aufirst%3DW.%2BH.%26aulast%3DEdeen%26aufirst%3DP.%2BT.%26aulast%3DFloyd%26aufirst%3DM.%26aulast%3DFord%26aufirst%3DJ.%2BM.%26aulast%3DGrotzfeld%26aufirst%3DR.%2BM.%26aulast%3DHerrgard%26aufirst%3DS.%26aulast%3DInsko%26aufirst%3DD.%2BE.%26aulast%3DMehta%26aufirst%3DS.%2BA.%26aulast%3DPatel%26aufirst%3DH.%2BK.%26aulast%3DPao%26aufirst%3DW.%26aulast%3DSawyers%26aufirst%3DC.%2BL.%26aulast%3DVarmus%26aufirst%3DH.%26aulast%3DZarrinkar%26aufirst%3DP.%2BP.%26aulast%3DLockhart%26aufirst%3DD.%2BJ.%26atitle%3DInhibition%2520of%2520drug-resistant%2520mutants%2520of%2520ABL%252C%2520KIT%252C%2520and%2520EGF%2520receptor%2520kinases%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci%2520U.S.A%26date%3D2005%26volume%3D102%26issue%3D31%26spage%3D11011%26epage%3D11016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group">Carpinelli, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ceruti, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giorgini, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cappella, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gianellini, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Croci, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Degrassi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Texido, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rocchetti, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vianello, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rusconi, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Storici, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zugnoni, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arrigoni, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Soncini, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alli, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patton, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marsiglio, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ballinari, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pesenti, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fancelli, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moll, J.</span><span> </span><span class="NLM_article-title">PHA-739358, a potent inhibitor of Aurora kinases with a selective target inhibition profile relevant to cancer</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x"> (</span><span class="NLM_issue">12</span><span class="NLM_x">) </span> <span class="NLM_fpage">3158</span><span class="NLM_x">–</span> <span class="NLM_lpage">3168</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Fjm901808w&amp;key=10.1158%2F1535-7163.MCT-07-0444" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Fjm901808w&amp;key=18089710" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Fjm901808w&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhsVCjsr3M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2007&pages=3158-3168&issue=12&author=P.+Carpinelliauthor=R.+Cerutiauthor=M.+L.+Giorginiauthor=P.+Cappellaauthor=L.+Gianelliniauthor=V.+Crociauthor=A.+Degrassiauthor=G.+Texidoauthor=M.+Rocchettiauthor=P.+Vianelloauthor=L.+Rusconiauthor=P.+Storiciauthor=P.+Zugnoniauthor=C.+Arrigoniauthor=C.+Sonciniauthor=C.+Alliauthor=V.+Pattonauthor=A.+Marsiglioauthor=D.+Ballinariauthor=E.+Pesentiauthor=D.+Fancelliauthor=J.+Moll&title=PHA-739358%2C+a+potent+inhibitor+of+Aurora+kinases+with+a+selective+target+inhibition+profile+relevant+to+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">PHA-739358, a potent inhibitor of Aurora kinases with a selective target inhibition profile relevant to cancer</span></div><div class="casAuthors">Carpinelli, Patrizia; Ceruti, Roberta; Giorgini, Maria Laura; Cappella, Paolo; Gianellini, Laura; Croci, Valter; Degrassi, Anna; Texido, Gemma; Rocchetti, Maurizio; Vianello, Paola; Rusconi, Luisa; Storici, Paola; Zugnoni, Paola; Arrigoni, Claudio; Soncini, Chiara; Alli, Cristina; Patton, Veronica; Marsiglio, Aurelio; Ballinari, Dario; Pesenti, Enrico; Fancelli, Daniele; Moll, Juergen</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">12, Pt. 1</span>),
    <span class="NLM_cas:pages">3158-3168</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">PHA-739358 is a small-mol. 3-aminopyrazole deriv. with strong activity against Aurora kinases and cross-reactivities with some receptor tyrosine kinases relevant for cancer.  PHA-739358 inhibits all Aurora kinase family members and shows a dominant Aurora B kinase inhibition-related cellular phenotype and mechanism of action in cells in vitro and in vivo. p53 status-dependent endoreduplication is obsd. upon treatment of cells with PHA-739358, and phosphorylation of histone H3 in Ser10 is inhibited.  The compd. has significant antitumor activity in different xenografts and spontaneous and transgenic animal tumor models and shows a favorable pharmacokinetic and safety profile.  In vivo target modulation is obsd. as assessed by the inhibition of the phosphorylation of histone H3, which has been validated preclinically as a candidate biomarker for the clin. phase.  Pharmacokinetics/pharmacodynamics modeling was used to define drug potency and to support the prediction of active clin. doses and schedules.  We conclude that PHA-739358, which is currently tested in clin. trials, has great therapeutic potential in anticancer therapy in a wide range of cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqfveLDPYzNGLVg90H21EOLACvtfcHk0lg8TKhpJHLZpw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhsVCjsr3M&md5=695fc55d72717a86f96818ca23fc71b8</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-07-0444&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-07-0444%26sid%3Dliteratum%253Aachs%26aulast%3DCarpinelli%26aufirst%3DP.%26aulast%3DCeruti%26aufirst%3DR.%26aulast%3DGiorgini%26aufirst%3DM.%2BL.%26aulast%3DCappella%26aufirst%3DP.%26aulast%3DGianellini%26aufirst%3DL.%26aulast%3DCroci%26aufirst%3DV.%26aulast%3DDegrassi%26aufirst%3DA.%26aulast%3DTexido%26aufirst%3DG.%26aulast%3DRocchetti%26aufirst%3DM.%26aulast%3DVianello%26aufirst%3DP.%26aulast%3DRusconi%26aufirst%3DL.%26aulast%3DStorici%26aufirst%3DP.%26aulast%3DZugnoni%26aufirst%3DP.%26aulast%3DArrigoni%26aufirst%3DC.%26aulast%3DSoncini%26aufirst%3DC.%26aulast%3DAlli%26aufirst%3DC.%26aulast%3DPatton%26aufirst%3DV.%26aulast%3DMarsiglio%26aufirst%3DA.%26aulast%3DBallinari%26aufirst%3DD.%26aulast%3DPesenti%26aufirst%3DE.%26aulast%3DFancelli%26aufirst%3DD.%26aulast%3DMoll%26aufirst%3DJ.%26atitle%3DPHA-739358%252C%2520a%2520potent%2520inhibitor%2520of%2520Aurora%2520kinases%2520with%2520a%2520selective%2520target%2520inhibition%2520profile%2520relevant%2520to%2520cancer%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2007%26volume%3D6%26issue%3D12%26spage%3D3158%26epage%3D3168" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group">Modugno, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Casale, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Soncini, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosettani, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Colombo, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lupi, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rusconi, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fancelli, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carpinelli, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cameron, A. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Isacchi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moll, J.</span><span> </span><span class="NLM_article-title">Crystal structure of the T315I Abl mutant in complex with the aurora kinases inhibitor PHA-739358</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">67</span><span class="NLM_x"> (</span><span class="NLM_issue">17</span><span class="NLM_x">) </span> <span class="NLM_fpage">7987</span><span class="NLM_x">–</span> <span class="NLM_lpage">7990</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=2007&pages=7987-7990&issue=17&author=M.+Modugnoauthor=E.+Casaleauthor=C.+Sonciniauthor=P.+Rosettaniauthor=R.+Colomboauthor=R.+Lupiauthor=L.+Rusconiauthor=D.+Fancelliauthor=P.+Carpinelliauthor=A.+D.+Cameronauthor=A.+Isacchiauthor=J.+Moll&title=Crystal+structure+of+the+T315I+Abl+mutant+in+complex+with+the+aurora+kinases+inhibitor+PHA-739358"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DModugno%26aufirst%3DM.%26aulast%3DCasale%26aufirst%3DE.%26aulast%3DSoncini%26aufirst%3DC.%26aulast%3DRosettani%26aufirst%3DP.%26aulast%3DColombo%26aufirst%3DR.%26aulast%3DLupi%26aufirst%3DR.%26aulast%3DRusconi%26aufirst%3DL.%26aulast%3DFancelli%26aufirst%3DD.%26aulast%3DCarpinelli%26aufirst%3DP.%26aulast%3DCameron%26aufirst%3DA.%2BD.%26aulast%3DIsacchi%26aufirst%3DA.%26aulast%3DMoll%26aufirst%3DJ.%26atitle%3DCrystal%2520structure%2520of%2520the%2520T315I%2520Abl%2520mutant%2520in%2520complex%2520with%2520the%2520aurora%2520kinases%2520inhibitor%2520PHA-739358%26jtitle%3DCancer%2520Res.%26date%3D2007%26volume%3D67%26issue%3D17%26spage%3D7987%26epage%3D7990" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group">Noronha, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cao, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chow, C. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dneprovskaia, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fine, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hood, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klebansky, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lohse, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mak, C. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McPherson, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Palanki, M. S. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pathak, V. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Renick, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Soll, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zeng, B.</span><span> </span><span class="NLM_article-title">Inhibitors of ABL and the ABL-T315I mutation</span> <span class="citation_source-journal">Curr. Top. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x"> (</span><span class="NLM_issue">10</span><span class="NLM_x">) </span> <span class="NLM_fpage">905</span><span class="NLM_x">–</span> <span class="NLM_lpage">921</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Fjm901808w&amp;key=10.2174%2F156802608784911635" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Fjm901808w&amp;key=18673174" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Fjm901808w&amp;key=1%3ACAS%3A528%3ADC%252BD1cXnsVantL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2008&pages=905-921&issue=10&author=G.+Noronhaauthor=J.+Caoauthor=C.+P.+Chowauthor=E.+Dneprovskaiaauthor=R.+M.+Fineauthor=J.+Hoodauthor=X.+Kangauthor=B.+Klebanskyauthor=D.+Lohseauthor=C.+C.+Makauthor=A.+McPhersonauthor=M.+S.+S.+Palankiauthor=V.+P.+Pathakauthor=J.+Renickauthor=R.+Sollauthor=B.+Zeng&title=Inhibitors+of+ABL+and+the+ABL-T315I+mutation"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibitors of ABL and the ABL-T315I mutation</span></div><div class="casAuthors">Noronha, Glenn; Cao, Jianguo; Chow, Chun P.; Dneprovskaia, Elena; Fine, Richard M.; Hood, John; Kang, Xinshan; Klebansky, Boris; Lohse, Dan; Mak, Chi Ching; McPherson, Andrew; Palanki, Moorthy S. S.; Pathak, Ved P.; Renick, Joel; Soll, Richard; Zeng, Binqi</div><div class="citationInfo"><span class="NLM_cas:title">Current Topics in Medicinal Chemistry (Sharjah, United Arab Emirates)</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">905-921</span>CODEN:
                <span class="NLM_cas:coden">CTMCCL</span>;
        ISSN:<span class="NLM_cas:issn">1568-0266</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Chronic myelogenous leukemia (CML) is a hematol. stem cell disorder caused by increased and unregulated growth of myeloid cells in the bone marrow, and the accumulation of excessive white blood cells.  Abelson tyrosine kinase (ABL) is a non-receptor tyrosine kinase involved in cell growth and proliferation and is usually under tight control.  However, 95% of CML patients have the ABL gene from chromosome 9 fused with the breakpoint cluster (BCR) gene from chromosome 22, resulting in a short chromosome known as the Philadelphia chromosome.  This Philadelphia chromosome is responsible for the prodn. of BCR-ABL, a constitutively active tyrosine kinase that causes uncontrolled cellular proliferation.  An ABL inhibitor, imatinib, was approved by the FDA for the treatment of CML, and is currently used as first line therapy.  However, a high percentage of clin. relapse has been obsd. due to long term treatment with imatinib.  A majority of these relapsed patients have several point mutations at and around the ATP binding pocket of the ABL kinase domain in BCR-ABL.  To address the resistance of mutated BCR-ABL to imatinib, 2nd generation inhibitors such as dasatinib, and nilotinib were developed.  These compds. were approved for the treatment of CML patients who are resistant to imatinib.  All of the BCR-ABL mutants are inhibited by the 2nd generation inhibitors with the exception of the T3151 mutant.  Several 3rd generation inhibitors such as AP24534, VX-680 (MK-0457), PHA-739358, PPY-A, XL-228, SGX-70393, FTY720 and TG101113 are being developed to target the T3151 mutation.  The early results from these compds. are encouraging and it is anticipated that physicians will have addnl. drugs at their disposal for the treatment of patients with the mutated BCR-ABL-T315I.  The success of these inhibitors has greater implication not only in CML, but also in other diseases driven by kinases where the mutated gatekeeper residue plays a major role.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpCjbrW8rt8HbVg90H21EOLACvtfcHk0lg7DL8Rj-TOiw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXnsVantL8%253D&md5=c61dc3941c9fd71ddd4ed02732e80998</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.2174%2F156802608784911635&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F156802608784911635%26sid%3Dliteratum%253Aachs%26aulast%3DNoronha%26aufirst%3DG.%26aulast%3DCao%26aufirst%3DJ.%26aulast%3DChow%26aufirst%3DC.%2BP.%26aulast%3DDneprovskaia%26aufirst%3DE.%26aulast%3DFine%26aufirst%3DR.%2BM.%26aulast%3DHood%26aufirst%3DJ.%26aulast%3DKang%26aufirst%3DX.%26aulast%3DKlebansky%26aufirst%3DB.%26aulast%3DLohse%26aufirst%3DD.%26aulast%3DMak%26aufirst%3DC.%2BC.%26aulast%3DMcPherson%26aufirst%3DA.%26aulast%3DPalanki%26aufirst%3DM.%2BS.%2BS.%26aulast%3DPathak%26aufirst%3DV.%2BP.%26aulast%3DRenick%26aufirst%3DJ.%26aulast%3DSoll%26aufirst%3DR.%26aulast%3DZeng%26aufirst%3DB.%26atitle%3DInhibitors%2520of%2520ABL%2520and%2520the%2520ABL-T315I%2520mutation%26jtitle%3DCurr.%2520Top.%2520Med.%2520Chem.%26date%3D2008%26volume%3D8%26issue%3D10%26spage%3D905%26epage%3D921" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group">Gumireddy, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baker, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cosenza, S. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">John, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kang, A. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robell, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reddy, M. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reddy, E. P.</span><span> </span><span class="NLM_article-title">A non-ATP-competitive inhibitor of BCR-ABL overrides imatinib resistance</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U.S.A</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">102</span><span class="NLM_x"> (</span><span class="NLM_issue">6</span><span class="NLM_x">) </span> <span class="NLM_fpage">1992</span><span class="NLM_x">–</span> <span class="NLM_lpage">1997</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=102&publication_year=2005&pages=1992-1997&issue=6&author=K.+Gumireddyauthor=S.+J.+Bakerauthor=S.+C.+Cosenzaauthor=P.+Johnauthor=A.+D.+Kangauthor=K.+A.+Robellauthor=M.+V.+Reddyauthor=E.+P.+Reddy&title=A+non-ATP-competitive+inhibitor+of+BCR-ABL+overrides+imatinib+resistance"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGumireddy%26aufirst%3DK.%26aulast%3DBaker%26aufirst%3DS.%2BJ.%26aulast%3DCosenza%26aufirst%3DS.%2BC.%26aulast%3DJohn%26aufirst%3DP.%26aulast%3DKang%26aufirst%3DA.%2BD.%26aulast%3DRobell%26aufirst%3DK.%2BA.%26aulast%3DReddy%26aufirst%3DM.%2BV.%26aulast%3DReddy%26aufirst%3DE.%2BP.%26atitle%3DA%2520non-ATP-competitive%2520inhibitor%2520of%2520BCR-ABL%2520overrides%2520imatinib%2520resistance%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A%26date%3D2005%26volume%3D102%26issue%3D6%26spage%3D1992%26epage%3D1997" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group">Huang, W. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Azam, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wen, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sundaramoorthi, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomas, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Banda, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lentini, S. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Das, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keats, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wardwell, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ning, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Snodgrass, J. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Broudy, M. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Russian, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Daley, G. Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iuliucci, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dalgarno, D. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clackson, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sawyer, T. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shakespeare, W. C.</span><span> </span><span class="NLM_article-title">9-(Arenethenyl)purines as Dual Src/Abl Kinase Inhibitors Targeting the Inactive Conformation: Design, Synthesis, and Biological Evaluation</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">52</span><span class="NLM_x"> (</span><span class="NLM_issue">15</span><span class="NLM_x">) </span> <span class="NLM_fpage">4743</span><span class="NLM_x">–</span> <span class="NLM_lpage">47565</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm900166t" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=4743-47565&issue=15&author=W.+S.+Huangauthor=X.+Zhuauthor=Y.+Wangauthor=M.+Azamauthor=D.+Wenauthor=R.+Sundaramoorthiauthor=R.+M.+Thomasauthor=S.+Liuauthor=G.+Bandaauthor=S.+P.+Lentiniauthor=S.+Dasauthor=Q.+Xuauthor=J.+Keatsauthor=F.+Wangauthor=S.+Wardwellauthor=Y.+Ningauthor=J.+T.+Snodgrassauthor=M.+I.+Broudyauthor=K.+Russianauthor=G.+Q.+Daleyauthor=J.+Iuliucciauthor=D.+C.+Dalgarnoauthor=T.+Clacksonauthor=T.+K.+Sawyerauthor=W.+C.+Shakespeare&title=9-%28Arenethenyl%29purines+as+Dual+Src%2FAbl+Kinase+Inhibitors+Targeting+the+Inactive+Conformation%3A+Design%2C+Synthesis%2C+and+Biological+Evaluation"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1021%2Fjm900166t&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm900166t%26sid%3Dliteratum%253Aachs%26aulast%3DHuang%26aufirst%3DW.%2BS.%26aulast%3DZhu%26aufirst%3DX.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DAzam%26aufirst%3DM.%26aulast%3DWen%26aufirst%3DD.%26aulast%3DSundaramoorthi%26aufirst%3DR.%26aulast%3DThomas%26aufirst%3DR.%2BM.%26aulast%3DLiu%26aufirst%3DS.%26aulast%3DBanda%26aufirst%3DG.%26aulast%3DLentini%26aufirst%3DS.%2BP.%26aulast%3DDas%26aufirst%3DS.%26aulast%3DXu%26aufirst%3DQ.%26aulast%3DKeats%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DF.%26aulast%3DWardwell%26aufirst%3DS.%26aulast%3DNing%26aufirst%3DY.%26aulast%3DSnodgrass%26aufirst%3DJ.%2BT.%26aulast%3DBroudy%26aufirst%3DM.%2BI.%26aulast%3DRussian%26aufirst%3DK.%26aulast%3DDaley%26aufirst%3DG.%2BQ.%26aulast%3DIuliucci%26aufirst%3DJ.%26aulast%3DDalgarno%26aufirst%3DD.%2BC.%26aulast%3DClackson%26aufirst%3DT.%26aulast%3DSawyer%26aufirst%3DT.%2BK.%26aulast%3DShakespeare%26aufirst%3DW.%2BC.%26atitle%3D9-%2528Arenethenyl%2529purines%2520as%2520Dual%2520Src%252FAbl%2520Kinase%2520Inhibitors%2520Targeting%2520the%2520Inactive%2520Conformation%253A%2520Design%252C%2520Synthesis%252C%2520and%2520Biological%2520Evaluation%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26issue%3D15%26spage%3D4743%26epage%3D47565" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group">Seeliger, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ranjitkar, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kasap, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shan, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shaw, D. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shah, N. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuriyan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maly, D. J.</span><span> </span><span class="NLM_article-title">Equally potent inhibition of c-Src and Abl by compounds that recognize inactive kinase conformations</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">69</span><span class="NLM_x"> (</span><span class="NLM_issue">6</span><span class="NLM_x">) </span> <span class="NLM_fpage">2384</span><span class="NLM_x">–</span> <span class="NLM_lpage">2392</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=69&publication_year=2009&pages=2384-2392&issue=6&author=M.+A.+Seeligerauthor=P.+Ranjitkarauthor=C.+Kasapauthor=Y.+Shanauthor=D.+E.+Shawauthor=N.+P.+Shahauthor=J.+Kuriyanauthor=D.+J.+Maly&title=Equally+potent+inhibition+of+c-Src+and+Abl+by+compounds+that+recognize+inactive+kinase+conformations"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSeeliger%26aufirst%3DM.%2BA.%26aulast%3DRanjitkar%26aufirst%3DP.%26aulast%3DKasap%26aufirst%3DC.%26aulast%3DShan%26aufirst%3DY.%26aulast%3DShaw%26aufirst%3DD.%2BE.%26aulast%3DShah%26aufirst%3DN.%2BP.%26aulast%3DKuriyan%26aufirst%3DJ.%26aulast%3DMaly%26aufirst%3DD.%2BJ.%26atitle%3DEqually%2520potent%2520inhibition%2520of%2520c-Src%2520and%2520Abl%2520by%2520compounds%2520that%2520recognize%2520inactive%2520kinase%2520conformations%26jtitle%3DCancer%2520Res.%26date%3D2009%26volume%3D69%26issue%3D6%26spage%3D2384%26epage%3D2392" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group">Dar, A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lopez, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shokat, K. M.</span><span> </span><span class="NLM_article-title">Small molecule recognition of c-Src via the Imatinib-binding conformation</span> <span class="citation_source-journal">Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x"> (</span><span class="NLM_issue">10</span><span class="NLM_x">) </span> <span class="NLM_fpage">1015</span><span class="NLM_x">–</span> <span class="NLM_lpage">1022</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Fjm901808w&amp;key=10.1016%2Fj.chembiol.2008.09.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Fjm901808w&amp;key=18940662" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Fjm901808w&amp;key=1%3ACAS%3A528%3ADC%252BD1cXht1KmsrfP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2008&pages=1015-1022&issue=10&author=A.+C.+Darauthor=M.+S.+Lopezauthor=K.+M.+Shokat&title=Small+molecule+recognition+of+c-Src+via+the+Imatinib-binding+conformation"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Small Molecule Recognition of c-Src via the Imatinib-Binding Conformation</span></div><div class="casAuthors">Dar, Arvin C.; Lopez, Michael S.; Shokat, Kevan M.</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry & Biology (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1015-1022</span>CODEN:
                <span class="NLM_cas:coden">CBOLE2</span>;
        ISSN:<span class="NLM_cas:issn">1074-5521</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Summary: The cancer drug, Imatinib, is a selective Abl kinase inhibitor that does not inhibit the closely related kinase c-Src.  This one drug and its ability to selectively inhibit Abl over c-Src has been a guiding principle in virtually all kinase drug discovery efforts in the last 15 years.  A prominent hypothesis explaining the selectivity of Imatinib is that Abl has an intrinsic ability to adopt an inactive conformation (termed DFG-out), whereas c-Src appears to pay a high intrinsic energetic penalty for adopting this conformation, effectively excluding Imatinib from its ATP pocket.  This explanation of the difference in binding affinity of Imatinib for Abl vs. c-Src makes the striking prediction that it would not be possible to design an inhibitor that binds to the DFG-out conformation of c-Src with high affinity.  The authors report the discovery of a series of such inhibitors.  The authors use structure-activity relationships and x-ray crystallog. to confirm the authors' findings.  These studies suggest that small mols. are capable of inducing the generally unfavorable DFG-out conformation in c-Src.  Structural comparison between c-Src in complex with these inhibitors allows the authors to speculate on the differential selectivity of Imatinib for c-Src and Abl.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpgbxnfmxtR-LVg90H21EOLACvtfcHk0lgv-6rqnGu6uw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXht1KmsrfP&md5=f1047f4a56359511939164a3c2604cb6</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1016%2Fj.chembiol.2008.09.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chembiol.2008.09.007%26sid%3Dliteratum%253Aachs%26aulast%3DDar%26aufirst%3DA.%2BC.%26aulast%3DLopez%26aufirst%3DM.%2BS.%26aulast%3DShokat%26aufirst%3DK.%2BM.%26atitle%3DSmall%2520molecule%2520recognition%2520of%2520c-Src%2520via%2520the%2520Imatinib-binding%2520conformation%26jtitle%3DChem.%2520Biol.%26date%3D2008%26volume%3D15%26issue%3D10%26spage%3D1015%26epage%3D1022" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group">O’Hare, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shakespeare, W. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eide, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rivera, V. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adrian, L. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, W.-S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Metcalf Iii, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tyner, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Loriaux, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Corbin, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wardwell, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ning, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keats, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sundaramoorthi, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomas, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Snodgrass, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Commodore, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sawyer, T. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dalgarno, D. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deininger, M. W. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Druker, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clackson, T.</span><span> </span><span class="NLM_article-title">AP24534, a Pan-BCR-ABL Inhibitor for Chronic Myeloid Leukemia, Potently Inhibits the T315I Mutant and Overcomes Mutation-Based Resistance</span> <span class="citation_source-journal">Cancer Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x"> (</span><span class="NLM_issue">5</span><span class="NLM_x">) </span> <span class="NLM_fpage">401</span><span class="NLM_x">–</span> <span class="NLM_lpage">412</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2009&pages=401-412&issue=5&author=T.+O%E2%80%99Hareauthor=W.+C.+Shakespeareauthor=X.+Zhuauthor=C.+A.+Eideauthor=V.+M.+Riveraauthor=F.+Wangauthor=L.+T.+Adrianauthor=T.+Zhouauthor=W.-S.+Huangauthor=Q.+Xuauthor=C.+A.+Metcalf+Iiiauthor=J.+W.+Tynerauthor=M.+M.+Loriauxauthor=A.+S.+Corbinauthor=S.+Wardwellauthor=Y.+Ningauthor=J.+A.+Keatsauthor=Y.+Wangauthor=R.+Sundaramoorthiauthor=M.+Thomasauthor=D.+Zhouauthor=J.+Snodgrassauthor=L.+Commodoreauthor=T.+K.+Sawyerauthor=D.+C.+Dalgarnoauthor=M.+W.+N.+Deiningerauthor=B.+J.+Drukerauthor=T.+Clackson&title=AP24534%2C+a+Pan-BCR-ABL+Inhibitor+for+Chronic+Myeloid+Leukemia%2C+Potently+Inhibits+the+T315I+Mutant+and+Overcomes+Mutation-Based+Resistance"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DO%25E2%2580%2599Hare%26aufirst%3DT.%26aulast%3DShakespeare%26aufirst%3DW.%2BC.%26aulast%3DZhu%26aufirst%3DX.%26aulast%3DEide%26aufirst%3DC.%2BA.%26aulast%3DRivera%26aufirst%3DV.%2BM.%26aulast%3DWang%26aufirst%3DF.%26aulast%3DAdrian%26aufirst%3DL.%2BT.%26aulast%3DZhou%26aufirst%3DT.%26aulast%3DHuang%26aufirst%3DW.-S.%26aulast%3DXu%26aufirst%3DQ.%26aulast%3DMetcalf%2BIii%26aufirst%3DC.%2BA.%26aulast%3DTyner%26aufirst%3DJ.%2BW.%26aulast%3DLoriaux%26aufirst%3DM.%2BM.%26aulast%3DCorbin%26aufirst%3DA.%2BS.%26aulast%3DWardwell%26aufirst%3DS.%26aulast%3DNing%26aufirst%3DY.%26aulast%3DKeats%26aufirst%3DJ.%2BA.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DSundaramoorthi%26aufirst%3DR.%26aulast%3DThomas%26aufirst%3DM.%26aulast%3DZhou%26aufirst%3DD.%26aulast%3DSnodgrass%26aufirst%3DJ.%26aulast%3DCommodore%26aufirst%3DL.%26aulast%3DSawyer%26aufirst%3DT.%2BK.%26aulast%3DDalgarno%26aufirst%3DD.%2BC.%26aulast%3DDeininger%26aufirst%3DM.%2BW.%2BN.%26aulast%3DDruker%26aufirst%3DB.%2BJ.%26aulast%3DClackson%26aufirst%3DT.%26atitle%3DAP24534%252C%2520a%2520Pan-BCR-ABL%2520Inhibitor%2520for%2520Chronic%2520Myeloid%2520Leukemia%252C%2520Potently%2520Inhibits%2520the%2520T315I%2520Mutant%2520and%2520Overcomes%2520Mutation-Based%2520Resistance%26jtitle%3DCancer%2520Cell%26date%3D2009%26volume%3D16%26issue%3D5%26spage%3D401%26epage%3D412" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group">Okram, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nagle, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adrian, F. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ren, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sim, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xie, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xia, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spraggon, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Warmuth, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gray, N. S.</span><span> </span><span class="NLM_article-title">A general strategy for creating “inactive-conformation” abl inhibitors</span> <span class="citation_source-journal">Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x"> (</span><span class="NLM_issue">7</span><span class="NLM_x">) </span> <span class="NLM_fpage">779</span><span class="NLM_x">–</span> <span class="NLM_lpage">786</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Fjm901808w&amp;key=10.1016%2Fj.chembiol.2006.05.015" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Fjm901808w&amp;key=16873026" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Fjm901808w&amp;key=1%3ACAS%3A528%3ADC%252BD28XntlGisL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2006&pages=779-786&issue=7&author=B.+Okramauthor=A.+Nagleauthor=F.+J.+Adrianauthor=C.+Leeauthor=P.+Renauthor=X.+Wangauthor=T.+Simauthor=Y.+Xieauthor=G.+Xiaauthor=G.+Spraggonauthor=M.+Warmuthauthor=Y.+Liuauthor=N.+S.+Gray&title=A+general+strategy+for+creating+%E2%80%9Cinactive-conformation%E2%80%9D+abl+inhibitors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">A General Strategy for Creating "Inactive-Conformation" Abl Inhibitors</span></div><div class="casAuthors">Okram, Barun; Nagle, Advait; Adrian, Francisco J.; Lee, Christian; Ren, Pingda; Wang, Xia; Sim, Taebo; Xie, Yongping; Wang, Xing; Xia, Gang; Spraggon, Glen; Warmuth, Markus; Liu, Yi; Gray, Nathanael S.</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry & Biology (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">779-786</span>CODEN:
                <span class="NLM_cas:coden">CBOLE2</span>;
        ISSN:<span class="NLM_cas:issn">1074-5521</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Summary: Kinase inhibitors that bind to the ATP cleft can be broadly classified into two groups: Those that bind exclusively to the ATP site with the kinase assuming a conformation otherwise conducive to phosphotransfer (type I), and those that exploit a hydrophobic site immediately adjacent to the ATP pocket made accessible by a conformational rearrangement of the activation loop (type II).  To date, all type II inhibitors were discovered by using structure-activity-guided optimization strategies.  Here, we describe a general pharmacophore model of type II inhibition that enables a rational "hybrid-design" approach whereby a 3-trifluoromethylbenzamide functionality is appended to four distinct type I scaffolds in order to convert them into their corresponding type II counterparts.  We demonstrate that the designed compds. function as type II inhibitors by using biochem. and cellular kinase assays and by cocrystallog. with Abl.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqEmN-Rh-LxOLVg90H21EOLACvtfcHk0liu8sD74aOqVw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XntlGisL0%253D&md5=84514353c00e20f85225f62d00dc2529</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1016%2Fj.chembiol.2006.05.015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chembiol.2006.05.015%26sid%3Dliteratum%253Aachs%26aulast%3DOkram%26aufirst%3DB.%26aulast%3DNagle%26aufirst%3DA.%26aulast%3DAdrian%26aufirst%3DF.%2BJ.%26aulast%3DLee%26aufirst%3DC.%26aulast%3DRen%26aufirst%3DP.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DSim%26aufirst%3DT.%26aulast%3DXie%26aufirst%3DY.%26aulast%3DXia%26aufirst%3DG.%26aulast%3DSpraggon%26aufirst%3DG.%26aulast%3DWarmuth%26aufirst%3DM.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DGray%26aufirst%3DN.%2BS.%26atitle%3DA%2520general%2520strategy%2520for%2520creating%2520%25E2%2580%259Cinactive-conformation%25E2%2580%259D%2520abl%2520inhibitors%26jtitle%3DChem.%2520Biol.%26date%3D2006%26volume%3D13%26issue%3D7%26spage%3D779%26epage%3D786" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group">Nagar, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bornmann, W. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pellicena, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schindler, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Veach, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, W. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clarkson, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuriyan, J.</span><span> </span><span class="NLM_article-title">Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571)</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">62</span><span class="NLM_x"> (</span><span class="NLM_issue">15</span><span class="NLM_x">) </span> <span class="NLM_fpage">4236</span><span class="NLM_x">–</span> <span class="NLM_lpage">4243</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Fjm901808w&amp;key=12154025" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Fjm901808w&amp;key=1%3ACAS%3A528%3ADC%252BD38XlvFeltLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2002&pages=4236-4243&issue=15&author=B.+Nagarauthor=W.+G.+Bornmannauthor=P.+Pellicenaauthor=T.+Schindlerauthor=D.+R.+Veachauthor=W.+T.+Millerauthor=B.+Clarksonauthor=J.+Kuriyan&title=Crystal+structures+of+the+kinase+domain+of+c-Abl+in+complex+with+the+small+molecule+inhibitors+PD173955+and+imatinib+%28STI-571%29"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571)</span></div><div class="casAuthors">Nagar, Bhushan; Bornmann, William G.; Pellicena, Patricia; Schindler, Thomas; Veach, Darren R.; Miller, W. Todd; Clarkson, Bayard; Kuriyan, John</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">4236-4243</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The inadvertent fusion of the bcr gene with the abl gene results in a constitutively active tyrosine kinase (Bcr-Abl) that transforms cells and causes chronic myelogenous leukemia.  Small mol. inhibitors of Bcr-Abl that bind to the kinase domain can be used to treat chronic myelogenous leukemia.  We report crystal structures of the kinase domain of Abl in complex with two such inhibitors, imatinib (also known as STI-571 and Gleevec) and PD173955 (Parke-Davis).  Both compds. bind to the canonical ATP-binding site of the kinase domain, but they do so in different ways.  As shown previously in a crystal structure of Abl bound to a smaller variant of STI-571, STI-571 captures a specific inactive conformation of the activation loop of Abl in which the loop mimics bound peptide substrate.  In contrast, PD173955 binds to a conformation of Abl in which the activation loop resembles that of an active kinase.  The structure suggests that PD173955 would be insensitive to whether the conformation of the activation loop corresponds to active kinases or to that seen in the STI-571 complex.  In vitro kinase assays confirm that this is the case and indicate that PD173955 is at least 10-fold more inhibitory than STI-571.  The structures suggest that PD173955 achieves its greater potency over STI-571 by being able to target multiple forms of Abl (active or inactive), whereas STI-571 requires a specific inactive conformation of Abl.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp-5qYZHMOZCrVg90H21EOLACvtfcHk0liu8sD74aOqVw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XlvFeltLY%253D&md5=843213cd6038ed82a0e43dce56e81a91</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DNagar%26aufirst%3DB.%26aulast%3DBornmann%26aufirst%3DW.%2BG.%26aulast%3DPellicena%26aufirst%3DP.%26aulast%3DSchindler%26aufirst%3DT.%26aulast%3DVeach%26aufirst%3DD.%2BR.%26aulast%3DMiller%26aufirst%3DW.%2BT.%26aulast%3DClarkson%26aufirst%3DB.%26aulast%3DKuriyan%26aufirst%3DJ.%26atitle%3DCrystal%2520structures%2520of%2520the%2520kinase%2520domain%2520of%2520c-Abl%2520in%2520complex%2520with%2520the%2520small%2520molecule%2520inhibitors%2520PD173955%2520and%2520imatinib%2520%2528STI-571%2529%26jtitle%3DCancer%2520Res.%26date%3D2002%26volume%3D62%26issue%3D15%26spage%3D4236%26epage%3D4243" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group">Tokarski, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Newitt, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, C. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheng, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wittekind, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kiefer, S. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kish, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, F. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Borzillerri, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lombardo, L. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xie, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klei, H. E.</span><span> </span><span class="NLM_article-title">The structure of Dasatinib (BMS-354825) bound to activated ABL kinase domain elucidates its inhibitory activity against imatinib-resistant ABL mutants</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">66</span><span class="NLM_x"> (</span><span class="NLM_issue">11</span><span class="NLM_x">) </span> <span class="NLM_fpage">5790</span><span class="NLM_x">–</span> <span class="NLM_lpage">5797</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Fjm901808w&amp;key=10.1158%2F0008-5472.CAN-05-4187" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Fjm901808w&amp;key=16740718" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Fjm901808w&amp;key=1%3ACAS%3A528%3ADC%252BD28XltFyjtbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=2006&pages=5790-5797&issue=11&author=J.+S.+Tokarskiauthor=J.+A.+Newittauthor=C.+Y.+Changauthor=J.+D.+Chengauthor=M.+Wittekindauthor=S.+E.+Kieferauthor=K.+Kishauthor=F.+Y.+Leeauthor=R.+Borzillerriauthor=L.+J.+Lombardoauthor=D.+Xieauthor=Y.+Zhangauthor=H.+E.+Klei&title=The+structure+of+Dasatinib+%28BMS-354825%29+bound+to+activated+ABL+kinase+domain+elucidates+its+inhibitory+activity+against+imatinib-resistant+ABL+mutants"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">The Structure of Dasatinib (BMS-354825) Bound to Activated ABL Kinase Domain Elucidates Its Inhibitory Activity against Imatinib-Resistant ABL Mutants</span></div><div class="casAuthors">Tokarski, John S.; Newitt, John A.; Chang, Chieh Ying J.; Cheng, Janet D.; Wittekind, Michael; Kiefer, Susan E.; Kish, Kevin; Lee, Francis Y. F.; Borzillerri, Robert; Lombardo, Louis J.; Xie, Dianlin; Zhang, Yaqun; Klei, Herbert E.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">66</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">5790-5797</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Chronic myeloid leukemia (CML) is caused by the constitutively activated tyrosine kinase breakpoint cluster (BCR)-ABL.  Current frontline therapy for CML is imatinib, an inhibitor of BCR-ABL.  Although imatinib has a high rate of clin. success in early phase CML, treatment resistance is problematic, particularly in later stages of the disease, and is frequently mediated by mutations in BCR-ABL.  Dasatinib (BMS-354825) is a multitargeted tyrosine kinase inhibitor that targets oncogenic pathways and is a more potent inhibitor than imatinib against wild-type BCR-ABL.  It has also shown preclin. activity against all but one of the imatinib-resistant BCR-ABL mutants tested to date.  Anal. of the crystal structure of dasatinib-bound ABL kinase suggests that the increased binding affinity of dasatinib over imatinib is at least partially due to its ability to recognize multiple states of BCR-ABL.  The structure also provides an explanation for the activity of dasatinib against imatinib-resistant BCR-ABL mutants.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqLZE4le_VTErVg90H21EOLACvtfcHk0liu8sD74aOqVw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XltFyjtbw%253D&md5=f48b46b8c7c38a9888a6de41f84c94fa</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-05-4187&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-05-4187%26sid%3Dliteratum%253Aachs%26aulast%3DTokarski%26aufirst%3DJ.%2BS.%26aulast%3DNewitt%26aufirst%3DJ.%2BA.%26aulast%3DChang%26aufirst%3DC.%2BY.%26aulast%3DCheng%26aufirst%3DJ.%2BD.%26aulast%3DWittekind%26aufirst%3DM.%26aulast%3DKiefer%26aufirst%3DS.%2BE.%26aulast%3DKish%26aufirst%3DK.%26aulast%3DLee%26aufirst%3DF.%2BY.%26aulast%3DBorzillerri%26aufirst%3DR.%26aulast%3DLombardo%26aufirst%3DL.%2BJ.%26aulast%3DXie%26aufirst%3DD.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DKlei%26aufirst%3DH.%2BE.%26atitle%3DThe%2520structure%2520of%2520Dasatinib%2520%2528BMS-354825%2529%2520bound%2520to%2520activated%2520ABL%2520kinase%2520domain%2520elucidates%2520its%2520inhibitory%2520activity%2520against%2520imatinib-resistant%2520ABL%2520mutants%26jtitle%3DCancer%2520Res.%26date%3D2006%26volume%3D66%26issue%3D11%26spage%3D5790%26epage%3D5797" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group">Pao, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, V. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Politi, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Riely, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Somwar, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zakowski, M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kris, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Varmus, H.</span><span> </span><span class="NLM_article-title">Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain</span> <span class="citation_source-journal">PLoS Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x"> (</span><span class="NLM_issue">3</span><span class="NLM_x">) </span> <span class="NLM_fpage">e73</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2005&pages=e73&issue=3&author=W.+Paoauthor=V.+A.+Millerauthor=K.+A.+Politiauthor=G.+J.+Rielyauthor=R.+Somwarauthor=M.+F.+Zakowskiauthor=M.+G.+Krisauthor=H.+Varmus&title=Acquired+resistance+of+lung+adenocarcinomas+to+gefitinib+or+erlotinib+is+associated+with+a+second+mutation+in+the+EGFR+kinase+domain"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPao%26aufirst%3DW.%26aulast%3DMiller%26aufirst%3DV.%2BA.%26aulast%3DPoliti%26aufirst%3DK.%2BA.%26aulast%3DRiely%26aufirst%3DG.%2BJ.%26aulast%3DSomwar%26aufirst%3DR.%26aulast%3DZakowski%26aufirst%3DM.%2BF.%26aulast%3DKris%26aufirst%3DM.%2BG.%26aulast%3DVarmus%26aufirst%3DH.%26atitle%3DAcquired%2520resistance%2520of%2520lung%2520adenocarcinomas%2520to%2520gefitinib%2520or%2520erlotinib%2520is%2520associated%2520with%2520a%2520second%2520mutation%2520in%2520the%2520EGFR%2520kinase%2520domain%26jtitle%3DPLoS%2520Med.%26date%3D2005%26volume%3D2%26issue%3D3%26spage%3De73" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group">Fabbro, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ruetz, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bodis, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pruschy, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Csermak, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Man, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Campochiaro, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wood, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Reilly, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyer, T.</span><span> </span><span class="NLM_article-title">PKC412-a protein kinase inhibitor with a broad therapeutic potential</span> <span class="citation_source-journal">Anti-Cancer Drug Des.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x"> (</span><span class="NLM_issue">1</span><span class="NLM_x">) </span> <span class="NLM_fpage">17</span><span class="NLM_x">–</span> <span class="NLM_lpage">28</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2000&pages=17-28&issue=1&author=D.+Fabbroauthor=S.+Ruetzauthor=S.+Bodisauthor=M.+Pruschyauthor=K.+Csermakauthor=A.+Manauthor=P.+Campochiaroauthor=J.+Woodauthor=T.+O%E2%80%99Reillyauthor=T.+Meyer&title=PKC412-a+protein+kinase+inhibitor+with+a+broad+therapeutic+potential"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DFabbro%26aufirst%3DD.%26aulast%3DRuetz%26aufirst%3DS.%26aulast%3DBodis%26aufirst%3DS.%26aulast%3DPruschy%26aufirst%3DM.%26aulast%3DCsermak%26aufirst%3DK.%26aulast%3DMan%26aufirst%3DA.%26aulast%3DCampochiaro%26aufirst%3DP.%26aulast%3DWood%26aufirst%3DJ.%26aulast%3DO%25E2%2580%2599Reilly%26aufirst%3DT.%26aulast%3DMeyer%26aufirst%3DT.%26atitle%3DPKC412-a%2520protein%2520kinase%2520inhibitor%2520with%2520a%2520broad%2520therapeutic%2520potential%26jtitle%3DAnti-Cancer%2520Drug%2520Des.%26date%3D2000%26volume%3D15%26issue%3D1%26spage%3D17%26epage%3D28" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group">Cools, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mentens, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Furet, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fabbro, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clark, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Griffin, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marynen, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gilliland, D. G.</span><span> </span><span class="NLM_article-title">Prediction of resistance to small molecule FLT3 inhibitors: implications for molecularly targeted therapy of acute leukemia</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">64</span><span class="NLM_x"> (</span><span class="NLM_issue">18</span><span class="NLM_x">) </span> <span class="NLM_fpage">6385</span><span class="NLM_x">–</span> <span class="NLM_lpage">6389</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=2004&pages=6385-6389&issue=18&author=J.+Coolsauthor=N.+Mentensauthor=P.+Furetauthor=D.+Fabbroauthor=J.+J.+Clarkauthor=J.+D.+Griffinauthor=P.+Marynenauthor=D.+G.+Gilliland&title=Prediction+of+resistance+to+small+molecule+FLT3+inhibitors%3A+implications+for+molecularly+targeted+therapy+of+acute+leukemia"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCools%26aufirst%3DJ.%26aulast%3DMentens%26aufirst%3DN.%26aulast%3DFuret%26aufirst%3DP.%26aulast%3DFabbro%26aufirst%3DD.%26aulast%3DClark%26aufirst%3DJ.%2BJ.%26aulast%3DGriffin%26aufirst%3DJ.%2BD.%26aulast%3DMarynen%26aufirst%3DP.%26aulast%3DGilliland%26aufirst%3DD.%2BG.%26atitle%3DPrediction%2520of%2520resistance%2520to%2520small%2520molecule%2520FLT3%2520inhibitors%253A%2520implications%2520for%2520molecularly%2520targeted%2520therapy%2520of%2520acute%2520leukemia%26jtitle%3DCancer%2520Res.%26date%3D2004%26volume%3D64%26issue%3D18%26spage%3D6385%26epage%3D6389" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Cools, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DeAngelo, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gotlib, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stover, E. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Legare, R. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cortes, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kutok, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clark, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Galinsky, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Griffin, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cross, N. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tefferi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Malone, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alam, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schrier, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schmid, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rose, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vandenberghe, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Verhoef, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boogaerts, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wlodarska, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kantarjian, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marynen, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coutre, S. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stone, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gilliland, D. G.</span><span> </span><span class="NLM_article-title">A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">348</span><span class="NLM_x"> (</span><span class="NLM_issue">13</span><span class="NLM_x">) </span> <span class="NLM_fpage">1201</span><span class="NLM_x">–</span> <span class="NLM_lpage">1214</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25a&amp;dbid=16&amp;doi=10.1021%2Fjm901808w&amp;key=10.1056%2FNEJMoa025217" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25a&amp;dbid=8&amp;doi=10.1021%2Fjm901808w&amp;key=12660384" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25a&amp;dbid=32&amp;doi=10.1021%2Fjm901808w&amp;key=1%3ACAS%3A528%3ADC%252BD3sXisVCqtrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=348&publication_year=2003&pages=1201-1214&issue=13&author=J.+Coolsauthor=D.+J.+DeAngeloauthor=J.+Gotlibauthor=E.+H.+Stoverauthor=R.+D.+Legareauthor=J.+Cortesauthor=J.+Kutokauthor=J.+Clarkauthor=I.+Galinskyauthor=J.+D.+Griffinauthor=N.+C.+Crossauthor=A.+Tefferiauthor=J.+Maloneauthor=R.+Alamauthor=S.+L.+Schrierauthor=J.+Schmidauthor=M.+Roseauthor=P.+Vandenbergheauthor=G.+Verhoefauthor=M.+Boogaertsauthor=I.+Wlodarskaauthor=H.+Kantarjianauthor=P.+Marynenauthor=S.+E.+Coutreauthor=R.+Stoneauthor=D.+G.+Gilliland&title=A+tyrosine+kinase+created+by+fusion+of+the+PDGFRA+and+FIP1L1+genes+as+a+therapeutic+target+of+imatinib+in+idiopathic+hypereosinophilic+syndrome"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25aR"><div class="casContent"><span class="casTitleNuber">25a</span><div class="casTitle"><span class="NLM_cas:atitle">A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome</span></div><div class="casAuthors">Cools, Jan; Daniel, Ph. D.; DeAngelo, J.; Gotlib, Jason; Stover, Elizabeth H.; Phil, M.; Legare, Robert D.; Cortes, Jorges; Lutok, Jeffrey; Clark, Jennifer; Galinsky, Ilene; Griffin, James D.; Cross, Nicholas, C. P.; Tefferi, Ayalew; Malone, James; Alam, Fafeul; Schrier, Stanley L.; Schmid, Janet; Rose, Michal; Vandenberghe, Peter; Verhoef, Gregor; Boogaerts, Marc; Wlodarska, Iwona; Kantarjian, Hagop; Marynen, Peter; Coutre, Steven E.; Stone, Richard; Gilliland, D. Gary</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">348</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">1201-1214</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Idiopathic hypereosinophilic syndrome involves a prolonged state of eosinophilia assocd. with organ dysfunction.  It is of unknown cause.  Recent reports of responses to imatinib in patients with the syndrome suggested that an activated kinase such as ABL, platelet-derived growth factor receptor (PDGFR), or KIT, all of which are inhibited by imatinib, might be the cause.  We treated 11 patients with the hypereosinophilic syndrome with imatinib and identified the mol. basis for the response.  Nine of the 11 patients treated with imatinib had responses lasting more than three months in which the eosinophil count returned to normal.  One such patient had a complex chromosomal abnormality, leading to the identification of a fusion of the Fip1H-like 1 (FIP1L1) gene to the PDGFRα (PDGFRA) gene generated by an interstitial deletion on chromosome 4q12.  FIP1L1-PDGFRα is a constitutively activated tyrosine kinase that transforms hematopoietic cells and is inhibited by imatinib (50% inhibitory concn., 3.2 nM).  The FIP1L1-PDGFRA fusion gene was subsequently detected in 9 of 16 patients with the syndrome and in 5 of the 9 patients with responses to imatinib that lasted more than three months.  Relapse in one patient correlated with the appearance of a T674I mutation in PDGFRA that confers resistance to imatinib.  The hypereosinophilic syndrome may result from a novel fusion tyrosine kinase-FIP1L1-PDGFRα-that is a consequence of an interstitial chromosomal deletion.  The acquisition of a T674I resistance mutation at the time of relapse demonstrates that FIP1L1-PDGFRα is the target of imatinib.  Our data indicate that the deletion of genetic material may result in gain-of-function fusion proteins.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo_ae4JFIom8LVg90H21EOLACvtfcHk0lhtK-3MQf3M4A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXisVCqtrY%253D&md5=1f0cc5760c701bf0ae35bcb7c0727d65</span></div><a href="/servlet/linkout?suffix=cit25a&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa025217&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa025217%26sid%3Dliteratum%253Aachs%26aulast%3DCools%26aufirst%3DJ.%26aulast%3DDeAngelo%26aufirst%3DD.%2BJ.%26aulast%3DGotlib%26aufirst%3DJ.%26aulast%3DStover%26aufirst%3DE.%2BH.%26aulast%3DLegare%26aufirst%3DR.%2BD.%26aulast%3DCortes%26aufirst%3DJ.%26aulast%3DKutok%26aufirst%3DJ.%26aulast%3DClark%26aufirst%3DJ.%26aulast%3DGalinsky%26aufirst%3DI.%26aulast%3DGriffin%26aufirst%3DJ.%2BD.%26aulast%3DCross%26aufirst%3DN.%2BC.%26aulast%3DTefferi%26aufirst%3DA.%26aulast%3DMalone%26aufirst%3DJ.%26aulast%3DAlam%26aufirst%3DR.%26aulast%3DSchrier%26aufirst%3DS.%2BL.%26aulast%3DSchmid%26aufirst%3DJ.%26aulast%3DRose%26aufirst%3DM.%26aulast%3DVandenberghe%26aufirst%3DP.%26aulast%3DVerhoef%26aufirst%3DG.%26aulast%3DBoogaerts%26aufirst%3DM.%26aulast%3DWlodarska%26aufirst%3DI.%26aulast%3DKantarjian%26aufirst%3DH.%26aulast%3DMarynen%26aufirst%3DP.%26aulast%3DCoutre%26aufirst%3DS.%2BE.%26aulast%3DStone%26aufirst%3DR.%26aulast%3DGilliland%26aufirst%3DD.%2BG.%26atitle%3DA%2520tyrosine%2520kinase%2520created%2520by%2520fusion%2520of%2520the%2520PDGFRA%2520and%2520FIP1L1%2520genes%2520as%2520a%2520therapeutic%2520target%2520of%2520imatinib%2520in%2520idiopathic%2520hypereosinophilic%2520syndrome%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2003%26volume%3D348%26issue%3D13%26spage%3D1201%26epage%3D1214" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit25b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Blencke, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zech, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Engkvist, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greff, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Orfi, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Horvath, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keri, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ullrich, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Daub, H.</span><span> </span><span class="NLM_article-title">Characterization of a conserved structural determinant controlling protein kinase sensitivity to selective inhibitors</span> <span class="citation_source-journal">Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x"> (</span><span class="NLM_issue">5</span><span class="NLM_x">) </span> <span class="NLM_fpage">691</span><span class="NLM_x">–</span> <span class="NLM_lpage">701</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25b&amp;dbid=16&amp;doi=10.1021%2Fjm901808w&amp;key=10.1016%2Fj.chembiol.2004.02.029" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25b&amp;dbid=8&amp;doi=10.1021%2Fjm901808w&amp;key=15157880" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25b&amp;dbid=32&amp;doi=10.1021%2Fjm901808w&amp;key=1%3ACAS%3A528%3ADC%252BD2cXktF2qsro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2004&pages=691-701&issue=5&author=S.+Blenckeauthor=B.+Zechauthor=O.+Engkvistauthor=Z.+Greffauthor=L.+Orfiauthor=Z.+Horvathauthor=G.+Keriauthor=A.+Ullrichauthor=H.+Daub&title=Characterization+of+a+conserved+structural+determinant+controlling+protein+kinase+sensitivity+to+selective+inhibitors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25bR"><div class="casContent"><span class="casTitleNuber">25b</span><div class="casTitle"><span class="NLM_cas:atitle">Characterization of a Conserved Structural Determinant Controlling Protein Kinase Sensitivity to Selective Inhibitors</span></div><div class="casAuthors">Blencke, Stephanie; Zech, Birgit; Engkvist, Ola; Greff, Zoltan; Orfi, Laszlo; Horvath, Zoltan; Keri, Gyoergy; Ullrich, Axel; Daub, Henrik</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry & Biology</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">691-701</span>CODEN:
                <span class="NLM_cas:coden">CBOLE2</span>;
        ISSN:<span class="NLM_cas:issn">1074-5521</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Some protein kinases are known to acquire resistance to selective small mol. inhibitors upon mutation of a conserved threonine at the ATP binding site to a larger residue.  Here, we performed a comprehensive mutational anal. of this structural element and detd. the cellular sensitivities of several disease-relevant tyrosine kinases against various inhibitors.  Mutant kinases possessing a larger side chain at the crit. site showed resistance to most compds. tested, such as ZD1839, PP1, AG1296, STI571, and a pyrido[2,3-d]pyrimidine inhibitor.  In contrast, indolinones affected both wild-type and mutant kinases with similar potencies.  Resistant mutants were established for pharmacol. anal. of βPDGF receptor-mediated signaling and allowed the generation of a drug-inducible system of cellular Src kinase activity.  Our data establish a conserved structural determinant of protein kinase sensitivity relevant for both signal transduction research and drug development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqWLToAufPZDbVg90H21EOLACvtfcHk0ljvQc_rzhrm2g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXktF2qsro%253D&md5=3224f7453efd9b60f5102e300d195aa0</span></div><a href="/servlet/linkout?suffix=cit25b&amp;dbid=16384&amp;doi=10.1016%2Fj.chembiol.2004.02.029&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chembiol.2004.02.029%26sid%3Dliteratum%253Aachs%26aulast%3DBlencke%26aufirst%3DS.%26aulast%3DZech%26aufirst%3DB.%26aulast%3DEngkvist%26aufirst%3DO.%26aulast%3DGreff%26aufirst%3DZ.%26aulast%3DOrfi%26aufirst%3DL.%26aulast%3DHorvath%26aufirst%3DZ.%26aulast%3DKeri%26aufirst%3DG.%26aulast%3DUllrich%26aufirst%3DA.%26aulast%3DDaub%26aufirst%3DH.%26atitle%3DCharacterization%2520of%2520a%2520conserved%2520structural%2520determinant%2520controlling%2520protein%2520kinase%2520sensitivity%2520to%2520selective%2520inhibitors%26jtitle%3DChem.%2520Biol.%26date%3D2004%26volume%3D11%26issue%3D5%26spage%3D691%26epage%3D701" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group">Kraker, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hartl, B. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Amar, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barvian, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Showalter, H. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moore, C. W.</span><span> </span><span class="NLM_article-title">Biochemical and cellular effects of c-Src kinase-selective pyrido[2,3-<i>d</i>]pyrimidine tyrosine kinase inhibitors</span> <span class="citation_source-journal">Biochem. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">60</span><span class="NLM_x"> (</span><span class="NLM_issue">7</span><span class="NLM_x">) </span> <span class="NLM_fpage">885</span><span class="NLM_x">–</span> <span class="NLM_lpage">898</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2000&pages=885-898&issue=7&author=A.+J.+Krakerauthor=B.+G.+Hartlauthor=A.+M.+Amarauthor=M.+R.+Barvianauthor=H.+D.+Showalterauthor=C.+W.+Moore&title=Biochemical+and+cellular+effects+of+c-Src+kinase-selective+pyrido%5B2%2C3-d%5Dpyrimidine+tyrosine+kinase+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKraker%26aufirst%3DA.%2BJ.%26aulast%3DHartl%26aufirst%3DB.%2BG.%26aulast%3DAmar%26aufirst%3DA.%2BM.%26aulast%3DBarvian%26aufirst%3DM.%2BR.%26aulast%3DShowalter%26aufirst%3DH.%2BD.%26aulast%3DMoore%26aufirst%3DC.%2BW.%26atitle%3DBiochemical%2520and%2520cellular%2520effects%2520of%2520c-Src%2520kinase-selective%2520pyrido%255B2%252C3-d%255Dpyrimidine%2520tyrosine%2520kinase%2520inhibitors%26jtitle%3DBiochem.%2520Pharmacol.%26date%3D2000%26volume%3D60%26issue%3D7%26spage%3D885%26epage%3D898" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Panek, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, G. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klutchko, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Batley, B. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dahring, T. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hamby, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hallak, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Doherty, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keiser, J. A.</span><span> </span><span class="NLM_article-title">In vitro pharmacological characterization of PD 166285, a new nanomolar potent and broadly active protein tyrosine kinase inhibitor</span> <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">283</span><span class="NLM_x"> (</span><span class="NLM_issue">3</span><span class="NLM_x">) </span> <span class="NLM_fpage">1433</span><span class="NLM_x">–</span> <span class="NLM_lpage">1444</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27a&amp;dbid=8&amp;doi=10.1021%2Fjm901808w&amp;key=9400019" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27a&amp;dbid=32&amp;doi=10.1021%2Fjm901808w&amp;key=1%3ACAS%3A528%3ADyaK1cXis1Kgtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=283&publication_year=1997&pages=1433-1444&issue=3&author=R.+L.+Panekauthor=G.+H.+Luauthor=S.+R.+Klutchkoauthor=B.+L.+Batleyauthor=T.+K.+Dahringauthor=J.+M.+Hambyauthor=H.+Hallakauthor=A.+M.+Dohertyauthor=J.+A.+Keiser&title=In+vitro+pharmacological+characterization+of+PD+166285%2C+a+new+nanomolar+potent+and+broadly+active+protein+tyrosine+kinase+inhibitor"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27aR"><div class="casContent"><span class="casTitleNuber">27a</span><div class="casTitle"><span class="NLM_cas:atitle">In vitro pharmacological characterization of PD 166285, a new nanomolar potent and broadly active protein tyrosine kinase inhibitor</span></div><div class="casAuthors">Panek, Robert L.; Lu, Gina H.; Klutchko, Sylvester R.; Batley, Brian L.; Dahring, Tawny K.; Hamby, James M.; Hallak, Hussein; Doherty, Annette M.; Keiser, Joan A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">283</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1433-1444</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">Williams & Wilkins</span>)
        </div><div class="casAbstract">PD 166285, a novel protein tyrosine kinase inhibitor of a new structural class, the 6-aryl-pyrido[2,3-d]pyrimidines, was synthesized as the most potent and sol. analog of a series of small mols. originally identified by screening a compd. library with assays that measured protein tyrosine kinase activity.  PD 166285 was found to inhibit Src nonreceptor tyrosine kinase, fibroblast growth factor receptor-1, epidermal growth factor receptor and platelet-derived growth factor receptor beta subunit (PDGFR-β), tyrosine kinases with half-maximal inhibitory potencies (IC50 values) of 8.4 ± 2.3 nM (n = 6), 39.3 ± 2.8 nM (n = 16), 87.5 ± 13.7 nM (n = 6) and 98.3 ± 7.9 nM (n = 16), resp.  PD 166285 also demonstrated inhibitory activity against mitogen-activated protein kinase (IC50 = 5 μM) and protein kinase C (IC50 = 22.7 μM).  PD 166285 was further characterized as an ATP competitive inhibitor of Src nonreceptor tyrosine kinase, PDGFR-β, fibroblast growth factor receptor-1 and epidermal growth factor receptor tyrosine kinases.  In addn., PD 166285 inhibited PDGF- and EGF-stimulated receptor autophosphorylation in vascular smooth muscle cells (VSMCs) and A431 cells, resp., and basic fibroblast growth factor-mediated tyrosine phosphorylation in Sf9 cells, with IC50 values of 6.5 nM, 1.6 μM and 97.3 nM, resp., further establishing a tyrosine kinase mechanism of inhibition.  The inhibition of PDGF receptor autophosphorylation in VSMCs by PD 166285 was long lasting and persisted for 4 days after a single 1-h exposure followed by extensive washing.  The PDGF-induced tyrosine phosphorylation of the 44- and 42-kDa mitogen-activated protein kinase isoforms was also blocked as a result of the inhibition of PDGF-stimulated receptor autophosphorylation by PD 166285 in VSMCs.  The effects of PD 166285 were also demonstrated in functional assays of cell attachment, migration and proliferation, in which vascular cell adhesion to vitronectin, PDGF-directed chemotaxis and serum-stimulated cell growth were all potently inhibited with IC50 values of 80 yo 120 nM.  Finally, PD 166285 uniquely demonstrated potent inhibition of phorbol ester-induced prodn. of 92-kDa gelatinase A (MMP-9) in VSMC without affecting 72-kDa gelatinase B (MMP-2) as measured by gelatin zymog.  These results highlight the biol. characteristics of PD 166285 as a broadly active protein tyrosine kinase capable of potently inhibiting a no. of kinase mediated cellular functions, including cell attachment, movement and replication.  The potential therapeutic utility of this broadly acting inhibitor as an antiproliferative and antimigratory agent could extend to such diseases as cancer, atherosclerosis and restenosis, in which redundancies in protein kinase signaling pathways are known to exist.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrHoOZBC_QVz7Vg90H21EOLACvtfcHk0ljvQc_rzhrm2g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXis1Kgtw%253D%253D&md5=3e7482966affffd55ac16f0f9b8d600e</span></div><a href="/servlet/linkout?suffix=cit27a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPanek%26aufirst%3DR.%2BL.%26aulast%3DLu%26aufirst%3DG.%2BH.%26aulast%3DKlutchko%26aufirst%3DS.%2BR.%26aulast%3DBatley%26aufirst%3DB.%2BL.%26aulast%3DDahring%26aufirst%3DT.%2BK.%26aulast%3DHamby%26aufirst%3DJ.%2BM.%26aulast%3DHallak%26aufirst%3DH.%26aulast%3DDoherty%26aufirst%3DA.%2BM.%26aulast%3DKeiser%26aufirst%3DJ.%2BA.%26atitle%3DIn%2520vitro%2520pharmacological%2520characterization%2520of%2520PD%2520166285%252C%2520a%2520new%2520nanomolar%2520potent%2520and%2520broadly%2520active%2520protein%2520tyrosine%2520kinase%2520inhibitor%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D1997%26volume%3D283%26issue%3D3%26spage%3D1433%26epage%3D1444" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit27b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Klutchko, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hamby, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boschelli, D. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kraker, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Amar, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hartl, B. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shen, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klohs, W. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steinkampf, R. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Driscoll, D. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nelson, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Elliott, W. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roberts, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stoner, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vincent, P. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dykes, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Panek, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, G. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Major, T. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dahring, T. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hallak, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bradford, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Showalter, H. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Doherty, A. M.</span><span> </span><span class="NLM_article-title">2-Substituted aminopyrido[2,3-<i>d</i>]pyrimidin-7(8<i>H</i>)-ones. Structure−activity relationships against selected tyrosine kinases and in vitro and in vivo anticancer activity</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">41</span><span class="NLM_x"> (</span><span class="NLM_issue">17</span><span class="NLM_x">) </span> <span class="NLM_fpage">3276</span><span class="NLM_x">–</span> <span class="NLM_lpage">3292</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm9802259" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=1998&pages=3276-3292&issue=17&author=S.+R.+Klutchkoauthor=J.+M.+Hambyauthor=D.+H.+Boschelliauthor=Z.+Wuauthor=A.+J.+Krakerauthor=A.+M.+Amarauthor=B.+G.+Hartlauthor=C.+Shenauthor=W.+D.+Klohsauthor=R.+W.+Steinkampfauthor=D.+L.+Driscollauthor=J.+M.+Nelsonauthor=W.+L.+Elliottauthor=B.+J.+Robertsauthor=C.+L.+Stonerauthor=P.+W.+Vincentauthor=D.+J.+Dykesauthor=R.+L.+Panekauthor=G.+H.+Luauthor=T.+C.+Majorauthor=T.+K.+Dahringauthor=H.+Hallakauthor=L.+A.+Bradfordauthor=H.+D.+Showalterauthor=A.+M.+Doherty&title=2-Substituted+aminopyrido%5B2%2C3-d%5Dpyrimidin-7%288H%29-ones.+Structure%E2%88%92activity+relationships+against+selected+tyrosine+kinases+and+in+vitro+and+in+vivo+anticancer+activity"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit27b&amp;dbid=16384&amp;doi=10.1021%2Fjm9802259&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm9802259%26sid%3Dliteratum%253Aachs%26aulast%3DKlutchko%26aufirst%3DS.%2BR.%26aulast%3DHamby%26aufirst%3DJ.%2BM.%26aulast%3DBoschelli%26aufirst%3DD.%2BH.%26aulast%3DWu%26aufirst%3DZ.%26aulast%3DKraker%26aufirst%3DA.%2BJ.%26aulast%3DAmar%26aufirst%3DA.%2BM.%26aulast%3DHartl%26aufirst%3DB.%2BG.%26aulast%3DShen%26aufirst%3DC.%26aulast%3DKlohs%26aufirst%3DW.%2BD.%26aulast%3DSteinkampf%26aufirst%3DR.%2BW.%26aulast%3DDriscoll%26aufirst%3DD.%2BL.%26aulast%3DNelson%26aufirst%3DJ.%2BM.%26aulast%3DElliott%26aufirst%3DW.%2BL.%26aulast%3DRoberts%26aufirst%3DB.%2BJ.%26aulast%3DStoner%26aufirst%3DC.%2BL.%26aulast%3DVincent%26aufirst%3DP.%2BW.%26aulast%3DDykes%26aufirst%3DD.%2BJ.%26aulast%3DPanek%26aufirst%3DR.%2BL.%26aulast%3DLu%26aufirst%3DG.%2BH.%26aulast%3DMajor%26aufirst%3DT.%2BC.%26aulast%3DDahring%26aufirst%3DT.%2BK.%26aulast%3DHallak%26aufirst%3DH.%26aulast%3DBradford%26aufirst%3DL.%2BA.%26aulast%3DShowalter%26aufirst%3DH.%2BD.%26aulast%3DDoherty%26aufirst%3DA.%2BM.%26atitle%3D2-Substituted%2520aminopyrido%255B2%252C3-d%255Dpyrimidin-7%25288H%2529-ones.%2520Structure%25E2%2588%2592activity%2520relationships%2520against%2520selected%2520tyrosine%2520kinases%2520and%2520in%2520vitro%2520and%2520in%2520vivo%2520anticancer%2520activity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1998%26volume%3D41%26issue%3D17%26spage%3D3276%26epage%3D3292" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Dorsey, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jove, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kraker, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, J.</span><span> </span><span class="NLM_article-title">The pyrido[2,3-<i>d</i>]pyrimidine derivative PD180970 inhibits p210Bcr-Abl tyrosine kinase and induces apoptosis of K562 leukemic cells</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">60</span><span class="NLM_x"> (</span><span class="NLM_issue">12</span><span class="NLM_x">) </span> <span class="NLM_fpage">3127</span><span class="NLM_x">–</span> <span class="NLM_lpage">3131</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2000&pages=3127-3131&issue=12&author=J.+F.+Dorseyauthor=R.+Joveauthor=A.+J.+Krakerauthor=J.+Wu&title=The+pyrido%5B2%2C3-d%5Dpyrimidine+derivative+PD180970+inhibits+p210Bcr-Abl+tyrosine+kinase+and+induces+apoptosis+of+K562+leukemic+cells"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DDorsey%26aufirst%3DJ.%2BF.%26aulast%3DJove%26aufirst%3DR.%26aulast%3DKraker%26aufirst%3DA.%2BJ.%26aulast%3DWu%26aufirst%3DJ.%26atitle%3DThe%2520pyrido%255B2%252C3-d%255Dpyrimidine%2520derivative%2520PD180970%2520inhibits%2520p210Bcr-Abl%2520tyrosine%2520kinase%2520and%2520induces%2520apoptosis%2520of%2520K562%2520leukemic%2520cells%26jtitle%3DCancer%2520Res.%26date%3D2000%26volume%3D60%26issue%3D12%26spage%3D3127%26epage%3D3131" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit28b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Wisniewski, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lambek, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Strife, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Veach, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nagar, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Young, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schindler, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bornmann, W. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bertino, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuriyan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clarkson, B.</span><span> </span><span class="NLM_article-title">Characterization of potent inhibitors of the Bcr-Abl and the c-kit receptor tyrosine kinases</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">62</span><span class="NLM_x"> (</span><span class="NLM_issue">15</span><span class="NLM_x">) </span> <span class="NLM_fpage">4244</span><span class="NLM_x">–</span> <span class="NLM_lpage">4255</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28b&amp;dbid=8&amp;doi=10.1021%2Fjm901808w&amp;key=12154026" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28b&amp;dbid=32&amp;doi=10.1021%2Fjm901808w&amp;key=1%3ACAS%3A528%3ADC%252BD38XlvFeltLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2002&pages=4244-4255&issue=15&author=D.+Wisniewskiauthor=C.+L.+Lambekauthor=C.+Liuauthor=A.+Strifeauthor=D.+R.+Veachauthor=B.+Nagarauthor=M.+A.+Youngauthor=T.+Schindlerauthor=W.+G.+Bornmannauthor=J.+R.+Bertinoauthor=J.+Kuriyanauthor=B.+Clarkson&title=Characterization+of+potent+inhibitors+of+the+Bcr-Abl+and+the+c-kit+receptor+tyrosine+kinases"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28bR"><div class="casContent"><span class="casTitleNuber">28b</span><div class="casTitle"><span class="NLM_cas:atitle">Characterization of potent inhibitors of the Bcr-Abl and the c-kit receptor tyrosine kinases</span></div><div class="casAuthors">Wisniewski, David; Lambek, Caryl L.; Liu, Chongyuan; Strife, Annabel; Veach, Darren R.; Nagar, Bhushan; Young, Matthew A.; Schindler, Thomas; Bornmann, William G.; Bertino, Joseph R.; Kuriyan, John; Clarkson, Bayard</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">4244-4255</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The early stage of chronic myelogenous leukemia (CML) is caused by the tyrosine kinase Bcr-Abl.  Imatinib mesylate (also known as STI-571 and Gleevec), a tyrosine kinase inhibitor, has shown encouraging results in CML clin. trials and has become a paradigm for targeted cancer therapeutics.  Recent reports of resistance to imatinib argue for further development of therapies for CML.  During studies of signal transduction, we obsd. that the pyrido[2,3-d]pyrimidine src tyrosine kinase inhibitor PD173955 inhibited Bcr-Abl-dependent cell growth.  Subsequently, a related compd., PD180970, was reported as a potent inhibitor of Bcr-Abl.  We have compared the potency of these two compds. and four other analogs with imatinib on Bcr-Abl-dependent cell growth, cytokine-dependent cell growth, and tyrosine kinase inhibition.  PD173955 inhibited Bcr-Abl-dependent cell growth with an IC50 of 2-35 nM in different cell lines.  Fluorescence-activated cell-sorting analyses of cells treated with PD173955 showed cell cycle arrest in G1.  PD173955 has an IC50 of 1-2 nM in kinase inhibition assays of Bcr-Abl, and in cellular growth assays it inhibits Bcr-Abl-dependent substrate tyrosine phosphorylation.  Of the six pyrido[2,3-d]pyrimidine analogs studied, PD166326 was the most potent inhibitor of Bcr-Abl-dependent cell growth.  PD173955 inhibited kit ligand-dependent c-kit autophosphorylation (IC50 = ∼25 nM) and kit ligand-dependent proliferation of M07e cells (IC50 = 40 nM) but had a lesser effect on interleukin 3-dependent (IC50 = 250 nM) or granulocyte macrophage colony-stimulating factor (IC50 = 1 μM)-dependent cell growth.  These compds. are potent inhibitors of both the Bcr-Abl and c-kit receptor tyrosine kinases and deserve further study as potential treatments for both CML and for diseases in which c-kit has a role.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq6S_NVW4-7b7Vg90H21EOLACvtfcHk0ljEYQ-em9XSlg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XlvFeltLc%253D&md5=4c570635dc54053856a8fb14e10aefa6</span></div><a href="/servlet/linkout?suffix=cit28b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWisniewski%26aufirst%3DD.%26aulast%3DLambek%26aufirst%3DC.%2BL.%26aulast%3DLiu%26aufirst%3DC.%26aulast%3DStrife%26aufirst%3DA.%26aulast%3DVeach%26aufirst%3DD.%2BR.%26aulast%3DNagar%26aufirst%3DB.%26aulast%3DYoung%26aufirst%3DM.%2BA.%26aulast%3DSchindler%26aufirst%3DT.%26aulast%3DBornmann%26aufirst%3DW.%2BG.%26aulast%3DBertino%26aufirst%3DJ.%2BR.%26aulast%3DKuriyan%26aufirst%3DJ.%26aulast%3DClarkson%26aufirst%3DB.%26atitle%3DCharacterization%2520of%2520potent%2520inhibitors%2520of%2520the%2520Bcr-Abl%2520and%2520the%2520c-kit%2520receptor%2520tyrosine%2520kinases%26jtitle%3DCancer%2520Res.%26date%3D2002%26volume%3D62%26issue%3D15%26spage%3D4244%26epage%3D4255" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group">Cowan-Jacob, S. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guez, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fendrich, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Griffin, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fabbro, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Furet, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liebetanz, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mestan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Manley, P. W.</span><span> </span><span class="NLM_article-title">Imatinib (STI571) resistance in chronic myelogenous leukemia: molecular basis of the underlying mechanisms and potential strategies for treatment</span> <span class="citation_source-journal">Mini-Rev. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x"> (</span><span class="NLM_issue">3</span><span class="NLM_x">) </span> <span class="NLM_fpage">285</span><span class="NLM_x">–</span> <span class="NLM_lpage">299</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2004&pages=285-299&issue=3&author=S.+W.+Cowan-Jacobauthor=V.+Guezauthor=G.+Fendrichauthor=J.+D.+Griffinauthor=D.+Fabbroauthor=P.+Furetauthor=J.+Liebetanzauthor=J.+Mestanauthor=P.+W.+Manley&title=Imatinib+%28STI571%29+resistance+in+chronic+myelogenous+leukemia%3A+molecular+basis+of+the+underlying+mechanisms+and+potential+strategies+for+treatment"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCowan-Jacob%26aufirst%3DS.%2BW.%26aulast%3DGuez%26aufirst%3DV.%26aulast%3DFendrich%26aufirst%3DG.%26aulast%3DGriffin%26aufirst%3DJ.%2BD.%26aulast%3DFabbro%26aufirst%3DD.%26aulast%3DFuret%26aufirst%3DP.%26aulast%3DLiebetanz%26aufirst%3DJ.%26aulast%3DMestan%26aufirst%3DJ.%26aulast%3DManley%26aufirst%3DP.%2BW.%26atitle%3DImatinib%2520%2528STI571%2529%2520resistance%2520in%2520chronic%2520myelogenous%2520leukemia%253A%2520molecular%2520basis%2520of%2520the%2520underlying%2520mechanisms%2520and%2520potential%2520strategies%2520for%2520treatment%26jtitle%3DMini-Rev.%2520Med.%2520Chem.%26date%3D2004%26volume%3D4%26issue%3D3%26spage%3D285%26epage%3D299" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Melnick, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Janes, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, J. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sipes, D. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gunderson, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jarnes, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matzen, J. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garcia, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hood, T. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beigi, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xia, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harig, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Asatryan, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yan, S. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gu, X. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saadat, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">King, F. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shaw, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Su, A. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Downs, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gray, N. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schultz, P. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Warmuth, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Caldwell, J. S.</span><span> </span><span class="NLM_article-title">An efficient rapid system for profiling the cellular activities of molecular libraries</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U.S.A</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">103</span><span class="NLM_x"> (</span><span class="NLM_issue">9</span><span class="NLM_x">) </span> <span class="NLM_fpage">3153</span><span class="NLM_x">–</span> <span class="NLM_lpage">3158</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=103&publication_year=2006&pages=3153-3158&issue=9&author=J.+S.+Melnickauthor=J.+Janesauthor=S.+Kimauthor=J.+Y.+Changauthor=D.+G.+Sipesauthor=D.+Gundersonauthor=L.+Jarnesauthor=J.+T.+Matzenauthor=M.+E.+Garciaauthor=T.+L.+Hoodauthor=R.+Beigiauthor=G.+Xiaauthor=R.+A.+Harigauthor=H.+Asatryanauthor=S.+F.+Yanauthor=Y.+Zhouauthor=X.+J.+Guauthor=A.+Saadatauthor=V.+Zhouauthor=F.+J.+Kingauthor=C.+M.+Shawauthor=A.+I.+Suauthor=R.+Downsauthor=N.+S.+Grayauthor=P.+G.+Schultzauthor=M.+Warmuthauthor=J.+S.+Caldwell&title=An+efficient+rapid+system+for+profiling+the+cellular+activities+of+molecular+libraries"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit30a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMelnick%26aufirst%3DJ.%2BS.%26aulast%3DJanes%26aufirst%3DJ.%26aulast%3DKim%26aufirst%3DS.%26aulast%3DChang%26aufirst%3DJ.%2BY.%26aulast%3DSipes%26aufirst%3DD.%2BG.%26aulast%3DGunderson%26aufirst%3DD.%26aulast%3DJarnes%26aufirst%3DL.%26aulast%3DMatzen%26aufirst%3DJ.%2BT.%26aulast%3DGarcia%26aufirst%3DM.%2BE.%26aulast%3DHood%26aufirst%3DT.%2BL.%26aulast%3DBeigi%26aufirst%3DR.%26aulast%3DXia%26aufirst%3DG.%26aulast%3DHarig%26aufirst%3DR.%2BA.%26aulast%3DAsatryan%26aufirst%3DH.%26aulast%3DYan%26aufirst%3DS.%2BF.%26aulast%3DZhou%26aufirst%3DY.%26aulast%3DGu%26aufirst%3DX.%2BJ.%26aulast%3DSaadat%26aufirst%3DA.%26aulast%3DZhou%26aufirst%3DV.%26aulast%3DKing%26aufirst%3DF.%2BJ.%26aulast%3DShaw%26aufirst%3DC.%2BM.%26aulast%3DSu%26aufirst%3DA.%2BI.%26aulast%3DDowns%26aufirst%3DR.%26aulast%3DGray%26aufirst%3DN.%2BS.%26aulast%3DSchultz%26aufirst%3DP.%2BG.%26aulast%3DWarmuth%26aufirst%3DM.%26aulast%3DCaldwell%26aufirst%3DJ.%2BS.%26atitle%3DAn%2520efficient%2520rapid%2520system%2520for%2520profiling%2520the%2520cellular%2520activities%2520of%2520molecular%2520libraries%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A%26date%3D2006%26volume%3D103%26issue%3D9%26spage%3D3153%26epage%3D3158" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit30b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Warmuth, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gu, X. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xia, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adrian, F.</span><span> </span><span class="NLM_article-title">Ba/F3 cells and their use in kinase drug discovery</span> <span class="citation_source-journal">Curr. Opin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x"> (</span><span class="NLM_issue">1</span><span class="NLM_x">) </span> <span class="NLM_fpage">55</span><span class="NLM_x">–</span> <span class="NLM_lpage">60</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30b&amp;dbid=16&amp;doi=10.1021%2Fjm901808w&amp;key=10.1097%2FCCO.0b013e328011a25f" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30b&amp;dbid=8&amp;doi=10.1021%2Fjm901808w&amp;key=17133113" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30b&amp;dbid=32&amp;doi=10.1021%2Fjm901808w&amp;key=1%3ACAS%3A528%3ADC%252BD28Xht1Cnt7%252FL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2007&pages=55-60&issue=1&author=M.+Warmuthauthor=S.+Kimauthor=X.+J.+Guauthor=G.+Xiaauthor=F.+Adrian&title=Ba%2FF3+cells+and+their+use+in+kinase+drug+discovery"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30bR"><div class="casContent"><span class="casTitleNuber">30b</span><div class="casTitle"><span class="NLM_cas:atitle">Ba/F3 cells and their use in kinase drug discovery</span></div><div class="casAuthors">Warmuth, Markus; Kim, Sungjoon; Gu, Xiang-ju; Xia, Gang; Adrian, Francisco</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Oncology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">55-60</span>CODEN:
                <span class="NLM_cas:coden">CUOOE8</span>;
        ISSN:<span class="NLM_cas:issn">1040-8746</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">A review.  Purpose of review: Due to their ability to function as dominant oncogenes, protein kinases have become favored targets in the quest for 'molecularly-targeted' cancer chemotherapeutics.  The discovery of a large no. of cancer-assocd. mutations in the kinome, and the progress in developing specific small-mol. kinase inhibitors has increased the need for accurate, reproducible, and efficient kinase activity-dependent cellular assay systems.  Recent findings: Ba/F3, a murine interleukin-3 dependent pro-B cell line is increasingly popular as a model system for assessing both the potency and downstream signaling of kinase oncogenes, and the ability of small-mol. kinase inhibitors to block kinase activity.  Facilitated by their growth properties, Ba/F3 cells have recently been adapted to high-throughput assay formats for compd. profiling.  Further, several published approaches show promise in predicting resistance to small-mol. kinase inhibitors elicited by point mutations interfering with inhibitor binding.  Summary: Ba/F3 cells are an increasingly popular tool in kinase drug discovery.  The ability to test the transforming capacity of newly identified kinase mutations, and to profile drug candidates and compd. libraries in high-throughput fashion, combined with the use of Ba/F3 cells to predict clin. resistance will greatly facilitate developments in this field.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqXQmhiRwGlDLVg90H21EOLACvtfcHk0ljw_ZRGXCQQtw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xht1Cnt7%252FL&md5=a7f8d84dfedea69d408edb571e2eead9</span></div><a href="/servlet/linkout?suffix=cit30b&amp;dbid=16384&amp;doi=10.1097%2FCCO.0b013e328011a25f&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FCCO.0b013e328011a25f%26sid%3Dliteratum%253Aachs%26aulast%3DWarmuth%26aufirst%3DM.%26aulast%3DKim%26aufirst%3DS.%26aulast%3DGu%26aufirst%3DX.%2BJ.%26aulast%3DXia%26aufirst%3DG.%26aulast%3DAdrian%26aufirst%3DF.%26atitle%3DBa%252FF3%2520cells%2520and%2520their%2520use%2520in%2520kinase%2520drug%2520discovery%26jtitle%3DCurr.%2520Opin.%2520Oncol.%26date%3D2007%26volume%3D19%26issue%3D1%26spage%3D55%26epage%3D60" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group">Liu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gray, N. S.</span><span> </span><span class="NLM_article-title">Rational design of inhibitors that bind to inactive kinase conformations</span> <span class="citation_source-journal">Nature Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x"> (</span><span class="NLM_issue">7</span><span class="NLM_x">) </span> <span class="NLM_fpage">358</span><span class="NLM_x">–</span> <span class="NLM_lpage">364</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Fjm901808w&amp;key=10.1038%2Fnchembio799" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Fjm901808w&amp;key=16783341" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Fjm901808w&amp;key=1%3ACAS%3A528%3ADC%252BD28XlvFGjs7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2006&pages=358-364&issue=7&author=Y.+Liuauthor=N.+S.+Gray&title=Rational+design+of+inhibitors+that+bind+to+inactive+kinase+conformations"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Rational design of inhibitors that bind to inactive kinase conformations</span></div><div class="casAuthors">Liu, Yi; Gray, Nathanael S.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">358-364</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The majority of kinase inhibitors, known as type I inhibitors that have been developed so far target the ATP binding site of the kinase in its active conformation, in which the activation loop is phosphorylated.  Recently, crystal structures of inhibitors such as imatinib, BIRB796, and sorafenib (BAY43-9006), known as type II inhibitors, have revealed a new binding mode that exploits an addnl. binding site immediately adjacent to the region occupied by ATP.  This pocket is made accessible by an activation-loop rearrangement that is characteristic of kinases in an inactive conformation.  The examn. of binding features of known type II inhibitors is discussed and a pharmacophore model currently used in the design of a new generation of structurally diverse type II inhibitors is presented.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrxahsMPlhgDbVg90H21EOLACvtfcHk0lhQUQDewJ-JJQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XlvFGjs7g%253D&md5=4a9347a44a2cf4a412c9741fdcc5696b</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1038%2Fnchembio799&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio799%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DGray%26aufirst%3DN.%2BS.%26atitle%3DRational%2520design%2520of%2520inhibitors%2520that%2520bind%2520to%2520inactive%2520kinase%2520conformations%26jtitle%3DNature%2520Chem.%2520Biol.%26date%3D2006%26volume%3D2%26issue%3D7%26spage%3D358%26epage%3D364" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group">McDermott, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sharma, S. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dowell, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greninger, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Montagut, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lamb, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Archibald, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raudales, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tam, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rothenberg, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Supko, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sordella, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ulkus, L. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iafrate, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maheswaran, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Njauw, C. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsao, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Drew, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hanke, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ma, X.-J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Erlander, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gray, N. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haber, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Settleman, J.</span><span> </span><span class="NLM_article-title">Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U.S.A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">104</span><span class="NLM_x"> (</span><span class="NLM_issue">50</span><span class="NLM_x">) </span> <span class="NLM_fpage">19936</span><span class="NLM_x">–</span> <span class="NLM_lpage">19941</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=104&publication_year=2007&pages=19936-19941&issue=50&author=U.+McDermottauthor=S.+V.+Sharmaauthor=L.+Dowellauthor=P.+Greningerauthor=C.+Montagutauthor=J.+Lambauthor=H.+Archibaldauthor=R.+Raudalesauthor=A.+Tamauthor=D.+Leeauthor=S.+M.+Rothenbergauthor=J.+G.+Supkoauthor=R.+Sordellaauthor=L.+E.+Ulkusauthor=A.+J.+Iafrateauthor=S.+Maheswaranauthor=C.+N.+Njauwauthor=H.+Tsaoauthor=L.+Drewauthor=J.+H.+Hankeauthor=X.-J.+Maauthor=M.+G.+Erlanderauthor=N.+S.+Grayauthor=D.+A.+Haberauthor=J.+Settleman&title=Identification+of+genotype-correlated+sensitivity+to+selective+kinase+inhibitors+by+using+high-throughput+tumor+cell+line+profiling"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMcDermott%26aufirst%3DU.%26aulast%3DSharma%26aufirst%3DS.%2BV.%26aulast%3DDowell%26aufirst%3DL.%26aulast%3DGreninger%26aufirst%3DP.%26aulast%3DMontagut%26aufirst%3DC.%26aulast%3DLamb%26aufirst%3DJ.%26aulast%3DArchibald%26aufirst%3DH.%26aulast%3DRaudales%26aufirst%3DR.%26aulast%3DTam%26aufirst%3DA.%26aulast%3DLee%26aufirst%3DD.%26aulast%3DRothenberg%26aufirst%3DS.%2BM.%26aulast%3DSupko%26aufirst%3DJ.%2BG.%26aulast%3DSordella%26aufirst%3DR.%26aulast%3DUlkus%26aufirst%3DL.%2BE.%26aulast%3DIafrate%26aufirst%3DA.%2BJ.%26aulast%3DMaheswaran%26aufirst%3DS.%26aulast%3DNjauw%26aufirst%3DC.%2BN.%26aulast%3DTsao%26aufirst%3DH.%26aulast%3DDrew%26aufirst%3DL.%26aulast%3DHanke%26aufirst%3DJ.%2BH.%26aulast%3DMa%26aufirst%3DX.-J.%26aulast%3DErlander%26aufirst%3DM.%2BG.%26aulast%3DGray%26aufirst%3DN.%2BS.%26aulast%3DHaber%26aufirst%3DD.%2BA.%26aulast%3DSettleman%26aufirst%3DJ.%26atitle%3DIdentification%2520of%2520genotype-correlated%2520sensitivity%2520to%2520selective%2520kinase%2520inhibitors%2520by%2520using%2520high-throughput%2520tumor%2520cell%2520line%2520profiling%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2007%26volume%3D104%26issue%3D50%26spage%3D19936%26epage%3D19941" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group">Adrian, F. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ding, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sim, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Velentza, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sloan, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hur, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ding, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Manley, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mestan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fabbro, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gray, N. S.</span><span> </span><span class="NLM_article-title">Allosteric inhibitors of Bcr-abl-dependent cell proliferation</span> <span class="citation_source-journal">Nature Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x"> (</span><span class="NLM_issue">2</span><span class="NLM_x">) </span> <span class="NLM_fpage">95</span><span class="NLM_x">–</span> <span class="NLM_lpage">102</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Fjm901808w&amp;key=10.1038%2Fnchembio760" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Fjm901808w&amp;key=16415863" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Fjm901808w&amp;key=1%3ACAS%3A528%3ADC%252BD28XkvF2rsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2006&pages=95-102&issue=2&author=F.+J.+Adrianauthor=Q.+Dingauthor=T.+Simauthor=A.+Velentzaauthor=C.+Sloanauthor=Y.+Liuauthor=G.+Zhangauthor=W.+Hurauthor=S.+Dingauthor=P.+Manleyauthor=J.+Mestanauthor=D.+Fabbroauthor=N.+S.+Gray&title=Allosteric+inhibitors+of+Bcr-abl-dependent+cell+proliferation"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Allosteric inhibitors of Bcr-abl-dependent cell proliferation</span></div><div class="casAuthors">Adrian, Francisco J.; Ding, Qiang; Sim, Taebo; Velentza, Anastasia; Sloan, Christine; Liu, Yi; Zhang, Guobao; Hur, Wooyoung; Ding, Sheng; Manley, Paul; Mestan, Juergen; Fabbro, Doriano; Gray, Nathanael S.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">95-102</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Chronic myelogenous leukemia (CML) is a myeloproliferative disorder characterized at the mol. level by the expression of Bcr-abl, a 210-kDa fusion protein with deregulated tyrosine kinase activity.  Encouraged by the clin. validation of Bcr-abl as the target for the treatment of CML by imatinib, we sought to identify pharmacol. agents that could target this kinase by a distinct mechanism.  We report the discovery of a new class of Bcr-abl inhibitors using an unbiased differential cytotoxicity screen of a combinatorial kinase-directed heterocycle library.  Compds. in this class (exemplified by GNF-2) show exclusive antiproliferative activity toward Bcr-abl-transformed cells, with potencies similar to imatinib, while showing no inhibition of the kinase activity of full-length or catalytic domain of c-abl.  We propose that this new class of compds. inhibits Bcr-abl kinase activity through an allosteric non-ATP competitive mechanism.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqqjXG0lHqHurVg90H21EOLACvtfcHk0lhQUQDewJ-JJQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XkvF2rsA%253D%253D&md5=c8617fecb6092d71ae163e7cda1e8f94</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1038%2Fnchembio760&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio760%26sid%3Dliteratum%253Aachs%26aulast%3DAdrian%26aufirst%3DF.%2BJ.%26aulast%3DDing%26aufirst%3DQ.%26aulast%3DSim%26aufirst%3DT.%26aulast%3DVelentza%26aufirst%3DA.%26aulast%3DSloan%26aufirst%3DC.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DG.%26aulast%3DHur%26aufirst%3DW.%26aulast%3DDing%26aufirst%3DS.%26aulast%3DManley%26aufirst%3DP.%26aulast%3DMestan%26aufirst%3DJ.%26aulast%3DFabbro%26aufirst%3DD.%26aulast%3DGray%26aufirst%3DN.%2BS.%26atitle%3DAllosteric%2520inhibitors%2520of%2520Bcr-abl-dependent%2520cell%2520proliferation%26jtitle%3DNature%2520Chem.%2520Biol.%26date%3D2006%26volume%3D2%26issue%3D2%26spage%3D95%26epage%3D102" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=1m52" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=1m52','PDB','1m52'); return false;">PDB: 1m52</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3cs9" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3cs9','PDB','3cs9'); return false;">PDB: 3cs9</a></li></ul></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Fjm901808w&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2010.53.issue-15%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text%3Barticle%3Aarticle%3A10.1021%2Fjm901808w" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/jm901808w" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                3MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-b425991822a79ada59b3.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-fb88834b824b41b135ad.js"></script>

<script type="text/javascript" src="/wro/ke1q~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"66797cee8e6125a5","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.6.0","si":10}'></script>
</body>
</html>
